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Synapses are an early pathological target in a wide range of neurodegenerative conditions 
including adult-onset Alzheimer’s and Parkinson’s, and diseases of childhood such as spinal 
muscular atrophy and neuronal ceroid lipofuscinoses (NCLs). However, our understanding of 
the mechanisms regulating the stability of synapses and their exceptional vulnerability to 
neurodegenerative stimuli remains in its infancy.  
To address this, we have used the NCLs to model the molecular alterations underpinning 
synaptic vulnerability.  Our primary objective is to identify novel regulators of synaptic 
stability as well as highlight novel therapeutic targets which may prove effective across multiple 
neurodegenerative conditions where synapses are an early pathological target. The NCLs, are 
the most frequent autosomal-recessive disease of childhood. There are currently 14 individual 
genes whose mutations result in similar phenotypes including blindness, cognitive/motor 
deficits, seizures and premature death. This suggests that despite the difference in the initiating 
mutation and the degenerative processes across this collective group are likely to impact on 
overlapping pathways.   
Focusing on two murine models of NCL; one with an infantile onset - CLN1 disease (Ppt1-/-) 
and one with a juvenile onset - CLN3 disease (Cln3-/-) we made use of the temporospatial 
synaptic vulnerability pattern in these mice to plan proteomic and in silico analyses. This 
pipeline was utilised to identify perturbed protein candidates and pathways correlating with 
differential regional synaptic vulnerability. This ultimately allowed the generation of a list of 
candidate proteins, some of which were relevant to human NCL as they were altered in post 
mortem brain samples. Interestingly, many of the correlative candidates also appear to show 
conserved alterations in both NCL forms examined and other neurodegenerative diseases. 
Next, candidates were genetically and/or pharmacologically targeted to study their modulatory 
effects on neuronal stability in vivo. This was done using CLN3 Drosophila as a rapid screening 
assay and led to the successful characterisation of a subset of candidates as either enhancers or 
suppressors of the CLN3-induced phenotype in vivo. 
As well as identifying regulators of neuronal stability, following a similar pipeline, we 
identified a set of putative biomarkers of disease progression in muscle and blood in the Ppt1-
/- mice, a subset of which appeared conserved in Cln3-/- mice. One of these conserved 
candidates presented the same directionality of change in human post mortem brain samples, 
indicating its relevance to the human NCL. 
Following this workflow from spatio-temporal profiling of murine synaptic populations, to in 
silico analyses and in vivo phenotypic assessment, we demonstrate that we can identify 
multiple protein candidates capable of modulating neuronal stability in vivo and identified 




Neurons are connected through complex structures called synapses which are responsible for 
many essential processes happening in the brain such as cognition or movement. In many 
neurodegenerative diseases, such as Alzheimer’s or Parkinson’s, it has been shown that 
synaptic changes happen early on in disease progression contributing to the dysfunction of the 
nervous system. Yet, why synapses are so sensitive in a variety of diseases remain unclear. For 
this reason, this study aims to elucidate the biological factors regulating synaptic loss, which 
may help our understanding of the mechanisms underpinning neurodegeneration as well as 
highlight novel therapeutic targets. 
To do so, genetically modified mice were used, which serve as models of a fatal childhood 
neurodegenerative disease called neuronal ceroid lipofucinosis (NCL). In this disease, 
synapses are an early pathological target. These mice reproduce various aspects of the human 
disease, such as blindness, motor and cognitive problems suggesting they may allow us to 
further understand how the disease works in humans. 
The brain is divided into various regions which are affected differently depending on the 
disease.   We used the structural patterns of synaptic vulnerability across different brain areas 
in these mice to characterise the changes at the molecular level (proteins).  Using a 
combination of bioinformatic tools, we identified proteins and biological pathways that were 
perturbed in the mice models correlating to this synaptic vulnerability pattern. This suggests 
that these proteins are likely to regulate the process of synaptic loss during neurodegeneration 
and were identified as candidates for further characterization. Importantly, some of these 
candidates, were also found to be changed in NCL patient synapses and therefore were disease-
relevant.  
Next, to test if these proteins just correlate or can also affect neuronal stability, we studied 
them in the nervous system of fruit fly models of NCL. The nervous system of the fly has been 
very well characterized and, unlike mammals, allows a straight-forward and rapid screening, 
providing further understanding of disease-related pathways. Thus, by genetically and/or 
pharmacologically disrupting these proteins in NCL fruit fly models, we identified a sublist of 
the candidates which were actually able to improve or worsen the “disease” in the flies. 
Following this workflow, which includes the examination of synaptic (neuronal connections) 
populations from mammalian models of diseases (mice) followed by bioinformatics analyses 
and studies using the fruit fly, we identified multiple proteins able to change neuronal stability 
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1.1 Socioeconomic impact of neurodegenerative diseases 
Neurodegenerative diseases are incapacitating conditions which are characterised by a 
progressive death of neurons. Since they are incurable, they place an enormous social, 
emotional and financial burden on affected individuals, care providers, health services and 
society at large. In the UK alone, there are around 850,000 people suffering from Alzheimer’s 
disease (AD) and other dementias, which represents over 60-70% of the total cases of 
neurodegenerative diseases (https://www.mrc.ac.uk). Other more prevalent 
neurodegenerative diseases include: Parkinson’s (Meek et al., 1998), Amyotrophic lateral 
sclerosis, and multiple sclerosis (Gustavsson et al., 2011). 
 
In terms of economics, it is estimated that these diseases cost the UK economy £26 billion 
per year (https://www.mrc.ac.uk). Scaling that to a larger economy, it is predicted that the 
U.S spends around $259 billion in the management of Alzheimer’s disease alone 
(http://www.alz.org/facts/overview.asp). Since, many neurodegenerative conditions are 
linked to aging, these numbers are expected to rise due to the increase in average human 
lifespan.  
 
Despite large efforts of the research community, effective treatments for neurodegenerative 
conditions are still lacking. Therefore, there is an urgent requirement to understand the 
mechanisms underlying these conditions in order to elucidate molecular drug targets for the 




1.2 Compartmentalised pathology in neurodegenerative 
diseases 
In order to understand the mechanisms regulating neurodegenerative processes, we need to 
consider the complexity of the nervous system, and neurons in particular. The high 
specialisation of intracellular communication of nerve cells translates into distinct 
morphological and biochemical properties which distinguishes neurons from other cell 
types. Broadly speaking, as represented in Fig. 1.1, (central) neurons can be divided into 
three main compartments: cell soma, axon and synapse. The cell soma, which contains the 
nucleus of the cell is characterized by its branching and arborisation of dendrites. Dendrites 
are the primary target for synaptic input coming from other neurons. They contain high 
numbers of ribosomes and have very organized cytoskeletal structures to receive and 
integrate information from other neurons. The axon is a unique extension from the cell body 
whose main function is signal conduction of the action potential to the synapse. Depending 
on the type of neuron and its location, axons can travel from a few micrometres to many 
centimetres in humans. It also contains an important cytoskeletal architecture which is key 
for axonal function. The synapse is made by contacts between the presynaptic cell, dendrites 
and the following neuron (post-synaptic side). It is responsible for the transmission of the 
action potential between neurons. Its main feature is the complex secretory apparatus by 
which synaptic transmission takes place in most of the neurons (Purves et al., 2004). 
 
It is therefore not surprising that the growing body of experimental evidence suggests that 
each of the neuronal compartments described above react differently to neurodegenerative 
stimuli (Gillingwater et al., 2001, Coleman, 2005, Wishart et al., 2012). Studies in “Wallerian 
degeneration slow” mice (Wlds), a model of neuroprotection, showed that each one of these 
neuronal subcompartments is able to degenerate independently from the others 
(Gillingwater et al., 2002, Gillingwater et al., 2006, Parson et al., 2004). The differential 
characteristics of neuronal cell death by apoptotic pathways and the “cytoplasmatic 
apoptosis” of axons suggests that different pathophysiological mechanisms may be 
orchestrating these processes (Gillingwater et al., 2001). Among these three compartments, 
synapses have been reported to be especially vulnerable to a variety of neurodegenerative 
stimuli, preceding cell body alterations (Wishart et al., 2006, Wishart et al., 2012). Therefore, 
it is likely that distinct molecular mechanisms residing in the synapse confer this exceptional 
vulnerability. Gillingwater & Ribchester observed that in the Wlds mice, where axonal 
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degeneration is delayed after axotomisation of the nerve, a novel form of synaptic-specific 
degeneration was unravelled (Gillingwater et al., 2006, Parson et al., 2004). They then 
proposed the term “synaptosis” to describe these specific mechanisms of synaptic 
degeneration (Gillingwater et al., 2001). 
For a few years, our group has been interested in the elucidation of these mechanisms 
underlying synaptic vulnerability. Importantly, Wishart et al. have recently showed that by 
targeting molecular changes happening in synapse, a beneficial effect can be seen beyond the 
synapse to the nervous system as a whole (Wishart et al., 2014, Powis et al., 2016). This has 
provided a proof of concept that through investigating differentially vulnerable synaptic 
compartments we can obtain a broad understanding of the whole process of 
neurodegeneration.  
 
For this reason, the main focus of this thesis will be on investigating the molecular 
mechanisms regulating the exceptional vulnerability of synapses as it may be a source of drug 





Fig. 1.1 Neuron schematic representation. A depiction of the three main functional and 
structural compartments of neurons: cell body/soma (in blue), where apoptosis is the main 
mechanisms of cell death. Axon (in pink), a specific “cytoplasmic apoptosis” (Wallerian 
degeneration) takes place. The synapse (in yellow) where a proposed mechanisms of specific 




1.3 The synapse 
As briefly described before, synapses are the connections between a pre-synaptic neuron and 
a post-synaptic cell, which is often another neuron. Synaptic junctions are responsible for 
transmitting action potential-encoded information from the presynaptic to the postsynaptic 
side (Sudhof, 2012). They can be divided into electrical and chemical, with the latter being 
the most abundant. In chemical synapses, there is a gap between pre- and post-synaptic cell 
(synaptic clefts) and the action potential is transmitted through neurotransmitters which are 
packed into synaptic vesicles. Synaptic vesicle exocytosis is triggered by the influx of Ca2+ 
through voltage-gated calcium channels, occurring when an action potential is reached. 
Vesicle exocytosis is restricted to a small area of the plasma membrane with electro-dense 
material, called an “active zone” (Couteaux et al., 1970). Released chemical 
neurotransmitters then activate the post-synaptic receptors. After exocytosis, synaptic 
vesicles can be recycled through endocytosis and neurotransmitter refilling mechanisms 
(Sudhof, 2004). 
 
It has been shown that synaptic terminals are not just secretory machines, but computational 
units where the relationship between action potential and neurotransmitter release changes 
continuously depending on intracellular messengers, extracellular modulators or repeated 
use of the synapse (Sudhof, 2004). The mammalian brain contains multiple types of synapse 
with particular sets of computational properties. These properties are defined by the 
differential neurotransmitter and/or post-synaptic receptor composition (Koester et al., 
2005).  
Synaptic plasticity is believed to underlie the process of learning new skills, storing memories 
or responding to injury. Such plasticity is determined by changes in synaptic strength which 
depends on the patterns of synaptic activity. The long-lasting increase in synaptic strength is 
known as long-term potentiation (LTP), whereas long-lasting decrease is named long-term 
depression (LTD) (Citri et al., 2007). A correct homeostasis of the synaptic compartments is 
therefore essential, for the maintenance of neuronal function. As stated before, defects in 
synaptic stability can trigger a series of events which will compromise the whole nervous 
system leading to neurodegenerative processes (Powis et al., 2016, Wishart et al., 2014, 





Fig. 1.2 Schematic representation of a chemical synapse and the synaptic vesicle cycle. Synaptic 
transmission occurs following a series of events. As indicated by the figure, the synaptic vesicle 
cycle is tightly regulated by multiple proteins some of which are represented here. The process is 
initiated when an action potential arrives to the pre-synaptic neuron. This changes the membrane 
potential and triggers the influx of calcium. As a consequence, synaptic vesicles containing a 
reserve pool of neurotransmitter bind to specialized sites of the membrane called active site 
(docking) and fuse in response to calcium influx (priming) releasing the contained 
neurotransmitters to the synaptic cleft. Next, neurotransmitters diffuse and bind to specific 
receptors of the post-synaptic cell. This causes the channels of the post-synaptic neuron to 
open/close, changing the flow of ions to go in and out of the post-synaptic neuron. This flow 
increase/decrease the probability of the neuron firing an action potential. The lumen of the 
synaptic vesicle exposed during neurotransmitter release is later internalized by endocytosis. 
After internalization the synaptic vesicle is refilled with neurotransmitter and a new cycle begins. 
Following these steps, information between neurons is transmitted. Syt=synaptotagmin.  (Figure 





1.4 The synapse as an early pathological target in 
neurodegenerative disease 
Traditionally, the most studied pathophysiological hallmarks of many neurodegenerative 
diseases were the aberrant protein accumulations preceding generalised neuronal loss, 
usually located in the cell soma  (Soto, 2003, Moreno-Gonzalez I, 2011). These abnormal 
misfolded proteins were often detected in post mortem tissue of patients suffering from 
conditions such as Alzheimer’s (Beta-amyloid and Tau) (Glenner, 1984, Grundke-Iqbal et 
al., 1986), Parkinson’s (⍺-synuclein) (Forno, 1996, Spillantini, 1997) and Huntington’s 
(huntingtin) (DiFiglia et al., 1997, Davies et al., 1997). For this reason, researchers have 
focused their strategies on stopping cell death targeting such mechanisms primarily located 
in somatic compartments (Wishart et al., 2006). 
 
Nevertheless, as indicated in section 1.2 above, more recent reports have highlighted the 
importance of early events happening at distal neuronal compartments such as axons and 
synapses, often preceding the appearance of characteristic pathophysiological disease 
hallmarks in the soma and eventual neuronal loss (Coleman, 2005, Gillingwater et al., 2001, 
Wishart et al., 2006). In fact, synapses have been described as an early pathological target in a 
wide range of conditions including diseases associated with ageing and infantile onset 
diseases, some of which are briefly described below. 
 
It is now known that synaptic loss is a major contributor of disease progression and that 
subtle synaptic dysfunction can be detected at pre-symptomatic stages in Alzheimer’s disease 
(Selkoe, 2002, Coleman et al., 2004). Moreover, synaptic loss is one of the more consistent 
pathological correlates of cognitive decline in Alzheimer’s disease and other dementias 
(Terry et al., 1991, Davies et al., 1976, DeKosky et al., 1990). Importantly, such cognitive 
alterations can be detected up to 10 years before the detection of clinical manifestations 
(Kawas et al., 2003, Elias et al., 2000), highlighting the importance of synaptic abnormalities 
early on during disease progression. As previously mentioned, synaptic disruption has also 
been detected in other dementias and may be also relevant to “normal healthy” aging-
associated cognitive decline (Brown et al., 1998, Zhou et al., 1998, Lipton et al., 2001, Uylings 
et al., 2002).  
 
For example, Parkinson’s Disease (PD) (Meek et al., 1998) targets specifically dopaminergic 
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neurons triggering high rates of degeneration in nigro-striatal brain areas. Synaptic 
alterations have also been described in striatum in early phases of experimental PD 
contributing to the clinical progression of the disease (Picconi et al., 2012). Also, in 
Huntington’s disease (HD) synaptic pathology correlates with the clinical manifestations of 
the disease in patients including the impairment of psychiatric, motor and cognitive 
functions (Li et al., 2003). Dendritic spine loss was shown to precede neuronal loss in animal 
models as well as synaptic transmission defects in the peripheral and central nervous system 
(CNS) (Guidetti et al., 2001, Kraemer et al., 2010, Klapstein et al., 2001). 
 
Synapses in the peripheral nervous system (PNS) are also an early pathological target in some 
neurodegenerative conditions. This is the case in motor neurone diseases (MND). In 
Amyotrophic lateral sclerosis, synaptic loss occurs at the neuromuscular junctions (NMJ), 
lower motor neurons in the spinal cord ventral horn, as well as in cortical areas in both 
patients and animal models of ALS (Sasaki et al., 1999, Sasaki et al., 1994, Zang et al., 2005, 
Maselli et al., 1993). Similarly, in spinal muscular atrophy (SMA), a monogenetic and 
devastating infantile onset MND, evidence shows early functional and structural disruption 
of synaptic connectivity at the NMJ and in the spinal cord (Murray et al., 2008, Kariya et al., 
2008, Ling et al., 2010, Mentis et al., 2011, Imlach et al., 2012), as well as molecular 
pathological changes in hippocampal synapses (Wishart et al., 2014). 
 
Early synaptic loss is also a key event in another mono-genetic, neurodegenerative disease 
group: the neuronal ceroid lipofuscinoses (NCL or Batten disease) (Kielar et al., 2009, 
Partanen et al., 2008). The NCLs are a group of neurodegenerative diseases and form of 
dementia characterized by intellectual and neurological deterioration (Goebel, 1995). The 
main differences between each NCL form is the age of onset which can be infantile, juvenile 
and adult onset. Like many of the neurodegenerative diseases described here, no effective 
treatment is currently available which leads to premature death in patients suffering this 
devastating disease (Cooper, 2003, Cooper, 2010).  
 
Since early synaptic loss seems to be a common event across multiple conditions regardless 
the initiating insult (whether genetic, infectious or injurious), it is highly likely that 
alterations in synaptic stability play an important role in the onset of neurodegeneration in 
multiple conditions. It has been suggested that these distinct, neurodegenerative stimuli may 
converge on a critical pathway which ultimately leads to synaptic degeneration (Wishart et 
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al., 2006). 
Elucidating the molecular regulators of synaptic stability could therefore provide further 
understanding of potentially conserved mechanisms underlying a wide range of diseases and 
yeild a valuable source of drug targets for the development of therapeutic intervention. 
 
 
1.5 Mechanisms of synaptic vulnerability 
It is evident now that synapses play an important role on the onset of neurodegeneration in 
multiple conditions as indicated above. Yet, the molecular mechanisms underlying this 
exceptional vulnerability remains in its infancy. Nevertheless, the increasing development of 
animal models and the improvement of the sensitivity of experimental techniques, have 
provided some clues into the potential pathological pathways and/or regional subcellular 
organelles contributing to synaptic stability. 
 
1.5.1 “Synaptosis” 
As explained in section 1.2 and Fig. 1.1, “synaptosis” is the term proposed to name the 
specific molecular cascades underlying synaptic degeneration (Gillingwater et al., 2001). 
Evidence indicates that apoptotic pathways can be initiated locally at the synapse after  
addition of proapoptotic components such as staurosporine, etoposide, and amyloid A 
peptide  (Mattson et al., 1998, Gilman et al., 2003, Gylys et al., 2004). However, the apoptotic 
pathways localised in the synapse may have a different nature from those in somatic 
compartments, since the global deletion of the apoptotic factor Bax, was able to rescue 
neuronal soma but not synapses (Chiesa et al., 2005). Moreover, the endogenous biochemical 
transduction signalling residing in the synapse can stop the activation of apoptotic cascades. 
For instance, by means of neurotrophic factors exhibiting synaptoprotective effects via 
activation of anti-apoptotic cascades (Mattson, 2000). 
 
1.5.2  Mitochondrial homeostasis 
Mitochondria are the power-houses of cells generating [adenosine-triphosphate (ATP) 
production] through coupled, electron-transport chain and oxidative phosphorylation. 
Mitochondria also display key functions including (but not limited to), apoptosis, heme and 
steroid synthesis, thermogenesis and Ca2+ buffering (Scheibye-Knudsen et al., 2015).  
Mitochondria are dynamic organelles constantly undergoing fission and fusion, and 
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exhibiting complex motility patterns (Sheng, 2014). They get produced in the cell body and 
are continuously trafficked through the axon to the distal synaptic compartments. Defects in 
the machinery regulating the complex antero/retrograde transport is thought to contribute to 
the pathogenesis of a number of neurodegenerative diseases (Chan, 2006, Itoh et al., 2013). 
 
Importantly, mitochondria can switch from being stationary to motile in response to 
synaptic function or metabolic changes (Sheng, 2014). It is believed that a population of 
mitochondria accumulate in the synapse displaying unique properties due to environmental 
adaptation (Gillingwater et al., 2013, Ly et al., 2006, Bertoni-Freddari et al., 1993). These 
differential properties between non-synaptic and synaptic mitochondria includes different 
Ca2+ buffering capabilities which are essential for neurotransmission (Brown et al., 2006), 
enzymatic activities (Lai et al., 1977) and very different proteome composition (Graham et 
al., 2017). 
 
Mitochondrial deficiencies affect all of these functions and will therefore impact synaptic 
function and stability (DiMauro et al., 2008). Furthermore, some authors suggested that 
these stationary mitochondria in synapses are older on average that those found in somatic 
compartments (Bertoni-Freddari et al., 1993, Brown et al., 2006) and consequently, this pool 
of “aged” mitochondria may be vulnerable to pathogenic insults (Bertoni-Freddari et al., 
1993). In fact, mitochondria have been implicated in the pathogenesis of many diseases 
where synapses are an early pathological target including Alzheimer’s (Lee et al., 2012), 
Parkinson’s (Ferrer et al., 2012), Huntington’s (Reddy et al., 2012) and the NCLs (Luiro et 
al., 2006). 
 
Altogether, it seems evident that mitochondria play an important role in synaptic stability as 
defects in its transport and/or function may contribute to the pathogenesis of multiple 
neurodegenerative diseases. Therefore, mitochondrial proteins represent attractive targets as 
potential modulators of synaptic stability.  
 
1.5.3 Metabolic pathways 
Accumulating evidence show a strong correlation between metabolism and 
neurodegeneration. The brain accounts for 20% of an individual’s energy expenditure at rest 
and 70-80% is spent by neurons (Harris et al., 2012). 
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This is not surprising taking into account the strong energetic requirements of brain cells 
needed to perform their complex cognitive functions. To maintain this constant biochemical 
milieu, membrane transporters, enzymatic pathways and regulatory networks work in a 
coordinated manner to maintain thermodynamic equilibrium and to avoid potentially toxic 
elevations of metabolite levels (Yudkoff, 2017).  
 
Most brain energy is used on synaptic transmission, therefore an adequate supply of ATP 
must be provided to assure an optimal, synaptic function (Harris et al., 2012). In addition to 
the production of ATP, glucose is also used for the generation of the metabolic intermediates 
required for the synthesis of fatty acids and other lipids needed for membrane and myelin 
synthesis (Jones et al., 1975, Ramsey et al., 1972). Importantly, neurons also require a correct 
balance of amino acids to ensure protein synthesis and neurotransmitter production (Vrba et 
al., 1962). As well as this, it has recently been found that branched-chain amino acids play an 
important role in the synthesis of glutamate. The replacement of neuronal glutamate is 
essential to ensure correct neurotransmission in excitatory synapses (Yudkoff, 2017), and 
any defects in its metabolism may impair synaptic function. 
 
Moreover, a growing number of reports are indicating that mid-life obesity is a risk factor for 
later-life development of dementia, Parkinson's (Abbott et al., 2002), Alzheimer's disease and 
vascular dementia (Hassing et al., 2009, Kivipelto et al., 2005, Xu et al., 2011). Evidence 
shows that decrease in glucose and oxygen metabolic rates of brain cells occur during normal 
aging (Hoyer, 1982b) and are more disrupted in diseases such as AD, ALS, PD and HD 
(Hoyer, 1982a). Furthermore, studies showed that ALS patients are hypercatabolic and have 
increased energy expenditure at rest. Additionally, glucose intolerance, insulin resistance and 
hyperlipidemia have all been identified in ALS patients (Camandola et al., 2017). 
 
Overall, it seems evident that bioenergetic pathways play an essential role in brain cells and 
especially in synaptic stability. Defects in any of these pathways may contribute to regulating 
synaptic vulnerability and for promoting pathogenesis in multiple, neurodegenerative 
diseases. Therefore, proteins regulating metabolic processes can also be considered as 
potential regulators of synaptic stability. 
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1.5.4 Protein homeostasis 
A growing number of reports indicate the high sensitivity of synapses to proteostasis 
imbalance. Recent studies highlighted that different proteolytic pathways participate in the 
synaptic homeostatic maintenance including: autophagy, molecular chaperones, lysosomal 
degradation or the ubiquitin proteasome system  (Rubin et al., 2000, Wang et al., 2017).  
As indicated in the sections above, the synaptic terminals are relatively small, but are packed 
with an extremely dense combination of dynamic organelles and molecular machinery 
needed for synaptic function. The synaptic proteome requires highly coordinated regulation 
in order to fulfil its bioenergetic demands and/or vesicle/neurotransmitter release. This 
demanding activity has been associated with a high susceptibility to molecular damage (Ellis, 
2001). The polarized nature of neurons has provided the synapse with mechanisms to 
develop its own local protein quality control pathways to regulate protein balance. 
Deregulation in these pathways has been associated with the pathogenesis of multiple 
neurodegenerative diseases (Neefjes et al., 2014, Bayer, 2015). 
Protein-protein interactions are essential for the correct functioning of molecular networks. 
Chaperones are a protein family whose core function is to assist the folding/unfolding and 
assembly/disassembly of macromolecular structures. They prevent or reverse incorrect 
interactions that may occur between macromolecular surfaces and the intracellular 
environment as a consequence of conformational changes. Therefore, chaperones assure that 
other protein complexes do not fail in carrying out an specific biological function (Ellis, 
2006).  
An example would be CSPα. This is a synaptic chaperone that forms a complex with heat 
shock cognate 70 – a small glutamine-rich tetratricopeptide repeat-containing protein (CSP-
Hsc70-SGT). This complex’s function is to maintain the correct functioning of the synaptic 
vesicle and exocytic machinery by refolding the SNARE complex into its competent state 
(Sharma et al., 2011). CSPα deficiency results in presynaptic degeneration at both peripheral 
and central nervous system synapses (Fernández-Chacón et al., 2004, Schmitz et al., 2006). 
Moreover, mutations in DNAJC5 (encoding CSPα) have been found to be the cause of 
autosomal-dominant, adult-onset, neuronal ceroid lipofuscinosis (CLN4 disease) (Nosková 
et al., 2011). 
 
The UPS is one of the major protein degradation pathways and targets misfolded or 
unwanted proteins to avoid cytotoxic effects (Hershko et al., 1998). Whilst UPS may play an 
essential role in somatic compartments preventing protein aggregates linked to multiple 
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neurodegenerative diseases (Zheng et al., 2016), it also plays a role in synapse formation and 
post-synaptic plasticity mechanisms (Haass et al., 2007, Ehlers, 2003). Moreover, studies by 
our laboratories have reported that the disregulation of ubiquitination homeostasis 
promoted SMA and its pharmacological targeting rescued the synaptic phenotype in animal 
models (Wishart et al., 2014). 
 
The other main proteolytic pathway at the synapse is via lysosomal degradation. Lysosomal 
substrates include misfolded proteins, protein aggregates and dysfunctional organelles 
(Wang et al., 2017). Importantly, macroautophagy is known to be required during 
synaptogenesis and participates in synaptic function (Shen et al., 2015). Collectively, reports 
seem to indicate that lysosomal degradation is upregulated upon presynaptic activity. 
Interestingly, recent findings indicate that lysosomes have more roles beyond their 
traditional degradation function. A growing body of evidence suggests that lysosomes serve 
as a Ca2+ storage organelle mediating various neuronal functions (Galione, 2015, Galione et 
al., 2010). It has been recently revealed that lysosomes mediate activity-dependent Ca2+ 
signalling in dendrites where they play an important role in long-term maintenance of 
structural plasticity (Padamsey et al., 2017). 
 
Furthermore, the essential role of lysosomes in autophagic pathways relates these organelles 
to several cellular processes which are implicated in multiple neurodegenerative diseases 
(Settembre et al., 2013). The lysosomal storage disorders (LSDs), are caused by genetic 
defects in specific lysosomal components that lead to the accumulation of undegraded 
material in the lysosomal lumen. This is followed by lysosomal dysfunction in several tissues 
that ultimately leads to neurodegeneration. However, the mechanisms by which the 
lysosomal storage material translates to neuronal loss is not understood. The NCLs are a 
group of LSD where synapses have been described to be an early pathological target, 
highlighting the connection between synaptic stability and lysosomal function in 
neurodegeneration pathogenesis (Cooper et al., 2015, Wishart et al., 2006). Lyosomal and 
autophagy dysfunction have also been implicated in the mechanisms underlying other 
synaptopathies previously mentioned here such as AD, PD and HD (Wong et al., 2010). 
 
Accumulating evidence suggests lysosomal signalling and autophagy are key to maintaining 
protein homeostasis in neurons. Moreover, lysosomes play significant regulatory roles at the 
synapse beyond its traditional, degradative function. Taking everything together, it all 
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1.6 The neuronal ceroid lipofuscinoses as a model of 
neurodegenerative disease 
In order to further investigate the critical pathways regulating synaptic stability and 
degeneration, animal models able to reproduce the human disease, are needed. The 
polygenic nature, and/or complex aetiologies (with potential implicated environmental 
components, not completely understood), of most prevalent neurodegenerative disease 
hampers the development of “good” animal models. This is the case for the more 
common/high profile neurodegenerative diseases such as Alzheimer’s (Escott-Price et al., 
2015) and Parkinson’s (La Cognata et al., 2017) diseases as well as many psychiatric disorders 
(Gandal et al., 2016). 
 
For this reason, in this project, we turned to the neuronal ceroid lipofuscinoses, a group of 
mono-genetic neurodegenerative disease whose individual prevalences are comparatively 
low, but whose genetic cause is very well understood. This has facilitated the development of 
mutant animals which replicate many aspects of the human disease (Mitchison et al., 1999, 
Pontikis et al., 2004, Cotman et al., 2002, Gupta et al., 2001, Kielar et al., 2007, Partanen et 
al., 2008). The study of animal models has shed light on the pathogenesis of these diseases 
and have highlighted that synaptic pathology occurs very early in disease progression before 
neuronal loss takes place (Partanen et al., 2008, Kielar et al., 2009, Koch et al., 2011, Cooper 
et al., 2015). Thus, animal models of NCL could serve as a tool to understand the 
mechanisms underlying neurodegeneration in NCL but also in other conditions where 
synapses are an early pathological target (Llavero Hurtado et al., 2017). 
 
The NCLs or Batten disease, are the most frequent, autosomal-recessive neurodegenerative 
disease and form of dementia in childhood (Goebel, 1995). The term “NCL” currently 
encompasses up to 13 disease subtypes, which are grouped together due the lysosomal 
accumulation of autofluorescent storage material, distinct ultrastructural properties, broadly 
similar pathology and clinical features and a severe neurodegenerative phenotype (Cooper, 
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2003, Cooper, 2010). Incidence in the USA is estimated at 1.6-2.4/100,000 whereas in 
Scandinavian countries it is 2-7/100,000 (Uvebrant et al., 1997, Mole et al., 2011). As 
mentioned before, synaptic disruption is a key early event in NCL, accurately predicting the 
distribution of subsequent neuronal loss (Kielar et al., 2009, Virmani et al., 2005, Partanen et 
al., 2008, Koch et al., 2011, Cooper, 2010). 
Although the NCL genes are ubiquitously expressed throughout the body, the most 
obviously affected tissues are neurological based. This feature is shared by other 
monogenetic, neurodegenerative conditions in which the causative mutations  ubiquitously 
affect expressed proteins [e.g. the survival motor neuron (SMN) protein in spinal muscular 
atrophy (SMA) (Hamilton et al., 2013)]. Yet, the reasons why neurons appear to be 
particularly vulnerable to defects in such broadly expressed proteins is not understood. 
 
As mentioned above, the knowledge of the underlying genetic cause and/or storage material 
composition has provided a base for the basic understanding of the pathogenesis and their 
correlation to the clinical progression of the disease. Also, it has aided the design of gene 
replacement therapies and the development of animal models (Mole et al., 2005, Cooper et 
al., 2006, Bond et al., 2013). However, the underpinning pathways and molecular cascades 




Mutations in the CLN1/PPT1 and CLN3 genes were the first ones to be discovered as the 
cause of infantile (INCL) and juvenile NCL (JNCL), respectively (The International Batten 
Disease Consortium, 1995, Vesa et al., 1995). Other forms were later added to the list of 
NCLs: CLN2/TPP1(classical late-infantile NCL -LINCL) (D.E. Sleat, 1997), CLN5 (Minna 
Savukoski et al., 2008) and CLN6 (variant LINCL) (Wheeler et al., 2002, Gao et al., 2002), 
CLN7/MFSD8 (Siintola et al., 2007), CLN8 (Susanna Ranta et al., 1999), CLN10/CTSD 
(congenital NCL) (Siintola, 2006) and more recently 3 adult forms; CLN4/DNAJC5 
(Nosková et al., 2011), CLN11/GRN (K.R. Smith, 2012), CLN13/CTSF (Smith et al., 2013), 
an infantile; CLN14/KCTD7 (Staropoli et al., 2012) and a juvenile; CLN12/ATP13A2 (Bras et 









symbol Locus Protein Protein Name Phenotypic spectrum 
CLN1 PPT1 1p34.2 Palmitoyl protein thioesterase 1 I, LI, J, A 
CLN2 TPP1 11p15.4 Tripeptidyl peptidase 1 LI, J, P 
CLN3 CLN3 16p11.2 CLN3 J, P 
CLN4 DNAJC5 20q13.33 DnaJ homolog/CSPα A (Parry disease) subfamily C member 5 
CLN5 CLN5 13q22.3 CLN5 LI, J, P, A 
CLN6 CLN6 15q23 CLN6 LI, P, A (Kufs type A) 
CLN7 MFSD8 4q28.2 Major facilitator superfamily 
LI, J domain-containing 
protein 8 
CLN8 CLN8 8p23.3 CLN8 LI, P 
CLN10 CTSD 11p15.5 Cathepsin D C, LI, J, A 
CLN11 GRN 17q21.31 Granulins A 
CLN12 ATP13A2 1p36.13 Probable cation-
transporting 
CLN12 J ATPase 13A2 
CLN13 CTSF 11q13.2 Cathepsin F A (Kufs type B) 
CLN14 KCTD7 7q11.21 BTB/POZ domain-containing I protein KCTD7 
A: adult; C: congenital; I: infantile; J: juvenile; LI: late-infantile; P: protracted.  
 
 
1.6.2 Differential progressive regional/neuronal vulnerability pathology 
As mentioned above, the growing knowledge of the NCL genetic causes have facilitated the 
generation of animal models which serve as tools for understanding the disease pathogenesis 
and for investigations into novel therapeutic interventions (Bond et al., 2013, Faller et al., 
2015, Shacka, 2012, Cooper et al., 2006, Palmer et al., 2013, Neverman et al., 2015). Despite 
the limitations of these models, (ie. in mice, the level of degeneration is never as strong as in 
human, possibly due to the differences in ageing between species), they have provided 
insights regarding the progressive events occurring throughout the time-course of disease 
progression.  
 
Although atrophy is widespread throughout the brain in terminal disease (Mitchison et al., 
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1999, Kuhl et al., 2013), differential vulnerability can be detected across brain regions and 
their respective resident cell types and associated pathways involved at early stages of the 
disease (Cooper et al., 2015). This differential degenerative progression follows similar 
patterns in the vast majority of NCL murine models: during pre-symptomatic stages there is 
an early selectivity for relay neurons within the thalamic nuclei followed by the 
corresponding cortical areas (Pontikis et al., 2005, Kielar et al., 2007, Partanen et al., 2008, 
Mitchison et al., 1999, Kuhl et al., 2013, Pontikis et al., 2004, Kuronen et al., 2012, Morgan et 
al., 2013), as well as GABAergic hippocampal interneurons and Purkinje neurons (Mitchison 
et al., 1999, Pontikis et al., 2004). These reports in murine models regarding the vulnerability 
of the thalamus correlates with MRI studies in human patients showing alterations in 
thalamic areas at “pre-clinical” stages (Santavuori et al., 2001, Autti et al., 2007, Järvelä et al., 
1997). Interestingly, a recent report by Shyng et al., denoted unexpected early and profound 
neuropathological changes taking place in all parts of the spinal cord of Ppt1−/− mice. 
Crucially, similar pathology was also present in human CLN1 spinal cord autopsy material 
(Shyng et al., 2017). 
 
Differential regional/neuronal vulnerability is a shared event in a great number of 
neurodegenerative diseases in which some brain regions seem affected earlier than others, 
such as in Alzheimer (Wang et al., 2010, Khan et al., 2014, Braak et al., 1995), Parkinson 
(Surmeier et al., 2017) or Huntington diseases (HD) (Lewandowski et al., 2013, Sieradzan et 
al., 2001).  
 
Yet, our understanding of the mechanisms governing the differential vulnerability across 
brain areas/cell types in the NCLs, as well as many other neurodegenerative diseases is not 
completely understood. For this reason, in this project such differential vulnerability is taken 
into consideration in the experimental design, the analyses and interpretation of the data. 
 
1.6.3 Mechanisms of neurodegeneration in NCLs 
Even though the genetic cause of the distinct forms of NCLs has been well-characterized, 
little is known about the functions of each gene product [reviewed in (Carcel-Trullols et al., 
2015, Kollmann et al., 2013)]. This has hampered the elucidation of the mechanisms 
underlying neurodegeneration in the NCLs.  
Traditionally, researchers tended to focus on the most obvious pathological hallmarks of the 
NCLs, which is the auto-fluorescence storage material (AFSM) assuming it is toxic to 
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neurons. However, it is now accepted that there is no relationship between the storage 
material and the distribution of neuronal loss [reviewed in (Cooper, 2010, Cooper et al., 
2006, Palmer et al., 2013) ]. Nevertheless, AFSM is still used as biomarker for therapeutic 
efficacy of novel therapies (Sarkar et al., 2013, Levin et al., 2014), even though in some cases 
where storage material was cleared, no improvement of brain atrophy was confirmed (Levin 
et al., 2014). 
 
Since the genetic cause for the NCLs is known, it seems logical to put efforts into the 
development of enzyme replacement (Chang et al., 2008b, Hu et al., 2012, Lu et al., 2015, 
Meng et al., 2012) and gene therapies (Griffey et al., 2004, Griffey et al., 2006, Macauley et al., 
2012, Passini et al., 2006, Shyng et al., 2017) [reviewed in (Neverman et al., 2015)]. However, 
it would also be valuable to investigate the downstream consequences of the NCL- deficient 
proteins that lead to disease. This will allow the development of mechanism-based therapies, 
especially important for transmembrane protein-deficiency NCLs (Cooper et al., 2015) (Fig. 
1.3). On the other hand, increased life-span following enzyme replacement or gene therapies, 
could lead to patients developing pathology in other organs, which, otherwise, would have 
been masked by the neuronal-based pathology. In this case, mechanistic-based therapies 
could act synergistically together with gene/enzyme therapies. It is therefore essential to 
define the disease mechanisms in order to find drug targets for therapeutic intervention. 
Animal models are key tools for this purpose. The study of their corresponding phenotypes 
(either morphologically or molecularly) presents many difficulties when investigating the 
downstream consequences of the genetic insults of any disease. It is very challenging to tell 
which phenotypes are a direct consequence of the genetic insult.  This is because phenotypes 
may reflect underlying mechanisms or compensating for cell death, and/or alternatively, be a 
consequence of a secondary effects of the already ongoing neurodegeneration. These are the 




Fig. 1.3. Mechanisms of neurodegeneration and therapies in the NCLs. This schematic 
represents the cascades of events leading to neurodegeneration in the NCLs and the different 
therapeutic points where one could intervene.  The NCLs are caused by monogenetic mutations. 
The loss of function of the protein product of that gene, will cause a series of molecular 
downstream consequences at the protein level. Some of these pathways will lead to 
neurodegeneration (ND). There will presumably be other molecular perturbations which are not 
directly related to neuronal cell death (ie. those leading to accumulation of storage material). In 
this context, the organism’s proteome will also influence (and be influenced by) this cascade of 
events. Amongst all this we identify neuroprotective proteins, and modifiers of the disease which 
could be potential mechanistic targets for drug development. 
 
 
The well characterised progressive spatio-temporal neuronal loss patterns of many animal 
(and particularly mouse) models of NCL offer key tools to address this issue. Differential 
vulnerability has been defined across brain areas and subcellular compartments (Kielar et al., 
2007, Kielar et al., 2009, Partanen et al., 2008, Kuronen et al., 2012, Morgan et al., 2013, 
Pontikis et al., 2005). These pathological events can then be used to design experiments with 
the objective to define mechanistic pathways. This information will relate to results in 
Chapter 3 & 4 where we made use of the differential spatio-temporal vulnerability patterns 
 19 
for experimental design and data analysis and interpretation. 
 
Currently, there is/are no clear pathway/s relating the loss of function of the NCL-related 
genes and neuronal loss. However, some potential mechanisms have been proposed to be 
involved. 
 
1.6.3.1 Synaptic vulnerability in NCL 
We use the NCLs as a model of synaptic degeneration because as stated above, early synaptic 
pathology has been described in various NCLs forms. Thus, synaptic vulnerability has been 
proposed as one of the potential targetable factors underlying pathogenesis in the NCL 
(Cooper et al., 2015). 
 
Interestingly, although both PPT1 and CLN3 genes are expressed in the lysosome system 
(encoding a soluble and transmembrane protein respectively) in non-neuronal cells, they 
have also been shown to localise in the synaptic compartments of neurons (Luiro et al., 2001, 
Kim et al., 2008b). Somatic endocytosis and trafficking pathways have been shown to be 
disrupted in fibroblast cultures and mouse models (Luiro et al., 2004, Fossale et al., 2004, 
Ahtiainen et al., 2006). Synaptic vesicle trafficking uses the same molecular machinery as the 
intracellular trafficking between ER and Golgi as well as endosome-lysosomal compartments, 
and therefore is also susceptible to perturbation. (Palmer et al., 2013). Furthermore, synaptic 
vesicles contain large amounts of palmitoylated proteins which regulate endo/exocytosis 
machinery and are potential targets of PPT1 (Prescott et al., 2009). Authors have reported a 
decrease in the synaptic vesicle pool and size  in PPT1 disease (Virmani et al., 2005, Kim et 
al., 2006), suggesting that PPT1 may play a role in the modulation of endocytotic pathways at 
the synapse. Conversely, in Cathepsin D deficient mice brains, models of congenital NCL, 
there is an increase in the number of synaptic vesicles (Koch et al., 2011). 
Moreover, PPT1 deficiency has been reported to cause difficulties in the recycling of synaptic 
vesicle components leading to a progressive loss of releasable vesicles and defects in 
neurotransmission (Kim et al., 2008b, Virmani et al., 2005). 
 
Studies in murine models of NCLs have revealed progressive, early synaptic loss starting in 
the thalamus and followed later in corresponding cortical areas in Ppt1-/-, Cln6-/- or CtsD-/-, 
models of CLN1/INCL, variant LINCL and CLN10/congenital NCL respectively (Partanen et 
al., 2008, Kielar et al., 2009, Koch et al., 2011). Hippocampal structures seem to also be 
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affected early, although to a lesser extent than seen in the thalamus (Kuhl et al., 2013). So far, 
synaptic vulnerability seems to mimic the regional-specific neuronal loss in many NCL 
forms (Pontikis et al., 2005, Kielar et al., 2007, Partanen et al., 2008, Mitchison et al., 1999, 
Kuhl et al., 2013, Pontikis et al., 2004, Kuronen et al., 2012, Morgan et al., 2013) (see section 
1.3.2), highlighting again that synaptic pathology precedes neuronal loss. 
 
Although, these synaptic phenotypes have not been systematically characterized across all 
forms of NCL, it is noticeable that synaptic pathology is an important event in multiple 
forms of NCLs. However, it would be necessary to have further studies to determine if 
synapses follow exactly the same patterns of vulnerability in all NCL forms. 
 
1.6.3.2 Neuroinflammation 
Synaptic changes are not the only early pathological event occurring in the NCLs. It is now 
evident that neuroinflammation plays a central role in many neurodegenerative diseases, 
including NCL [Reviewed in (Ransohoff, 2016, Palmer et al., 2013)]. Glial activation has been 
reported to precede neurodegeneration in both sheep  (Tammen et al., 2006, Oswald et al., 
2005) and mouse models of NCL (Kielar et al., 2007, Pontikis et al., 2004, Pontikis et al., 
2005, Griffey et al., 2006, Macauley et al., 2011, Kuronen et al., 2012). Therefore, glia could 
be contributing to mechanisms triggering neuronal loss. In fact, in Cln3 mouse models it was 
detected that there is an early low-level activation of astrocytes and microglia which appear 
to be attenuated as a result of a failure in the morphological transformation of these cells 
(Pontikis et al., 2004, Pontikis et al., 2005). Thus, it appears that glia are themselves 
dysfunctional per se, contributing to neuronal loss (Parviainen et al., 2017). 
 
Studies in Cln3 mutant mice have shown that immunosuppressive therapies are able to 
rescue motor performance (Seehafer et al., 2011). These findings using animal models were 
translated into clinical trials using mycophenolate mofetil with CLN3 patients. It all indicates 
an important role in inflammation in the NCL pathogenesis. Nevertheless, inflammatory 
cascades are very complex and have multiple points of activation. Therefore, it would be 
necessary to have an in-depth characterisation of the specific steps where the inflammatory 
cascade is disrupted in the different forms of NCL. This will allow a strategic development of 
therapeutic interventions. 
 
Whilst neuroinflammation pathways are very important, it all indicates that the dysfunction 
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in both glia and neurons have a role in the on-going pathological cascade of events 
contributing to exacerbate disease progression. The fact that both synaptic pathology and 
neuroinflammation happen at very similar times in the NCL mouse models points at a 
collaborative contribution to neurodegeneration. Therefore, therapeutic strategies will 
possibly have to be addressed at both glia and neurons. Cooper and colleagues have 
developed cell-type based experiments to study the contribution of each of these cell types to 
the NCL pathogenesis (Cooper et al., 2016). The results from these experiments are starting 




As pointed out in section 1.5.4, autophagy is the mechanism by which macromolecules, 
organelles, toxic protein aggregates and intracellular pathogens get degraded via the 
lysosomal/vacuolar system of the cell (Mizushima et al., 2008). Autophagy is also one of the 
three mechanisms by which cell death may take place (Yuan et al., 2003). Abnormal 
autophagy has been described in CtsD (Mitchison et al., 2004, Koike et al., 2005), Cln3 (Cao 
et al., 2006) and Cln6 (Thelen et al., 2012, Cao et al., 2011) mutant mice, contributing to 
disease pathogenesis. The lipidated autophagosomal marker microtubule-associated protein 
1 light chain 3-II (LC3-II) is increased in Cln3 and Cln6 mutant mice (Cao et al., 2006, 
Thelen et al., 2012), suggesting a disruption in autophagic pathways in these mice. Some 
authors believe that the disruption of the autophagic vacuolar maturation leads to activation 
of autophagy as pro-survival response (Cao et al., 2006). Others suggest that the defects in 
autophagy promotes neuronal cell death (Thelen et al., 2012). More studies are needed to 
clarify the role of lysosomal/vacuolar system in the mechanisms of pathogenesis of NCL. 
 
1.6.3.4 Mitochondrial dysfunction 
There is a growing body of evidence suggesting that mitochondrial dysfunction and 
oxidative stress are related to NCL pathogenesis [reviewed in (Jolly et al., 2002)]. 
Mitochondria started to be a focus of attention of the NCL community due to the fact that 
the main storage molecule detected in the AFSM in most NCL forms was identified as the 
subunit C of the ATP synthase (Palmer et al., 2013). However, mitochondrial perturbances 
have now been identified in various NCL models as well as in patients suggesting that other 
mechanistic pathways are involved in mitochondrial malfunctioning which are independent 
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of the storage material composition (Jolly et al., 2002)  
Morphological studies have revealed the presence of enlarged mitochondria in GABAergic 
neurons of the neocortex, claustrum and basket cells of the cerebellum in the English setter 
dog model (Cln8 mutant) (March et al., 1995). Mitochondrial shape abnormalities have also 
been detected in cerebellar precursor cells carrying the Cln3∆ex7/8 mutation (Fossale et al., 
2004). Studies in mouse models of different forms of NCL also found increased levels of 
reactive oxygen species (ROS) in Cln3∆ex7/8 (Herrmann et al., 2008), Ppt1-/- (Kim et al., 2010) 
and mnd/Cln8 mouse models (Guarneri et al., 2004). The Cln3 protein has been recently 
found to localise in mitochondria in Drosophila (Mohammed et al., 2017) where it seems to 
have a role in the response towards oxidative stress as indicated by experiments in Cln3- 
deficient Drosophila (Tuxworth et al., 2011). 
 
Molecular and omics studies also indicated perturbations in genes related to mitochondrial 
functions. In this case there are studies of gene expression in the eye of a Cln3 disease mouse 
model, where authors found a decrease in expression of multiple mitochondrial genes 
associated to energy production (Chattopadhyay et al., 2004). Transcriptomic studies in Cln3 
deficient embryonic primary cell cultures also indicated disturbances in mitochondrial-
related pathways (Luiro et al., 2006).  Moreover, more recent proteomic studies in Ppt1-
deficient mice also showed perturbations in mitochondrial-related cascades (Tikka et al., 
2016). 
 
Functional assays regarding mitochondrial respiratory chain activities have also been studied 
in CLN1 patient fibroblasts, indicating a reduced activity (Das et al., 1996). Later studies by 
Das et al. also detected perturbances in ATP synthase activity in CLN1, CLN2 and CLN3 
cells (Das et al., 1999). 
 
Taken all together, mitochondrial dysfunction reported at morphological, molecular and 
functional level in both animal models and human patients seem to be potentially 
contributing to NCL pathogenesis. Nevertheless, the specific pathways mediating these 
perturbations remain to be elucidated. 
 
 23 
1.6.4 CLN1/PPT1 disease 
1.6.4.1 PPT1 gene and protein 
The PPT1 gene codifies for Palmitoyl protein thioesterase 1 (PPT1), a soluble lysosomal 
enzyme whose main function is to remove palmitate residues from S-acylated proteins, as 
demonstrated in vitro (A.K.A depalmitoylation) (Vesa et al., 1995, Camp et al., 1993). 
However, the specific function of the PPT1 substrates is not completely understood. To date, 
67 mutations have been described in CLN1 disease (http://www.ucl.ac.uk/ncl), causing a loss 
of function of PPT1 leading to infantile onset NCL (Vesa et al., 1995).  
 
PPT1 expression is ubiquitous (Ahtiainen et al., 2003, Camp et al., 1993) and is not enriched 
in any human tissue type (Chattopadhyay et al., 2000). However, its expression increases in 
the human embryonic brain from the beginning of cortical neurogenesis through to cortical 
development. Therefore, it has relevant implications for neuronal development (Heinonen et 
al., 2000). Besides its lysosomal localization, in neurons PPT1 is also present in axons 
(Ahtiainen et al., 2003) and at the presynaptic level is especially enriched in synaptosomes 
and in synaptic vesicles where it has implications in the regulation of the synaptic vesicle 
machinery (Lehtovirta et al., 2001, Kim et al., 2008a). Moreover, palmitoylation has 
important implications in intracellular protein sorting and trafficking, cell signalling 
(Greaves et al., 2007) and apoptotic pathways (Nita et al., 2016). Overall, the reported 
localisation and function of PPT1 suggests it has a potential role in regulating synaptic 
neurotransmission. 
 
1.6.4.2 PPT1 clinical progression 
PPT1 deficiency leads to infantile NCL (INCL), the most common in Finland (Gupta et al., 
2001, Kielar et al., 2007, Kielar et al., 2009, Santavuori, 1998) and the U.S. population (Sleat 
et al., 2016). The majority of patients follow the classic INCL clinical spectrum and start 
developing their first symptoms within the first two years of life. However, some individuals 
may have late-infantile, juvenile, and even adult-onset NCL (Ramadan et al., 2007, Van 
Diggelen et al., 2001). Classic INCL patients are born completely normal and start 
manifesting delays in development, irritability, deceleration of head growth, central 
hypotonia and defects in fine motor skills at the end of the first year of life. This is followed 
by myoclonic jerks and optic atrophy with subsequent vision loss (Mole et al., 2005). Death 
usually occurs between 8 and 13 years old. Studies by brain magnetic resonance imaging 
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(MRI) showed low intensity signals early on in thalamic areas, whereas with T-weighted 
imaging there is a high intensity signal in white matter later on in disease progression 
(Vanhanen et al., 2004). 
Saposins A and D, also named sphingolipid activator protein, are the most abundant 
component of the storage autofluorescence material (Tyynelä et al., 1993), with a hallmark 
ultrastructure of granular omiophilic deposits (GRODs) (Santavuori et al., 1973). 
 
1.6.4.3 Ppt1 mouse models 
Two distinct mouse models targeting PPT1 genes have been generated. The first one was 
produced by the insertion of a neomycin cassette into exon 9 (Gupta et al., 2001), whereas 
the second one was generated by the deletion of exon 4 by means of Cre/lox technique 
(Jalanko et al., 2005). Both approaches lead to the complete loss of PPT1 enzymatic activity 
and/or protein levels (Gupta et al., 2001, Jalanko et al., 2005). 
 
For this study (Chapter 4&6), we utilised the first one generated by Gupta et al. 2001. Ppt1 
null mice (Ppt1-/-) exhibit various aspects of the human disease. It presents an abundant 
accumulation of autofluorescent storage material with GROD ultrastructure as well as 
increased levels of saposins A and D (Gupta et al., 2001).   Ppt1-deficient mice display 
progressive onset of seizure, decline of motor coordination, vision loss correlating with the 
marked decrease of brain mass and a premature death between 8-9 months (Gupta et al., 
2001, Bible et al., 2004, Macauley et al., 2009). 
 
They exhibit a dramatic widespread neurodegeneration by terminal stage. However, as stated 
before, studies have indicated a specific spatio-temporal pattern of neuronal vulnerability. 
Thalamus, hippocampus and cortical areas are the areas which present more pronounced 
neuronal loss and marked reactive gliosis (Bible et al., 2004, Kielar et al., 2007, Kuhl et al., 
2013). There is also an early loss of Purkinje neuron population in the cerebellum followed 
by granular cell loss (Gupta et al., 2001, Bible et al., 2004, Macauley et al., 2009). Crucially, 
for the purpose of this work the spatio-temporal synaptic loss profile of the Ppt1-/- mice have 
already been characterized (Kielar et al., 2009). Kielar and colleagues showed that an early 
synaptic loss takes place in the thalamic nuclei (3 months) and only later in the cortex (5 
months) preceding neuronal loss (Kielar et al., 2007, Kielar et al., 2009). The loss of thalamic 
relay neurons that innervate the cortex (S1BF and V1) may explain the visual defects 
detected in the disease. An enhancement of reactive gliosis as well as oxidative stress has also 
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been  reported and may contribute to neuronal loss (Bible et al., 2004, Kim et al., 2006, Kielar 
et al., 2007, Macauley et al., 2009).  
 
Overall, these studies highlight the progressive and differential vulnerability of synaptic 
populations across brain regions in this model (see also sections 1.6.2 & 1.6.3.1). 
 
Fig.1.4. Time-course schematic in Ppt1-/- mice. Ppt1 null mouse present its first signs of synaptic 
pathology at 3 months in thalamus and 5 months in the cortex. These mice die prematurely 




1.6.5 CLN3 disease 
1.6.5.1 CLN3 gene and protein 
Mutations in CLN3 underlie a juvenile form of NCL, the most prevalent form worldwide 
(The International Batten Disease Consortium, 1995, Mitchison et al., 1999, Pontikis et al., 
2004, Kuhl et al., 2013). To date, there are 67 mutations described in CLN3 
(http://www.ucl.ac.uk/ncl). The most common (85% of the patients) is a ~1kb deletion 
resulting in a truncated protein that retains partial activity (Phillips et al., 2005, Kitzmuller et 
al., 2008). 
The CLN3 gene encodes a very hydrophobic putative transmembrane protein whose 
function is not completely understood. Whilst traditionally, CLN3 protein was considered to 
be located mainly in the endosomal/lysosomal membrane (Järvelä I, 1998), more recent 
findings indicate that CLN3 is also located in  synaptosomes (Luiro et al., 2001), lipid rafts 
(Rakheja et al., 2004, Persaud-Sawin et al., 2004), Golgi (Persaud-Sawin et al., 2004), 
mitochondria (Katz et al., 1997), glia (Mohammed et al., 2017) and endothelial cells (Phillips 
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et al., 2005, Katz et al., 1997, Mohammed et al., 2017, Tecedor et al., 2013), where it may play 
other roles such as regulation of oxidative stress (Mohammed et al., 2017, Tuxworth et al., 
2011), glial function (Pontikis et al., 2004, Pontikis et al., 2005) or blood-brain barrier 
homeostasis (Tecedor et al., 2013). For more information regarding localization and function 
of CLN3 see this review (Phillips et al., 2005). 
 
The initial findings regarding the role of CLN3 protein has been found in experiments in 
yeast. Btn1, the CLN3 ortholog in yeast, has been involved in the regulation of vacuolar pH 
(Pearce et al., 1999) Also, in vitro experiments suggested the involvement of CLN3 in 
endocytic membrane trafficking (Luiro et al., 2004). These results were later confirmed in 
human studies (Golabek et al., 2000, Holopainen et al., 2001). In mitochondria, it has been 
suggested that CLN3 assists the processing of mitochondrial membrane proteins (Margraf et 
al., 1999). Interestingly, CLN3 has also been described to have an anti-apoptotic function via 
the C-terminus contributing in the modulation of the cell cycle (Puranam et al., 1999). CLN3 
has also been implicated in the biosynthesis of bismonoacylglycerol phosphate (BMP) 
(Hobert et al., 2007). 
 
1.6.5.2 CLN3 clinical progression 
In humans, the onset of CLN3 disease typically occurs between 4-7 years of age, when loss of 
visual acuity is identified. Later, progressive dementia occurs with learning deficits and 
retardation. During adolescence, motor difficulties start with epilepsy and 
extrapyramidal/parkinsonian signs that include rigidity, hypokinesia and impaired balance. 
Motor deficits lead to complete immobility (Gardiner, 2002, Haltia, 2003, Nita et al., 2016). 
Neuropsychiatric symptoms with anxiety and aggression are also frequently observed 
(Marshall et al., 2005). As no effective treatment is currently available, premature death 
results at a mean age of 24 years old (Järvelä et al., 1997). Its main pathological hallmark is 
the fingerprint shape profile of the autofluorescent lysosomal storage accumulations 
(Wisniewski et al., 1988) and the subunit C of the ATP-synthase protein is the main 
component (SCMAS) of these accumulations (Palmer et al., 1989). 
 
1.6.5.3 CLN3 mouse models 
Four distinct Cln3-deficient mouse models of juvenile NCL have been generated. Two 
knock-out (KO) (Katz et al., 1999, Mitchison et al., 1999) and two knock-in mice (Cotman et 
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al., 2002, Eliason et al., 2007). Whilst KO mice were generated by the targeted disruption of 
either exons 1-6 (Mitchison et al., 1999) or 7-8 (Katz et al., 1999) with a neomycin cassette, 
knock-in mice were produced using Cre/lox approach, mimicking the ~1kb deletion that 
human JNCL have (Cotman et al., 2002). 
For this study (Chapter 3), we also used the Cln3-null mouse generated by Mitchinson et al.  
(Mitchison et al., 1999). Cln3 null mice (Cln3-/-) reproduce various aspects of the human 
disorder (Mitchison et al., 1999, Pontikis et al., 2004). It exhibits the characteristic 
autofluorescent storage material with fingerprint profiles and its main component is the 
SCMAS (Mitchison et al., 1999). Cln3-/- mice exhibit a delayed but progressive onset of 
neuronal loss which follows similar patterns as other NCL mouse models. During pre-
symptomatic stages, there is an early vulnerability in relay neurons within the thalamic 
nuclei followed by other corresponding cortical areas (Mitchison et al., 1999, Kuhl et al., 
2013, Pontikis et al., 2004)(Weimer JM, 2006 #81), as well as GABAergic hippocampal 
interneurons and Purkinje neurons (Mitchison et al., 1999, Pontikis et al., 2004).  
 
In Cln3-/- mice and in patients, an autoantibody against glutamic acid decarboxylase 
(GAD65) was detected. This autoantibody is able to inhibit GAD65 ability to transform 
glutamate into GABA which could contribute to excitotoxicity mechanisms (Chattopadhyay 
et al., 2002) and to the vulnerability of GABAergic neurons in CLN3 disease. It is not clear, 
however, what the role of these auto-antibodies in the pathogenesis of the disease and 
suggests that more studies will be needed to clarify that. 
 
In terms of synaptic pathology, no studies have been published yet. However, preliminary 
experiments by Cooper et al., indicated early synaptic pathology happening in the Cln3-/- 
mice. In Chapter 3, experiments regarding the spatio-temporal synaptic pathology in these 
mice are addressed. 
 
 
1.7 Drug target and biomarker discovery approaches 
1.7.1 Proteomic technologies as a data-driven approach 
Most of the current therapies for neurodegenerative diseases are based on symptomatic 
treatment which may be beneficial at early phases of the disease, but fail to succeed towards 
late stages of the disease (Zhang et al., 2014). Moreover, some of the therapeutics cause large 
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side-effects affecting the daily life of the patient (Corbett et al., 2012, Meissner et al., 2011). 
The reasons why no effective drugs are available to prevent the progression of these diseases 
could be due to the high complexity of the pathogenesis, and the unknown aetiology of many 
of these conditions. Another reason contributing to this lack of successful therapies by both 
pharmaceutical industry and academia is believed to be the current reductionist approach 
taken, that has uniquely focused on preselected molecular targets (Prior et al., 2014, Pangalos 
et al., 2007).  
For these reasons, drug discovery for neurodegenerative disease has been shifted to the 
identification of disease-modifying molecules that may halt or delay disease progression.  
 
In the last few years, mass-spectrometry (MS) based proteomics has seen an exponential 
development and expansion in multiple research areas (Angel et al., 2012). This includes, the 
use of proteomic technologies for drug target and biomarker discovery [reviewed in (Savino 
et al., 2012, Yan et al., 2015, Miller et al., 2014)]. Great progress has been made in MS 
instrumentation, improving the sensitivity, quality and number of identifications in each 
experiment (Angel et al., 2012, Aebersold et al., 2016). MS approaches have become powerful 
tools to investigate the proteome compositional differences between multiple sample types. 
This includes the analysis of specific organelles such as synaptic vesicles, endoplasmic 
reticulum (ER) or Golgi apparatus (Au et al., 2007) as well as its use in the generation of 
interaction maps in simple organisms such as yeast (Collins et al., 2007). Importantly, 
proteomic approaches have become valuable tools for the investigation of disease animal 
models or clinical samples such as cell lysates, tissues or body fluids for the discovery of 
disease-specific drug targets and biomarkers (Savino et al., 2012). 
 
Moreover, MS technologies can also be utilised for the elucidation of the biological pathways 
and mechanistic networks providing insight into underlying disease processes. Such 
transduction pathways are key for the drug discovery pipeline (Kocher et al., 2007, Tedford 
et al., 2009). For instance, the use of proteomic technologies by our laboratory, followed by 
in silico analyses in murine models of SMA, allowed the identification of the ubiquitin 
homeostatic pathway deregulation (Wishart et al., 2014). Targeting this pathway allowed the 
rescue of the neuromuscular system and the whole organism in animal models of the disease 
(Wishart et al., 2014, Powis et al., 2016). 
 
Taken all together, it seems evident that there is potential in the using proteomic 
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technologies for elucidating mechanistic drugs to target neurodegenerative diseases. As 
indicated in Fig. 1.3, proteins as effector molecules in the cell, should not be considered as 
individual entities. Instead, we should take into account that each protein implies a series of 
interactions which lead to complex mechanistic pathways. In the words of Dr. Bruce Alberts 
“Indeed, the entire cell can be viewed as a factory that contains an elaborate network of 
interlocking assembly lines, each of which is composed of a set of large protein machines” 
(Alberts, 1998). Therefore, in the context of disease, genetic mutations will deregulate the 
whole cellular machinery (Fig. 1.3).  
 
As mentioned before, proteomic technologies now provide large proteome coverage. To put 
this data into context, it is necessary to utilise in silico tools that allow filtering, data mining 
and interpretation of the MS data. All the omic approaches developed in the last few years 
have produced large amounts of data which has lead to the generation of multiple databases 
for bioinformatic analysis purposes such as: OMIM (Online Mendelian Inheritance in Man), 
TTD (Therapeutic Target Database) or DrugBank (Yan et al., 2015). Based on these 
databases, bioinformatics gene ontology tools have also been elaborated such as the Database 
for Annotation, Visualization and Integrated Discovery (DAVID) (Huang et al., 2009b, 
Huang et al., 2009a) or Gene Ontology enRIchment anaLysis and visuaLizAtion tool (GOrilla) 
(Eden et al., 2009), as well as network generator tools based on large set of functional 
association data; GeneMANIA (Warde-Farley et al., 2010) or Search Tool for the Retrieval of 
Interacting Genes/Proteins (STRING) (Jensen et al., 2009). Proteomic technologies are also 
able to provide quantitative expression data based on sample normalisation (Patel et al., 
2009, Wang et al., 2012). Such expression data based on ratio or fold-change provides 
another layer of information regarding a specific biological question. Pattern recognition 
softwares such as BioLayout, allow a visualisation of the data based solely on the expression 
data input. It groups proteins/genes based on their expression trend across multiple samples 
(as well as between tissue types or time-points) (Theocharidis et al., 2009). Other commercial 
softwares such as Ingenuity Pathway Analysis (IPA) allow the combination of both 
expression and functional data to generate knowledge-based interaction networks. It also 
allows the prediction of upstream regulators and its activation/inhibition state (Savli et al., 
2008). 
 
Certainly, these tools offer great insight into specific biological questions. However, they also 
imply a number of caveats we should take into consideration when interpreting results. For 
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instance, knowledge-based interaction networks may bias the data generated towards current 
volumes of research which focus on popular pathways/diseases such as cancer signalling 
pathways. Overall, the combination of these bioinformatics tools provides a powerful 
analysis uncovering the significance of omics data and help improve the understanding and 
identification of candidate targets and/or biomarkers within the context of biological 
system/disease. 
 
1.7.2 Phenotypic assessment in drug discovery 
Following good quality proteomic and in silico analysis from animal models or clinical 
samples, we obtained a potential list of promising proteins and pathways. These candidates 
which are perturbed in relation to control samples are potentially involved in the 
mechanisms of neurodegeneration. In order to validate these results and identify potential 
drug targets, further validation is required. To do so, target-based and phenotypic screens are 
a broad approach used in drug discovery (Zhang et al., 2014, Cooper et al., 2017, Dawson et 
al., 2014, Prior et al., 2014). 
 
Both screening strategies have contributed 45 first-in-class new small-molecule entities 
(NME) approved by the U.S. Food and Drug Administration (FDA) between 1999 and 2008 
(Swinney et al., 2011). Target-based screening via pharmacological or genetic targeting in 
specific disease models platforms can be used to establish if the modulation of a specific 
candidate has any beneficial therapeutic effect. Such disease platforms can be based on cell 
cultures (Cooper et al., 2017, Vargas-Caballero et al., 2016, Khurana et al., 2015), or simple 
organisms such as yeast (Outeiro et al., 2006), zebrafish (Prusothman et al., 2017) or 
Drosophila (Konsolaki, 2013, Nichols, 2006). 
 
Whilst all of the early drugs were discovered by phenotypic screening, in the past years there 
has been an increasing rise of new technologies for making large chemical libraries 
(combinatorial chemistry) and high throughput screening (HTS) (robotics) that have since 
dominated the pharmaceutical industry (Prior et al., 2014). However, it has been proposed 
that such new technologies present many caveats for drug discovery in neurodegenerative 
diseases, as it cannot be assumed that the activity of a single molecule is responsible for the 
condition or that a single target drug can halt the entire process of neurodegeneration (Prior 
et al., 2014). 
Instead, many benefits of using phenotypic assessment for drug/target discovery approaches 
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over high-throughput screening (HTS) are highlighted here.  1. It Avoids the 
incompatibilities with the robotic equipment. For instance, most drugs targeting the brain 
are hydrophobic, which have the risk to bind to the equipment; 2. Derived-natural products 
are a promising family of lead compound for neurodegeneration (Rishton, 2008). However, 
they are often discarded based on erroneous pharmacological assumptions as they interfere 
with some of the assays used (promiscuous binders). 3. By doing phenotypic assessments a 
readout is obtained regarding the bioavailability of the compound as well as toxicity effects 
that can possibly be caused to a living organism. In HTS, such assays will have to be taken 
afterwards and many compounds could be lost later in the pipeline. More information 
regarding phenotypic assessment benefits can be found in (Prior et al., 2014). 
 
1.7.3 Translational approaches 
Nevertheless, following the outlined pipeline above (see Fig. 1.5) does not guarantee the 
translatability of the targets or compounds found to the clinic. It is estimated that only 10% 
of the agents entering clinical trials phase 1 result in a clinically used drug (Hay et al., 2014, 
Marchetti et al., 2007). Therefore, there is a requirement for the establishment of bridges to 
translate the findings in bench research to clinical practice. Ways to do this include:  
1. Improvement of animal models that better reflect human disease, 
2. Careful planned experimental design to reduce noise of the experimental observations 
(ie..tissue vulnerability status or time-points are key for interpretation of results);  
3. Instrumentation used will depend on the experimental design (ie. some proteomic 
techniques are better than others depending on the quantity and sample nature);  
4. Use of human samples as a validation of the findings based on animal models. This last 
one may be controversial. First of all, most samples used in pre-clinical research are post 
mortem samples. In the context of neurodegenerative disease, these samples will be likely at 
the end stage of the disease. This indicates that the molecular changes detectable at the end 
stage might not be that informative regarding the pathological molecular mechanisms of 
neurodegeneration. Moreover, the collection protocol of the samples often varies between 
hospitals/laboratories making it more difficult to establish direct comparisons between 
samples from different sources. Furthermore, unlike animal models, human disease is 
intrinsically highly heterogeneous between each individual which hampers the statistical 
power of human studies. Ways to overcome these caveats are the use of tissue dissected from 
neurosurgical procedures, this tissue can remain electrophysiological active for up to 24 
hours (Verhoog et al., 2013). Because such resected tissue is very limited, the development of 
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public databases has become very valuable in this context. An example of a resource is 
CARMEN (Code Analysis, Repository & Modelling for e-Neuroscience. Available from: 
http://www.carmen.org.uk/), which allows data-sharing across laboratories using human 
tissue providing strict standardised reporting requirements (Vargas-Caballero et al., 2016). 
 
In this project, the main objective is to elucidate molecular regulators of synaptic stability in 
neurodegenerative disease that could serve as drug targets for the development of therapeutic 
approaches. As explained above, we are using murine models of the infantile NCL (Ppt1-/-) 
and the juvenile NCL (Cln3-/-). In the NCLs, there has been a growing number of gene 
therapy and enzyme replacement trials that are generating promising results (Neverman et 
al., 2015). However, as further developed in section 1.6.3, mechanistic-based therapies could 
act synergically together with gene/enzyme therapies (Cooper et al., 2015). To do so, we have 
taken into consideration some of the information contained in this section, summarised in 
Fig. 1.5.  We combine proteomic technologies and some of the bioinformatic tools described 
in this section to further characterise the molecular changes occurring in these mice. 
Ultimately, we generated a list of protein candidates which were tested using Drosophila in 
vivo phenotypic assessment for target validation. The use of Drosophila as a model system is 
further developed in the following sections. 
 
  
Fig. 1.5. Strategies of drug target discovery based on omics. Pipeline for the discovery of targets 
and biomarkers based on omic approaches, including proteomics. After target identification, a 
validation step to assess the modulatory effects of candidates is taken. In this project we propose 
in vivo phenotypic assessment using Drosophila as a model organism. Figure adapted from Fig. 3 
in (Yan et al., 2015). 
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1.8 Drosophila melanogaster as a model system 
Drosophila melanogaster, commonly known as fruit fly, has become one of the most studied 
organisms for geneticists since 1908 when Thomas Hunt Morgan started working using the 
model during his studies on chromosomal inheritance (Kohler, 1994). The growing 
sophistication of the technology surrounding fly genetics has led to multiple studies 
regarding organism development, the molecular mechanisms underlying biological processes 
as well as physiology and behavior (Martinez-Arias, 2008, Green, 2010, O’Kane, 2003, 
Mehregan et al., 2016). Classical genetic studies in Drosophila helped in finding the 
functional role of many genes due to the availability of a broad range of tools and techniques 
for its genetic manipulation, short generation time, large number of progeny, and relatively 
well known phenotypes (St Johnston, 2002, Venken et al., 2005). 
Furthermore, half of the Drosophila genes show a significant homology to human genes and 
it is estimated that 77% of genes associated with human diseases have an ortholog in the fruit 
fly (Reiter et al., 2001). Additionally, in spite of the evolutionary distance, comparative 
genomic studies between human and Drosophila have indicated a high conservation in 
fundamental biological pathways (Rubin et al., 2000). Thus, the balance between similarities 
to human biology and simplicity has made the fruit fly an excellent model organism for the 
study of the molecular and cellular pathology of human diseases, including 
neurodegenerative conditions. 
 
1.8.1 Drosophila use in studies of neurodegenerative diseases 
Drosophila has been used as a model for the study of many relevant neurodegenerative 
conditions where synapses are an early pathological target, including but not limited to 
polyglutamine diseases (SCA and HD), PD, MND (including ALS and SMA) and also the 
NCLs (Bilen et al., 2005, Vanhauwaert et al., 2015, Hirth, 2010, Bond et al., 2013). Different 
approaches are utilised (alone or in combination) with Drosophila, in order to elucidate 
pathogenic pathways underlying neurodegeneration.  Some of the approaches include: 1. 
Misexpression of a human disease gene (WT or mutant): 2. Loss (LOF) and gain of function 
(GOF) of the Drosophila homolog of a human disease gene; and 3. Genetic/pharmacological 
screen to identify modifiers (enhancers or suppressors) of the disease phenotype induced by 
1 or 2 (Hirth, 2010). 
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Some examples of Drosophila models of the most common neurodegenerative disease are 
outlined here. 
 
The insertion of SCA1 human gene led to the generation of a Drosophila model that helped 
develop the understanding of the pathogenesis of Spinocerebelalar ataxia type 1 (Fernandez-
Funez et al., 2000). Later studies proved the relevance of the fly model compared to 
mammalian systems by showing conserved perturbations in the RAS–MAPK–MSK1 
pathway in both Drosophila and mice models of SCA1 (Park et al., 2013). 
 
Likewise, Jackson et al. generated the first Drosophila model of HD, another polyglutamine 
disease. In a similar way to the human condition, the pathogenicity was proportional to the 
length of polyQ repeats (Jackson et al., 1998). Later models generated targeting HTT in 
different ways also demonstrated the disruption of the release of neurotransmitter (Rozas et 
al., 2011), transcriptional deregulation (Steffan et al., 2001) and fast-axonal transport (Lee et 
al., 2004). 
 
Like mammals, developing and adult Drosophila have dopaminergic neurons that are also 
involved in locomotion control (Monastirioti, 1999, Lima et al., 2005). Targeting specific 
gene orthologs related to human PD, such as SNCA, PINK,  PRKN and LRRK2 triggers the 
loss of a specific subset of dopaminergic neurons leading to parkinsonian-like phenotype in 
the flies (Vanhauwaert et al., 2015). These investigations have provided insights into the 
pathomechanisms regulating neuronal loss in PD including the involvement of abnormal 
protein aggregation, vesicle trafficking defects, oxidative stress and mitochondrial 
dysfunction (Vanhauwaert et al., 2015, Hirth, 2010). Furthermore, studies by Tuffi et al. 
demonstrated that it was possible to target mitochondrial impairment genetically and 
pharmacologically rescuing the phenotypes observed in Pink1 mutant flies (Tufi et al., 2014). 
 
Motor neurone diseases such as ALS and SMA also have disease models in Drosophila. Most 
cases of ALS are sporadic and of unknown aetiology and therefore, difficult to model. 
However, 5-10 % of ALS are familial cases for which some disease-related genes have been 
identified. These include SOD1, TDP43, C9orf72, VAPB or TARDBP (Robberecht et al., 
2013), some of which have orthologs in Drosophila (Chai et al., 2015). The motor neuron 
specific expression of either WT or mutant SOD1 produced progressive climbing defects, 
impaired neuronal circuit and stress response in glial cells (Watson et al., 2008). 
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Furthermore, targeting TDP-43 showed a decrease in lifespan, locomotion defects and 
alterations in NMJ synaptic number (Feiguin et al., 2009, Lu et al., 2009) as well as larvae 
lethality (Fiesel et al., 2010).  
 
Drosophila VAPB mutants have also been generated modeling a rare late onset ALS.  
DVAP-P58S fruit fly recapitulates the major features of the human disease including 
aggregate formation, neurodegeneration, locomotion defects and decreased life-span (Chai et 
al., 2015, Forrest et al., 2013). Adult flies present progressive motor phenotype and 
disruption of the neuromuscular junction (NMJ) in the larvae when driven paneuronally 
(Sanhueza et al., 2015). Other Drosophila mutants such as DVAP-V260I, a gain of function 
mutation, cause a muscle phenotype when driven postsynaptically (Sanhueza et al., 2014). 
Moreover, loss-of-function of dSMN, a homolog of SMN in flies,  results in recessive larval 
lethality, NMJ defects as well as muscle atrophy (Rajendra et al., 2007, Chan et al., 2003).  
 
As pointed above, Drosophila models of neurodegenerative disease have provided valuable 
tools for genetic and pharmacological screens for the identification of modifiers of the 
disease phenotype (Chang et al., 2008a, Sanhueza et al., 2015, Park et al., 2013, Fernandez-
Funez, 2000, Tufi et al., 2014, Kaltenbach et al., 2007, Pandey et al., 2011, Buff et al., 2007, 
Saja et al., 2010).  
 
1.8.2 Drosophila nervous system 
Drosophila nervous system (NS) can be divided into 3 distinct systems, defined by their 
developmental stage: embryonic, larval and adult stages. Each one of these systems provides 
different layers of information with regard to mechanisms of specific biological processes 
involved in neurodegeneration. 
 
1.8.2.1 Larvae neuromuscular junction  
Whilst, the embryonic CNS is very useful for the study of cell fate decisions and axon path-
finding (Nichols, 2006), the larval NS provides a great tool for the study of synapses, and 
more specifically, the NMJ. 
The larva is divided into two symmetrical segments each containing 36 motor-neurons 
innervating 30 individual body-wall muscles (Nichols, 2006, Johansen et al., 1989, 
Keshishian et al., 1996). The larva has a stereotyped connectivity that follows similar 
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arborisation patterns for specific muscles across all abdominal segments. This allows a 
relatively easy tracking and visualisation of individual NMJs to characterise their 
morphological as well as their electrophysiological properties with regards to synaptic 
transmission (Menon et al., 2013). 
 
Motor neurons in Drosophila, in contrast to mammals, are glutamatergic and their synapses 
are very similar to those in the vertebrate CNS, providing an excellent model for mammalian 
brain synapses (Johansen et al., 1989, Keshishian et al., 1996). Glutamatergic larval NMJ are 
characterized by postsynaptic density scaffolding complexes that are very similar to 
mammalian ones. Larval synapses use ionotropic glutamate receptors (GluRs) that are 
homologous to AMPA-type GluRs in the mammalian brain (Menon et al., 2013, Nichols, 
2006). Moreover, many of the vertebrate synaptic proteome have orthologs in Drosophila. 
Such proteins include Neurexin (Tabuchi et al., 2002), Neuroligin (Banovic et al., 2010, Sun 
et al., 2011), PSD-95 (Lahey et al., 1994) and Phosphodiesterase 4 (PDE-4) (Chen et al., 1986, 
Davis et al., 1989). Importantly, many pathways have been shown to be conserved across 
larval NMJ and mammalian synapses (Nichols, 2006). Studies carried out by our laboratory 
showed that the disruption of ubiquitination pathways in mouse models of SMA was also 
translatable to these lower organisms by showing the rescue of the NMJ phenotype in both 
mice and Drosophila using the same compound (Wishart et al., 2014). 
 
Furthermore, studies of the synapses of larval NMJ have been very important for the 
elucidation of the mechanisms underlying presynaptic signalling including plasticity and 
synaptic vesicle machinery (Zhang, 2003, Yoshihara et al., 2004, Prokop et al., 2006, Nichols, 
2006). 
 
1.8.2.2 The Drosophila compound eye 
Despite the considerable morphological and structural differences between Drosophila and 
the mammalian eye, they are believed to have a common evolutionary ancestor which may 
explain why most molecular pathways underlying eye formation are conserved between 
human and flies (Arendt et al., 2004). Some of these pathways include cell fate 




The visual system of the adult fly develops from the larval imaginal eye/antenna discs 
forming a compound eye (Dickson et al., 1993). Each eye is composed by around 750 facets 
(called ommatidium) which are clusters of differentiated eye cells. As illustrated in Fig. 1.6,  
each ommatidium is an assembly of 14 cells grouped in columns: 8 photoreceptor cells (R 
cells), 4 cone cells and 2 primary pigment cells (Cagan et al., 1989, Ready et al., 1976). The 
Drosophila visual system consists of the retina, lamina, medulla, lobula, and lobula plate 
(Heisenberg et al., 1984). Each optic lobe is formed by 60,000 to 70,000 neurons on each side 
of the brain and their pattern of nerves and synaptic connectivity have been well 
characterized (Prokop et al., 2006). The axons from a single ommatidium travel in a bundle 
from the retina to the optical ganglia of the brain in a precise retinotopic map 
(Meinertzhagen, 1989). Every R1-R6 photoreceptor terminal establishs around 50 
presynaptic sites that arrange in tetrads into L1, L2, L3 or amacrine cells, while each cell from 
lamina L1 or L2 forms synapses with photoreceptor terminals of its lamina module or 
cartridge (Meinertzhagen et al., 2001) (Fig 1.6). 
 
Because of the very well established organized architecture of the Drosophila compound eye, 
it is easy to detect abnormalities in its structure. When a mutation or a protein produces a 
toxic effect, the number of ommatidium that are damaged is proportional to the degree of 
severity of the degenerative effect (Thomas et al., 1999). For this reason, the eye has been an 
accepted system for the study of neurodegenerative diseases and are used to carry out genetic 
and pharmacological modifier screens (Bilen et al., 2005, Sanhueza et al., 2015, Fernandez-





































Fig. 1.6. Synaptic connections in the lamina. A. The retina (re) is composed 750 ommatidia (om) 
each containing eight photoreceptor neurons (R1–R8) which project onto the two outermost 
optic neuropiles of the brain, lamina (la) and medulla (me); central to these lie the lobula (lo) and 
lobula plate (lp). R7 and R8 terminate in the medulla, R1–R6 of each ommatidium sort into 
adjacent cartridges in the lamina. B. R1–R6 terminals are joined by projections of interneurons, 
the cell bodies of which lie in the surrounding cortex;  L1 (pink) and L2 (orange) cells, a T1 (grey) 
and an amacrine cell (am, brown). C. Wiring diagram of synaptic microcircuits (green box) and 
including the most numerously represented synaptic circuits D. Cross-sectioned cartridge 
showing its conserved spatial organisation; each column comprises a ring of 6 photoreceptor 
terminals (each from a different ommatidium) surrounding L1 and L2 at the centre, separated by 
the paired neurites of amacrine (am) and T1 cells, and other interneurons (open circles: L3-L5, 
C2, C3). E. Schematic of the synaptic tetrad in C showing a presynaptic T-bar ribbon of the 
photoreceptor terminal, postsynaptic cisternae (cs) anchored via whiskers (w) in spines of lamina 
cells L1 and L2, and capitate projections (Khan et al., 2014) from surrounding epithelial glia (gl) 
that penetrate the photoreceptor terminal, sites of vesicle endocytosis (ec). Figure adapted from 




1.8.3 NCL Drosophila models 
Drosophila models are used to encode homologs of some of the most common NCL-causing 
genes in humans. These include the lysosomal enzymes Ppt1/CLN1 (75% similarity) (Glaser 
et al., 2003) and cathepsin D/CLN10 (65% similarity) (Myllykangas et al., 2005), the endo-
lysosomal transmembrane proteins, CLN3 (60% similarity) (Tuxworth et al., 2009) and 
CLN7/ MFSD8 (56% similarity) (Muzaffar et al., 2008) and the synaptic vesicle protein 
cysteine string protein (CSP/DNAJC5 or CLN4, 56% similarity). NCL fly orthologs display 
very similar expression patterns to those seen in mammals. It has been shown that the 
expression of tagged forms of Ppt1, Cln3 and Cln7 are also localized in the lysosome 
(Bannan et al., 2008, Tuxworth et al., 2009, Mohammed et al., 2017). Moreover, Ppt1 was 
shown to have the same enzymatic activity as the human protein (Glaser et al., 2003). Since 
these proteins are conserved from humans to more simple organisms, it is likely that they 
perform essential core functions in the Drosophila CNS similar to their role in humans. 
 
Thus, targeting Drosophila NCL orthologs could provide good animal models to study 
mechanisms underlying NCL. Both LOF and GOF models have been generated for NCL-
related ortholog genes and some of them recapitulate key hallmarks of the human disease. 
Mutations in Ppt1 lead to loss of enzymatic activity and show an accumulation of 
autofluorescent storage material with a 30% shorter lifespan in flies, which is not caused by 
neuronal cell loss (Hickey et al., 2006). However, studies in the developmental stages of the 
fruit fly showed that a disruption of embryonic neural development of Ppt1 mutants, with 
defects in cell fate organization and axon guidance, which triggered defects in both CNS and 
PNS (Chu-LaGraff et al., 2010). Later studies by Aby et al. showed the importance of Ppt1 
function in the stability of synapse at the larval NMJ. In this report investigators showed 
electrophysiological and synaptic exo/endocytosis abnormalities. They also showed larval 
locomotion defects consistent with perturbations in the synaptic function (Aby et al., 2013). 
 
Loss-of-function models have also been generated for Cln3 disease (Tuxworth et al., 2011). 
Cln3 mutant flies have a shorter lifespan and are hypersensitive to oxidative stress (Tuxworth 
et al., 2011). Furthermore, the Cln3 protein has been described to have a role in synaptic 
morphology at the larval NMJ. Non-published studies by Tuxworth and colleagues suggests 
that synapses from flies lacking Cln3 fail to mature appropriately and have alterations in 
bouton size (Bond et al., 2013, Faller et al., 2015). The recent development of CRISPR 
genome editing techniques is contributing to more detailed characterization studies of NCL-
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related protein localization by generating knock-in tagged constructs. A recent study by 
Mohammed et al. using this technology, has indicated that Cln3 protein is highly enriched in 
glial cells, microvilli, glia, lysosomes and mitochondria, which may explain its previously 
identified role in oxidative stress (Tuxworth et al., 2011, Mohammed et al., 2017). 
 
Both Ppt1 and Cln3 expression levels seem to be extremely important for the stability of the 
nervous system in Drosophila. The targeted overexpression of Ppt1 and Cln3 by means of the 
UAS/GAL4 system results in a severe neurodegeneration of the adult compound eye (Korey 
et al., 2003, Tuxworth et al., 2009). This pathology is thought to be caused by an increase of 
activity in Cln3 and Ppt1 since the overexpression (OE) of a truncated version of the Cln3 or 
Ppt1 does not cause degeneration. Cln3 OE was shown to have an impact on Notch and Jnk 
signaling pathways and interestingly, the OE of human CLN3 caused a very similar 
neurodegenerative phenotype in the eye (Tuxworth et al., 2009). Therefore, we can interpret 
that the phenotypes caused by an overexpression of NCL-related genes may be disrupting 
similar pathways as those found in the loss of function flies of the same respective proteins.  
 
The OE models of both Ppt1 and Cln3 have provided excellent tools for the study of genetic 
modifiers in large-scale screenings which have provided insight into the pathomechanisms of 
Ppt1 and Cln3 (Buff et al., 2007, Saja et al., 2010, Tuxworth et al., 2011). A GOF modifier 
screen by Buff and colleagues identified a set of suppressors and enhancer genes that were 
involved in synaptic development, morphology and vesicle recycling as well as to endo-
lysosomal trafficking (Buff et al., 2007). Later, a LOF genetic modifier screen carried out in 
the same laboratory, also indicated that the synaptic and cellular trafficking pathways may be 
related to Ppt1 interactors (Saja et al., 2010). GOF modifier screen in Cln3-OE flies indicated 
the link between the modifier genes of the Cln3-induced phenotype and stress-related 
pathways. These findings supported the role of Cln3 in the oxidative stress response 
suggested by experiments carried out in Cln3 LOF fly that showed to be hypersensitive to 







1.9 Experimental aims 
Given the lack of effective therapeutic approaches targeting neurodegenerative diseases, 
there is a need for the understanding of molecular pathways underlying these conditions. 
Synapses are an early pathological target preceding somatic pathological changes in many of 
these conditions. Therefore, understanding the mechanisms regulating synaptic stability may 
help the elucidation of pathways modulating degeneration in the whole nervous system.  
Using well-characterized murine models of NCL, a monogenetic childhood 
neurodegenerative disease, we carried out a data-driven target discovery approach. This 
involved a spatio-temporal proteomic study followed by in vivo phenotypic assessment in 
Drosophila models. In this study I aimed: 
1. To characterise the molecular changes correlating to synaptic vulnerability across 
brain areas at an early stage of disease progression in Cln3-null mice (Chapter 3). 
In the NCLs as well as in many other neurodegenerative diseases, not all brain 
regions are affected equally. In Chapter 3, we take into account the region-specific 
pattern of synaptic vulnerability to identify molecular correlates. Individual protein 
candidates and pathways identified here have the potential to be modulators of 
synaptic stability. 
2. To characterise the regional molecular changes correlating to synaptic 
vulnerability throughout disease progression in Ppt1-deficient mice (Chapter 4). 
Here we wanted to characterise and identify protein candidates and pathways  
changes correlating to the spatio-temporal pattern of synaptic vulnerability. 
Moreover, datasets from Chapter 3 were overlapped to those in Chapter 4 in order to 
identify conserved perturbations across the two mice models. Therefore these 
conserved proteins represent potential modulators of disease progression in both 
conditions. A subset of these candidates were also examined in post mortem patient 
brain samples to assess their relevance to the human disease. 
 
3. In vivo phenotypic assessment of protein candidates in Drosophila melanogaster 
models (Chapter 5). After studying different fruit fly disease models, the 
modulatory effects of each candidate was assessed for their ability to modulate Cln3-
induced neurodegenerative phenotype in the Drosophila nervous system in vivo. 
Candidates identified in Chapter 3&4 with the potential to modulate disease 
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progression were targeted genetically and/or pharmacologically in Drosophila 
disease and wild-type backgrounds. 
4. To identify molecular biomarkers of neurodegeneration correlating to disease 
progression in peripherally accessible tissues (Chapter 6). The identification of 
molecular factors providing a read-out of the progression of neurodegeneration are 
essential to assess the effectiveness of new therapies in preclinical and clinical trials. 
Then, the molecular changes happening throughput the time-course of disease 
progression in Ppt1-deficient mice muscle samples were analysed. We identified a 
set of proteins changes which correlate to disease progression in a predictable 
manner in muscle and blood, some of which were also changed in Cln3-/- mice 
muscle and human post mortem brain samples from NCL patients. 
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Chapter 2 
General materials and methods 
 
2.1 Animals and tissues 
2.1.1 Mice 
Ethics statement: All animal experiments were performed under license by the UK Home 
Office (project license numbers 70/6567 and 70/7364). All the mice tissues were harvested 
alongside ongoing experiments in Prof Jonathan Cooper laboratory at Institute of Psychiatry, 
Psychology & Neuroscience, King’s College London. 
 
2.1.1.1 Cln3-/- mice  
Cln3-/- and control (+/+, WT) mice were used in Chapters 3 and 6. Cln3-/- (Mitchison et al., 
1999) were bred on a C57BL/6 background for at least 10 generations which is generally 
considered sufficient to be congenic on this strain background. Littermates resulting from 
heterozygous crosses were used in this study. Cln3-/- mice were genotyped as described in the 
reference (Mitchison et al., 1999). Five Cln3-/- and five wild-type control mice (WT) at 6.5 
months and 12-13 months of age were used for immunohistochemistry experiments. Four 
Cln3-/- and four control mice (WT) at 12-13 months were used for the proteomics and 
biochemical experiments. Numbers of animals required for experiments were based on 
experience and data in the Wishart laboratory, refining and reducing from numbers derived 
through power calculations. 
 
2.1.1.2 Ppt1-/- mice 
Ppt1-/- mice were used in Chapters 4 and 6. The Ppt1-deficient mice (Ppt1-/-) used in this 
study were originally created through a targeted disruption strategy which eliminates the last 
exon in the coding sequence of Ppt1 (Gupta et al., 2001). These mice were subsequently 
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backcrossed for 10 generations with C57BL/6 control mice (Gupta et al., 2001). C57BL/6 
congenic Ppt1-/- mice and age-matched C57BL/6 control mice were bred and housed in the 




Human post mortem cortical samples were used to validate Cln3-/- and Ppt1-/-  proteomic data 
from Chapter 3 & 4. Samples were obtained from the Human Brain and Spinal Fluid 
Resource Center, Los Angeles and from The MRC London Neurodegenerative Disease Brain 
Bank, Institute of Psychiatry, Psychology & Neuroscience, King’s College London. Samples 
were obtained at routine autopsy with fully informed written consent by the families. Study 
protocols for the use of this human material were approved by the Ethical Research 
Committees of the Institute of Psychiatry under the approval numbers 223/00 and 181/02. 
Anonymised details relating to samples are described in Table 2.1.  
 
Table 2.1. Post mortem NCL and control patient sample details 
Samples Age Sex Brain Area 
Control 1 2 F Parietal Cortex 
Control 2 16 F Parietal Cortex 
Control 3 20 M Parietal Cortex 
Control 4 22 M Parietal Cortex 
Control 5 25 M Parietal Cortex 
INCL 1 unknown unknown Frontal Cortex 
INCL 2 unknown unknown Frontal Cortex 
JNCL 1 23 M Parietal Cortex 
JNCL 2 unknown unknown Motor Cortex 
JNCL 2.1 unknown unknown Frontal Cortex 
F= female M= male 
 
2.1.3 Drosophila 
Drosophila melanogaster was used in Chapter 5 as a model organism to study the role of 
identified candidates from Chapters 3&4 in modulating the stability of the nervous system in 
vivo. During the second year of my PhD Dr. Giusy Pennetta hosted me in her laboratory 
(Centre of Integrative Physiology, University of Edinburgh) to learn Drosophila-related 
tecniques to use during my project. Dr Mario Sanhueza and Dr Giusy Pennetta advised and 
trained me in the Drosophila experiments carried out in Chapter 5. Additionally, during a 
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collaborative visit to OHSU (Portland, Oregon) I was able to observe advanced larval 
dissection techniques in the laboratory of Dr Mary Logan. More information regarding 




2.2.1 Primary antibodies 
Table 2.2 Primary antibodies 
Target Species Supplier Cat. number IHC WB 
ROCK2 Rabbit Abcam 71598  1:1000 
ROCK2 Rabbit Abcam 125025  1:1000 
HIBCH Rabbit Abcam 101672 1:500 1:1000 
HIBCH Rabbit Proteintech 4603-1-AP  1:1000 
HADHA Rabbit Abcam 54477  1:1000 
β-catenin Mouse BD bioscience 610153  1:1000 
SNCA Rabbit Santa Cuz 7011-R  1:500 
Calretinin Rabbit Abcam 14689  1:1000 
H2Ax Rabbit Abcam 20669  1:1000 
Synaptobrevin Mouse Abcam 11104  1:1000 
ANXA5 Rabbit Abcam 14196  1:500 
Calreticulin Rabbit Thermo PA3-900  1:1000 
UchL1 Mouse Novus Biologicals NB300676  1:5000 
P4HB Rabbit Abcam 137110  1:2000 
NDUFS3 Mouse Abcam 110246  1:2000 
Ubiquitin Mouse Milipore MAB1510  1:100 
Uba1 Mouse Abcam 24623  1:5000 
Syp Mouse Upstate  1:100  
Syp Mouse Abcam 8049  1:500 
DBN1 Rabbit Thermo PA1-20222  1:1000 
HRP Rabbit Jackson ImmunoResearch 323-005-021 1:500  
Dlg Mouse DSHB  1:500  
PSD-95 Rabbit Abcam 18258 1:1000 1:1000 
CS Rabbit OriGene TA310356  1:1000 
CFL1 Rabbit Abcam 42824  1 µg/mL 
SYN1 Rabbit Abcam 64581  1:1000 
SPTB2 Rabbit Santa Cruz 9660  1:1000 
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2.2.2 Secondary antibodies 
Table 2.3 Secondary antibodies 
Target Species Supplier Cat. number IHC WB 
anti-rabbit IgG 
(H+L) 800CW Goat 
LI-COR 
Biosciences 926-32211  1:5000 
anti-rabbit IRDye 
680 RD Goat 
LI-COR 
Biosciences 926-68071  1:5000 
 anti-mouse IRDye 
680 RD Donkey 
LI-COR 
Biosciences 926-68072  1:5000 
Alexa anti-rabbit Goat Jackson immunoresearch 111-545-003 1:500   
Anti-mouse Cy3 Goat Jackson immunoresearch 115-165-146 1:500   
Bioltynilated anti-
rabbit IgG Goat 
Vector 




2.3.1 Mouse brain 
During the first year of my PhD I spent one month in Prof Jonathan Copper’s laboratory in 
Kings College London (KCL), learning his well-established tissue sectioning, processing, 
immunostaining and quantification techniques for brain samples. IHC in brain tissue 
sections was used at the beginning of Chapter 3. 
 
Five Cln3-/-  and five wild-type control mice (WT) at 6.5 months and 12-13 months of age 
were terminated and brains rapidly removed and immersed for fixation in 4% 
paraformaldehyde (pH 7.4). After cryoprotection in a solution containing 30% sucrose, 
0.05% sodium azide and 50 mmol/L Tris-buffered saline (TBS), frozen coronal sections of 40 
μm were cut with Microm HM430 Sliding Microtome (Microm international, Walldorf, 
Denmark) as previously described in (Bible et al., 2004). The IHC protocol used allows 
quantitative and qualitative comparisons between animal tissues as previously described in 
(Bible et al., 2012, Tegelberg et al., 2012). Briefly, endogenous peroxidase activity was 
quenched by immersion of floating sections in 1% H2O2 in TBS, followed by blocking non-
specific protein binding sites in 15% normal goat serum (NGS) (Vector laboratories). The 
primary antibody Synaptophysin  (1:100; Upstate) was incubated overnight at 4°C followed 
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by incubation with the biotinylated secondary antibody incubated for 2 hours (goat anti-
rabbit IgG 1:1000, Vector Laboratories). After that, sections were incubated for 2 hours in 
avidin biotinylated peroxidase-complex incubation (Vectastain® Elite® ABC kit, Vector 
laboratories). Visualization was carried out with 3,3’-diaminobenzidine tetra-hydrochloride 
(DAB) reaction catalysed by H2O2 (Sigma). Finally, stained sections were mounted onto 
Super-frost plus slides and air-dried overnight at room temperature, cleared in xylene and 
coverslipped with DPX. 
 
2.3.2 Drosophila larvae neuromuscular junctions 
Drosophila were used in Chapter 5. To study the synaptic morphology in Drosophila, 
wandering third instar larvae were dissected and processed as previously described in 
(Pennetta et al., 2002). Dissected larval NMJs (fillet preparation) were fixed in Bouin's 
fixative (15:5:1 mixture of saturated picric acid, 37% formaldehyde and glacial acetic acid) for 
10 min, washed extensively in PBT (PBS +0,1% TritonX-100), blocked in 10% normal goat 
serum in PBT for 2 hours. Next, Drosophila tissues were incubated with the primary 
antibody overnight at 4°C. Primary antibodies were rabbit anti-HRP antibodies (1:500, 
Jackson ImmunoResearch Laboratories) and mouse anti-Dlg monoclonal antibody (1:500, 
Developmental Studies Hybridoma). On the following day, larval tissues were respectively 
washed for 2 hours with PBT and incubated in secondary antibodies for 2 more hours. 
Secondary antibodies were alexa anti-rabbit and anti-mouse Cy3 (1:500, Jackson 
ImmunoResearch Laboratories). After secondary antibody incubation, larvae NMJ were 
washed again in PBT 2 hours and mounted in vectashield mounting media on superfrost 
slides. Once slides were dried, they were imaged using conventional fluorescence and 
confocal microscopy (see section 2.9 Imaging). 
 
 
2.4 Synaptosome preparation 
Mouse tissue dissections and synaptosome preparation for initial iTRAQ and label free 
proteomics was carried out by Dr. Thomas Wishart before the start of my PhD. Brains from 
each corresponding genotype were harvested and briefly chilled in ice cold ACSF (125mM 
NaCl, 26mM NaHCO3, 25mM glucose, 2.5mM KCl, 1.25mM NaH2PO4, 1mM CaCl2, 4mM 
MgCl2) before regional microdissection. Thalamus, cortex (predominantly pre-/frontal) and 
hippocampus were microdissected bilaterally (Kielar et al., 2009, Wishart et al., 2014, 
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Wishart et al., 2010) and immediately processed for “crude” synaptosome production as 
previously described (Wishart et al., 2010, Wishart et al., 2014, Wishart et al., 2007). Briefly, 
microdissected bilateral thalami, cortex and hippocampi were homogenised in an ice-cold 
isotonic sucrose solution (0.32 M sucrose, 1 mM EDTA, 5 mM Tris-HCl, pH 7.4).  The 
homogenate was centrifuged in a continuously chilled (4 oC ) fixed-angle rotor at 900g for 10 
min and the supernatant (S1) was collected. The pellet (P1) was resuspended in sucrose 
solution and centrifuged again at 900g for 10 min in an effort to free any “trapped” 
synaptosomes and thus increase the yield. The resulting pellet (P1’) containing ‘non-
synaptic’ material (synapse depleted) i.e. white matter tracts, nuclei, microglia etc. was 
immediately frozen and stored for later use. The resulting supernatant (S1’) was combined 
with S1 and centrifuged in a continuously chilled (4 oC ) fixed angle rotor at 20,000g for 20 
min. The supernatant (S2) was discarded and the pellet (P2) containing synaptosomes was 
then kept and stored at -80oC for future protein extraction. 
 
For post mortem cortical human samples, a portion of the total sample was obtained from 
frozen tissue (stored at -80 °C) and transferred into an eppendorf tube containing cold 
isotonic sucrose solution. The procedure was followed as described above. Protein extracts 
from synaptic and “non-synaptic” fractions were blotted for synaptic and nuclear markers to 
validate the enrichment of both fractions (Fig 3.11, Chapter 3). 
 
 
2.5 Protein extraction 
Resuspended brain homogenate, synaptosomes, muscle or blood were homogenised in each 
corresponding buffer (iTRAQ/label-free/RIPA) depending on the purpose of the extraction 
(iTRAQ/label-free proteomics or QWB) and 1% protease inhibitor. Unless otherwise stated, 
samples were spun at 20,000g for 20 minutes at 4°C and the supernatant was aspirated and 
collected as extracted sample. Pellets and extracted samples were stored at -80°C for 






Although proteomic analysis was carried out as as specified below I was able to spend a week 
at the Dundee “Fingerprints” proteomic facility. In order that I should better understand the 
sample handling and processing workflows and the subsequent limitations in terms of 
analysis and data interpretation. This visit was under the supervision of Douglas Lamont and 
Amy Tavendale. Processed mice synaptosomes samples through the FASP and label free 
proteomic workflow. Additionally, I attended a two-day course specifically arranged by Non-
Linear Dynamics for the training of the Wishart lab and “Fingerprints” staff in the use of 
Progenesis LC MS-MS software for label free data handling. 
 
2.6.1 ITRAQ 
Isobaric tags for relative and absolute quantitation (iTRAQ) proteomics was used in 
Chapters 3 & 6. ITRAQ was carried out by Dr. Heidi Fuller (Keele University) in a similar 
way to other studies (Fuller et al., 2010). Four Cln3-/- and four control mice (WT) at 12-13 
months were used for the proteomics and biochemical experiments. Protein extracts from 
thalamic, hippocampal, cortical synaptosomes and muscle were prepared for iTRAQ 
proteomics. 
 
Sample preparation for mass spectrometry analysis: Reduction, alkylation and digestion 
steps were performed using the reagents and according to the recommendations in the 
iTRAQ labelling kit (AB Sciex). The extracts were diluted with 50mM TEAB so that the urea 
concentration was less than 1M, before the addition of trypsin and overnight incubation at 
37°C. The digests were then dried down in a vacuum centrifuge and iTRAQ labelling was 
carried out according to the instructions in the iTRAQ labelling kit. Each tag was incubated 
with 85µg of total protein (as determined by a Bradford protein assay). 
 
iTRAQ-labelled peptides were pooled and made up to a total volume of 2.4mL in SCX buffer 
A (10mM phosphate, pH3 in 20% acetonitrile (Romil, UK). The pooled peptides (2.4mL) 
were then separated by strong cation-exchange chromatography (SCX) using a 
polysulfoethyl A column, 300A, 5uM (PolyLC) at a flow rate of 400ul/minute. Following 
sample injection, the column was washed at with SCX buffer A until the baseline returned. 
The gradient was run as follows: 0-50% SCX buffer B (10mM phosphate, 1M NaCl, pH3 in 
20% acetonitrile) over 25 minutes followed by a ramp up from 50% to 100% SCX buffer B 
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over 5 minutes. The column was then washed in 100% SCX buffer B for 5 minutes before 
equilibrating for 10 minutes with SCX buffer A. Fractions were collected (400ul) during the 
elution period and dried down completely in a vacuum centrifuge. 
 
Protein identification and quantification by mass spectrometry: The iTRAQ tryptic 
peptide fractions were each resuspended in 35µl of RP buffer A (2% acetonitrile, 0.05% 
trifluoroacetic acid (TFA) in water (Sigma Chromasolv plus). Prior to mass spectrometry 
analysis, fractions were first separated by liquid chromatography (Dionex Ultimate 3000) on 
a Pepmap C18 column, 200µm x 15cm (LC Packings) at a flow rate of 3µl/minute. Fractions 
were injected by full-loop injection (20µl) and the order of loading was randomized to 
minimise effects from carry-over. The eluants used were: A. 0.05% TFA in 2% acetonitrile in 
water and B. 0.05% TFA in 90% acetonitrile in water. The gradient was run as follows: 10 
minutes isocratic elution pre-run at 100% A, followed by a linear gradient from 0-30% B over 
100 minutes, followed by another linear gradient from 30%-60% over 35minutes. The 
column was then washed in 100% B for a further 10 minutes, before a final equilibration step 
in 100% A for 10 minutes. During the elution gradient, sample was spotted at 10 second 
intervals using a Probot (LC Packings) with α-cyano-4-hydroxycinnamic acid (CHCA) at 
3mg/ml (70% MeCN, 0.1% TFA) at a flow rate of 1.2µl/min. 
 
Both MS and MS/MS analysis was performed on the fractionated peptides using an Applied 
Biosystems 4800 MALDI TOF/TOF mass spectrometer. The mass spectrometer was operated 
under control of 4000 Series Explorer v3.5.2 software (Applied Biosystems). A total of 1000 
shots per MS spectrum (no stop conditions) and 2500 shots per MS/MS spectrum (no stop 
conditions) were acquired. The following MS/MS acquisition settings were used: 2KV 
operating mode with CID on and precursor mass window resolution set to 300.00 (FWHM). 
Peak lists of MS and MS/MS spectra were generated using 4000 Series Explorer v3.5.2 
software and the following parameters were used after selective labelling of monoisotopic 
mass peaks: MS peak lists: S/N threshold 10, Savitzky Golay smoothing ((3 points across peak 
(FWHM)), no baseline correction, MS/MS peak lists: S/N threshold 14; smoothing 
algorithm: Savitzky Golay, smoothing (7 points across peak (FWHM)).  
 
An automated database search was run using GPS Explorer v3.6 (AB Sciex). MASCOT was 
used as the search engine to search the NCBI non-redundant database using the following 
search parameters: precursor ion mass tolerance of 150ppm, MS/MS fragment ion mass 
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tolerance of 0.3Da, iTRAQ fragment ion mass tolerance of 0.2Da, the taxonomy was selected 
as rodents, oxidation of methionine residues were allowed as variable modifications and N-
term (iTRAQ), lysine (iTRAQ) and MMTS modification of cysteine residues were set as 
fixed modifications. Quantification of the iTRAQ peptides was performed using the GPS 
Explorer v3.6 software. The identification criterion was at least 2 peptides by MS/MS with 
the most stringent search settings (peptide rank 1 and total ion score confidence intervals of 
at least 95%). iTRAQ Ratios were normalized using the following formula: iTRAQ Ratio = 
Ratio / (median iTRAQ Ratio of all found pairs) that was applied in GPS Explorer software. 
 
2.6.2 Label-free 
Label free proteomics was used in Chapters 4 & 6 to study the molecular changes happening 
throughout the time-course of disease progression in Ppt1-/- mice vs. controls. Label free 
proteomics was carried out on synaptosome preparations from thalamus and cortex 
(Chapter 4) and in limb muscle protein extractions (Chapter 6) as represented in Fig. 2.1. 
Each individual sample group was run in 3 replicates by Dr. Abdel Atrih (Proteomics 
Fingerprint facility, University of Dundee), before the start of my PhD. This experiment was 
carried out similarly to now published studies (Aghamaleky Sarvestany et al., 2014, Mutsaers 
et al., 2013). 
 
FASP processing of samples: An equivalent of 1.5 mg of proteins from each sample pool 
were reduced with 20 mM DTT and samples are then processed using FASP  protocol 
(Wisniewski et al., 2009) with some modifications. After removal of SDS with 8 M urea, 
filters were washed 3 times with 100 mM Tris-HCL pH 8 then another 3 times with 100 mM 
triethyl ammonium bicarbonate (TEAB). Proteins on the filters were then digested twice at 
30oC with trypsin (2x6.25 µg), first overnight and then for another 6h in a final volume of 
200 µl.  Resulting peptides were desalted using C18 solid phase extraction cartridge (Empore, 
Agilent technologies) and dried prior to LC-MS analysis. 
 
LC-MS analysis: Analysis of peptides was performed on an LTQ Velos-Pro orbitrap (Thermo 
Scientific) mass spectrometer coupled with a Dionex Ultimate 3000 RS (Thermo Scientific). 
LC buffers were the following:  buffer A (2% acetonitrile and 0.1% formic acid in Milli-Q 
water (v/v)) and buffer B (80% acetonitrile and 0.08% formic acid in Milli-Q water (v/v). 
Samples were resuspended in 50 μL 1% formic acid and aliquots of 3.5 μL of each sample was 
loaded at 5 μL/min onto a trap column (100 μm × 2 cm, PepMap nanoViper C18 column, 5 
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μm, 100 Å, Thermo Scientific) equilibrated in 98% buffer A. The trap column was washed for 
3 min at the same flow rate and then the trap column was switched in-line with a Thermo 
Scientific, resolving C18 column (75 μm × 50 cm, PepMap RSLC C18 column, 2 μm, 100 Å). 
The peptides were eluted from the column at a constant flow rate of 300 nl/min with a linear 
gradient from 98% buffer A to 40% buffer B in 90 min, and then to 98% buffer B by 92 min. 
The column was then washed with 98% buffer B for 10 min and re-equilibrated in 98% buffer 
A for 25 min. Each of the 8 samples were run in triplicate using LTQ-Orbitap Velos in data 
dependent mode. A scan cycle comprised MS1 scan (m/z range from 335-1800) in the velos 
orbitrap followed by 15 sequential dependant MS2 scans (the threshold value was set at 5000 
and the minimum injection time was set at 200 ms) in LTQ with collision induced 
dissociation. The resolution of the Orbitrap Velos was set at to 60,000. To ensure mass 
accuracy, the mass spectrometer was calibrated on the first day that the runs are started.  
 
 
Fig. 2.1. Experiment design workflow of all the label-free proteomics datasets. Protein extracts 
from thalamic and cortical synaptic fractions (Chapter 4) and muscle (Chapter 6) were processed 
following the “In vivo”, “MS processing” and “In silico” steps represented here. 
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2.7 Quantitative fluorescent western blotting (QWB) 
QWB was used to validate the results from the proteomic and bioinformatics comparative 
analyses in mice and human tissue in Chapters 3, 4 & 6. Samples were denatured in NuPage® 
LDS Sample buffer 4X (Invitrogen, UK) at 98oC and 10-50 µg of protein loaded and run on 4-
12% Bis-Tris gel (Invitrogen).  Accuracy of loading and protein estimation was confirmed by 
total protein analysis of Instant Blue (Expedeon) stained gels [as previously described (Eaton 
et al., 2013)]. Protein transfer to a polyvinylidene fluoride (PDVF) membrane was carried 
out using the I-Blot® transfer system (Invitrogen, UK).  Membranes were incubated with 
Odyssey blocking buffer (Li-Cor) prior to incubation with primary antibodies directed 
against the protein of interest, overnight at 4oC (Table 2.2).  Secondary antibodies were 
applied for 90 minutes at room temperature prior to washing with PBS (Table 2.3). 
Visualisation and quantification was carried out with the LI-COR Odyssey® scanner and 
Image Studio software (LI-COR Biosciences). Blots (and gels) were imaged using an Odyssey 
Infrared Imaging System. Scan resolution of the instrument ranges from 21 to 339 μm, and 
in this study blots (and gels) were imaged at 169 μm. Quantification was performed on single 
channels with the analysis software provided as previously described (Wishart et al., 2014, 





Progenesis was used to analyse the Ppt1 label free time-course proteomics data from Chapter 
4 & 6. At the beginning of my PhD I attended a personalized course given by Martin Wells 
about the use of Progenesis to analyse our proteomics datasets.  Raw label-free proteomic 
data from each brain area/muscle was imported into Progenesis LCMS for differential 
analysis and identification of peptides followed by quantification of relative ion abundance of 
peptides and corresponding proteins. Following alignment of all MS data, preliminary 
filtering of peptides (only those with power > 0.8, fold-change > 2, p value < 0.05). 
Furthermore, we only exported those ion peptides with stronger signals (which have a rank 
of at least 3).  Peptide information was then exported from Progenesis for subsequent 
identification of individual peptide sequences using mouse database via Mascot Search 
Engine (V2.3.2). Enzyme specificity was set to that of trypsin, allowing for cleavage N-
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terminal to proline residues and between aspartic acid and proline residues. Other 
parameters used were as follows. (i) Variable modifications: methionine oxidation, 
methionine dioxidation, protein N- acetylation, gln, pyro-glu. (ii) Fixed modifications: 
cysteine carbamidomethylation. (iii) MS/MS tolerance: FTMS- 10 ppm, ITMS- 0.6 Da. (iv) 
Minimum peptide length: 6. (v) Maximum missed cleavages: 2. (vi) False discovery rate: 1%. 
A cutoff score of >34 was used based on Mascot probability threshold of 0.05 that the 
observed hit is a random event. As an indication of identification certainty, the false 
discovery rate for peptide matches above identity threshold was set at 1%.  
 
Mascot-generated data were then reimported into Progenesis for subsequent protein 
expression comparison and filtering. PCA was generated in order to confirm the correct 
distribution of the data as well as the reproducibility of technical replicates. Next, each time-
point (1, 3, 5 and 7 months) was analysed as an independent 2-way comparison (Ppt1-/- vs. 
WT). Further filtering was applied to each individual time-point (ie. >2 unique peptides, p-




The Database for Annotation, Visualization and Integrated Discovery (DAVID) software 
(available at http://david.abcc.ncifcrf.gov) provides a relatively comprehensive set of 
functional annotation tools for large data set interpretation (Huang et al., 2009b, Huang et 
al., 2009a). One the one hand, DAVID was used to obtain an indication of the level of sample 
enrichment afforded through the process of synaptosome production inputting un-filtered 
mass spectrometry data as previously used in (Amorim et al., 2017).  On the other hand, it 
was also used to characterize the functions associated to the protein clusters from BioLayout 
(see below). DAVID was used in Chapters 3&4. 
 
2.8.3 BioLayout Express 
BioLayout software was used for the analysis of synaptic proteomic data in order to correlate 
their expression profile to the differentially vulnerable synaptic population across brain 
regions (Chapter 3) or time-points (Chapter 4) (Theocharidis et al., 2009, Enright et al., 
2002). BioLayout was also used to track proteins through disease progression in Chapter 6 in 
order to identify muscle biomarkers in Ppt1-/- mice. BioLayout incorporates a complex 
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pattern recognition algorithm which groups protein data based only on expression profile. It 
allows the visualization and graphing of expression trends of co-expressed proteins to allow 
better characterization and understanding of large complex datasets (Theocharidis et al., 
2009). This software was developed by Prof Tom Freeman’s research group at the Roslin 
Institute (The University of Edinburgh) and further information on the use of this program 
and free access can be found here: http://www.biolayout.org. BioLayout generates a three 
dimensional representation of the data in where each sphere represents an individual protein 
and its colour and proximity to its neighbour indicates the similarity in protein expression.  
Clusters (groupings of proteins delineated by colour) can be further analysed for cell type or 
functional association with other in silico tools such as DAVID enrichment tool (see above). 
I was trained by Dr. Tom Freeman on the application of BioLayout and the interpretation of 
its outputs at a course run within the Roslin Institute. 
 
 
2.8.4 Ingenuity Pathway Analysis (IPA) 
IPA application (Ingenuity Systems) is used to obtain further insight into potential cellular 
pathways that may be perturbed in our proteomic datasets. IPA was used, as previously 
described (Wishart et al., 2010, Wishart et al., 2014, Wishart et al., 2007, Wishart et al., 
2012). IPA dynamically generates networks of gene, protein, small molecule, drug, and 
disease associations on the basis of “hand-curated” data held in a proprietary database. More 
than 90% of the information in this database is “expert-curated” and is drawn from the full 
text of peer reviewed journals. Less than 10% of interactions have been identified by 
techniques such as natural language processing.  
Canonical pathways function was used for the identification of known pathways within this 
dataset. IPA contains a library of biological pathways published in the literature that are 
ranked by significance of the association between the dataset and the canonical pathway. The 
significance is defined by two parameters: (1) the ratio of the number of proteins from the 
dataset that map on the pathway divided by the total number of genes within the canonical 
pathway and, (2) a P value calculated using Fischer’s exact test that determines if the 
probability of association between proteins in the dataset and in the pathway are due to 
chance. Prediction activation scores (z-score) is a statistical measure of the match between an 
expected relationship direction and the observed protein expression. Positive z-score 
indicates activation (orange) and negative z-score indicate inhibition (blue) (Savli et al., 
2008). 1.2 Fold-change threshold filter was applied in IPA to each dataset analysed and only 
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experimentally observed interactions were selected for each analysis. Further information on 
the computational methods implemented in IPA can be obtained from Ingenuity Systems. 
Available at http://www.ingenuity.com/. 





Mouse brain Immunohistochemistry: Micrographs were taken with Leica DMRB x5/0.12 
objective and AxioCam HRC Zeiss from the following brain regions: 1. The thalamic nuclei 
ventral posterior medial/ventral posterior lateral thalamic nucleus (VPM/VPL) and the 
dorsal lateral geniculate nucleus (LGNd); 2. Their respective cortical projections in the 
primary somatosensory cortex (S1BF) and primary visual cortex (V1) respectively, and 3; the 
hippocampal stratum radiatum and stratum oriens (See Fig 1A). Immunoreactivity 
measurements were carried out using a thresholding image analysis in ImageJ (National 
Institute of Health, Bethesda, MD), USA), as previously described (Pontikis et al., 2004, 
Pontikis et al., 2005, Bible et al., 2004). Thirty non-overlapping images (x40) were taken, on 
three consecutive sections, through the brain areas described above. All parameters including 
lamp intensity, video camera setup and calibration were kept constant throughout image 
capturing. 
 
Drosophila NMJ: Dr Anisha Kubasik-Thayil and Dr Giusy Pennetta assisted in taking 
Drosophila NMJ confocal micrographs. Images were captured using a laser scanning confocal 
microscope (Nikon A1R) with 60X objective lens (Plan APO OIL NA=1.4) . Size of the 
images are set to 1024 x 1024 pixels (with pixel size 200nm) and z step size 500nm. Frame 
rate of the acquisition was 0.5 frames per second. 
 
Drosophila eye images: For the HIBCH and HADHA experiments fruit fly eye images were 
photographed with a Nikon D5100 camera attached to a SZX9 Nikon stereomicroscope. For 
the the rest of experiments, eye images were taken with an AxioCam ERc 5s Rev.2 attached 
to a Zeiss Stemi 305 trino stereomicroscope. Images were analyzed with ImageJ software 
(National Institute of Health, Bethesda, MD, USA) as previously described in (Sanhueza et 
al., 2015). 
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2.10 Data collection and statistical analyses 
All the data including proteomics raw data was exported/recorded and stored in Excel 
spreadsheets. QWB data was analysed using Image studio software as per manufacture 
guidelines and as previously described (Eaton et al., 2013, McGorum et al., 2015, Wishart et 
al., 2014). Data was graphed and statistical comparisons for IHC thresholding, QWB protein 
intensity and Drosophila eye surface area quantification were carried out using GraphPad 
Prism as previously described (Wishart et al., 2010, Sanhueza et al., 2015). For QWB and 
IHC, Student T test was applied. 
For Drosophila eye quantifications when comparing more than 3 samples a one-way 
ANOVA was carried out, followed by Tukey’s multiple comparison test as a post-hoc when a 
significant difference was found in the ANOVA. When comparing 2 samples Student T test 
was applied. P values <0.05 were considered to be statistically significant for all analyses 
(*P<0.05; **P<0.01; ***P<0.001; ns (not significant) >0.05).  
Statistical analysis of proteomic data was automatically carried out by MASCOT and 
Progenesis. P & Benjamini values to determine enrichment were automatically calculated by 
DAVID software (see above and http://david.abcc.ncifcrf.gov). P values/Fishers exact tests 
and z-scores for pathway and networking analysis were automatically determined by IPA 
(see above and http://www.ingenuity.com/). 
Heatmaps representing the differentially expressed proteins across brain regions and/or 
time-points were produced using “R” (http://www.R-project.org) (R Development Core 
Team, 2008).  
BioLayout display was generated using pearson correlation and Marckov clustering 













Characterisation of differentially 
vulnerable synaptic populations at 
an early disease stage using Cln3-/- 
mice as a model 
 
3.1 Introduction 
Our understanding of the reasons why specific synaptic populations are so vulnerable to 
such a broad range of neurodegenerative stimuli and the mechanisms that govern their 
stability, remains in its infancy (Wishart et al., 2006, Wishart et al., 2012, DeKosky et al., 
1990, Selkoe, 2002, Forno, 1996, Kielar et al., 2009, Virmani et al., 2005, Partanen et al., 2008, 
Koch et al., 2011, Cooper, 2010) (See Chapter 1. General Introduction). Some attempts have 
been made in order to shed light into the mechanisms regulating synaptic degeneration.  
 
Our lab has been developing novel workflows based on identifying potential regulators of 
synaptic and neuronal stability using high-throughput proteomics on rodent models. 
Candidates identified in these screens are then tested in lower order organisms such as 
Drosophila and Zebrafish to study their role in modulating neuronal stability in-vivo 
(Wishart et al., 2014, Wishart et al., 2012, Fuller et al., 2016). Studies using iTRAQ 
proteomics in synapses isolated from an injury-induced degeneration mouse model, found 
13 individual proteins whose missexpression was able to modulate axonal-degeneration in-
vivo (Wishart et al., 2012). Later studies also by Wishart el al., attempted to do a similar 
study, but in this case, using mouse models of SMA. Proteomics carried out in isolated 
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synapses from SMA mouse model followed by in silico analyses, identified the dysruption of 
ubiquitination pathways. Targeting such pathways they were capable of rescuing not only the 
synaptic phenotype, but also the whole neuromuscular system in Drosophila and mouse 
models of SMA (Wishart et al., 2014). Moreover, by tracking these molecular cascades 
further upstream, they we able to identify molecular modifiers capable of affecting disease 
progression in every organ system examined (Powis et al., 2016). 
 
In this project, we wanted to elucidate molecular regulatos of brain synapses and shed light 
into the reasons why the distal compartments of neurons are so vulnerable to a broad range 
of neurodegenerative stimuli. Moreover, we wanted to consider the differential vulnerability 
across brain areas (See Chapter 1. General Introduction). In order to do so we used a Cln3-/- 
mice model of juvenile NCL, (Mitchison et al., 1999). Although neuronal loss is widespread 
by the end of the disease (Mitchison et al., 1999, Kuhl et al., 2013), there is a differential 
vulnerability across brain regions and their resident cell types/subcellular compartments. 
This differential degenerative progression follows the same pattern in the vast majority of 
NCL mouse models: during pre-symptomatic stages there is an early selectivity for relay 
neurons within the thalamic nuclei followed by the corresponding cortical areas (Pontikis et 
al., 2005, Kielar et al., 2007, Partanen et al., 2008, Mitchison et al., 1999, Kuhl et al., 2013, 
Pontikis et al., 2004)(Weimer JM, 2006 #81), as well as GABAergic hippocampal 
interneurons and Purkinje neurons (Mitchison et al., 1999, Pontikis et al., 2004). For more 
information, see General Introduction (Chapter 1). 
 
Therefore, mouse models of CLN3 disease represent a useful tool to study the molecular 
pathways underlying differential vulnerability across brain areas. In this chapter, we aimed to 
define the molecular regulators of both synaptic stability and vulnerability using Cln3-/- mice 
(Mitchison et al., 1999). We initially characterized differential patterns of synaptic pathology 
in Cln3-/- mice (Mitchison et al., 1999) of two different time-points. This enabled the 
subsequent application of high-throughput proteomics followed by a combination of in silico 
tools in order to map the molecular fingerprint of differentially vulnerable biochemically-
isolated synaptic populations.  We identified multiple cascades correlating with synaptic 
vulnerability and described valine degradation and rho signalling as two promising pathways 
to target in subsequent in vivo studies (Chapter 5). Finally, we identified regulators of 
synaptic vulnerability and degeneration in the context of NCL, which are also likely 
conserved in their expression across other neurodegenerative conditions, where synapses are 
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an early pathological target (Wishart et al., 2012). These results therefore open a window for 
further investigation into common molecular therapeutic targets and strategies for novel 
interventions across a range of neurodegenerative conditions during early disease stage. 
 
 
3.2 Materials and methods 
3.2.1 Animals and tissue harvesting 
Cln3 null mice (Cln3-/-) and C57BL/6  littermates (WT) (Mitchison et al., 1999) were used in 
this Chapter for IHC, proteomics and QWB analyses. Human post mortem cortical tissue was 
used for synaptosome production and subsequent QWB examination. Please refer to General 
materials and methods (Chapter 2) for more details. 
 
3.2.2 Immunohictochemistry (IHC) 
IHC using synaptophysin primary antibody (Syp) was performed with the objective to 
confirm the expected vulnerability pattern across distinct synaptic populations in Cln3-/- 
mice. Details of the methodology are described in General materials and methods (Chapter 
2). 
 
3.2.3 Synaptosome production 
Once we confirmed the pathological pattern of synaptic vulnerability across brain areas in 
the Cln3-/- mice, we wanted to examine the proteomic composition of synapses in these 
differentially vulnerable brain areas (cortex, hippocampus and thalamus) and in cortical post 
mortem JNCL patients. To do so, synaptic enriched fractions were produced. Brains were 
harvested from six Cln3-/- and wild-type (WT) control mice at 13 months old and post 
mortem human cortical samples were processed for synaptosome production as previously 
described (Wishart et al., 2007, Wishart et al., 2014, Wishart et al., 2012) . Please refer to 
General materials and methods (Chapter 2) for more details. 
 
3.2.4 Protein extraction 
For iTRAQ proteomics, crude synaptosomes were resuspended and homogenised in 4 
volumes (w/v) of 6M Urea, 2M thiourea, 2% CHAPS, 0.5% SDS and 5% protease inhibitor 
cocktail (Roche) using a pellet pestle (50 strokes with the pestle, left on ice for 10mins, 
followed by another 50 strokes with the pestle). The extracts were sonicated briefly and left 
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on ice for 10 minutes, followed by centrifugation at 13,000 x g for 10 minutes at 4°C to pellet 
any insoluble material. For mass spectrometry analysis, an aliquot of extracted proteins from 
each mouse (n=6) and each brain region was pooled and precipitated in 6 volumes of ice cold 
acetone overnight at -20°C. The remaining extracts were stored (un-pooled) at -80°C for 
quantitative Western blotting validation (QWB). The acetone precipitates were pelleted by 
centrifugation at 13,000 x g for 10 minutes at 4°C and the supernatant was carefully remove 
and discarded. The pellets were resuspended in 6M Urea in 50mM TEAB. The protein 
concentration in each sample was determined using a Bradford protein assay. 
 
Human synaptosomes were extracted in SDT lysis buffer containing 100 mM Tris-HCl (pH 
7.6), 4% (W/V) Sodium dodecyl sulphate and 1% protease inhibitor cocktail (Roche). Please 
refer to General materials and methods (Chapter 2) for more details. 
 
3.2.5 iTRAQ proteomics 
Protein extracts from synaptosomes produced from Cln3-/- and wild-type (WT) controls 
mice at 13 months (cortex, hippocampi and thalamus) were processed for iTRAQ 
proteomics by Dr. Heidi Fuller (Keele University). Please refer to General materials and 
methods (Chapter 2) for iTRAQ methodology. 
 
3.2.6 Quantitative fluorescent western blotting (QWB) 
15 µg of protein was loaded for all the QWB within this chapter, except for the detection of 
ROCK2 in human synaptosome samples were gels were loaded with 50 µg of protein. QWB 
methodology and antibodies used can be found in the General materials and methods 
section (Chapter 2). 
 
3.2.7 In silico analyses 
Our collaborator Dr. Heidi Fuller provided raw iTRAQ proteomic data for its analyses. I 
utilized a combination of bioinformatics tools each one for a different purpose and used the 
identified pattern of synaptic pathology established by IHC, as a guide to analyzing and 
interpreting the data. 
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3.2.7.1 Ingenuity pathway analyses (IPA) 
IPA was used at two different stages of the proteomic analyses. Firstly, it was used to 
investigate which canonical pathways were disrupted across cortex-hippocampus-thalamic 
synapses (following the described vulnerability pattern). To do so, common proteins which 
were identified by more than 2 peptides across the three brain areas (709 proteins) where 
inputed for comparative analyses. Secondly, IPA was used to analyse the thalamic synaptic 
dataset in more detail to further characterize the most vulnerable synaptic population. Please 
refer to General materials and methods (Chapter 2) for more details. 
 
3.2.7.2 BioLayout Express 
BioLayout was used to further define the proteins which pattern of expression correlated to 
synaptic vulnerability accross cortical, hippocampal and thalamic synaptic populations. 
Please refer to General materials and methods (Chapter 2) for more details. 
 
3.2.7.3 DAVID 
DAVID was used to investigate the basic biological functions of proteins showing expression 
pattern correlating to synaptic vulnerability (clusters identified using BioLayout, see above) 
and as a quality control to analyse the level of enrichment of synaptic terms from thalamic 





3.3.1 Quantitative immunohistochemistry identifies differential rates of 
synaptic pathology between brain regions in Cln3-/- mice 
Although the spatio-temporal pattern of neuron loss in Cln3-/- mice has already been studied 
(Pontikis et al., 2004, Kuhl et al., 2013), little is known about the progression of synaptic 
pathology across differentially vulnerable brain regions. Studies in other NCLs using Ppt1-/-, 
Cln6-/- or CtsD-/- mice have revealed progressive synaptic loss starting in the thalamus and 
following later in corresponding cortical areas (Partanen et al., 2008, Kielar C, 2009). 
Hippocampal structures seem to be also affected early, although to a lesser extent than seen 
in the thalamus (Kuhl et al., 2013). 
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To investigate whether a similar pattern of synaptic pathology might be present in Cln3-/- 
mice we studied the expression of the presynaptic marker synaptophysin (Syp; as previously 
described in (Kielar et al., 2009)) in three brain regions that exhibit different degrees of 
neuronal vulnerability (Fig. 3.1) using quantitative immunohistochemistry at 6.5 and 13 
months (as guided by Prof. Jonathan Cooper; see methods – Fig. 3.2 and  Fig. 3.3). The three 
brain regions studied were: 1. Thalamus – ventral posteromedial/ventral posterolateral nuclei 
(VPM/VPL) and lateral geniculate nucleus (LGNd); 2. The corresponding cortical target 
regions in the primary somatosensory barrel field (S1BF) and primary visual areas (V1) 
respectively, and 3; Hippocampus- stratum radiatum and stratum oriens (Fig. 3.1).  
 
At 6.5 months no significant changes in Syp expression were detected between Cln3-/- and 
control mice in any of the brain regions studied (Fig. 3.2). However, by 13 months, some 
differences between genotypes were apparent (Fig. 3.3). Similar to mouse models of other 
NCLs, thalamic nuclei demonstrated greater synaptic loss at 13 months as indicated by the 
lower Syp immunoreactivity to synaptophysin in Cln3-/-  vs. controls. Hippocampal structures 
were also affected, although as predicted, the difference in Syp immunoreactivity between 
genotypes in both hippocampal subfields was much less than in thalamic nuclei. In contrast, 
cortical regions such as S1BF and V1 (corresponding to the thalamic nuclei VPM/VPL and 
LGNd) showed no statistical differences between genotypes in Syp immunoreactivity at 13 
months (Fig. 3.3). 
 
Thus, the synaptic pathology followed a similar pattern to that previously reported in mouse 
models of other forms of NCL (Partanen et al., 2008, Kielar et al., 2009), with the thalamus 
being the most affected region, followed by the hippocampus, whereas cortical synapses were 
still unaffected at this stage of disease. We would categorize these synaptic alterations as 



























Fig. 3.1. Brain region schematic. Brain areas measured are shown in grey. Thalamic regions 
includes the ventral posterior medial/ventral posterior lateral thalamic nucleus (VPM/VPL) (up 
left) and the dorsal lateral geniculate nucleus (LGNd) (down left); their respective cortical 
projections in the primary somatosensory cortex (S1BF) (up left) and primary visual cortex (V1) 
respectively (down left); hippocampal regions measured were the stratum radiatum and stratum 











































Fig. 3.2. Pre-synaptic immunostaining detects no pathological change at 6.5 months across 
brain regions in Cln3-/-.  A. Representative photomicrographs of coronal sections of thalamic 
regions includes the ventral posterior medial/ventral posterior lateral thalamic nucleus 
(VPM/VPL) and the dorsal lateral geniculate nucleus (LGNd); their respective cortical 
projections in the primary somatosensory cortex (S1BF) and primary visual cortex (V1) 
respectively; hippocampal stratum radiatum and stratum oriens from CA1-3 immunostained 
with synaptophysin and a histogram showing its corresponding quantification based on are of 
Syp immunoreactivity a at 6.5 months in control and Cln3-/- mice. B. Histogram indicating 
measurements of immunoreactivity area for the corresponding brain regions at 6.5 months in 
WT controls and Cln3-/- mice. No significant changes were detected in any of the brain regions 
measured. Mean ± SEM; ns P>0.05.  Student T test, 5 mice per each genotype and time-point 






























Fig. 3.3. Spatio-temporal synaptic loss study in Cln3-/- detected differentially vulnerable 
synaptic populations across brain regions. A&B. Representative photomicrographs of coronal 
sections of the same brain regions immunostained with synaptophysin and bar chart showing its 
corresponding quantification based on the area of immunoreactivity at 13 month old in control 
and Cln3-/- mice. Syp immunoreactivity was lower in thalamic regions (VPM/VPL and LGNd) in 
the Cln3-/- mice when compared to controls indicating a major synaptic loss starting in the 
thalamus. Hippocampal stratum oriens and stratum radiatum also showed reduced Syp 
immunostaining, although the difference between genotypes was smaller. Cortical regions did 
not show difference in immunoreactivity for synaptophysin indicating that no synaptic loss is 
happening in these cortical areas at 13 months. Mean ± SEM; *P<0.05; **P<0.01; ***P<0.001; ns 
P>0.05. Student T test, 5 mice per each genotype and time-point were used, Scale bar= 200 um. 
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3.3.2 Comparative molecular profiling reveals proteomic perturbations that 
correlate with the extent of synaptic vulnerability 
Despite advances in the characterization of the mammalian synaptic proteome, little is 
known about how these proteins interact and the molecular mechanisms that govern 
synaptic vulnerability. After confirming the synaptic vulnerability pattern across three 
distinct brain regions, we wanted to examine if the onset of synaptic pathology correlated 
with distinct molecular alterations in the synaptic proteome. To address this, we examined 
biochemically isolated synapse enriched fractions (synaptosomes) produced from 
microdissected brain regions from Cln3-/- mice and controls at 13 months of age where we 
characterise the pre-synaptic pathology as thalamus>hippocampus>cortex. 
 
After synaptosome production and protein extraction, iTRAQ proteomics was carried out as 
detailed in Fig. 3.4 in collaboration with Dr Heidi Fuller (Keele University). 
1536 total proteins were identified in hippocampus and thalamic samples whereas 2068 were 
detected in cortex. We then pre-filtered the proteins by those which were identified by at 
least 2 peptides and therefore are more likely to be reliable identifications. 914 proteins 
passed that filter in hippocampus and thalamus and 1295 in cortex. DAVID enrichment 
analysis was applied to the unfiltered thalamic data to confirm that the starting material was 
suitably enriched for synaptic proteins (Table 3.1). 
 
Almost 40% of our pre-filtered thalamic proteome was altered when compared to control 
littermates. In contrast, only 20% and 17.6% of the synaptic proteome was altered in the 
cortex and hippocampus relative to controls respectively. The number of protein alterations 
also correlates with pre-synaptic pathology being more apparent in thalamic areas at this 
“moderate” stage of disease progression. 
Table 3.1.  DAVID analysis of proteomic data confirms synaptic protein enrichment 
Term Fold Enrichment P-Value Benjamini 
Clathrin coat of coated pit 20.5 9.30E-02 2.70E-01 
Synaptic vesicle membrane 9.7 3.70E-02 1.50E-01 
Synaptic vesicle 8.2 1.30E-05 1.20E-04 
Dendritic spine 6.8 7.00E-02 2.20E-01 
Presynaptic membrane 6.6 7.50E-02 2.30E-01 
Axon 5.2 3.40E-04 2.50E-03 
Mitochondrial inner membrane 5.2 7.10E-11 1.90E-08 
Synaptosome 4.7 2.20E-02 9.50E-02 

























Fig. 3.4. Experimental design workflow. Experiments are divided into in vivo (animal models), 
MS processing and in-silico where the different bioinformatics tools are detailed. A & B were 
replicated for the three brain regions of interest: cortex, hippocampus, and thalamus. 
 
Next, these pre-filtered proteins from the three pre-synaptic populations were aligned to 
look for overlapping proteins. 709 proteins were identified in all three brain regions and 
these were taken forward for comparative analysis (Fig. 3.5).  
 
In order to gain a broad and unbiased overview for the types of processes that may be 
represented by the protein alterations detected in all three synaptic populations, we used 
Ingenuity pathway analysis (IPA) (see 3.2 Materials and methods – Fig. 3.5). Interestingly, we 
identified multiple canonical pathways which IPA designated as perturbed in a strikingly 
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progressive manner, consistent with the degree of synatic pathology outlined above i.e. –log 
P value = higher in thalamus>hippocampus>cortex (Fig. 3.5B).  An example cascade, is the 
valine degradation pathway, where increasing number of disrupted proteins correlate to 
synaptic pathology across brain areas (Fig. 3.6). This analysis therefore indicates that in 
general, alterations in specific molecular cascades were increasing with pre-synaptic 
pathology, further confirming the differential vulnerability pattern previously identified by 
IHC. Thus, the synaptic vulnerability pattern described here appears consistent at both the 
morphological and molecular level. 
 
 
Fig. 3.5. Molecular changes correlate with the synaptic vulnerability characterized across brain 
areas. A. Venn diagram and heat map show the 709 common proteins identified and overlapped 
in cortical, hippocampus and thalamic synaptic proteomic datasets. B. Heat map representing the 
significance (-log P value) of the canonical pathways identified in IPA across cortex, 
hippocampus and thalamus datasets. It is observed a progressive increase in significance 
correlating to the synaptic vulnerability pattern described previously. C. Heat map showing the 




Fig. 3.6. Representation of the valine degradation pathway in cortex, hippocampus and 
thalamus using IPA. The amount of differentially expressed proteins between Cln3-/- and 
controls correlates with the disease vulnerability status of synapses across brain regions. Red 
arrows highlight proteins whose expression is disrupted by more than 20%. green = 




Whilst canonical cascade analysis is an interesting tool to use at the outset, multiple members 
of the same cascade do not necessarily need to change in the same manner, and whilst the 
trend of the majority of canonical cascades seen in Fig. 3.5B are consistent with the regional 
pathology reported, the individual protein alterations are far more complex (as seen in the 
heatmap in Fig. 3.5C). Thus, to better understand and visualize the different molecular 
expression trends occurring across the three datasets, individual proteins were tracked using 
BioLayout Express (see Methods). Simplistically, BioLayout is a complex pattern recognition 
software which generates a visual representation of the data based on protein abundance 
(Theocharidis et al., 2009). In this case the software interrogates a regional expression profile 
generated by arranging the individual proteomic sets in order of increasing pre-synaptic 
pathology/vulnerability (cortex<hippocampus<thalamus). The outcome of this is that 
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proteins were found to cluster into 14 different groups according to similarities in their 
relative expression across these three regions (Fig. 3.7A) (Enright et al., 2002). Of interest to 
us were Clusters 3 (70 proteins), 4 (68 proteins), 6 (51 proteins) and 7 (50 proteins). These 
clusters comprise proteins whose expression can be grouped (or clustered) together as 
having either a gradual upregulation or downregulation, therefore correlating (directly or 
inversely with) with synaptic vulnerability (Fig. 3.7 Appendix I-Tables A1-A4). Next, we 
applied an enrichment analysis to these distinct clusters in order to determine if each 
expression trend could be associated with a specific biological or functional category (using 
the DAVID software tool – see methods & Fig. 3.7B). Unexpectedly, clusters with proteins 
that were increasingly upregulated in vulnerable regions were enriched for structural 
associated candidates like cytoskeletal-related proteins, and specific biological functions such 
as endocytosis (Cluster 4&7). Perhaps more surprisingly, clusters whose protein expression 
decreased with increasing vulnerability were related to specific mitochondrial functions 
(Clusters 3&6) (Fig. 3.7). Thus, comparative proteomic profiling of differentially vulnerable 
synaptic populations revealed that significant alterations to the synaptic proteome correlated 
with the degree of pathology seen at these relatively moderate disease stages. 
 
 
Fig. 3.7. Differentially vulnerable synaptic population molecular profiling. A. BioLayout 
clustering 3D representation of proteomic expression data across differentially vulnerable 
synaptic populations orientated at 3 different angles. Each sphere represents a single protein and 
the edge represents how similar their expression trend is towards the other proteins in the 
dataset. The closer the spheres are the more similar expression trend they have. The colours 
represent the different clusters of co-expressed proteins. B. Expression profile means in log scale 
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(Cln3-/-/WT) of co-expressed proteins in clusters 3, 4, 6 and 7 (Appendix I-Tables A1-A4) and 
its main biological function/subcellular compartment identified by DAVID enrichment analysis. 
Clusters highlighted show steady up or downregulation across cortex (C), hippocampus (H) and 
thalamic (T) regions correlating with the vulnerability status of synapses. 
 
 
3.3.3 In silico analysis highlights alterations in valine catabolic and ROCK2 
signalling cascades in vulnerable thalamic synapses 
After confirming that the synaptic proteome changes in a manner consistent with the 
differential vulnerability to disease in Cln3-/- mice, we next sought to tease out the potential 
molecular regulators of stability from our complex proteomic datasets. To do this, we 
focused our analyses on the thalamus, because synapses here were perturbed to a much 
greater extent than those in the hippocampus or cortex. In the thalamus dataset, 1536 total 
proteins were identified following iTRAQ processing. As described above, we applied 
filtering criteria based on the number of peptides (more than 2 unique peptides), those 
changed >20% (1.2 fold-change) and those which were mapped by Ingenuity Pathway 
Analysis (IPA) software. A total of 374 proteins met these criteria (Fig. 3.8A and Appendix I-
Tables A5&A6).  
 
To confirm the veracity of the filtered data before proceeding to IPA analysis, we carried out 
quantitative fluorescent Western blotting (QWB). Proteins for validation were chosen by a 
combination of their previous implication in neurodegeneration processes, and on their 
magnitude of change (Wishart et al., 2014, Mutsaers et al., 2013, Wishart et al., 2012, 
McGorum et al., 2015). For example, beta-catenin and alpha-synuclein are good 
representatives of validated large changes; HIBCH and ROCK2 are representative of 
validated moderate changes, and calretinin is a good example of an unchanged protein from 
the data set (Fig. 3.8B-G).  
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Fig. 3.8. Synaptic thalamic proteome filtering and validation. A. Dot plot demonstrating the 
process of proteomic data filtering. Each data point represents an individual protein identified 
using iTRAQ proteomic technique. LHS 1536 proteins were identified across all thalamic 
samples. Following filtering (see Methods) a molecular fingerprint for thalamic synaptic 
alterations comprising 374 candidate proteins was produced.  B. Representative bands for two 
upregulated, two downregulated and one unchanged protein candidate verifying the proteomic 
data of in Cln3-/- mice at 13 months of age. C – G. Quantification and statistical analysis of the 
magnitude of alteration in Cln3-/- thalamic synaptic fractions. All the selected candidate proteins 
were altered as indicated by this iTRAQ analysis. Mean ± SEM; *P<0.05; ***P<0.001; T Student 
test, n= 6 mice per each genotype. 
 
 
Higher order functional clustering highlights similarities with other neurodegenerative 
conditions 
Once we confirmed the quality of the data by enrichment analysis and QWB, we wanted to 
elucidate which molecular pathways and biological networks were disrupted in “affected” 
thalamic synapses. In order to do this, IPA analysis was carried out. 
We input the total pre-filtered thalamic data into IPA (those filtered by >2 peptides only) and 
applied the 1.2 fold-change cut-off in the software. Of the three-hundred and seventy-four 
proteins recognised by IPA, 68.3% have previously been reported in the literature as being 
associated with neurological disease (Fig. 3.9A). The majority of the diseases and disorders 
which fall under the category of “neurological disease” have synaptic pathology as an early 
event (Wishart et al., 2006). Interestingly, the main molecular and cellular functions 
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identified in IPA were “molecular transport” and “cellular assembly and organization”. These 
functional categories are consistent with the comparative analysis of differentially vulnerable 
synaptic populations carried out above (see Fig. 3.7), where clusters showing increases in 
protein expression from the levels detected in the comparatively spared cortical synapses 
through to higher levels again in the more vulnerable thalamic populations highlighted 
cytoskeletal protein alterations. 
 
Molecular cascade tracking identified potentially conserved regulators of vulnerability The 
“Canonical pathways” function in IPA uses an algorithm to interrogate a library of known 
generalized biological pathways that represent common properties of a particular signaling 
module or pathway, which are ranked according to their relevance to the dataset analyzed 
(Savli et al., 2008) (see Chapter 2, General materials and methods). In this analysis, 
mitochondrial dysfunction was the most significant canonical pathway identified. The 
contribution of synaptic mitochondria in neurodegeneration has been highlighted in recent 
years (Gillingwater et al., 2013), and mitochondrial abnormalities have also been related to 
CLN3 disease and other NCLs (Luiro et al., 2006, Kang et al., 2013, Kolikova et al., 2011, 
Jolly et al., 2002), and therefore our data is consistent with these previous findings. However, 
in this study we wanted to consider pathways that have not been related to the NCLs before 
that could have been overlooked previously. Within the top canonical pathways identified 
with IPA, we could also detect perturbations in ROCK signalling and valine degradation 
pathways (Fig. 3.7B&C). Examining these pathways, proteins such as ROCK2 and HIBCH 
were differentially expressed key “hub” components. Their expression tracked in clusters 4 
and 6 respectively correlating to the vulnerability status of synapses in the Cln3-/- mice (see 
above, Fig. 3.7 and Fig. 3.9).  Moreover, we have previously identified ROCK2 and HIBCH as 
showing similar expression alterations in synapses following cortico-striatal lesion injury, 
and also having the potential to alter neurodegeneration in an injury specific context 
(Wishart et al., 2012). Collectively these findings suggest that there may be a common 
molecular cascade underlying synaptic degeneration in a range of neurodegenerative 
contexts ranging from injury through to genetic causes. ROCK2 signaling and valine 
degradation pathways and specifically proteins such as ROCK2 and HIBCH, represent 
potentially novel regulators of synaptic stability in an NCL disease context, which have not 
been investigated yet. Therefore, we next sought to determine if such candidates have the 







































Fig. 3.9. IPA analysis of the thalamic synaptic proteome. A. Table of top 5 “diseases and 
disorders” and “molecular and cellular functions”. B-C. Canonical pathways bar chart of 
representative pathways showing, B. The percentage of upregulated and downregulated proteins 
within each pathway. Numbers on the top indicate the total number of proteins within the 
canonical pathway. C. Significance of the association between the dataset and the canonical 
pathway (–log(p-value) and ratio) and z-score prediction of activation/inhibition (see Methods). 
Pathways highlighted in green and blue are associated to ROCK2 and HIBCH, respectively. D. 
HIBCH and ROCK2 protein expression ratio across cortex (“spared’) and thalamic 
(“degenerating”) synapses In these moderately affected Cln3-/- mice (Cln3-/-/WT). E. HIBCH and 
ROCK2 protein expression is conserved in models of injury, following similar pattern of 




Valine catabolic cascade is disrupted in Cln3-/- mice and it is relevant to the human disease 
HIBCH is a 3-hydroxyisobutyryl-CoA hydrolase protein that fulfils a core function within 
the valine degradation cascade (Loupatty et al., 2007). Mutations in HIBCH cause a 
progressive infantile neurodegeneration in humans, characterized by hypotonia, motor delay 
and neurological regression (Loupatty et al., 2007, Brown et al., 1982, Ferdinandusse et al., 
2013). Moreover, manipulation of HIBCH has been suggested to modulate injury-induced 
axonal degeneration (Wishart et al., 2012). However, despite this apparently restricted 
function, very little is known about its role (if any) in synaptic compartments or its 
binding/interaction partners (see Fig. 3.10A). 
 
Using QWB techniques we confirmed that HIBCH protein was less abundant in thalamic 
synaptosome extracts relative to wild type controls. Interestingly, HIBCH protein levels 
trended towards a slight up-regulation of HIBCH in “non-synaptic” compartments. Whilst 
not statistically significant, this non-synaptic increase may indicate a redistribution or altered 










Fig. 3.10. HIBCH downregulation in thalamic synapses impacts in valine catabolism pathway. 
A. HIBCH proteome interactome represented by IPA. Only 6 genes/proteins are known to 
interact with HIBCH. B. QWB bands and quantification of HIBCH in synaptic and “non 
synaptic” fractions of Cln3-/- and control mice in thalamic protein extracts showing a 
downregulation in synapses and upregulation in non-synaptic parts Mean ± SEM; **P<0.01, ns 
P>0.05 (Student T test).  C. HIBCH and HADHA are co-expressed and their expression trend 
correlates to the vulnerability status of synapses: unchanged in cortex (“spared”) and 
downregulated in thalamus (“degenerating”). D. Valine degradation pathway represented with 
IPA. The first protein which expression is perturbed in the degradation process of valine is 
HADHA; upstream of HIBCH. A&D. Colored nodes illustrate proteins present in the thalamic 
dataset in Cln3-/- with respect to WT.  Nodes in grey represent proteins changed <20%, down-
/up-regulated proteins by >20% are represented in green and red respectively. Orange box 
highlights the steps that are disrupted in the valine degradation cascade. 
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Examination of human post mortem samples from patients with JNCL and controls was 
carried out in order to determine the relevance of our findings to the human condition. 
Synaptosomes were isolated from cortical brain areas from 5 controls and 3 JNCL patients 
(see methods). In order to confirm that the synaptosomes were indeed enriched for synaptic 
proteins and depleted from nuclear material, I carried out western blots using a synaptic and 
nuclear markers in both synaptic and non-synaptic fractions from the control human 
samples. Results show that whilst the nuclear marker H2Ax was clearly enriched in the non-
synaptic fractions (Fig. 3.11A), synaptobrevin (synaptic marker) was more abundant in the 
synaptic enriched fractions (Fig. 3.11B). Moreover, to confirm that there was no obvious 
abnormalities in proteome composition in the synaptic fraction from controls and patients, 
total protein staining using instant blue was performed (Eaton et al., 2013). The even 
banding pattern and equal loading of samples indicated the well-preserved protein content in 
the samples and therefore they were ready to be used for the detection of our protein 
candidates (Fig. 3.11C). 
Fig. 3.11. QWB validation of fractionation of post mortem brain samples from JNCL patients 
and controls. A&B. QWB bands and corresponding quantification of protein histone H2Ax 
(nuclear marker) and synaptobrevin (synaptic vesicle marker) respectively. C. Instant blue 
staining of total protein as a loading control and validation of integrity of the protein content 
within synaptic isolates. The banding pattern and quantification showed no obvious protein 
degradation of the samples. C=Controls, P=Patient. Mean ± SEM; *P<0.05; ns P>0.05; Student T 
test.  
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The examination of human post mortem synaptic fractions showed that HIBCH protein 
levels were significantly reduced also in JNCL patients (Fig. 3.12), strengthening the 








Fig. 3.12. HIBCH QWB bands and quantification of cortical synaptosomes isolated from post 
mortem human JNCL patients (P) and controls (C) showing its downregulation also at end stages 
in human disease. Mean ± SEM; *P<0.05; Student T test. 
 
From comparing synaptic vulnerability (Fig. 3.7), HIBCH belonged to Cluster 6 (gradual 
downregulation profile) and was co-expressed with other mitochondria-related proteins 
(Fig. 3.7B) including Hydroxyacyl-CoA Dehydrogenase/3-Ketoacyl-CoA Thiolase/Enoyl-
CoA Hydratase (Trifunctional Protein), Alpha Subunit (HADHA), which also fulfils an 
enzymatic role within the valine degradation pathway (Fig. 3.10C). HADHA sits upstream of 
HIBCH in the valine catabolism cascade (Fig. 3.10D) and catalyzes the final three steps of 
mitochondrial long chain fatty acid β-oxidation (Kamijo et al., 1994). HADHA codes for the 
α subunit of the mitochondrial trifunctional protein (αMTP), and its deficiency causes a 
metabolic disease that presents with Reye-like syndrome, with cardiomyopathy, 
neuromyopathy and sudden death in infancy (Ibdah et al., 2001). More recent reports have 
indicated that HADHA deficiency results in a pigmentary retinopathy leading to vision loss 
(Fletcher et al., 2012).  
Given the important role of these two proteins in the valine catabolism cascade, we included 
HIBCH and HADHA in our list of candidates for our in vivo experiments in order to assess 
their influence on synaptic and neuronal stability in an NCL-disease specific context 
(Chapter 5).  
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Increased ROCK2 expression is conserved across a range of diseases  
ROCK cascades were also identified as being perturbed in degenerating thalamic synapses 
and they were predicted to be activated when compared to wildtype controls (Fig. 3.9 B&C). 
ROCK2 is a Rho-kinase belonging to a family of serine/threonine kinases, of which isoform 2 
is the most predominant in the brain (Riento et al., 2003). ROCK2 directly interacts with, 
and is activated by, Rho GTPases. These are the central mediators of actin reorganization 
(Riento et al., 2003), which are reported to have a key role in synaptic plasticity and long 
term potentiation (LTP) (Zhou et al., 2009). Activation of ROCK2 has been implicated in 
several adult-onset neurodegenerative conditions where synaptic pathology is present, such 
as HD, AD, ataxia, and in Purkinje cell degeneration (Deyts et al., 2009, Herskowitz et al., 
2011, Zhou et al., 2003, Blaise et al., 2012, Wishart et al., 2012). Moreover, ROCK2 has been 
shown to influence childhood neurodegenerative conditions such as SMA, where 
pharmacological inhibition partially recued symptoms and increases lifespan in an SMA 
mouse model (Bowerman et al., 2012, Coque et al., 2014). ROCK2 also was reported to 
influence axonal degeneration following injury (Wishart et al., 2012). Taken together with 
our current data, this is consistent with a model whereby upregulation/activation of ROCK2 
signalling correspons to increased neuronal vulnerability or degeneration in multiple 
infantile- and late-onset neurodegenerative conditions. 
 
The ROCK2 interactome (displayed in Fig. 3.13A) illustrates its reported interactions with 
other gene/proteins, many of which were also altered in Cln3-/- thalamic synaptic extracts 
(coloured symbols represent proteins from this dataset: green – downregulated; red – 
upregulated; grey- identified but not crossing threshold). In the Cln3-/- thalamus, QWB 
confirmed that ROCK2 was upregulated by 53.7% in the synaptic fractions, and by 27.7% in 
the corresponding “non synaptic” Cln3-/- isolates, relative to controls (Fig. 3.13B), suggesting 
a more synaptically-focussed response to altered CLN3 expression. Our in silico analysis 
added support for this model by highlighting specific sub-cascades under multiple pathways 
related to ROCK2 such as “Signalling by Rho Family GTPases” and “Rho A signalling” (Fig. 
3.9B&C). These cascades regulate actin dynamics and cytoskeletal organization (as shown in 
Fig. 3.13C&D) and can impact synaptic structure and affect synaptic transmission. Thus, the 
conserved increased expression of ROCK2 in Cln3-/- mice, and in other related conditions, is 




Fig. 3.13. ROCK2 upregulation is a synaptic specific change conserved across a range of 
neurodegenerative conditions including NCL. A. ROCK2 protein/gene interactome represented 
with IPA showing that some of the interactor partners of ROCK2 are also altered in thalamic 
synaptosome. B. QWB bands and quantification of control and Cln3-/- synaptic and “non 
synaptic” fraction. Upregulation of ROCK2 is higher in synapses than in the non-synaptic 
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fraction indicating a potential synaptic specific response Mean ± SEM; *P<0.05 (Student T test). 
C. “Signaling by Rho family GTPases” canonical pathway represented by IPA with the prediction 
activation tool (MAP). Upregulation/activation of ROCK2 impacts in actin nucleation and 
polymerization that may disrupt actin dynamics in the synapse. A&C. Coloured nodes illustrate 
proteins present in the thalamic dataset in Cln3-/- with respect WT.  Nodes in grey represent 
proteins changed <20%, down-/up-regulated proteins by >20% are represented in green and red 
respectively, orange indicates predicted activation and blue; predicted inhibition. D. ROCK2 
upregulation at early stage of disease is a converved event across animal models of injury, two 
adult-onset neurodegenerative diseases (Huntington and Spinocerebelar ataxia) (Wishart et al., 
2012) and two childhood neurodegenerative conditions (SMA and the lysosomal storage 
disorders-NCLs). 
 
Conversely, in post mortem human cortical synaptic extracts, ROCK2 was found to be 
downregulated in JNCL patients with respect to controls (Fig. 3.14). Nevertheless, the 
interpretation of the results from post mortem tissue is challenging as at end stage of the 
disease brain atrophy is much more pronounced, making it difficult to distinguish which 
molecular alterations are more likely to be causative, and which are a consequence of the 
ongoing degeneration taking place. ROCK2 upregulation could be a disease stage-specific 
change that contributes to the initiation of degenerative stimuli, and it is not necessarily 










Fig. 3.14. QWB bands and quantification of ROCK2 in synaptic fractions showing 
downregulation of this protein at end stages of the disease. C=Controls, P=Patient. Mean ± 






In this chapter we have confirmed that Cln3-/- murine synapses follow the same differentially 
vulnerability pattern as other NCL subtypes including infantile NCL (CLN1/PPT1) and 
congenital NCL (CLN10/CTSD) (Partanen et al., 2008, Kielar et al., 2009). We show that, at 
13 months of age in Cln3-/- mice the synaptic pathology is more pronounced in the thalamus 
(although still <10%), followed by hippocampal synaptic compartments, while cortical 
synaptic populations remain relatively unaffected (Fig. 3.3). iTRAQ proteomic and 
bioinformatics showed that differential synaptic pathology was also reflected at the molecular 
level, showing a progressive increase in the disruption of multiple canonical pathways 
correlating with our observations at the immunohistological level (Fig. 3.5B).  Further 
analyses by means of a complex pattern recognition software identified alterations in the 
synaptic proteome (identified by iTRAQ analysis of “crude” synaptosomes) that correlated 
with the assigned vulnerability status of pre-synaptic populations in the Cln3-/- mice.  
Pathway analysis highlighted perturbations in valine catabolism and rho signaling pathways, 
of proteins including HIBCH, HADHA and ROCK2 as key players, correlating with synaptic 
vulnerability. Furthermore, HIBCH and ROCK2 displayed a conserved direction of change 
in multiple neurodegenerative conditions, and we have previously demonstrated that they 
can alter axonal degeneration in an injury dependent context (Wishart et al., 2012). 
 
In humans, both HIBCH and HADHA deficiency cause infantile onset diseases with 
neurologic clinical scheme (Ferdinandusse et al., 2013, Peters et al., 2015, Stiles et al., 2015). 
This may indicate that perturbations in valine catabolic pathways might be a shared event 
across multiple neurodegenerative conditions. 
 
Interestingly, the upregulation of ROCK2 has been reported in a range of conditions by our 
laboratory and others (Wishart et al., 2012, Deyts et al., 2009, Herskowitz et al., 2011, Blaise 
et al., 2012). ROCK2 upregulation seemed to be a more synaptic-specific perturbation (at 
least at early stages) in the Cln3-/- mice and its magnitude of change tracked across 
differentially vulnerable brain regions (i.e. Thalamus>Hippocampus>Cortex). Its genetic 
and/or pharmacological downregulation has been shown to ameliorate the phenotype of 
several conditions including SMA, another relatively early onset neurodegenerative disease 
(Bowerman et al., 2012, Coque et al., 2014). However, in post mortem human cortical 
synaptic extracts from JNCL patients, and therefore, end-stage of disease progression, 
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ROCK2 was found to have opposite profile (Fig. 3.14). Further investigations will be needed 
in order to determine whether these differences in ROCK2 expression are a disease stage or a 
species difference.  A study of the molecular alterations and pathways taking place 
throughout the time-course of disease progression in NCL would contribute to further 
understand the mechanisms underlying the initiation and progression of neurodegeneration.  
 
In contrast, no lysosomal specific pathways were identified in our in silico analysis in 
synapses, indicating that loss of CLN3 may be impacting in other pathways beyond 
lysosomal function. This is supported by studies in which CLN3 was found to be expressed 
in other locations such as in synaptosomes (Luiro et al., 2001), lipid rafts (Rakheja et al., 
2004, Persaud-Sawin et al., 2004), Golgi (Persaud-Sawin et al., 2004), mitochondria (Katz et 
al., 1997), glia (Mohammed et al., 2017) and endothelial cells (Phillips et al., 2005, Katz et al., 
1997, Mohammed et al., 2017, Tecedor et al., 2013), where it may play other roles such as 
regulation of oxidative stress (Mohammed et al., 2017, Tuxworth et al., 2011) and glial 
function (Pontikis et al., 2004, Pontikis et al., 2005) or blood-brain barrier homeostasis 
(Tecedor et al., 2013). For more information regarding localization and function of CLN3 see 
review (Phillips et al., 2005). However, individual NCL and lysosomal-storage disorder-
related proteins were identified, such as cathepsin D (Steinfeld et al., 2006), prosaposin 
(O'Brien et al., 1991, Tyynelä et al., 1993) and acid ceramidase (Sugita et al., 1972).  
 
Overall, valine degradation and rock signaling pathways appear to be attractive pathways to 
further study in our in vivo experiments (Chaper 5). By targeting these specific cascades we 
might be able to elucidate regulatory pathways not only for NCL, but also in a wide range of 








Spatio-temporal analysis of 
differentially vulnerable synaptic 
populations in Ppt1-/- mice 
 
4.1 Introduction 
Following the characterization of the molecular changes happening at a static early time-
point across three differentially vulnerable synaptic populations (Chapter 3), we next sought 
to build on this analysis by investigating such region-specific synaptic molecular fingerprints 
throughout the time-course of disease progression in NCLs. 
As shown in Chapter 3, the synaptic upregulation of ROCK2 appears to be an early-specific 
change, as it was downregulated in post mortem human brain samples which are end stage by 
definition (Fig. 3.14). However, it is always possible that in such instances, the difference may 
be species specific, but the literature supports the notion of a dynamic neuronal proteome 
which changes in response to disease progression (Kielar et al., 2009, Wishart et al., 2014, 
Wishart et al., 2012). Thus, we believe that a characterisation of the synaptic molecular 
changes throughout the time-course of disease progression, could provide a more complete 
picture of the mechanisms underpinning neurodegeneration. 
 
Having demonstrated in Chapter 3 that using Cln3-/- mice and a combination of proteomics 
and bioinformatics analyses, we are able to identify potential protein regulators of synaptic 
stability, we sought to carry out more comprehensive and ambitious time-course analyses. 
However, the Cln3-/- model is not necessarily the most appropriate model for this type of 
temporal investigation. Reasons for this include (but are not limited to), the time-course 
length (approximately 23 months) (Pontikis et al., 2004) and the increased potential for 
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molecular noise through protracted systemic chronic disease. Additionally, the 
morphological profiling of the Cln3-/-  model is not as detailed in the later time-points as 
other shorter lived models. In contrast, Ppt1-/- mouse model of infantile NCL (INCL) has a 
shorter lifespan only reaching 8-8.5 months of age (Gupta et al., 2001) and has been 
characterised in more detail at the pathological level (Kielar et al., 2007, Kielar et al., 2009) 
(Fig. 4.1). Given the more manageable time-span of disease progression and the extensive 
previous characterization of the Ppt1-/- model according to the degree of neuronal alterations, 
we identified four disease stages which from this point on will be referred to as pre-, early-, 
mid- and late symptomatic stages at 1, 3, 5 and 7 months of age respectively (Kielar et al., 
2007, Kielar et al., 2009). Studies by Kielar et al. showed the temporal differential pathology 
across thalamus and cortex in the Ppt1-/-  mice at both the neuronal (Kielar et al., 2007) and 
the synaptic level (Kielar et al., 2009). Such studies report thalamus as the first area of the 
brain to show synaptic pathology at 3 months. Cortical areas (corresponding to thalamic 
projections) did not show an equivalent degree of pathology until 5-month of age (Fig. 4.1.). 
Therefore, thalamic synapses are the most vulnerable (with pathological changes detectable 
at 3 months) followed by cortical synapses (with pathological changes detectable at 5 
months) (Kielar et al., 2009). 
 
Importantly, after establishing the time-point in which the onset of synaptic pathology 
occurs in Cln3-/- model (Chapter 3), and after conversations with the pathologist Prof. 
Jonathan Cooper, we established for future comparisons that the 3 month early-symptomatic 
disease stage in Ppt1-/- could be considered to be equivalent to the 13 month disease stage in 
the Cln3-/- model for synaptic alterations (Kielar et al., 2009) (Llavero Hurtado et al., 2017). 
 
In this project, we decided to focus on these two differentially vulnerable brain regions: 
thalamus and cortex. Therefore, similar to the approach from Chapter 3, we used this 
pathological characterization to design our analyses and map the molecular changes 
correlating with synaptic pathology. This type of temporal investigation also warranted a 
shift from iTRAQ to label-free proteomic techniques as it offers a higher protein coverage 
with less starting material (Craft et al., 2013, Patel et al., 2009, Bantscheff et al., 2007), greater 
sample processing and data handling flexibility without the need and cost of multiple label 
incorporation  (Xie et al., 2011).  
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In this study, we carried out one of our most complex proteomic analyses consisting of 4 
time-points (1, 3, 5 and 7 months), 2 conditions (Ppt1-/- and age-matched WT controls) and 2 
differentially vulnerable synaptic populations (thalamus and cortex). Similar to Chapter 3, a 
combination of comparative (but in this case label-free) proteomics followed by 
bioinformatic analyses was utilised to identify the pathways and protein candidates which 
better correlate to the spatio-temporal synaptic vulnerability in Ppt1-/- mice, and are therefore 
more likely to be regulators of neurodegeneration. 
 
 
Fig. 4.1. Synaptic pathology in thalamus and cortex throughout disease progression in Ppt1-/- 
mice A. Changes in immunostaining for SNAP25 in VPM/VPL and LGNd thalamic nuclei of 1, 
3, 5 and 7-month-old Ppt1-/- mice (Ppt1) and controls (+/+). Levels of SNAP 25 staining in both 
VPM/VPL and LGNd are very similar between Ppt1-/- and control mice at 1 month. However, 
levels of SNAP25 were markedly reduced in Ppt1-/- thalamus from 3 months of age and continued 
to decrease with increased age. The boundaries of thalamic nuclei are indicated by white dashed 
lines. B. SNAP25 immunoreactivity in the cortex was decreased by 3 months of age, but 
subsequently increased in intensity over time compared with age-matched control mice (+/+). 
Laminar boundaries are indicated by roman numerals on a Nissl-stained section through the 
same region of cortex. A&B. Representative images from experiments on >3 mice per genotype. 
Scale bar = 200 µm; 30 µm in higher magnification views. Figure adapted from Fig. 1 in  (Kielar et 
al., 2009). 
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4.2 Materials and methods 
4.2.1 Animals and tissue harvesting 
For the study of molecular changes happening throughout the time-course of disease 
progression, Ppt1-deficient mice (Ppt1-/-) (Gupta et al., 2001) and age-matched C57BL/6 
control were terminated (WT) at 1, 3, 5 and 7 months of age. Human cortical post mortem 
samples were used to examine the relevance of specific protein candidates to the human 
disease. Please refer to General materials and methods (Chapter 2) for more details. 
 
4.2.2 Synaptosome preparation 
Both mice and human tissues were processed for synaptosome production. Mice tissue 
processing was carried out by Dr. Thomas Wishart and sent to The fingerprint proteomic 
facility (University of Dundee) for label free proteomics experiment. Mice were terminated 
and brains were rapidly removed and briefly chilled in ice cold ACSF (125mM NaCl, 26mM 
NaHCO3, 25mM glucose, 2.5mM KCl, 1.25mM NaH2PO4, 1mM CaCl2, 4mM MgCl2) 
before regional microdissection. Cortex (predominantly pre-/frontal) and thalamus were 
dissected bilaterally from four Ppt1-/- and four WT littermates at 1, 3, 5, and 7 months old 
and used for production of synaptosomes. Half of the synaptosomes were extracted for label-
free proteomics processing and the other half was stored at -80 for later QWB.  
 
Human post mortem cortical sample processing for synaptosome production was carried out 
for the analysis of human proteome. Please refer to General materials and methods (Chapter 
2) for more details. 
 
4.2.3 Protein extraction  
For label-free proteomics (mice): Half of the synaptosomes from Ppt1-/- and WT controls at 1, 
3, 5 and 7 months were resuspended and each corresponding genotype and time-point were 
pooled and massagrated using a pestle and morter in SDT lysis buffer containing 100 mM 
Tris-HCl (pH 7.6), 4% (W/V) Sodium dodecyl sulphate, 0.1 M D/L-dithiothreitol and 1% 
protease inhibitor cocktail (Wishart et al. 2014). Tissue underwent 7 rounds of 
homogenization and sonication. Next, samples were homogenized using the Gentle Macs 
dissociator (Miltenyl Biotech Inc) and M tubes (Miltenyl Biotech Inc). Please refer to General 
materials and methods (Chapter 2) for more details. 
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For QWB:  the other half of synaptosomes from Ppt1-/- mice and corresponding WT controls 
and INCL, JNCL and control human synaptosomes were resuspended homogenized 
individually in SDT lysis buffer containing 100 mM Tris-HCl (pH 7.6), 4% (W/V) Sodium 
dodecyl sulphate and 1% protease inhibitor cocktail (Wishart et al. 2014) Please refer to 
General materials and methods (Chapter 2) for more details. 
 
4.2.4 Label free proteomics 
Time-course label free proteomics was carried out from thalamic and cortical synaptosomes. 
from Ppt1-/- and WT controls protein extracts (1, 3, 5 and 7 months), by Dr. Abdel Atrih 
(Fingerprints proteomics facility, University of Dundee). Please refer to General materials 
and methods (Chapter 2) for more details. 
 
4.2.5 Quantitative fluorescent western blotting (QWB) 
15 µg of protein was loaded for all the QWB within this chapter. QWB methodology and 
antibodies used can be found in the General materials and methods section (Chapter 2). 
 
4.2.6 In silico proteomic analysis 
4.2.6.1 Progenesis 
Label-free proteomic thalamic and cortical synaptic raw data was imported into Progenesis 
LCMS for differential analysis and identification of peptides followed by quantification of 
relative ion abundance of peptides and corresponding proteins. Each individual brain area 
was analysed separately.  
Thalamus: All the samples (Ppt1-/- and WT at 1, 3, 5 and 7 months) were aligned to the same 
sample reference to allow the identification of the same ion peptides across all the samples. 
This allows to obtain the same protein identifications throughout all the time-course. 
Reference sample WT-3B was automatically identified by Progenesis as the least different 
sample to all the others. Alignment scores were optimal, in between 96.8-98.9 % of overlap. 
Next, before the detection of ion peptides, a filtering step was applied based on 1. Retention 
times; in this case only the ions detected between 9-94 min were analysed as features outside 
this area are often not separated adequately for an optimal detection. Retention times were 
manually identified by looking at the 2-dimentional representation of each sample run. 2. 
Only peptides with maximum ion charge of 5 were considered. Peptides obtained after 
trypsin digestion rarely are long enough to contain more than 5 charges. And if there are, 
 90 
they tend to not get detected due to its size. Therefore, by applying this filter we reduce 
computational time when analysing the experiment.  
Cortex: Following the same criteria as stated above, all samples were aligned to the sample 
reference was Ppt1-1B. Alignment scores were also very good, in between 88.9—98.8 % 
overlap. Only peptides within the retention times between 9-93 min with less than 5 ion 
charges were considered for the analysis.  
 
After pick picking, peptide data was then exported for each brain area and imported to 
MASCOT for protein ID assignment. Please refer to General materials and methods 
(Chapter 2) for more details. 
 
Protein data generated in MASCOT was then imported back to Progenesis for further 
analysis. And an individual experiment from each time-point was carried out. An initial 
filtering of each individual time-point was applied to study the global changes taking place in 
each time-point (≥2 unique peptides, p-value<0.05 and >2 Fold-change). However, for the 
tracking of individual proteins across the 4 time-points, only proteins with ≥ 2 unique 
peptides were used. Excel spreadsheet with protein data was then exported for each time-




The Database for Annotation, Visualization and Integrated Discovery (DAVID) software 
(available at http://david.abcc.ncifcrf.gov) was used to obtain an indication of the level of 
sample enrichment afforded through the process of synaptosome production inputting un-
filtered mass spectrometry thalamic data and to characterize the functions associated to the 
protein clusters from BioLayout in both thalamic and cortical time-course datasets (see 
below). Please refer to General materials and methods (Chapter 2) for more details. 
 
4.2.6.3 BioLayout Express 
BioLayout was also used for clustering of proteins following similar expression trend in order 
to correlate their expression profile to the progression of the disease.  
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Clusters or group of clusters with similar expression trend were further analysed using 
DAVID (see above). Please refer to Generals materials and methods (Chapter 2) for more 
details. 
 
4.2.6.4 Ingenuity Pathway analysis (IPA) 
IPA was used for comparative analyses between thalamic and cortical synaptic proteomic 
time-course data. Please refer to General materials and methods (Chapter 2) for more details. 
 
4.2.6.5 Data analysis and figure production 
Protein candidates with “delayed” profile were identified using Python (jupyter notebook and 
pandas package) filtering by proteins changed in the same direction between 3 months in 
thalamus (3-T) & 5 months in thalamus (5-T) time-points and 5 months in cortex (5-C) & 7 
months in cortex (7-C) time-points and which presented more than 1.2 fold-change in 3-T 





4.3.1 Processing and analysis of thalamic proteomic data 
Prior to this current work, Ppt1-/- (Gupta et al., 2001) and age-matched C57BL/6 control 
(WT) were terminated and brains were rapidly removed. Thalamus and cortical brain areas 
were dissected bilaterally by Dr. Thomas Wishart and synaptosomes were produced for all 
the time-points and genotypes. Samples were processed for label free proteomics by the 
fingerprint facility in The university of Dundee.  At the start of this project, the raw mass 
spectrometry (MS) data was then analysed (see 4.2 Materials and methods). 
 
The thalamic synaptosomes MS were analysed first, because thalamus had been shown to be 
the most vulnerable area of the brain in the NCLs (see 4.1 Introduction). To process raw 
label-free MS data, we utilized Progenesis software. As explained in Chapter 2, Progenesis 
consists in a series of steps to convert the MS/MS data into a reliable lists of protein 
identifications and the respective fold-change between the different comparisons made. 
Unfortunately, at the time, Progenesis was not designed to process such complex time-course 
comparative analyses between two conditions (WT and Ppt1-/-). For this reason, and after 
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assessing different experimental designs, it was decided that each time-point should be 
analysed separately (ie. Ppt1-/- vs. WT at 1 months, Ppt1-/- vs. WT at 3 months, etc). All the 
samples were aligned for the identification of the same peptides across all the samples (see 
4.2 Materials and methods) In order to reduce the computational load, we filtered the 
peptides by the standard criteria where cutoffs where as follows:  P value<0.05, fold-
change>2 and power>0.8. Proteins were assigned to peptides using MASCOT database (see 
4.2 Materials and methods). A total of 726 proteins were identified. As a quality control, 
Principal Component Analysis (PCA) was then generated by Progenesis. PCA shows a 2-
dimentional representation of the distribution of the data that allows the detection of outliers 
as well as a means to visualize how well the samples group (Fig. 4.2A). As observed in Fig. 
4.2A, each genotype and time-point cluster together, indicating that there are no outliers 
across each technical replicate for any of the groups. Also, the elliptical shape formed by each 
of the protein identifications (represented by its accession number in grey), indicates a 
normal distribution of the data. From Fig. 4.2A, it is evident that Ppt1-/- at 3 months is the 
most different group. This time-point group, correlates to the onset of synaptic pathology 
starting in the thalamus (Kielar et al., 2009) (Fig. 4.1). 
Fig. 4.2. Thalamus time-course quality control. A. PCA of all the thalamic samples generated in 
Progenesis indicating the presence of no outliers in the data, the optimal clustering of the different 
genotype-time-point groupings and the normal distribution of the data indicated by the elliptical gray 
shape of the protein identifications. Red oval indicates Ppt1-/- samples at 3 months are the most 
different when compared to the other groups. B. Standardized normalized abundance of Ppt1 protein 
 93 
across the time-course and each technical replicate of WT control mice (left side 4xsections) and Ppt1-
/- (right side 4xsections).  
 
 
Furthermore, we detected Ppt1 protein to be consistently downregulated in Ppt1-/- samples 
across all the time-points and, very interestingly, showed a steady upregulation throughout 
the time-course in the WT controls (Fig. 4.2B). This finding supports the quality of the data. 
Importantly, previous studies reported that Ppt1 expression increases in the human 
embryonic brain from the beginning of cortical neurogenesis through cortical development 
indicating its potential implications for neuronal development (Heinonen et al., 2000). 
However, no evidence was found yet regarding Ppt1 expression progressive increase through 
time-course postnatally. 
 
Moreover, in order to assess the level of enrichment of the samples for synaptic terms, 
DAVID enrichment analysis was performed in the unfiltered thalamic proteome (726 
proteins identified) (Amorim et al., 2017). As shown in Table 4.1, synaptic terms were 
significantly enriched with fold-enrichments of 21.41-4.26. Therefore, we can be confident 
that we are working with synaptic enriched samples. 
 
After standard quality control checks, we continued the analysis. A common analysis archive 
was used for the whole time-course and was reused as a new experiment for each time-point.  
Each time-point was processed independently in order to obtain the correct comparisons 
and statistical tests output (i.e. Fold-change between age-matched Ppt1-/- and WT and p-
value (ANOVA)). 
 
Table 4.1. DAVID enrichment analysis of unfiltered thalamic proteome 
GO terms Term p-value Fold Enrichment Benjamini 
GO:0033269 internode region of axon 6.31E-03 21.41 3.03E-02 
GO:0048488 synaptic vesicle endocytosis 7.15E-05 12.15 1.39E-03 
GO:0048489 synaptic vesicle transport 8.96E-09 10.06 3.52E-07 
GO:0000149 SNARE binding 1.27E-04 6.74 2.68E-03 
GO:0050804 regulation of synaptic transmission 3.31E-09 5.10 1.52E-07 
GO:0007268 synaptic transmission 6.80E-15 4.92 1.66E-12 
GO:0019226 transmission of nerve impulse 3.24E-15 4.41 8.86E-13 
GO:0005739 mitochondrion 1.55E-46 4.26 3.19E-44 
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Global changes occurring at each time-point were examined through a stringent filtering 
criterion which emphasise  the changes happening in each time-point between Ppt1-/- and 
WT. Selected proteins were identified by ≥2 unique peptides, p-value <0.05 and fold-change 
≥2 (see Appendix I-Table A7 for information regarding proteins identified by ≥2 peptides).  
Out of the total 726 proteins identified across the 4 time-points, many did not pass the 
filtering criteria for each time-point (Fig. 4.3). The distribution of fold-change across the 4 
time-points before and after filtering can be observed in Fig. 4.3A. Fig. 4.4B shows in more 
detail the differentially expressed proteins between WT (pink shaded) and Ppt1-/- (blue 
shaded) in each time-point. Importantly, and as predicted by the PCA (Fig. 4.2A), the time-
point with more proteins differentially expressed was the 3 month time-point (146 proteins 
changed by at least 2 fold-change). It is also noticeable, that most of these proteins were 
downregulated at 3 months. Conversely, at the 5 month time-point, 98 proteins had at least a 
2 fold-change and the major trend showed upregulation. Surprisingly at 7 months, where the 
atrophy and the pathological changes in these mice was very high, only 22 proteins were 
differentially expressed ≥2 fold-change, suggesting that the 3 and 5 month time-points (early 
and mid stages) are dynamically more active at the molecular level than end stages of the 
disease (Fig. 4.3B) 
 
With these initial analyses, we could identify that the time-point with a higher number of 
differentially expressed proteins correlated to the onset of synaptic pathology (Kielar et al., 
2009), Fig. 4.1). The molecular pathology resembled the Cln3-/- brain-region proteomic 
analyses (Chapter 3), in which higher number of protein changes were occurring in thalamus 
in relation to less-vulnerable brain areas (hippocampus and cortex). 
 
Further investigation was carried out to see if the highly changed proteins at 3 and 5 months 
were the same subset of the 726 proteins identified in total. After demonstrating that 3 
months is a key time-point at both morphological and molecular level, the 146 proteins 
presenting at least 2 fold-change at 3 months were aligned to the other time-points to profile 







Fig. 4.3. Data filtering of thalamic proteomic data. A. Scatterplot representing the distribution 
of fold-changes of the 726 proteins identified in each time-point before (black dots) and after 
filtering (grey dots). B. Line graphs representing the standardized normalized abundance of the 
filtered proteins in each time-point in both WT (pink shaded background) and Ppt1-/- (blue 
shaded background). Each dot represents a technical replicate and each line the expression of an 
individual protein. The numbers of the protein that met the filtering criteria for each time-point 





Fig. 4.4A represents how these 146 proteins are changing throughout disease progression. 
The different line colours represent groups of proteins with similar expression trend that 
were manually identified (Fig. 4.4B). As represented by lines in red, most proteins showed a 
“down-up” trend between 3 and 5 months, indicating that most downregulated proteins at 3 
months have indeed, the opposite change at 5 months. This trend was validated by QWB by 
looking at the most interesting 3 month time-point. At 3 months, synapses start to 
degenerate corresponding to a peak of differentially expressed proteins. As shown in Fig. 4.5, 
examples of up and downregulated proteins were validated based on the availability of 
antibodies and proteins which have been identified to be disrupted in other 







Fig. 4.4. Expression tracking of 3-month changed proteins throughout time-course of disease 
progression in thalamus. A. Line graph representing the fold-change expression of the 146 
proteins that were changed ≥2 fold at 3 months across all the 4 time-points. B. Individual line-
graph representation of protein subgroups presenting similar expression trends. 
 
 
Due to the complexity of the molecular trends observed, BioLayout Express was used for 
further characterization. BioLayout recognizes the patterns of expression in more detail 
allowing the breakdown of the data into smaller lists (See Chapter 2. General materials and 
methods). For this analysis, all the proteins were identified by at least 2 unique peptides 
regardless of their magnitude of change (265 proteins). BioLayout identified 13 clusters of 
proteins which followed specific expression trends (Fig. 4.6). Afterwards, each cluster (or 
group of clusters following similar trends) was queried in DAVID in order to identify the 
biological pathways and GO terms associated with these proteins (Fig. 4.6).  
DAVID enrichment analysis determined that clusters showing a down-up trend (Clusters 1, 
2, 4 &5) were very enriched in mitochondrial proteins, including but not limited to oxidative 
phosphorylation (OXPHOS) and TCA cycle pathways. Proteins showing the opposite profile, 
up-down (Clusters 3, 8, 9, 12 and 6) were enriched for carbon metabolism, neuron 









Fig. 4.5 QWB validation of thalamic proteomics. A&B. Bar chart showing the quantification as 
% ratio of Ppt1-/-/WT and corresponding representative bands. Instant blue staining of total 






Interestingly, similar results between differentially vulnerable synaptic population across 
brain areas were found in Chapter 3. In the Cln3-/- proteomic analyses, we showed that 
downregulated proteins correlating to synaptic vulnerability were enriched for 
mitochondrial proteins, whereas upregulated proteins were enriched for synaptic-related 









Fig. 4.6. Molecular profiling of protein changes through the time-course of disease progression 
in thalamic synaptosomes in Ppt1-/- mice. A. 3-dimentional representation of the proteomic 
data. Each sphere represents a protein (fold-change Ppt1-/-/WT across 1, 3, 5 and 7 months). The 
colours and numbers represent clusters of proteins which display similar expression trend 
through the time-course.  B. Line graphs of individual or group of clusters representing the mean 
expression trend of the proteins within each cluster (indicated by colour) and biological 







The work provided a more in-depth insight into the possible biological functions linked to 
each molecular trend happening throughout the time-course of disease progression. 
However, it was intriguing and unexpected that the pronounced downregulation at 3 months 
corresponds to a reversed upregulation at 5 months of many proteins related to 
mitochondrial function. Such unexpected results denote the complexity of the time-course 
analysed. Previous degenerative proteomics studies by our group had short time-scales (ie. 
SMA, 6 days; injury induced neurodegeneration, 2 days). Because of this, it is likely that the 
same population of synapses was being sampled across time-points. However, in the time-
course analysed here, it is probable that the composition of the population of synapses at 5 
months is very different compared to 3 months.  Thus, by 5 months a larger proportion of 
degeneration-resistant synapses will be sampled whereas at 3 months there will be a 
combination of both (degenerating and “resistant”) meaning that the data could be analysed 
in multiple ways. These questions are addressed in more detail later in the chapter. 
 
4.3.2 Processing and analysis of cortical proteomic data 
Following the in-depth characterization of the thalamic synaptosomes, the cortical data was 
characterized. Progenesis was used in exactly the same way as in the thalamus (see section 
4.3.1). PCA was generated in order to detect any potential outlier and confirm that the 
genotype-time-point groups were clustered adequately. The normality of the data 
(statistically speaking) was also assessed by the elliptical shape of the distribution of the 
proteins identified (Fig. 4.7). 
Fig. 4.7. Cortex time-course quality control.  PCA of all the cortical samples generated in 
Progenesis indicating the presence of no outliers in the data, the optimal clustering of the different 
genotype-time-point groupings and the normal distribution of the data indicated by the elliptical 
gray shape of the protein identifications. 
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In order to get a general idea of the changes happening throughout the time-course of 
disease progression in the cortex, each time-point was filtered by the same criteria as the 
thalamus (≥2 unique peptides, p value <0.05 and fold-change ≥2, see Appendix I-Table A8 
for information regarding proteins identified by ≥2 peptides). A total of 1326 proteins were 
identified across all the samples but only some met the filtering criteria for each time-point 
(Fig. 4.8). It is known in the literature that the synaptic pathology in the cortex starts at 
around 5 months of age (Kielar et al., 2009). However, we identified 110 differentially 
expressed proteins already at 3 months. And similarly to protein changes in the thalamus at 
the same time-point, the main trend in protein changes is downregulation (Fig. 4.8B). 
Importantly, at 5 months of age (onset of synaptic pathology in cortex), we do see a 
downregulation trend followed by an upregulation trend at 7 months mirroring the 3 and 5 
months in the thalamus. 
 
 
Fig. 4.8. Data filtering of cortical proteomic data. A. Scatterplot representing the distribution of 
fold-changes of the 1326 proteins identified in each time-point before filtering (black dots) and 
after filtering (grey dots). B. Line graphs representing the standardized normalized abundance of 
the filtered proteins in each time-point in both WT (pink shaded background) and Ppt1-/- (blue 
shaded background). Each dot is representing a technical replicate and each line the expression of 
an individual protein. The numbers of the protein that met the filtering criteria for each time-





Importantly, between the 146 proteins that were changed at 3 months in the thalamus and 
the 110 proteins that changed at 3 months in the cortex, there were only 25 proteins in 
common. This indicates, that even though there is a common downregulation at the same 
time-point in both synaptic populations, they are mostly different proteins. Therefore, it is 
unlikely that the same molecular processes are happening in both thalamic and cortical 
synapses at the same time-point. 
 
To get a more in-depth insight into the biological functions disrupted throughout the time-
course of disease progression in the cortex, BioLayout was used in the same manner as was 
done with the thalamic data. Proteins identified by ≥2 unique peptides, regardless their 
magnitude of change to study all the expression trends taking place were investigated. 
BioLayout identified 18 different clusters, which were grouped by similarity and were 
analysed using DAVID enrichment analysis. As seen in Fig. 4.9, more heterogeneous 
molecular trends were identified in the cortical data compared to the thalamic. In contrast to 
the thalamic data, a high number of proteins displayed a steady upregulation correlating to 
disease progression (264 proteins), which were related to mitochondria and synaptic terms 
(Fig. 4.9). Interestingly, proteins displaying an upregulation peak at 5 months (onset of 
synaptic degeneration in the cortex, clusters 6 &18), were associated to synaptic terms and 
neuronal development, similarly to the “up-down” clusters in thalamus. However, there was 
no clear correlation between “expression trend” and biological function. Instead, each 
biological function appeared to be linked to multiple expression profiles, demonstrating the 















Fig. 4.9a. Molecular profiling of protein changes though the time-course of disease progression 
in cortical synaptosomes in Ppt1-/- mice. A. 3-dimentional representation of the proteomic data. 
Each sphere represents a protein (fold-change Ppt1-/-/WT across 1, 3, 5 and 7 months). colours 
and numbers represent clusters of proteins which display similar expression trend through the 
time-course.  B. Line graphs of individual or group of clusters representing the mean expression 
trend of the proteins within each cluster (indicated by the colour) and biological 
functions/organelles for which these proteins are enriched for, according to DAVID annotation 





Fig. 4.9b. Molecular profiling of protein changes though the time-course of disease progression 
in cortical synaptosomes in Ppt1-/- mice. Line graphs of individual or group of clusters 
representing the mean expression trend of the proteins within each cluster (indicated by the 
colour) and biological functions/organelles for which these proteins are enriched for, according to 
DAVID annotation analyses indicated by the table below each graph. Related functions were 
shaded with the same colour. 
 
 
4.3.3 Thalamus and cortex comparative analysis 
By looking at both thalamic and cortical data separately, the complexity of synaptic 
molecular protein changes happening throughout the time-course of degeneration is evident. 
The analysis helped us understand that the synaptic proteome dynamically changes from one 
time-point to another and is differentially constituted in each brain area. Moreover, we 
identified which pathways are perturbed in relation to WT controls. However, we do not 
know which changes are related to synaptic vulnerability and stability, which ones are 
compensatory responses to synaptic loss and which ones are simply consequences of 
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prolonged Ppt1 loss but are not related to synaptic loss at all [see General Introduction 
(Chapter 1, Fig. 1.3)]. Having demonstrated in Chapter 3 that analysing differentially 
vulnerable synaptic populations (same time-point, but different brain areas) can help 
refining and identifying which proteins are more likely to contribute to synaptic stability, we 
designed an experiment comparing thalamus and cortex to refine our list of candidates here. 
 
A comparative analysis between thalamus and cortex was carried out, focusing on strategic 
time-points for each brain area, based on previous morphological studies (Kielar et al., 2009). 
As shown in Fig. 4.10A, and as explained in the introduction of this chapter, the onset of 
synaptic pathology takes place at 3 months in thalamus and at 5 months in cortex. Synapses 
at such time-points in each area could be considered to have equivalent “vulnerability status” 
and therefore, those proteins modulating synaptic stability, would be expected to change in 




Fig. 4.10. Schematic and rationale used for comparative analysis of thalamic and cortical 
synaptic data. A. Sagital section of a mouse brain representation where each color represents a 
brain region. Thalamus in purple and cortex in green are the areas used in this study and 3 and 5 
months are the time-points in which synaptic pathology starts for each brain area, respectively.  




Thus, the same would also be expected at 5 months in the thalamus and 7 months in the 
cortex. Changes happening at 3 months in the thalamus (3-T) and 5 months in the cortex (5-
C) are therefore more likely to be early modulators of synaptic degeneration. However, 5 
months in the thalamus (5-T) and 7 months in the cortex (7-C) are much more complex 
time-points. At such time-points, the population of synapses are very different to the ones at 
earlier stages. The population sampled at 5-T and 7-C are more likely to be a mixture of 
degenerating and resistant synapses. The changes expected at this mid/late stage time-point 
are more likely to be; 1. Late modulators; 2. Responses to the synaptic loss taking place or; 3. 
Compensatory mechanisms. Additionally, all time-points expected to change as a direct 
consequence of Ppt1 loss. 
 
Comparative ingenuity pathway analysis of thalamic and cortical synapses  
With this in mind, comparative analyses were carried out using ingenuity pathway analysis 
(IPA) to look for similarities between 3-T & 5-C and 5-T & 7-C. Similar changes at these 





Fig. 4.11. Comparative analysis of biological functions perturbed in thalamic and cortical 
synapses at two equivalent stages. Heat-map representing the z-score measuring the level of 




When looking at the most significant “Diseases and biological functions” associated to each 
time-point and brain area, some specific functions which correlated to the comparative 
strategy were identified (Fig. 4.11). IPA predicts the level of activation/inhibition of specific 
functions/pathways given by a z-score based on the proteomic data inputted. The more 
negative the score (dark blue), the more inhibited a specific pathway or function is 
considered to be, whereas more active scores are indicated by a higher positive score 
(orange) (see Chapter 2. General materials and methods for more details). The heat-map in 
Fig. 4.11, highlights perturbations (activation/inhibition in relation to age-matched WT 
controls) correlating to the vulnerability status of synapses that are key for synaptic function 
such as endocytosis, metabolism of nucleotides, apoptotic pathways of morphogenesis of 
neurons.  
 
Endocytosis was inhibited in 3-T but activated in all the other datasets. Nucleotide 
metabolism-related pathways were consistently inhibited at “early” time-points (3-T & 5-C) 
and activated at later time-points (5-T & 7-C). Conversely, an activation of cell-death 
pathways at 3-T & 5-C that was inhibited at 5-T & 7-C was identified which seems to 
indicate that at 5-T & 7-C there may be a strong neuroprotective response which fits with the 
initial hypothesis that at such a stage we could be sampling “resistant” synapses.  
 
Next, proteins involved with this hypothetical neuroprotective response were examined. In 
Fig. 4.12 such proteins are highlighted in 4 different networks according to time-point and 
brain area. Such a response is predicted to be reflected in many proteins which may be 
involved in synaptic stability. 
 
Looking at the upstream regulator analysis, a similar trend of activation/inhibitions across 
distinct synaptic populations was identified (Fig. 4.13). As we can see in the heat-map of Fig. 
4.13, some proteins are predicted to be activated at 3-T & 5-C whereas they present an 
inhibited profile at 5-T and 7-C. The same happens in the opposite case where inhibition 
occurs when synapses start to degenerate but they appear activated at later stages of synaptic 
degeneration. Therefore, some of these proteins are likely to be upstream of the molecular 







Fig. 4.12. Cell death-related protein networks generated in IPA in thalamus and cortex. 
Network representing which protein are related to “apoptosis of neurons”, “cell death of central 
nervous system cells” and “neuronal cell death”. Activation states of such networks are very 
similar at equivalent synaptic vulnerability status between thalamus and cortex (3-T & 5-C and 5-
























Fig. 4.13. Comparative analysis of predicted upstream regulators perturbed in thalamus and 
cortex at two equivalent stages. Heat-map representing the z-score measuring the level of 
activation/inhibition predicted by IPA of specific proteins, which are not in my datasets, but they 





To confirm whether biological functions described in Fig. 4.11 and proteins in Fig. 4.13 were 
related, a regulatory network analysis was carried out in IPA. Such analysis highlighted that 
these elements were indeed significantly related through complex interaction networks. An 
example is shown in Fig. 4.14, where we find upstream regulator proteins such as ESRRA 
and INSR inhibited at 3-T and IGF1R, INSR, PPARGC1A and PTEN activated at 5 months. 
All these proteins are related to proteins identified in the proteomic data which, at the same 
time, relate to their biological functions.  Some of these functions are cell survival and 




Fig. 4.14. Regulatory networks generated in IPA in thalamic synaptosomes at 3 (A) and 5 
months (B). Network representing the interactions taking place between the predicted upstream 
regulators and the biological function identified which better correlated to the vulnerability status 
of synapses in thalamus and cortex. Upstream regulators are represented on the top of the 
network. In the middle there are the proteins within the thalamic dataset that sit downstream, 
and on the bottom layer are the biological function on which these proteins relate to. 
Red=upregulated, green=downregulated, orange=predicted activation, blue=predicted inhibition. 




The upstream regulators identified in Fig. 4.13 are therefore excellent candidates to target in 
in vivo experiments (Chapter 5), as their activation state correlates with the vulnerability 
status of synapses. These experiments are presented in Chapter 5, and allow determination of 




Identification of protein candidates with mirroring profiles between thalamus and cortex  
After characterisation and comparisons between thalamic and cortical synapses at specific 
key time-points, it was of interest to identify specific proteins which were more likely to have 
a role in the stability of synapses. These proteins could then be added to the refined list of 
candidates from Chapter 3 (HIBCH, HADHA and ROCK2) and the 13 upstream regulators 
identified above (Fig. 4.13). 
To do this, we took the overlapping proteins identified by ≥2 unique peptides in thalamic 
synapses (265 proteins) and cortical synapses (629 proteins) to look for common proteins 
across brain areas and be able to track specific candidates. 207 proteins were identified in 




















Fig. 4.15. Overlapping protein identifications between thalamic and cortical synaptosome 
proteomic data in Ppt1-/- mice. A. Venn diagram representing the overlapping proteins identified 
in thalamus and cortex identified ≥2 unique peptide. B.  Heat-map representing how each 




Heat-map in Fig. 4.15B, indicates once again the level of complexity of these common 207 
proteins identified and how they dynamically change across two brain regions throughout 
disease progression. 
Again the focus was on the key time-points explained above (Fig. 4.10) to look for proteins 
whose expression profile is very similar at 3-T & 5-C and at 5-T & 7-C. The Pandas package 
of Python was used to filter my datasets. Using 1.2-fold cut-off for both up and 
downregulated proteins at 3-T & 5-C time-points, a total of 17 proteins were identified 
following the trends: 4 proteins followed the “up-down” trend in 3-T & 5-T and at 5-C & 7-C 
(Fig. 4.16) and 13 proteins the opposite profile, “down-up” trend in 3-T & 5-T and at 5-C & 
7-C (Fig. 4.17). 
 
Further investigations were done to see which pathways were related to these 17 proteins 
which displayed a delayed profile. These 17 proteins alone were analysed in IPA. 
Surprisingly, the top canonical pathway at early synaptic loss time-points for both thalamus 
and cortex was valine degradation (Table 4.2 & Fig. 4.18). 
 
Interestingly, this is the same pathway identified to correlate to differentially vulnerable 
synaptic populations in the analysis of Cln3-/- (Chapter 3). And therefore, it seems relevant to 
both juvenile and infantile models of NCL. Although HIBCH was not detected in this 
proteomic study, enzymes such as HADHA, HIBADH or DLD were and showed the same 
trends as in the Cln3-/- analysis in the same brain region (thalamus) at equivalent disease 
stages (early). This time-course analysis provides more detail regarding the expression of 
these proteins with disease progression, and we can study how molecules in this pathway 
evolve with time. Looking at later time-points, we can detect that this pathway has the 
opposite profile than the one seen at early stages (Fig. 4.19). 
Studying the different disrupted enzymes within the valine degradation pathway in vivo 
experiments (Chapter 5) could provide more insight into the role of this pathway, and each 










Fig. 4.16. Identified protein candidates with a “delayed up-down” profile between thalamus 





Fig. 4.17. Identified protein candidates with a “delayed down-up” profile between thalamus 





Table 4.2. Top canonical pathways identified in candidates with “delayed profile” between 





Fig. 4.18. Valine degradation cascade in the thalamus at 3 and 5 months. Top canonical 
pathway identified in relation to proteins with “delayed” profile between thalamic and cortical 
synapses. Two enzymes within this pathway, HADHA and HIBADH present downregulation at 3 
months and upregulation at 5 months in thalamus and mirroring profiles can be seen in the 
cortex at 5 and 7 months. Red and names in bold=upregulated, green and names in 
bold=downregulated, orange=predicted activation, blue=predicted inhibition, white=not 
detected in the dataset and no prediction state. 
 
 
Name p-value Overlap 
Valine degradation I 8.17E-05 11.10% 
TCA cycle II 1.35E-04 8.70% 
Semaphorin signaling in neurons 7.25E-04 3.80% 
Huntington's disease signaling 7.36E-04 1.20% 
Oxidative phosphorylation 3.02E-03 1.80% 
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4.3.4 Ppt1-/- and Cln3-/- comparative analysis 
As pointed out above, another way to refine the list of candidates will be to look for 
conserved changes at equivalent disease stages in both Ppt1-/- and Cln3-/-datasets. To do so, 
the most vulnerable synaptic population in the brain, the thalamus was focused on.  This was 
compared to the equivalent disease stages of 3 months time-point in the Ppt1-/- mice and 13 
months in the Cln3-/-mice.  
 
After finding the overlapping proteins between both datasets, 68 proteins were found to be 
identified in both mice models and from those, 31 presented a conserved up or 
downregulatation in the two mouse models (Table 4.3). Surprisingly, within this small list of 
31 proteins there were 9 proteins (almost 30%) presenting a delayed profile (see above and 
Table 4.3). These candidates seem to correlate to the synaptic vulnerability status of synapses 
in Ppt1-/- and seem to be a conserved change at equivalent disease stage in Cln3-/-. Therefore, 
these proteins seem to be very important in both mouse models of INCL and JNCL. But an 
important question is, are these candidates relevant to the human disease? 
 
To answer this question, the QWB expression was examined for three examples of conserved 
changes between Ppt1-/- and Cln3-/- and “delayed” profile in Ppt1-/-, in synaptosomes 
generated from post mortem cortical samples from patients with INCL and JNCL and healthy 
controls. These proteins were DBN1 (example of “up-down” profile) and HADHA and 
ANXA5 (examples of “down-up” profiles) (Fig. 4.19). The quality of the synaptic enriched 
fractions extracts of these samples were already examined and validated in Chapter 3 (see 
Fig. 3.11).  
 
Next, the results were compared to the label free proteomics data and QWB of Ppt1-/- mice 
cortical synaptosomes at end stage (7 months) to be equivalent disease stage as the human 
samples (Fig. 4.19). Results indicated that these 3 candidates were changed in the same way 
in synaptosomes from Ppt1-/- mouse model (by label free proteomics and QWB) and in both 
INCL and JNCL indicating that these proteins are indeed relevant to the human condition in 
both infantile and juvenile forms, and ideal candidates to prioritize in future in vivo 










-/- Cln3-/- “Delayed” profile 
Upregulated 
NEFL Nefl protein (Fragment) 1.808 1.229  
GPRIN1 G protein-regulated inducer of neurite outgrowth 1 1.542 1.899  
CACNG8 Voltage-dependent calcium channel gamma-8 subunit 1.332 1.764  
DBN1 Drebrin 1.326 1.82 a 
BSN Protein bassoon 1.286 1.643  
SRCIN1 SRC kinase-signaling inhibitor 1 1.242 1.379  
DPYSL4 Dihydropyrimidinase-like 4 1.236 1.557 a 
Downregulated 
BIN1 Bin1 protein -1.515 -1.275  
ASAH1 Acid ceramidase -1.543 -1.786 a 
ANXA5 Annexin A5 -1.608 -1.944 a 
S100A1 Protein S100 -1.661 -2.308  
ATP5H ATP synthase subunit d, mitochondrial (Fragment) -2.239 -1.307  
HADHA Trifunctional enzyme subunit alpha, mitochondrial -2.392 -1.456 a 
PYGM Glycogen phosphorylase, muscle form -2.834 -1.928  
AHCYL2 Adenosylhomocysteinase -3.277 -1.397  
NDUFA13 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 13 
-3.494 -1.206  
MYO18A Myo18a protein -4.144 -1.782  
ATP1A3 Sodium/potassium-transporting ATPase subunit α-3 -4.177 -1.298  
SACM1L Phosphatidylinositide phosphatase SAC1 -4.749 -1.343  
PDHA1 Pyruvate dehydrogenase E1 alpha 1 -4.853 -1.299  
NDUFA9 
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 9, mitochondrial 
-4.959 -1.231  
UQCRC2 Cytochrome b-c1 complex subunit 2, mitochondrial -6.060 -1.226  
HIBADH 3-hydroxyisobutyrate dehydrogenase -7.145 -1.504 a 
GLUD1 Glutamate dehydrogenase 1, mitochondrial -7.148 -1.204  
SDHA 
Succinate dehydrogenase [ubiquinone] flavoprotein 
subunit, mitochondrial -7.356 -1.243 
a 
TKT Transketolase -7.505 -1.547 a 
SLC32A1 Vasicular inhibitory amino acid transporter 10D -8.797 -2.002  
SLC12A5 Solute carrier family 12 member 5 -9.531 -1.266  
ATP1A2 Sodium/potassium-transporting ATPase subunit α-2 -10.435 -1.497 a 
ATP5O ATP synthase subunit O, mitochondrial -11.183 -1.241  
HSPA5 Heat shock protein 5 -15.594 -1.227  
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Fig. 4.19. Validation of proteomic data by QWB in mouse and human samples at end stage of 
the disease. A&B. DBN1, HADHA and ANXA5 expression quantification of cortical 
synaptosome extracts from Ppt1-/- mouse model through label free proteomics and QWB (with its 
corresponding representative bands) showing the same expression trend. C. QWB quantification 
and representative bands of the same proteins in post mortem cortical synaptic extracts of INCL 
and JNCL patients and controls showing the same trends as in the mouse in the same brain and 
disease stage. B&C. Instant blue total protein staining as loading control quantification and 
representative gel images for both mouse and human cortical synapstosome extracts showing 
even loading of the samples used (bottom). Mean ± SEM; * p-value<0.05, ** p -value<0.01, *** p-
value<0.001, ns p-value>0.05 (Student T test). 
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4.4 Discussion 
In this chapter, we pursued an understanding of the molecular changes taking place 
throughout the time-course of disease progression during the whole process of 
neurodegeneration. To do so, we carried out a complex spatio-temporal proteomic analysis 
of synaptic fractions with the aim to identify potential regulators of synaptic stability to take 
forward to in vivo experiments (Chapter 5). We investigated 4 distinct time-points (1, 3, 5 
and 7 months), 2 conditions (Ppt1-/- and age-matched WT controls) and 2 differentially 
vulnerable synaptic populations (thalamus and cortex). 
It was a challenging analysis at both a technical and analytical level. For this reason, I outline 
some of the caveats of the pipeline in the following sections. 
 
Sampling of different synaptic populations across time-points 
As pointed out above, in our laboratory we were accustomed to looking at molecular changes 
throughout shorter time-courses (Wishart et al., 2012). This means that we were most likely 
to be sampling the same, or very similar, populations of synapses. In Wishart et al., 2012, a 
study of the molecular changes in synapses after injury (injury-induced degeneration) was 
carried out.  Synaptosomes were isolated at 0, 1 and 2 days post-injury (DPI). By 2 DPI, only 
around 10% of synapses were lost, therefore, the population of synapses were highly likely to 
not be that different from the ones at 0 and 1 DPI. In such a study, they were probably 
looking at the molecular changes happening throughout the same population of synapses. In 
contrast, in the time-course analysed here, even though we chose to study the most severe 
mouse model of NCL, we are extracting samples from a time period of 7 months. The level of 
synaptic loss at 7 months in the Ppt1-/-  mice, is much higher than in the injury–induced 
degeneration mouse model, and therefore, very different populations of synapses are 
sampled at each time-point. That might be the explanation of why in thalamic synapses, 
there is a large shift in the level of expression of many proteins (from down to up) between 3 
and 5 month time-points (Fig. 4.4), suggesting that we are sampling a very different 
population of synapses at 3 and 5 months respectively. Looking at the studies carried out by 
Kielar et al. in whole thalamic extracts, it was already detected by QWB that protein 
expression differ greatly between 3 and 5 months in several protein candidates (Kielar et al., 
2009). This molecular study carried out in the Ppt1-/-  mice is in consensus with our results 
correlating with our time-course results.  Bioinformatic analyses were also done using IPA at 
these two time-points highlighted.  A strong activation of neuronal death pathways at 3 
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months as well as a detected inhibition of the same pathways at 5 months were predicted. 
This may indicate that at 3 months we are sampling mostly “degenerating synapses” whereas 
at 5 months, such synapses are gone and we are sampling synaptic populations which are 
resistant. Therefore, changes at 5 months might provide insight into potential 
neuroprotective pathways.  Further studies addressing this specific point will be necessary to 
validate if synapses at 5 months are truly composed by a population of “resistant” synapses. 
 
Differences between thalamic and cortical synapses 
When examining cortical synaptic molecular changes, we identified similar profiles between 
5 and 7 months to the ones between 3 and 5 months in the thalamus (which are 
morphologically equivalent time-points). However, we also detected a large number of 
changes at 3 months (where synapses are still intact in the cortex). Such proteins were not 
the same as the ones changed at 3 months in the thalamus and therefore, a distinct molecular 
fingerprint could be clearly detected across two differentially vulnerable synaptic 
populations. Importantly, we should also bear in mind that the vulnerability of cortical 
synapses was established by looking at only S1BF and V1 (which corresponded to VPM/VPL 
and LGNd thalamic nuclei) (Kielar et al., 2009). However, the vulnerability status of synapses 
in other cortical regions such as the motor cortex, may be slightly different and since all the 
cortex was dissected and used for synaptosome production in this study, the other cortical 
areas not examined by IHC will be contributing to the overall molecular changes detected in 
the cortical synaptic proteomic data in this study. The larger heterogeneity of cortical 
synapses compared to thalamic synapses might be contributing to the larger variety of 
molecular profiles detected in cortex (10 different molecular trends, Fig. 4.9) compared to 
thalamus (5 different molecular trends, Fig. 4.6). Further IHC studies looking at the different 
cortical areas will help understand the exact contribution of each of the cortical synaptic 
populations to the overall molecular output. 
 
Using morphological pathology to map molecular changes 
To overcome sampling caveats, previously characterized morphological changes at different 
time-points are correlated to the molecular data. An examination of the molecular changes 
happening through disease progression in the thalamus (most vulnerable area) showed that 3 
and 5 months are the two most “affected” time-points with very dynamic changes taking 
place.  Afterwards, similar protein expression patterns mirroring the thalamic ones in the 
cortical samples with a 2 month delay in expression trend were looked for. This identified the 
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protein candidates without biasing the findings by other factors. Such biases include previous 
findings in the literature (which could hamper the identification of novel target) or the 
magnitude of change (which might be biologically irrelevant). In this way, 12 proteins were 
predicted to be upstream regulators and 17 proteins within the datasets that correlated with 
such a profile and that were further investigated in studies described in Chapter 5 using in 
vivo approaches. 
 
These candidate identifications were based on the premise that equivalent morphological 
changes in two brain areas are accompanied by the same molecular changes. This may be 
true but there is the possibility that different synaptic populations/brain areas might 
degenerate in slightly different ways (especially very early on). Such subtle differences may 
not be detectable through IHC studies but omics studies could potentially see these 
differences. A specific protein change might be critical for a specific brain area at a specific 
time-point but might not be that relevant for another brain area. Such proteins will be 
overlooked in the approach used here. However, the use of the temporal morphological 
patterns described by IHC, increases confidence that only the major protein regulators of 
synaptic stability are detected. 
 
Conserved molecular changes across NCL models 
Interestingly, an IPA analysis of the 17 identified candidates with a “delayed” profile, 
detected “Valine degradation” as the top-canonical pathway most significantly disrupted. 
Valine degradation was already an implicated pathway in the previous chapter and was 
identified as important in Cln3-/- degenerating synapses. In the Ppt1-/- time-course two of the 
enzymes within this pathway (HADHA and HIBADH) had a characteristic “delayed profile” 
(Fig. 4.18).  
 
Therefore, further studies were sought to identify conserved changes in the two mouse 
models at equivalent disease stages since this seemed most likely to detect regulators of 
synaptic stability. Comparing the molecular changes detected in thalamic synapses at 3 
months in Ppt1-/- and 13 months in Cln3-/-, similar expression trends were identified which 
were consistently linked to similar molecular functions (ie. upregulated proteins related to 
synaptic and vesicle functions whereas downregulated proteins were related to 
mitochondria). By tracking specific protein candidates in these two mice models to look for 
conserved changes, 31 proteins were identified with a similar up/down trend. Surprisingly, 9 
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out of 31 conserved proteins in Ppt1-/-  and Cln3-/- also presented a “delayed” profile between 
thalamus and cortex in the Ppt1-/- time-course (Table 4.3).  
 
Conserved molecular changes in Ppt1-/- & Cln3-/- mice and INCL & JNCL patients 
A further analysis was done to investigate whether the changes detected in Ppt1-/-  and Cln3-/- 
mice were also detectable in human post mortem INCL and JNCL patient samples.  Only an 
end stage patient cortical tissue was available so, the study focused on the 7 month cortical 
samples in the Ppt1-/-. Unfortunately, no end-stage Cln3 mice tissue was available for 
comparative analyses. Examination of three examples of the most promising candidates: 
DBN1, ANXA5 and HADHA (“delayed profile” in Ppt1-/- time-course and conserved 
changed between Ppt1-/-  and Cln3-/-), showed the same change seen in mice (by proteomics 
and QWB) and human (by QWB) (Fig. 4.19). We could then be more confident that at least 
these three candidates could be relevant to the human disease. 
 
Overall, despite initial concerns regarding the difficulty of interpreting the proteomic data 
due to the differences in synaptic sampling, multiple different analyses utilising all  available 
data such as morphologic (Kielar et al., 2009), proteomics of Ppt1-/- (thalamus and cortex) 
and proteomics in Cln3-/- (Chapter 3) were combined  to  shortlist a final list of candidates by 
a consensus of evidences. With so many protein identifications and datasets it could have 
been easy to get lost in the noise. The workflow implemented here could be used as a 
protocol for analysing similar datasets with an unbiased knowledge-based experiment 
design. Such methodologies could increase the likelihood of identifying proteins which are 
more likely regulators of synaptic stability in an unbiased way but may be transferrable to 
other mechanistic studies. In order to determine if such candidates do indeed have a role in 








 In vivo phenotypic assessment of 




This far in the project we have carried out in depth proteomic analysis of Cln3-/- and Ppt1-/- 
murine model synaptic populations (Chapters 3 & 4 respectivly), followed by in-depth in 
silico analyses. These distinct -omic experiments have enabled the development of specific 
workflows for the production and handling of data of increasing complexity. The outcome of 
which was the generation of a list of 33 protein candidates, identified in an unbiased manner, 
but centred around the correlation between their expression profile and synaptic 
vulnerability across brain regions and/or disease progression. 
 
Up until this point in the workflow, the identification of such candidates can only suggest 
that they may play a role in the degenerative process. Next, we therefore wanted to determine 
the role, if any, of each candidate in modulating the stability of the nervous system in vivo. 
To do so we turn to the Drosophila melanogaster model system. As extensively covered in the 
General Introduction (Chapter 1, Section 1.8), the fruit fly is an excellent and commonly 
used organism for the study of neurodegenerative diseases. The availability of multiple 
genetic tools allows the manipulation of specific genes of interests in order to assess their role 
in modulating the stability in the different organ systems of the Drosophila (Martinez-Arias, 
2008, Green, 2010, O’Kane, 2003, Mehregan et al., 2016). During the second year of my PhD 
I was hosted in the laboratory of Dr Giusy Pennetta (Centre for integrative physiology, 
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University of Edinburgh) for a year, where I was trained in all of the techniques and 
experiments required for this analysis, and I subsequently used this training to set up the 
Drosophila screening facility in the Wishart Laboratory at the Roslin Institute.  
 
As outlined in my general introduction (Chapter 1, Section 1.8.3), there are overexpression 
(OE) and loss of function (LOF) CLN3 and PPT1 Drosophila available, which could be used 
as tester lines for our in vivo experiments (Tuxworth et al., 2011, Tuxworth et al., 2009, Aby 
et al., 2013, Hickey et al., 2006, Buff et al., 2007, Saja et al., 2010). We initially aimed to use 
each corresponding CLN3 and PPT1 model and cross them with the misexpressed 
candidates identified in Chapters 3 & 4 respectively. In that way we could study their role as 
modulators of the nervous system in each disease condition. However, each one of the 
disease models, would require a detailed examination and characterization to reproduce the 
phenotypes described by other authors before its use in my modifier genetic screen. 
Therefore, due to time limitations, the high degree of molecular overlap in the pathways and 
cascades identified in chapter 3 & 4, and the convenience of the phenotypes in the CLN3 
Drosophila models, we decided to focus on CLN3 for this chapter. Additionally, despite the 
effort of the NCL research community, very little is actually known about CLN3 function. 
Unlike PPT1 Drosophila models, no extensive modifier sceens have been carried out in the 
CLN3 fruit flies to date. Therefore, the results coming from the current genetic screen should 
prove valuable, not only in the context of the identification of regulators of neuronal 
stability, but also, to identify CLN3 interactors that might give clues about its wider function. 
 
LOF CLN3 Drosophila have been generated by Tuxworth et al. (Tuxworth et al., 2011). The 
LOF mutant fly (Cln3êMBI), was shown to be hypersensitive to oxidative stress, but authors 
did not note any obvious developmental or neurological defects (Tuxworth et al., 2011). For 
this reason we decided to start looking at a CLN3 OE Drosophila, also generated by 
Tuxworth et al. (Tuxworth et al., 2009). Using the UAS/GAL4 system (see Section 5.2.3), OE 
of CLN3 (UAS-CLN3) driven in the eye under the control of GMR-GAL4, presents with a 
noticeable degenerative eye phenotype indicated by glazing, reduction of surface area and 
loss of the regular shape of crystalline array of the compound eye including fusion of 
ommatidia and perturbations in somatosensory bristle patterns. Authors estimated that this 
model driving expression in the eye increased CLN3 level 2.86-fold (+0.42 SD) over basal 
CLN3 expression in the wing  (Tuxworth et al., 2009). Tuxworth and colleagues have added 
to the field by using this model to show that CLN3 interacts with Notch, inhibiting its 
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function at the protein level by regulating its processing and/or cleavage (Tuxworth et al., 
2009). Thus, such “simplified” in vivo model systems can inform on the molecular processes 
taking pace in response to perturbations in a protein of interest. 
 
First, we aimed to reproduce the phenotypes described in a CLN3 overexpression (OE) in the 
eye system (Tuxworth et al., 2009), and investigate the presense or absence of a synaptic 
phenotype (in the neuromuscular junction (NMJ) in the larvae). Moreover, since the human 
CLN3 disease is caused by the LOF of CLN3 protein, we also wanted to investigate the effects 
of CLN3 LOF in Drosophila (eye and NMJ). Second of all, once we confirmed that the OE 
CLN3 driven in the eye would be a suitable tool for the genetic modifier screen, we studied 
the effects of the misexpression of identified candidates (from Chapter 3&4) on a CLN 
induced phenotype i.e. in the presence or absence of CLN3-induced degenerative eye (CLN3 
OE & WT background respectively). 
 
In this chapter we show that we can reproduce the phenotype described by Tuxworth et al. in 
a fly overexpressing CLN3 under the control of the GMR-GAL4 driver. We also show that 
this model is a suitable tester line for the desired genetic modifier screen. Results of the 
genetic screen indicated that most of the candidates identified in proteomic studies in 
Chapter 3 & 4 are capable of modulating the stability of the nervous system in vivo. Thus 
confirming the veracity of the proteomic comparisons and the validity of the data filtering 
strategies used to generate the candidate lists. Interestingly, we show that some of the 
candidates are doing this in a CLN3-dependent manner. In contrast, other candidates are 
shown to be global regulators of the nervous system as their misexpression was capable of 
disrupting eye structure also in a WT background.  
 
Overall, we demonstrated that protein candidates identified in an unbiased way from 
proteomic studies in synapses from murine neurodegenerative disease models can be 
targeted into lower order organisms such as Drosophila for the identification of regulators of 
neuronal stability (both in general and in a neurodegeneration specific context) in vivo. 
Candidates identified here warrant follow up as potential targets for the development of 





5.2 Materials and methods 
5.2.1 Drosophila husbandry and maintenance 
Stocks were maintained on standard cornmeal food at room temperature (RT) and flies were 
raised at specific temperatures according to the experiment. General stock information can 
be found in Table 5.1. Drosophila mouse orthologs for candidate proteins were identified 
using Drosophila RNAi Screening Center (DRSC) Integrative Ortholog Prediction Tool 
(DIOPT) (see below), and RNAi and OE lines were chosen from Flybase and obtained from 
Vienna Drosophila stock centre (VDSC) (Dietzl et al., 2007), Bloomington Drosophila Stock 
Centre (BDSC) (Perkins et al., 2015) and FlyORF (Bischof et al., 2013) (see Table 5.2). All the 
RNAi and OE lines used in this study carry the UAS construct (ie. CLN3-UAS-RNAi) and 
therefore they will be expressed under the control of GAL4 drivers (see section 5.2.3). 
However, all the RNAi lines utilized in this study will be referred as the “gene of interest” 
plus RNAi for short (ie. CLN3-RNAi). 
 
5.2.2 DIOPT 
Drosophila orthologs for mouse candidate proteins were identified using DRSC Integrative 
Ortholog Prediction Tool (DIOPT) as previously used in (Sanhueza et al., 2015). This 
bioinformatic tool has been developed by the Drosophila RNAi screening center at the 
Harvard medical school (Hu et al., 2011, Zoghbi et al., 2000). It uses ten different algorithms 
to find ortholog matches for a specific gene. The number of positive results is represented by 
a score, the higher it is, the better the match. All the fly genes utilised in this study had a 
DIOPT score of at least 2  with proteins scoring less not being considered for these 
experiments as this indicates that the identification as an ortholog is only supported by one 
algorithm (Sanhueza et al., 2015). DIOPT did not identify high rank orthologs for ASAH1, 
S100A1, HEPACAM and HBA-A2, therefore these candidates were not targeted in vivo in 
this chapter. Dpysl3 and Dpysl4 were shown to have the same ortholog in Drosophila 
(CRMP). More information regarding candidate misexpression lines purchased can be found 







Table 5.1. Drosophila general stocks 
Line Source Description Reference 
Canton S BDSC Wild type line N/A 
UAS-CLN3 Richard Tuxworth CLN3 overexpression 
(Tuxworth et 
al., 2009) 
CLN3-RNAi/CyO VDRC (v5322) CLN3 RNAi line 
(Dietzl et al., 
2007, Jones et 
al., 2014) 
GMR-GAL4;UAS-
CLN3/CyOGFP This study Recombinant line 
(Llavero 
Hurtado et al., 
2017) 
CLN3-
RNAi/CyOGFP This study 
CLN3 RNAi line with larvae 
balancer N/A 
D42-GAL4 BDSC Motor neuron expression driver 
(Parkes et al., 
1998) 
elavC155-GAL4 BDSC Pan-neuronal expression driver 
(Yannoni et al., 
1997) 
Bg57-GAL4 BDSC Muscle expression driver (Budnik et al., 1996) 
GMR-GAL4 BDSC Eye expression driver (Freeman, 1996) 
Eyeless-GAL4 BDSC Eye expression driver (Tseng et al., 2002) 
L/CyOGFP Giusy Pennetta Larvae balancer N/A 
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Table 5.2a Drosophila candidate stocks 









AnxB9-RNAi Anxa5 V w1118; P{GD11750}v27493 CG5730 27493 2 Down 
Atpalpha-OE Atp1a2 F M{UAS-Atpα.ORF}ZH-86Fb CG5670 F001458 8 Down 
ATPsynbeta RNAi TRiP Atp5b B y1 v1; P{TRiP.JF02892}attP2 CG11154 28056 11 Down 
Abp1-RNAi Dbn1 V w1118; P{GD6858}v38331 CG10083 38331 9 Up 
CRMP RNAi KK Dpysl4/Dpysl3 V P{KK108924}VIE-260B CG1411 101510 7 Up 
ERR RNAi KK Esrra V P{KK108422}VIE-260B CG7404 108349 8 Down* 
Gbeta13F RNAi KK Gnb4 V P{KK102923}VIE-260B CG10545 100011 10 Up 
MTPαRNAi Hadha V w1118; P{GD11299}v21845 CG4389 v21845 10 Down 
CG15093 RNAi TRiP Hibadh B y1 sc* v1; P{TRiP.HMC04926}attP40 CG15093 57736 11 Down 
HibchRNAi Hibch V w1118; P{GD11513}v40570 CG5044 v40570 9 Down 
Hnf4-OE Hnf4a F M{UAS-Hnf4.ORF.3xHA.GW}ZH-86Fb CG9310 F000144 9 Down* 
InR-OE Igf1r/InsR B y1 w1118; P{UAS-InR.Exel}2 CG18402 8262 8/6 Down* 
msn RNAi KK Map4k4 V P{KK108948}VIE-260B CG16973 101517 8 Up 
Oga RNAi GD Mgea5 V w1118; P{GD10644}v41822 CG5871 41822 11 Up* 
Mitf RNAi KK Mitf V P{KK113614}VIE-260B CG43369 108519 8 Down* 
Rel RNAi GD Nfkb1 V P{GD1199}v49414 CG11992 49414 6 Up* 
N RNAi GD Notch1 V w1118; P{GD144}v1112 CG3936 1112 10 Up* 
Nc73EF RNAi KK Ogdhl V P{KK100395}VIE-260B CG11661 107713 10 Down 
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Table 5.2b Drosophila candidate stocks 
 
 
*Based on z-score prediction IPA tool 
**Based on KO/WT ratio from proteomic studies 
V: Vienna Drosophila stock centre (VDSC); B: Bloomington Drosophila Stock Centre (BDSC); F: FlyORF









zen RNAi KK Pdx1 V P{KK113335}VIE-260B CG1046 102915 2 Up* 
Eip75B-OE Pparg F M{UAS-Eip75B.ORF.3xHA.GW}ZH-86Fb CG8127 F002207 3 Down* 
Pten-OE Pten F M{UAS-Pten.ORF.3xHA}ZH-86Fb CG5671 F001033 11 Down* 
Rictor RNAi TriP Rictor B y1 sc* v1; P{TRiP.GL00544}attP40 CG8002 36584 9 Up* 
RokRNAi GD Rock2 V w1118; P{GD1522}v3793 CG9774 v3793 9 Up 
RokRNAi TRiP Rock2 B y1 v1; P{TRiP.JF03225}attP2 CG9774 28797 9 Up 
SdhA RNAi KK Sdha V P{KK101728}VIE-260B CG17246 110440 11 Down 
Aralar1 RNAi TRiP Slc25a12 B y1 sc* v1; P{TRiP.HMC04105}attP40 CG2139 56884 11 Down 
CG8036 RNAi KK Tkt V P{KK101051}VIE-260B CG8036 105633 10 Down 
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5.2.3 UAS/GAL4 system 
This is a widely used two-component system in Drosophila studies to direct the expression of 
a gene of interest in a tissue and time specific manner (Brand, 1993). One of the components 
expresses a yeast transcription factor called GAL4 which contains a P element vector for a 
specific cell type (promoter). The second component contains the Upstream Activating 
Sequence (Galione et al., 2010) next to a specific gene of interest that will bind to GAL4 in a 
temperature dependent manner. Many tissue specific GAL4 drivers have been developed to 
target expression of genes in specific cell types including (but not limited to) pan-neuronal 
drivers (elavC155-GAL4) (Yannoni et al., 1997), motor-neuron drivers (D42-GAL4) (Sanyal, 
2009, Parkes et al., 1998, Gustafson et al., 1996, Nitz et al., 2002) and eye drivers (GMR-
GAL4) (Freeman, 1996). 
This approach provides a powerful system for experimentation ideal for the study of a 
phenotype when a gene is misexpressed in a spatio-temporal manner. The UAS/GAL4 
system is widely used in modifier screens in a clean and efficient manner (St Johnston, 2002). 
 
5.2.4 Drosophila phenotypic assessment  
Drosophila were used as a model system to study the ability of the protein candidates 
identified through proteomics and bioinformatics analyses (Chapters 3 & 4), to modulate 
neuronal stability in vivo.  
We first needed to characterize the phenotypes in different neuronal systems in NCL fly 
models in order to identify which system was the optimal for performing our candidate 
genetic screen. We studied the neuromuscular junction (NMJ) of musculature body wall in 
the third instar larvae and the adult eye in both OE and LOF of CLN3. 
 
We utilized the well-characterized temperature-inducible UAS/GAL4 system (see above). 
For the phenotype characterisation experiments, 8-10 virgin females from each driver were 
crossed to 7-8 males (UAS-CLN3 or CLN3-RNAi). Flies were raised at different temperatures 
to modulate the expression of the genes of interest including: 25, 27, 28 and 30oC. As a 
control, crosses with the driver and a wild-type fly (Canton S (+/+)) were carried out in 
parallel for all the experiments. 
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5.2.4.1 Neuromuscular junction morphology 
The synaptic phenotype was studied at the NMJ of the musculature body wall in the third 
instar larvae. To do so we studied the effects of CLN3 downregulation (CLN3-RNAi) and 
overexpression (UAS-CLN3) to the morphology of the NMJ. Homozygous UAS-CLN3 fly 
was donated by Dr Richard Tuxworth. RNAi-CLN3/CyO line was obtained from Vienna 
Drosophila Resource Centre (VDRC) (Dietzl et al., 2007, Jones et al., 2014) and crossed to 
L/CyOGFP to generate a fly stock containing CLN3-RNAi over a larval balancer (CLN3-
RNAi/CyOGFP) (see Table 5.2). UAS-CLN3 and CLN3-RNAi/CyOGFP flies were crossed 
with a range of neuronal drivers including a motor-neuron driver (D42-GAL4) (Sanyal, 2009, 
Parkes et al., 1998, Gustafson et al., 1996, Nitz et al., 2002), a pan-neuronal driver (elavC155-
GAL4) (Yannoni et al., 1997) and to a post-synaptic/muscle driver (Bg57-GAL4) (Budnik et 
al., 1996) (See Table 5.1). 
 
In terms of the expression patterns of GAL4 drivers, D42-GAL4 expression is restricted to 
motor-neurons although it has also been found in some sensory neurons of the musculature 
body wall of the larvae (Sanyal, 2009). In contrast elavC155-GAL4 is expressed in all neurons in 
all developmental stages (Robinow et al., 1988). Importantly, although elavC155-GAL4 tends to 
be used as an exclusive pan-neuronal by the research community, elav has also been 
described to be expressed in embryonic glial cells and in transiently proliferating progenitor 
cells (neuroblasts and glioblasts) (Berger et al., 2007). Therefore, any effects triggered by 
either UAS-CLN3 or CLN3-RNAi under the control of elavC155-GAL4 could not be uniquely 
attributed to the role of neurons. BG57-GAL4 is expressed in all larval muscles, from mid 
first to third instar stage. Additionally, with BG57, GAL4 expression is also observed in two 
sensory cell bodies in the body wall and in other mesodermally derived tissues, such as the 
gut. Importantly, no expression has been detected in ectodermal tissues, such as other areas 
of the CNS (Budnik et al., 1996). 
 
Crosses were left at room temperature for flies to mate and lay eggs. After 48 hours parents 
were removed and eggs were transferred to incubator/water bath and incubated at 25, 27, 28 
and 30o C. F1 third instar larvae were dissected and immunostained with pre- and post-
synaptic markers as explained in IHC in General materials and methods (Chapter 2, Section 
2.3.2). For RNAi-CLN3/CyOGFP crosses, only CyO+ flies were dissected which were 




Fig. 5.1. Confocal imaging of NMJ in muscle 12/13 of WT Drosophila larvae fillet preparation 
stained with pre-synaptic (HRP) and post-synaptic markers (Dlg). A. 4x magnification 
micrographs of larvae filler preps with segment A3 highlighted with a white-dashed box. B. 
Micrograph of segment A3 of the same larva at 10x highlighting NMJs in muscles 6/7 &12/13 in a 
white-dashed box. C. Micrograph at 20x of NMJ 6/7 (left) & 12/13 (right). It is noticeable the 
tree-branching pattern of 6/7 NMJ whereas 12/13 (highlighted with white-dashed box) has a 
more defined triangular shape towards the distal side of the larvae. It is also obvious that the axon 
coming from the ventral side. D. High magnification (60x) micrographs of NMJ from muscle 
12/13. WT (Canton S) NMJ displays an even beading of boutons with regular rounded shapes. 
Glutamatergic boutons (type I) are surrounded by Dlg staining whereas smaller boutons (type II 






The same NMJ in muscle 12/13 within segment A3 was qualitatively characterized across all 
the genotypes in at least 8 larvae (See Fig. 5.1). This specific NMJ was chosen because: 1. It is 
relatively easy to find; and 2. It contains all bouton types (Menon et al., 2013) and therefore 
can be used to determine whether a phenotype is bouton-specific. An initial characterization 
of the phenotype was performed through fluorescence imaging. If a phenotype was obvious 
we then proceeded to image the slides with confocal microscopy (see imaging section). Dr 
Giusy Pennetta confirmed all the NMJ phenotypes described in this thesis. 
 
 
5.2.4.2 Eye structure 
It has previously been described that overexpression of CLN3 in the eye triggers a 
degenerative phenotype in Drosophila using the GMR-GAL4 eye driver (Tuxworth et al., 
2009) (See 5.1 Introduction). First of all, we investigated whether we could replicate this 
phenotype in our lab, and secondly, if we could obtain a similar phenotype by using a 
different eye driver (Eyeless-GAL4) (Tseng et al., 2002). Additionally, we wanted to 
investigate if knocking-down CLN3 (CLN3-RNAi) also causes degeneration in the eye under 
the control of the same drivers (GMR-GAL4 and Eyeless-GAL4). 
 
Importantly, we needed to consider the expression pattern of both GMR-GAL4 and Eyeless- 
GAL4 drivers when interpreting results. GMR is found to be primarily expressed in the 
posterior region of the morphogenic furrow area, where ommatidia cells are starting to 
differentiate (Freeman, 1996). However, it has been recently found to be expressed also in 
specific neuronal cells in larval and pupal brain and the ventral ganglia as well as in the 
Bolwig’s organ and the eye primodia in embryonic stages (Ray et al., 2015). Studies by Li et 
al. also reported the expression of GMR in the wing and leg discs (Li et al., 2012). Therefore, 
although flies are able to survive in the absence of eyes, due to the fact that GMR is also 
expressed in the CNS, some genes driven under the control of GMR-GAL4 may cause 
lethality (Ray et al., 2015). In contrast, Eyeless-GAL4 driver, is a transgenic line based on the 
eyeless gene (ey). Ey is a key gene for the eye development in Drosophila. Driving the ectopic 
expression of ey is sufficient to induce eye formation in various tissues. Ey is expressed in the 
embryonic ventral nerve cord and in some areas of the brain. In larval stages, it is expressed 
in the eye imaginal disc and in third instar larvae its expression is restricted to 
undifferentiated cells located anterior to the morphogenic furrow (Halder et al., 1995). Due 
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to these differences in expression patterns, the use of these two drivers allows the study of 
both LOF an OE of CLN3 at different stages of the developing eye. 
 
Each eye driver was crossed with UAS-CLN3 and CLN3-RNAi and were left to mate and lay 
eggs at room temperature. After 72 hours, the parents were removed and eggs were 
transferred and raised at different temperatures to study different degrees of 
overexpression/downregulation (ie. 25, 27 and 28oC). F1 adults were counted and eyes 
examined for the identification of defects in eye structure which indicated 
neurodegeneration. Photographs of the eyes were taken for further examination and 
quantification (see Chapter 2 General materials and methods, Section 2.9). Eye surface area 
was quantified using ImageJ as previously described (Sanhueza et al., 2015).  
 
5.2.4.3 Genetic modifier screen 
After assessing the different phenotypes triggered by both overexpression and knockdown of 
CLN3 in both NMJ and eye, we chose UAS-CLN3 driven in the eye via GMR-GAL4 as the 
system for performing a modifier screen. We then explored whether the misexpression of the 
identified candidates from Chapter 3 & 4 have the ability to modify CLN3-induced 
degeneration in the eye. 
 
Because both driver and overexpression allele are in the second chromosome, we needed to 
build a recombinant fly with GMR-GAL4 and UAS-CLN3 to make sure that the candidate 
RNAi/OE construct is found on the same chromatid as the driver. To do so (taking the 
advice of Dr Mario Sanhueza – Pennetta Lab), a recombinant stock was established by 
conventional recombination methods to be used as a tester line for the modifier screen. 
According to the chromosomal position of CLN3, and using the web-based tool Drosophila 
melanogaster Recombination Rate Calculator (RRC, Version 2.3) (Comeron et al., 2012, 
Fiston-Lavier et al., 2010), recombination rates for CLN3 were predicted to be 0.14-0.70%. 
As shown in Fig. 5.2A, individual F1 GMR-GAL4/UAS-CLN3 virgins were placed with 2-3 
males which carried second chromosome balancers (H16/CyOGFP) into individual food 
vials.  Resulting F2 offspring from each female virgin were then examined. Recombinant flies 
are then distinguishable by their phenotype - displaying CyO- phenotype (curly wings) and 
the previously characterized CLN3-degenerative eye - as they will contain the eye driver 
(GMR-GAL4), the CLN3 overexpression construct (UAS-CLN3) and the CyO- balancer (CyO 
GFP) (Fig. 5.2B). 
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Fig. 5.2 Generation of GMR-GAL4 and UAS-CLN3 recombinant Drosophila line. A. Mating 
scheme for the generation of recombinant tester fly line which requires two crosses: F0; regular 
eye driver (GMR-GAL4) x overexpression construct (UAS-CLN3) which will generate F1 flies 
GMR-GAL4/UAS-CLN3. Next, F1 individual female virgins will be crossed to males carrying a 
second chromosome balancer (H16/CyO GFP). With 0.14-0.70% probabilities, F2 will be 
expected to contain a fly carrying a recombinant construct over a CyOGFP balancer (GMR-
GAL4; UAS-CLN3/CyOGFP). These flies are then amplified to keep as a stock ($) . B. 
Representative image of the recombinant fly obtained after 25 individual crosses. The small and 




Once the recombinant flies are established (GMR-GAL4;UAS-CLN3/CyO GFP), these were 
used as a tester line to cross with misexpressed candidate lines (Table 5.2), as described in 
Fig. 5.3. 8-9 RNAi or OE candidate males were crossed to 10-12 virgin recombinant female. 
F1 progeny were sorted by genotype and flies carrying the recombinant and the 
misexpression candidate constructs (GMR-GAL4;UAS-CLN3/Candidate-RNAi/OE) were 
assessed for suppression or enhancement of the CLN3-derived small and rough eye 
phenotype (Fig. 5.3; right side). These flies are distinguishable by their regular wings (CyO+). 
Flies carrying the CyOGFP balancer over a Candidate-RNAi/OE construct did not display 
any phenotype as they will be lacking the GAL4 driver. Such flies are distinguished by their 
curly wings (CyO-). These flies represent good internal controls, as any defects in eye 
structure or viability will indicate a problem within the experiment. 
 
A control cross was carried out in parallel by crossing GMR-GAL4;UAS-CLN3/CyO GFP to a 
WT fly (+/+) (Fig. 5.3; left side). The control cross gave rise to F1 flies carrying the CyOGFP 
balancer over a WT allele (+/CyOGFP) which have curly wings (CyO-). CyO- have no 
 134 
phenotype and are used as control flies. F1 flies containing the recombinant construct over a 
WT allele (GMR-GAL4;UAS-CLN3/+) have normal wings (CyO+),  and present a typical 
CLN3-induced degenerative eye.  For this reason, they could be used as neurodegeneration 
model flies to compare against.  All flies in the crosses of this sceen, were raised at 25 °C in a 
circadiarian light incubator.  
 
To have a quantitative read out of the severity of the phenotypes obtained in our experiments 
the eye surface area was measured in ImageJ as previously described (Sanhueza et al., 2015). 
Normalised surface areas of candidates identified in Chapter 4 were calculated as: (x- average 
eye surface area of CLN3 OE)/(average of eye surface area of the control - average eye surface 
area of CLN3 OE) x100.  
 
 
Fig. 5.3. Genetic modifier screen mating scheme. A. As indicated on the right; recombinant 
female virgins (GMR-GAL4;UAS-CLN3/CyO GFP) were crossed with misexpressed candidate 
lines (in this example RNAi homozygous in the second chromosome). In F1 50% of flies contain 
the misexpression construct and the CyO- balancer (internal control, distinguishable by the curly 
wing phenotype). The other 50% will contain the recombinant allele GMR-GAL4;UAS-CLN3 and 
the misexpression construct (RNAi-Candidate), which do not have curly wings (CyO+). These 
flies are assessed for suppression or enhancement (or no effect) of the CLN3-induced phenotype. 
In parallel (indicated on the left), recombinant female virgins (GMR-GAL4;UAS-CLN3/CyO GFP) 
are crossed with a wild-type fly (Canton S) to generate control flies: GMR-GAL4;UAS-CLN3/+ 
(CLN3 OE control) and +/CyO GFP (WT phenotype control). B. Graphic representation of the 
resulting phenotypes in the adult Drosophila eye. Control and internal control will show no 
defects on the eye. CLN3 OE will show the previously characterized CLN3-induced degenerative 
eye. The fly containing the eye driver, CLN3 overexpression and candidate misexpressed 
construct will either have no effect (eye will be comparable to CLN3 OE) an enhancement of the 
phenotype (smaller eye and/or with more black puncta), or suppression of the phenotype 
(increased surface area and/or improvement of the compound structure of the eye). 
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5.2.4.4 Viability assay 
To investigate the effect of CLN3 misexpression in the adult viability, we analysed the 
number of eclosed flies expressing UAS-CLN3 or CLN3-RNAi under the control of different 
neuronal drivers: GMR-GAL4, D42-GAL4, ElavC155-GAL4 and Bg57-GAL4. 
For UAS-CLN3 crosses viability was calculated as a percentage of the number of eclosed OE 
CLN3 flies/Number of eclosed control flies. A value of 100% is expected if the cross is non-
toxic. A value lower than 100% indicates a toxic effect. For CLN3-RNAi crosses, the total 
number of eclosed flies for each F1 genotype was plotted so CyO+ (containing RNAi-CLN3) 
expressing flies were compared to their CyO- internal controls, as each of them are expected 
to be 50% of the total. 
 
5.2.4.5 Fasudil drug assay 
ROCK2 upregulation was found to correlate to synaptic vulnerability in Chapter 3. After a 
rescue was obtained when targeting ROCK2 genetically in Drosophila CLN3-induced 
degenerative eye phenotype (via ROCK2-RNAi), we wanted to investigate if we could also 
target ROCK2 upregulation pharmacologically. To do so we used the ROCK inhibitor 
Fasudil, Monohydrochloride Salt (LC laboratories, F-4660), which was previously used in 
mice models of SMA improving survival and skeletal muscle development (Bowerman et al., 
2012). 
 
To establish the optimal dosage window GMR-GAL4 x UAS-CLN3 crosses were raised in 
regular food containing different concentrations of Fasudil as recommended in (0.1, 1 and 10 
mM) (Pandey et al., 2011). However, results were very variable between experiment and we 
thought there was difficulty mixing the drug with the pre-made food to an even consistency.  
Therefore, experiments were repeated using Nutri-Fly instant food (Genesee Scientific, 66-
118) prepared and mixed in the laboratory. Results started to become more consistent and a 
therapeutic window dose was established to be between 1.4 and 5 mM (Fig. 5.4). The optimal 
dose established was 1.4 mM, in which a small but consistent improvement of the eye 
phenotype was observed. Therefore, three independent experiments were carried out with 
1.5 mM of Fasudil to confirm the results. Eyes of the offspring were photographed and total 
surface area was measured with ImageJ. Suppression of the CLN3-degenerative eye were 
calculated from 3 independent experiments as “(x- average eye surface area of the CLN3 
OE)/(average of eye surface area of the control - average eye surface area of CLN3 OE) x100” 

















Fig. 5.4. Fasudil therapeutic window concentration is between 1.4 and 5 mM. Bar chart showing 
the normalised suppression effect of Fasudil in GMR-GAL4/UAS-CLN3 flies which were raised 
in food containing 0.14, 1.4, 3, 5 and 15 mM of Fasudil. 0.14 mM did not cause any effect in 
CLN3-induced phenotype, whereas 15 mM showed to enhance the eye phenotype by 




5.3.1 Characterization on CLN3 Drosophila models 
First, we needed to characterize the phenotypes in different neuronal systems in CLN3 
Drosophila models in order to identify which system was the optimal to perform our 
candidate genetic screen. We utilized the well-characterized temperature-inducible 
UAS/GAL4 system which allows the misexpression of a gene of interest in a spatio-temporal 
manner (Brand et al., 1993, St Johnston, 2002) (see 5.2 Materials and methods).  
 
5.3.1.1 CLN3 OE in the eye 
There seemed to be a dosage window in which too much or too little CLN3 caused a 
disruption of the nervous system in Drosophila (Tuxworth et al., 2009, Tuxworth et al., 
2011). The targeted overexpression of CLN3 by means of the UAS/Gal4 system, using the 
GMR-GAL4 driver (Freeman, 1996) was shown to cause severe neurodegeneration of the 
adult compound eye, which was indicated by fused ommatidia (glazing) and smaller eyes 
(See 5.1 Introduction) (Korey et al., 2003, Tuxworth et al., 2009). 
 
First, we wanted to reproduce the phenotype described by Tuxworth et al., and explore if we 
could utilize such a model as a tool to assess the role of our candidates in vivo. To do so, two 
eye drivers were used: GMR-GAL4 (the same used by Tuxworth et al. and commonly used in 
genetic screens (Fernandez-Funez et al., 2000) and eyeless-GAL4 (Tseng et al., 2002), also 
commonly used for genetic screens (Sanhueza et al., 2015). 
UAS-CLN3 flies (donated by R. Tuxworth) were crossed to the temperature inducible GMR-
GAL4 eye driver (see Table 5.1). Crosses were raised at 25, 27 and ≥28oC in order to study the 
effects of CLN3 dosage in the eye. After eclosion, adults were examined under the 
stereomicroscope and eyes were photographed for total surface area quantification. At 25oC, 
eye size was significantly smaller than control eyes, the structure of the compound eye was 
completely disrupted showing a glazing phenotype (fused ommatidia) and alteration of 
somatosensory interommatidial bristles, as previously described by Tuxworth et al.  There 
was a detectable presence of black puncta in some flies, which indicates necrotic cell death. 
Very interestingly, the same crosses raised at 27oC showed a more severe phenotype with an 
increase in lethality (Fig. 5.5). GMR-GAL4 x UAS-CLN3 offspring raised at 28oC proved to be 
100% lethal at the pupa stage. 
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Conversely, UAS-CLN3 driven with eyeless-GAL4 did not cause any phenotype at 25 or 28o C. 
As mentioned in section 5.2.4.2, Ey is a key gene for the eye development in Drosophila and 
its expression is restricted to undifferentiated cells located anterior to the morphogenic 
furrow (Halder et al., 1995). In contrast, GMR-GAL4 driver (Freeman, 1996) is expressed in a 
different area than the eyeless gene. GMR is found to be primarily expressed in the posterior 
region of the morphogenic furrow area, where ommatidia cells are starting to differentiate 
(Freeman, 1996). Therefore, these results indicate that the role of CLN3 is likely to be more 
important to the the cells of the ommatidia when they are starting to differentiate and it 
might not play an essential role in previous steps of eye development in Drosophila 
(undifferentiated cells). 
 
Importantly, here we show that we could successfully reproduce the already published 
phenotype in Drosophila eye using the same GMR-GAL4 driver as the one reported by 
Tuxworth et al. Additionally, we established a way to quantify this phenotype by measuring 
the total surface area of the eye and demonstrated that the effects in the phenotype (eye and 















































Fig. 5.5. CLN3-induced neurodegeneration in the eye is dose-dependent. A. Representative light 
microscope images of fruit fly eyes of control line (GMR-GAL4/+) and CLN3 OE line (GMR-
GAL4/UAS-CLN3) at 25oC and 27oC. The higher the temperature the greater the expression of 
CLN3. B. Quantification of the eye surface area of these genotypes showing that the higher the 
dose of CLN3 gene, the greater the effect seen in the eye. C.  Normalised viability to control cross 
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at 25, 27 and 28o C showing the progressive decrease in viability correlating to increase in CLN3 
expression driven in the eye. One-way ANOVA with Tukey’s multiple comparison post-hoc; * p-




5.3.1.2 CLN3 OE in the NMJ 
To date, no studies have been published regarding the effects of CLN3 OE at the synaptic 
level. Since, CLN3 OE causes neurodegeneration in the adult developing eye (see above), we 
also wanted to explore if CLN3 OE caused synaptic disruption in the neuromuscular 
junction of the musculature body wall in Drosophila larvae (see Chapter 1. General 
introduction, section 1.8.2.1 & 1.8.3). 
To do so, we crossed UAS-CLN3 to a motor-neuron driver (D42-GAL4) (Sanyal, 2009, 
Parkes et al., 1998, Gustafson et al., 1996, Nitz et al., 2002), a pan-neuronal driver (elavC155-
GAL4) (Yannoni et al., 1997) and to a post-synaptic/muscle driver (Bg57-GAL4) (Budnik et 
al., 1996) (see Table 5.1 and 5.2 Materials and methods). Flies from these crosses were raised 
at 25, 27 and 28oC, to assess the effects of CLN3 dose. To visualize larval NMJs, dissection of 
third instar larvae and fillet preparation was carried out followed by the use of primary and 
secondary antibodies labeling pre-synaptic neuron (HRP) and the post-synaptic side of 
glutamatergic boutons (Dlg) (see Chapter 2. General materials and methods; section 2.3.2). 
 
Flies carrying UAS-CLN3 under the control of a motor-neuron driver (D42-GAL4), 
presented a very severe phenotype at 27 oC (Fig. 5.6A). They have a small number of boutons 
left and the remaining ones presented an abnormal shape. Axons were also affected, 
indicated by the lack of HRP (green) staining. Additionally, loss of Dlg (red) seemed 
proportional to the loss of its corresponding pre-synaptic side. At 25o C, abnormalities in the 
NMJ architecture were also detected although, as expected, they were milder than those at 
higher temperature. 
 
Therefore, using a motor-neuron driver, we can also detect the dose-dependent effect of 































Fig. 5.6. Overexpression of CLN3 driven to the motor-neuron causes a dose-dependent 
disruption of the NMJ architecture in the third instar Drosophila larvae and a decreased 
viability of adult flies. A. Confocal micrographs NMJ of muscle 12/13 of control (D42-GAL4/+) 
and CLN3 OE Drosophila third instar larvae (D42-GAL4/UAS-CLN3) raised at 27o C. Larvae fillet 
preparations were stained with a neuronal (HRP, green) and post-synaptic glutamatergic markers 
(DLG1, red). The architecture of the OE NMJ larvae is severely disrupted with loss of axons, 
boutons at both pre- and post-synaptic level. B. Bar chart representing the normalised viability of 
the same crosses at 25 and 27o C showing that the dose-dependent effect of CLN3 OE was also 
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reflected in the surviving offspring. Mean ± SEM; One-way ANOVA with Tukey’s multiple 
comparison post-hoc; ** p -value<0.01, *** p-value<0.001, N=2-3. 
 
 
Some crosses were left in the incubator for a viability assay of eclosed adult flies. Flies raised 
at 25 o C presented a viability of around 60%, whereas at 27o C viability was almost 0% and the 
Drosophila were dying between third instar and pupal stages (Fig. 5.6B). 
 
 
In contrast, CLN3 OE under the control of a pan-neuronal driver (elavC155-GAL4), caused 
100% embryonic lethality at 27o C and above. Indicating, that CLN3 is needed for the stability 
of the PNS (consistent with the D42-GAL4 experiment) as well as the CNS of the flies. CLN3 
OE in both areas may have a synergistic toxic effect for the Drosophila, since CLN3 OE are 
driven only in the motor-neuron, allowing development of flies through larval stages. At 25o 
C, viability of adult flies was lower than with D42-GAL4 (around 20%), but it was enough to 
allow the study of the phenotype of the NMJ in the third instar larvae (Fig. 5.7B). CLN3 OE 
driven with elavC155-GAL4 at 25o C, caused a disruption of the NMJ architecture with an 
absence of synaptic boutons (especially type Is). The phenotype caused was milder compared 
to the one caused when driven by D42-GAL4 at 27o C and the axons were mostly unaffected. 
However, abnormalities in the boutons were still very obvious presenting irregular shapes 
and loss of parts of the boutons (Fig. 5.7A).  
 
Importantly, here we demonstrate disruption of NMJ architecture caused by CLN3 OE using 
two independent neuronal drivers and highlight that it is consistently CLN3 dose-dependent. 
 
Interestingly, CLN3 OE construct driven post-synaptically (muscle) at 25oC caused a slightly 
different effect at the NMJ. There were detected abnormalities in synaptic bouton size, as 
indicated in Fig. 5.8. However, there seemed to also be an enlarged size of the boutons caused 
by the driver in the control cross, although to a lesser extent that in the UAS-CLN3 flies. The 
dose-dependent effect was also detectable using a post-synaptic driver: the same cross raised 





























Fig. 5.7. Overexpression of CLN3 driven pan-neuronally causes a disruption of the NMJ 
architecture in the third instar Drosophila larvae and a dose-dependent decrease in viability of 
adult flies. A. Confocal micrographs NMJ of muscle 12/13 of control (elavC155-GAL4/+) and 
CLN3 OE Drosophila third instar larvae (elavC155-GAL4/UAS-CLN3) raised at 25oC. Larvae fillet 
preparations were stained with a neuronal (HRP, green) and post-synaptic glutamatergic markers 
(DLG1, red). The architecture of the OE NMJ larvae is severely disrupted with a loss of boutons 
at both pre- and post-synaptic level. However, axons were not that severely affected. B. Bar chart 
representing the normalised viability of the same crosses at 25 and 27o C showing that the dose-
























Fig. 5.8. Overexpression of CLN3 driven post-synaptically caused disruption of the NMJ 
architecture in the third instar Drosophila larvae and a dose-dependent decrease in the 
viability of adult flies. Confocal micrographs NMJ of muscle 12/13 of control (Bg57-GAL4/+) 
and CLN3 OE Drosophila third instar larvae (Bg57-GAL4/UAS-CLN3) raised at 25o C. Larvae 
fillet preparations were stained with a neuronal (HRP, green) and post-synaptic glutamatergic 
markers (DLG1, red). The bouton size of OE NMJ larvae were enlarged when compared to 
controls, although controls also seemed to have boutons of an irregular, larger size than normal. 
 
 
As summarized on Table 5.3, OE of CLN3 caused a range of phenotypes depending on where 
and level of expression. CLN3 OE in both CNS and PNS caused severe effects in synaptic 
stability, causing embryonic lethality at 27o C and medium disruption of the synapse at 25 oC. 
A specific motor-neuron driver, also severely affected the viability of Drosophila, and the 
surviving animals presented a complete disruption of NMJ architecture with almost no 
synaptic boutons left at 27o C. Following the CLN3 dose-dependent toxic effect, a mild 
disruption of NMJ morphology was also detected at lower temperatures (25 oC). In contrast, 
using a post-synaptic driver (Bg57-GAL4), bouton sizes were larger whereas bouton number 
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seemed to be less affected. Nevertheless, there was also a detected increase in bouton size in 
the control animals, meaning a toxic effect caused by the driver might be contributing to the 
phenotype observed in the CLN3 OE animals. 
 
Table 5.3 Summary of phenotypes observed in CLN3 OE driven in the synapse 




5.3.1.3 CLN3 LOF in the NMJ 
Unpublished studies by Tear laboratory [as stated in (Bond et al., 2013, Faller et al., 2015)] 
suggested that synapses in the NMJ of the larvae lacking CLN3 fail to mature appropriately 
and have alterations in bouton size. Therefore, since human CLN3 disease is caused by its 
LOF, we also wanted to investigate by means of the UAS/GAL4 system if a LOF could be 
suitable for genetic screening of our candidates. 
 
Since, the Bg57-GAL4 driver seemed to have a toxic effect on its own, we decided to focus 
only on the motor-neuron (D42-GAL4) and pan-neuronal drivers (elavC155-GAL4) and 
crossed them with a CLN3-RNAi line (Table 5.1) to knock-down the expression of CLN3 at 
25, 27 and 30o C. 
 
Interestingly, decreasing the expression of CLN3 with both pan-neuronal and motor-neuron 
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number of boutons. 
Pupal lethal 
Embryonic lethal Larval lethal 
≥28 Embryonic lethal Embryonic lethal Embryonic lethal 
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the control of elavC155-GAL4 at 27 oC was qualitatively mild, with abnormalities in bouton 
number and shape and it was much more severe at 30o C (Fig. 5.4). Axons seemed not to be 
affected but there was a reduction in the number of boutons. Moreover, there was a loss of 
DLG staining in some of the boutons as indicated by the white arrows in Fig. 5.5A. Similar 
results were observed with D42-GAL4 although to a lesser extent than with elavC155-GAL4 at 
the same temperatures. In terms of viability, the results of the assay were very variable due to 
CyO- flies getting attached to the walls of the vials due to humidity issues in the water bath 
(used at 27 and 30o C for this experiment). At 25o C when using the D42-GAL4 system, the 
incubator was used and eclosed adults counted suggesting a small but significant decrease in 
viability of the flies carryng the CLN3-RNAi construct (Fig.5.9B). Many experiments using 
the incubator (where humidity is better controlled) will be necessary in order to draw solid 
conclusions regarding the viability of RNAi-CLN3 driven in the synapse. 
 
Thus, in this section we confirm as previously reported (Faller et al., 2015, Tuxworth et al., 
2011, Tuxworth et al., 2009, Bond et al., 2013), that either too much or too little expression of 
CLN3 disrupts nervous system stability in Drosophila. 
We also show for the first time, that increasing CLN3 in the synapse leads to disruption of its 
general architecture and bouton morphology. We also confirm that lack of CLN3 in the 
synapse also produces perturbations in its morphology, consistent with unpublished 
observations stated in (Bond et al., 2013, Faller et al., 2015). However, the disruption is more 
severe when CLN3 is overexpressed.  
 
Both CLN3 OE and CLN3-RNAi flies using either the D42-GAL4 or the elavC155-GAL4 
drivers, would have been excellent tools for the study of the role of my candidates in the 
larvae NMJ system. However, due to the fact that NMJ assay requires dissection, staining and 
posterior confocal imaging of the animals, we concluded that the more sensible assay 
protocol to perform candidate genetic screening as a first pass was the eye phenotype using 
the OE of CLN3 driven with GMR-GAL4. Misexpression of CLN3 driven in the NMJ would 
have be an excellent model for a secondary screen or a further characterization of the role of 




























Fig. 5.9. Knocking down CLN3 in the nervous system causes bouton loss in the NMJ of the third 
instar Drosophila larvae. A. Confocal micrographs of NMJ of muscle 12/13 of the control 
(elavC155-GAL4/+) and CLN3 OE Drosophila third instar larvae (elavC155-GAL4/UAS-CLN3) raised 
at 30o C. Larvae fillet preparations were stained with a neuronal (HRP, green) and post-synaptic 
glutamatergic markers (DLG1, red). There was a decrease in the number of boutons as well as a 
loss of DLG staining in some of the samples (white arrows). In contrast, axons did not seem 
affected by the loss of CLN3. The number of eclosed adult flies from RNAi-CLN3 driven with 
D42-GAL4 and elavC155-GAL4 in bar charts B&C respectively. Mean ± SEM; * p-value<0.05, ns 
p-value>0.05 (Student T test). 
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5.3.2 Modifier screening in the eye 
To summarise the sections within this chapter so far, we have decided to use a CLN3 
overexpression system driven in the Drosophila eye to study the potential modulatory effects 
of my candidates (identified in Chapters 3&4) in a CLN3-induced degenerative model.  
The use of the eye for modifier screens is very common in the study of neurodegenerative 
disease, and gross examination does not require dissection or staining (see Chapter 1. 
General Introduction, section 1.8.2.2). Here, we employed a system to quantify the 
degenerative phenotype in Drosophila by measuring the total surface area of the eye [as 
previously described in (Sanhueza et al., 2015)]. This allowed a rapid, objective and unbiased 
quantitative assessment of the potential modulatory effects of candidate proteins on the 
CLN3-induced eye phenotype, 
  
5.3.2.1 Generation on CLN3 recombinant stock 
To begin with, we needed to generate an appropriate fly to use as a tester line for the study of 
my candidates on a “neurodegeneration” background. Since both UAS-CLN3 and GMR-
GAL4 constructs are placed on the second chromosome, and many candidate lines carried 
out with an RNAi construct also found in the second chromosome, we needed to generate a 
recombinant fly carrying both GMR-GAL4 and UAS-CLN3 in the same allele, so they would 
inherit both drivers together in the offspring, leaving a “chromosomal space” for a potential 
Candidate-RNAi/OE construct (see 5.2 Materials and methods). As indicated in Fig. 5.2, a 
recombinant fly (GMR-GAL4;UAS-CLN3/CyOGFP) was obtained after 25 individual attempt 
crosses and was amplified to be used as a tester line (See 5.2 Materials and methods). 
Before beginning the screen, some quality control was required to generate the new 
recombinant CLN3 OE fly. First, we wanted to confirm, that the degenerative eye phenotype 
was indeed caused by CLN3 OE. To do so, a double dosage experiment was carried out by 
generating flies carrying two UAS-CLN3 constructs (GMR-GAL4;UAS-CLN3/UAS-CLN3). 
Both crosses raised at at 25 and 27o C caused 100% lethality of GMR-GAL4;UAS-CLN3/UAS-
CLN3 flies indicating again the dose-dependent toxicity of CLN3 protein (Fig. 5.10A). 
 
Moreover, we carried out a second quality control experiment to confirm that any 
suppressor effects observed in the genetic screening were not due to the dilution effect of the 
GAL4 driver over two UAS constructs. To do this, we crossed the recombinant fly to UAS-
GFP and to a WT fly line. F1 was sorted by CyO+ and CyO- for both GFP and control crosses, 
eyes were photographed and surface area was measured. We also measured the eyes of a WT 
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fly (Canton S, +/+) and compared that to our CyO- from the control cross to confirm that the 
CyO balancer was not affecting the eye phenotype. Results indicated on the one hand that 
the presence of an extra UAS construct under the control of GMR-GAL4 driver did not 
produce any effect in the CLN3-dependent eye phenotype. On the other hand, it showed that 
























Fig. 5.10. Quality control of the CLN3 recombinant fly as a tester line. A. Bar chart indicating 
the number of eclosed flies from GMR-GAL4;UAS-CLN3 crosses with UAS-CLN3 and WT fly 
(+/+). Results showed that CLN3 (DD) double dosage was lethal at 25 and 27o C confirming the 
dose-dependent effects of CLN3 OE. B. Dot plot indicating the eye surface area of a WT fly (+/+), 
+/CyOGFP (CyO-), GMR-GAL4;UAS-CLN3/+ and GMR-GAL4;UAS-CLN3/UAS-GFP. No 
significant difference was observed between +/+ and CyO- flies indicating no effects of the CyO 
balancer to the eye. No differences were either seen between GMR-GAL4;UAS-CLN3/+ and 
GMR-GAL4;UAS-CLN3/UAS-GFP indicating no dilution effects of the GAL4 driver. Mean ± 
SEM ns= p value>0.05 (Student T test) (N>15 flies per genotype). 
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We therefore concluded that our GMR-GAL4;UAS-CLN3 recombinant fly is suitable for 
genetic modifier screening and that CyO- flies resulting from GMR-GAL4;UAS-CLN3 
crossed to a WT fly (+/+) is equivalent to WT fly,  and this was therefore used as a control fly 
during the genetic screen. 
 
 
5.3.2.2 CLN3 regional candidates: Valine degradation and Rock2 
signaling pathways 
Once we confirmed that our GMR-GAL4;UAS-CLN3 recombinant fly was suitable as a tester 
line, we proceeded to screen our protein candidates identified in Chapter 3 & 4 (Table 5.2). 
We started with examples of downregulated and upregulated candidates from Chapter 3 
which sit in specific pathways related to valine degradation (HIBCH and HADHA) and 
ROCK2 signaling pathways (ROCK2) respectively (see Fig. 3.10 and 3.13 in Chapter 3).  
 
Both HIBCH and HADHA were found to sit in the same metabolic pathway involved in the 
degradation of the valine amino acid. Both enzymes were downregulated in thalamic 
synapses (the most vulnerable brain area) whereas they were unchanged in cortical synapses 
(a less vulnerable area), and their expression profile therefore correlated to the pattern of 
synaptic vulnerability across brain areas as described in Chapter 3 (Fig. 3.3 & 3.5). Moreover, 
the valine degradation cascade itself was found to be progressively disrupted following the 
same vulnerability pattern across brain areas (Fig. 3.6).  
 
Following the mating scheme described in Fig. 5.3, we crossed HIBCH and HADHA RNAi 
lines (Table 5.2) to the tester line. F1 was sorted by genotype and eyes were phenotypically 
assessed. Eyes were photographed and surface area was measured with ImageJ. Results 
indicated that knocking down both candidates in a CLN3 OE background enhanced the 
CLN3-induced degenerative phenotype. Eyes were visibly smaller for both HIBCH and 
HADHA RNAi crosses (Fig. 5.11). Interestingly, this correlated with the downregulation of 































Fig. 5.11. CLN3-induced degeneration is enhanced by the genetic downregulation of HIBCH 
and HADHA in vivo. A. Representative light microscope images of fruit fly eyes of the CLN3 OE 
(GMR-GAL4;UAS-CLN3), CLN3 OE with HIBCH-RNAi (GMR-GAL4;UAS-CLN3/HIBCHRNAi) 
and CLN3 OE with HADHA RNAi (GMR-GAL4;UAS-CLN3/RNAiMTPα). B. Quantification of 
the eye surface area of these genotypes. Scale bar=100um. Mean ± SEM ***P<0.001 (One-way 
ANOVA and Tukey’s multiple comparison test as a post-hoc analysis). C. Schematic 
representation of the fourth and fifth steps of the valine catabolism cascade showing the enzymes 
HADHA and HIBCH catalyzing each step respectively. Downregulating both HADHA or 
HIBCH in the CLN3 fly enhanced the degenerative phenotype in the eye. Defects in HADHA 
enhanced the degenerative phenotype more than HIBCH downregulation, indicating that the 




Interestingly, the enhancement was more pronounced when knocking down HADHA, as 
indicated by a much smaller eye size and a more disrupted surface structure with a lack of 
pigmentation in some areas (Fig. 5.11). Interestingly, HADHA was shown to be upstream of 
HIBCH and was not changed in less vulnerable synaptic populations such as those of the 
hippocampal and cortical regions (See Chapter 3, Fig. 3.6). This indicates that both enzymes 
have the ability to modulate the CLN3-OE-induced degenerative eye and that the more 
upstream we disrupt the valine degradation pathway, the stronger the effect seen in the 
phenotype. Thus, proteins down regulated in vulnerable mammalian synapses, make a 
CLN3-OE induced phenotype worse when downregulated in Drosophila in vivo. 
 
Conversely, the protein candidate ROCK2 was found to be upregulated in thalamic synapses, 
but not in cortical synapses, correlating again to the vulnerability pattern described (Fig. 
3.13). As described in Chapter 3, ROCK2 has been reported (by our laboratory and others) to 
be upregulated in a wide range on neurodegenerative conditions (injury induced, adult-onset 
and childhood neurodegenerative conditions) (Fig. 3.1E). Therefore, ROCK2 might be a 
potential modulator of synaptic stability in a variety of conditions. To confirm if that was 
true, the same mating scheme was followed (Fig. 5.3). Two ROCK2-RNAi (GD and TRiP, see 
Table 5.2) lines were crossed to CLN3-OE tester line. Results indicated that both RNAi lines 
tested were able to suppress the CLN3-OE-induced degeneration in the eye. The TRiP line 
showed a 100% rescue and the eye surface structure was almost fully recovered (Fig. 5.12C-
E). Thus, proteins up regulated in vulnerable mammalian synapses, alleviate a CLN3-OE 
induced phenotype when downregulated in Drosophila in vivo. 
 
Due to the rescue obtained when targeting ROCK2 genetically and since there are multiple 
Rock inhibitors available, we decided to explore the possibility of targeting ROCK2 
pharmacologically. Several ROCK inhibitors have been characterized, but their specificity for 
individual ROCK kinases is still unclear. Fasudil is a small molecule that non-specifically 
inhibits ROCK2.  It was originally discovered as a blocker of cerebral vasospasm in animal 
models (Takayasu et al., 1986). Importantly, fasudil has been demonstrated to be safe and 
effective in clinical trials of cerebral vasospasm, pulmonary hypertension, Raynaud 
phenomenon and cancer (Olson, 2008, Suzuki et al., 2008, Masumoto et al., 2002, Velat et al., 
2011, Bharadwaj et al., 2005, Hinsenkamp et al., 2016). Moreover, fasudil has previously been 
applied to murine models of SMA yeilding an improvement of the phenotype and lifespan of 
these mice (Bowerman et al., 2012, Coque et al., 2014). However, fasudil also targets other 
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kinases such as MAP4K4, PKC, PRKAA1 or PRKAA2 (Anastassiadis et al., 2011), which are 
predicted to be activate using IPA in Cln3-/- thalamic synapses (Fig. 5.13). The activation of 
these kinases seem to have downstream consequences on biological functions relevant to 
NCL such as autophagy (Fig. 5.13A) or/and “Protein kinase A signalling” (Fig. 5.13B&C). 
Despite these caveats, given the success of the compound in mammalian systems (Bowerman 
et al., 2012, Coque et al., 2014, Hinsenkamp et al., 2016), including humans (Masumoto et 
al., 2002, Suzuki et al., 2008), and the consistent conserved ROCK2 alterations across 
multiple-neurodegenerative paradigms, we decided to test Fasudil in CLN3 Drosophila 
(GMR-GAL4/UAS-CLN3). The drug was added into the fly food in order to obtain 1.5 mM of 
fasudil, and the Drosophila were raised as normal (see 5.2 Materials and methods for 
therapeutic dosage window establishment). Pharmacological inhibition with fasudil caused a 
significant, albeit modest suppression of the CLN3-derived eye phenotype. Quantification of 
eye surface areas confirmed a 17% rescue of the CLN3 eye phenotype in the treated animals 
(Fig. 5.12E-F&I). 
 
Thus, targeting of ROCK cascades with fasudil was sufficient to result in a beneficial effect on 




















Fig. 5.12. CLN3-induced degeneration is suppressed by the downregulation of ROCK2 
genetically and pharmacologically. A-D. Representative light microscope images of Drosophila 
eyes and corresponding 200x zoom of eye structure of A. CLN3 OE (GMR-GAL4;UAS-CLN3). B. 
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CLN3 OE + 1.5 mM Fasudil. C. CLN3 OE + Rok RNAi TRiP and D.  Control fly (WT, Canton S). 
E. Bar chart representing the % of normalized suppression calculated from the average eye 
surface areas of three independent experiments as “(x- average eye surface area of the CLN3 
OE)/(average of eye surface area of the control - average eye surface area of CLN3 OE) x100” for 
each of the three independent experiments. Scale bar=100um. Mean ± SEM N=3 ***P<0.001, 
*P<0.05 (One-way ANOVA and Tukey’s multiple comparison test as a post-hoc analysis). 
 
 
Fig. 5.13. Fasudil inhibition of ROCK2 and other kinases might contribute to the suppression of 
CLN3-OE induced degeneration. A. Network representation showing upstream regulator kinases 
predicted to be activated using IPA upstream regulator analysis that are targeted by Fasudil. 
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Activation of MAP4K4, PPKAA1 and PPKAA2 (center of the network) impacts on the disrupted 
expression of proteins such as HADHA, OGDH or SIRT2 (proteins in the thalamic dataset): 
proteins involved in mitochondria permeability, neuromuscular disease, or autophagy. B. The 
fasudil interactome highlights the interaction of fasudil with other proteins whose expressions are 
perturbed in thalamic degenerating synapses. Some of these proteins overlap with disrupted 
pathways such as “Signaling by Rho family GTPases” and “Protein Kinase A signaling”). C. 
“Protein kinase A signaling” pathway represented by IPA. Upregulation of PKAc (hub in this 
network), which is also a target of fasudil, impacts in the upregulation of some proteins such as 
ROCK2 or β-catenin. Orange = predicted activation, blue = predicted inhibition, red = 
upregulated >20% green = downregulated >20%. 
 
 
So, the candidates identified in Chapter 3 (HIBCH, HADHA and ROCK2) are able 
tomodulate the CLN3-dependent phenotype in the eye. Next, we wanted to see if knocking 
down these candidates had an effect in a wild-type background. To do so GMR-GAL4 driver 
were crossed to RNAi lines of HIBCH, HADHA and ROCK2. Crosses were raised at the 
same temperature as the modifier screen (25 oC). 
 
As shown in Fig. 5.14, knocking down these candidates had no effect on a wild-type 

























Fig. 5.14 Downregulation of candidates does not give any phenotype in the eye of a WT fly. A. 
Representative light microscope images of fruit fly eyes of control line, GMR-GAL4/UAS-CLN3, 
GMR-GAL4/HibchRNAi, GMR-GAL4/RNAiMTPα, GMR-GAL4/RokRNAi GD and GMR-
GAL4/RokRNAi TRiP. B. Normalized quantification of the eye surface area of these genotypes 
showing no statistically significant change when compared to the control line. Scale bar=100um. 




5.3.2.3 Study of candidates identified in Ppt1-/- time-course analyses 
As shown in the section above, the genetic and/or pharmacological screening using the 
CLN3 OE Drosophila eye system proved to be a robust system for the testing of modifiers 
when applied to candidates identified in our regional differential vulnerability -omic study 
(Chapter 3). Next, we proceeded to examine candidates identified in the much more complex 
-omic (spatio-temporal) study from Chapter 4. Candidates in Chapter 4 were identified 
based on their expression profile correlating to synaptic vulnerability between thalamus and 
cortex and throughout the time-course of disease progression.  These candidates were 
divided into two subsets:  
1. Those detected to be changed in the proteomic dataset (17 proteins); and  
2; those predicted to be upstream regulators of the proteins in the dataset (13 proteins).  
As explained in 5.2 Materials and methods, DIOPT tool was used to identify which 
Drosophila ortholog was more similar to the mouse protein candidates. Information about 
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Drosophila candidate lines purchased can be found in Table 5.2. ASAH1, S100A1, 
HEPACAM and HBA-A2 did not have high rank orthologs in Drosophila and therefore, 
were not tested in this experiment. For the rest of the candidates, RNAi lines were purchased 
except for downregulated candidates where overexpression lines were available.  
 
We began by targeting proteins from subset 1. As shown before, misexpressed candidate 
lines were crossed to the recombinant fly (CLN3-OE background) and to GMR-GAL4 driver 
(WT background). F1 CyO+ flies were then examined under the stereomicroscope, eyes were 
photographed and surface area was measured with ImageJ. Results indicated that 9 out of 11 
lines tested, showed significant modifier effect in a CLN3-induced degenerative eye (Fig. 
5.15A&B). Surprisingly, knocking down candidates that were upregulated at 3 months in 
thalamus (3-T) and 5 months in cortex (5-C) (Dbn1, Gnb4, Dpysl4, see Chapter 4 and Table 
5.2), did not suppress the phenotype but enhanced it. Although knocking down Dpysl4 did 
not produced a significant effect in the eye surface area, there was an increased number of 
black puncta indicative of necrosis (highlighted by the white arrows in Fig. 5.15A). This 
suggests that the downregulation of Dpysl4 indeed has an effect on the CLN3-induced 
phenotype which is not detectable through eye surface area quantification, but it is visible 
through a qualitative examination. Conversely, knocking down Atp5b (which was 
downregulated at 3-T and 5-C, see Table 5.2), suppressed the CLN3-induced degenerative 
eye by 57.26% in size. Importantly, the compound structure of the eye was noticeably 
improved as well (Fig. 5.15A). 
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Fig. 5.15. Candidates identified in Ppt1-/- time-course dataset modulate eye morphology in 
CLN3-OE dependent manner. A. Representative light microscope images of Drosophila eyes of 
WT control (control, GMR-GAL4;UAS-CLN3/+), CLN3 OE control (CLN3 OE, GMR-
GAL4;UAS-CLN3) and example candidates Atp1a2-OE (strongest enhancer), Dpysl4-RNAi 
(although eye size showed no difference to the CLN3 OE, there was a detected increased number 
of black puncta (white arrows), which indicate cell death) and Atp5b-RNAi (suppressor) in 
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CLN3-OE background. B&D. Dot plot quantification of the normalised eye surface area (%) of 
misexpressed candidates driven in the eye identified in Chapter 4 (subset 1) in CLN3-OE (B) and 
WT background (D). C. Representative light microscope images of Drosophila eyes of WT 
control (control, GMR-GAL4/+) and example candidates Atp1a2-OE, Dpysl4-RNAi and Atp5b-
RNAi driven in the eye in a WT background. Mean ± SEM One-way ANOVA with Tukey’s 
multiple comparison post-hoc analysis; ** p-value<0.01, *** p-value<0.001, ns p-value>0.05, 
N>15 flies per genotype. 
 
 
In a manner similar to candidates from Chapter 3, the misexpression of these candidates on a 
wild-type background, did not cause any overt effect in the compound structure or size of 
the eye (Fig. 5.15C&D), indicating that the effects observed are again, CLN3-dependent. 
 
Next, predicted upstream regulator candidates (subset 2) were targeted in both CLN3-OE 
and WT backgrounds. Ten out of twelve candidates again showed a range of effects in the 
CLN3-induced phenotype (Fig. 5.16A&B). The strongest enhancer was Pparg, which caused 
lethality at pupal stage. Similarly, to Dpysl4, Map4k4, did not show any effect to the surface 
area but showed necrosis (pointed out by the white arrows in Fig. 5.16A). Conversely, OE of 
InsR rescued the eye size until reaching equivalence to the control fly. However, compound 
eye structure still revealed the presence of fused ommatidium similar to the CLN3 OE fly and 
surface area showed an irregular elliptical shape. 
 
In contrast to candidates tested from subset 1, some of the identified upstream regulators 
caused an effect in a WT background (Fig. 5.16C&D). Pparg overexpression caused lethality 
at pupal stage also in the WT fly. Surprisingly, Notch was shown to be lethal at pupal stages 
in a WT fly. However, as shown in Fig. 5.16A&B, although Notch was a very strong 
enhancer, it did not cause 100% lethality in CLN3-OE background. Interestingly, it has been 
reported that CLN3 inhibits Notch and that targeting delta protein, which is a ligand of 
Notch, enhances the CLN3 OE phenotype in the macrochaetae on the scutellum of the adult 
fly (Tuxworth et al., 2009) (see 5.2 Introduction). Here we show that by knocking down 
Notch directly at the genetic level, also enhances the phenotype in the eye. However, at the 
same time, CLN3 OE seems to have a protective effect preventing lethality of Notch knock 
down effects. More experiments will be needed in order to clarify the regulatory effects seen 








































Fig. 5.16. Predicted upstream regulators modulate neurodegeneration in CLN3-OE and WT 
background. A. Representative light microscope images of Drosophila eyes of WT control 
(control, GMR-GAL4;UAS-CLN3/+), CLN3 OE control (CLN3 OE, GMR-GAL4;UAS-CLN3) and 
example candidates Notch-RNAi (strongest enhancer), Map4k4-RNAi (eye size showed no 
difference to CLN3 OE, however, there was detected an increasing number of black puncta-white 
arrows-, which indicate cell death) and InsR-OE (suppressor) in CLN3-OE background. B&D. 
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Dot plot quantification of the normalised eye surface area (%) of the upstream regulators driven 
in the eye identified in Chapter 4 in CLN3-OE (B) and WT background (D). C. Representative 
light microscope images of fruit fly eyes of WT control (control, GMR-GAL4/+) and example 
candidates Pten-OE, Hnf4-OE, Rictor-RNAi and InsR driven in the eye in a WT background. 
Mean ± SEM, One-way ANOVA with Tukey’s multiple comparison post-hoc analysis; ** p -
value<0.01, *** p-value<0.001, ns p-value>0.05, n>15 flies per genotype. 
 
 
Other candidates such as Pten or Hnf4 also produced an effect in the Drosophila WT eye 
(Fig. 5.16C&D). OE of Pten under the control of GMR-GAL4 resulted in a smaller eye, 
although the compound structure was not affected. In contrast, Drosophila overexpressing 
Hnf4, presented a small and rough eye with an abnormal bristle pattern and less fused 
ommatidia. 
 
Interestingly, 12 out of 14 candidates whose expression was perturbed in proteomic analyses 
from Chapter 3 and Chapter 4 (subset 1) were identified as correlates with the vulnerability 
status of synapses, and were able to modulate neuronal stability in a CLN3-dependent 
manner. This was indicated by the absence of detectable phenotype when these candidates 
were misexpressed in a WT fly under the control of the same driver (GMR-GAL4). In 
contrast, most of the upstream regulators identified in Chapter 4, were also able to modulate 
neuronal stability in WT Drosophila, and therefore their effects were not CLN3 dependent. 
That is not that surprising, since these candidates were identified because they were potential 
master regulatory proteins impacting upon multiple cascades (see Chapter 4, Fig. 4.14). 
Thus, the effects of their misexpression is likely to regulate neuronal stability at a level 












Table 5.4. Summary of genetic modifier screen results 
*Based on z-score prediction IPA tool 
**Based on KO/WT ratio from proteomic studies 
Significance was assessed with One-way ANOVA with Tukey’s multiple comparison post-hoc 
analysis; ** p -value<0.01, *** p-value<0.001, ns p-value>0.05.  in relation to CLN3 OE 









Effect in CLN3-OE 





Anxa5 RNAi Down Enhancer ** No ns 
Atp1a2 OE Down Enhancer *** No ns 
Atp5b RNAi Down Suppressor *** No ns 
Dbn1 RNAI Up Enhancer ** No ns 
Dpysl4/ 
Dpysl3 
RNAi Up Enhancer ns No ns 
Esrra RNAi Down* Enhancer *** No ns 
Gnb4 RNAi Up Enhancer *** No ns 
Hadha RNAi Down Enhancer *** No ns 
Hibadh RNAi Down Enhancer *** No ns 
Hibch RNAi Down Enhancer *** No ns 
Hnf4a OE Down* Enhancer *** Yes *** 
Igf1r/ 
InsR 
OE Down* Suppressor *** Yes *** 
Map4k4 RNAi Up Enhancer ns No ns 
Mgea5 RNAi Up* Enhancer *** Yes ** 
Mitf RNAi Down* Enhancer *** No ns 
Nfkb1 RNAi Up* Enhancer *** Yes ** 
Notch1 RNAi Up* Enhancer *** Lethal N/A 
Ogdhl RNAi Down Enhancer *** No ns 
Pdx1 RNAi Up* No effect ns No ns 
Pparg OE Down* Lethal N/A Lethal N/A 
Pten OE Down* Enhancer *** Yes *** 
Rictor RNAi Up* Enhancer *** No ns 
Rock2 RNAi GD Up Suppressor ** No ns 
Rock2 RNAi TRiP Up Suppressor *** No ns 
Sdha RNAi Down No effect ns No ns 
Slc25a12 RNAi Down Enhancer *** No ns 
Tkt RNAi Down Enhancer *** No ns 
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5.4 Discussion 
In this chapter, we evaluated multiple Drosophila body systems and CLN3 misexpression 
models for their potential as screening tools. Interestingly, we demonstrated that 
overexpression CLN3 at the synapse using three different neuronal drivers (a motor neuron, 
a pan-neuronal and post-synaptic driver) disrupts NMJ morphology affecting bouton 
number and size, as well as lethality of eclosed adult flies. Importantly, we replicated the 
degenerative-eye phenotype caused by CLN3 OE under the control of GMR-GAL4 described 
by Tuxworth and colleagues (Tuxworth et al., 2009). The generation of a GMR-GAL4; UAS-
CLN3 fly allowed the screen of genetic modifiers of the CLN3-induced phenotype 
demonstrating that a subset of the identified candidates in Chapter 3&4 are indeed able to 
regulate CLN3 induced phenotype in vivo.  
 
The Drosophila nervous system requires an optimal CLN3 dosage window for its stability 
Importantly, our data is consistent with the previous reports suggesting that there is a CLN3 
optimal dosage window for the proper stability of the nervous system and that either too 
much or too little of it disrupts neuronal homeostasis in vivo (Faller et al., 2015, Tuxworth et 
al., 2011, Tuxworth et al., 2009). In this chapter, we detected a CLN3 dose-dependent effect 
under the control of all the neuronal drivers used for the characterisation of CLN3 OE 
phenotypes, supporting the previous statement regarding CLN3 optimal physiological dose. 
Furthermore, we know that in the human disease, CLN3 (and other NCL-related proteins) 
dose is crucial to the phenotype as heterozygous humans are not obviously affected. Dose is 
also crucial for the other monogenetic neurodegenerative diseases such TDP-43 linked ALS 
and frontotemporal dementia (FTD) where the mechanisms of the disease are not yet clearly 
defined as  GOF or a LOF (Xu, 2012). Interestingly, in other monogenetic infantile 
neurological diseases such as Rett Syndrome a similar conundrum has been found. Rett 
syndrome is caused by the LOF of MeCP2 gene. However, when MeCP2 is overexpressed 
there are overlapping phenotypes including alterations in synaptic strength and number 
(Chao et al., 2007), synaptic plasticity (Chahrour et al., 2007, Collins et al., 2004) and similar 
neurodevelopmental defects characterized by autism features, seizures, motor impairments, 
stereotyped behaviors, and intellectual disability (Chahrour et al., 2007, Ramocki et al., 
2008). More recently it was reported that both GOF and LOF of MeCP2 cause very similar 
disfunction of hippocampal circuit (Lu et al., 2016).  This optimal dosage window, which 
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seems to be a common feature of some monogenetic neurodegenerative diseases, may give 
clues regarding the function of CLN3, which is still unclear. 
 
Results of candidate genetic screen in Drosophila eye 
In this chapter we demonstrated, that the unbiased identification of protein candidates based 
on their expression profile correlate to synaptic vulnerability throughout brain areas 
(Chapter 3) and/or disease progression (Chapter 4), is a robust approach for the 
identification of molecular modulators of neuronal stability. As summarized in Table 5.3, 
most of the candidates identified following such criteria, were indeed, able to modulate 
neuronal stability in a neurodegeneration context (CLN3 OE) in CLN3-dependent manner. 
Only a subset of the upstream regulators identified in the Ppt1 time-course analyses (Chapter 
4) were demonstrated to be global regulators causing neurodegenerative phenotypes in a WT 
background under the control of the same driver (GMR-GAL4) (Fig. 5.17). Since candidates 
in subset 2 are known to be master regulators of complex mechanistic pathways, it is not 
surprising that their effects are shown to be global, as their misexpression is likely to impact a 
broad range of pathways. Such phenotypes in a WT background varied from candidate to 
candidate. For instance, some altered the size but the structure of the eye was less affected 
(Pten), whilst others altered both size and structure (Hnf4). It has been suggested that similar 
phenotypes between targeted genes may indicate higher enrichment of converging disrupted 
biological pathways (Oortveld et al., 2013). Therefore, since most of the candidates tested 
were able to alter eye size in the CLN3 OE background, the misexpression of these candidates 
may be perturbing converging or overlapping pathways. In Fig. 5.18, published, known 
(direct and indirect) interactions between the candidates identified in Chapter 3&4 are 
highlighted, showing the complexity of these connections. It will take years of investigations 
to unravel such complex, potentially converging pathways and therefore, in this chapter I 




Fig. 5.17. Summary of candidate genetic screening in CLN3-induced degeneration in the eye. 
Two-axis plot expressing the correlation between eye size modification in CLN3 OE background 
(X axis) and WT background (Y axis) for all the candidates tested that were viable in both 
backgrounds tested. Each point represents the normalised eye size average of each candidate. 
Enhancers are coloured in green and suppressors in red, CLN3 OE in orange and control fly in 
purple. Pten was a candidate with strongest enhancing effects in CLN3 OE background and was 
also able to affect neuronal stability in WT background. Completely opposite to Pten, InR was 
shown to be a suppressor of the CLN3-derived eye and also increased eye size in WT background. 
Rock2 was the candidate which best rescued the CLN3-OE phenotype without affecting a WT fly. 
Most of the enhancers from subset 1, are very close to the x-axis which indicate no effects in WT 





Fig. 5.18. Converging networks between candidates able to modulate neuronal stability in 
CLN3-induced neurodegeneration. The top network found using an IPA analysis of identified 
candidates. The network is involved in “Energy Production, Lipid Metabolism, Small Molecule 
Biochemistry” and incorporates 17 of the identified candidates. Upstream regulators were used as 
inputs in the analysis as either up/downregulated according to the IPA prediction tool. Dashed 
and solid lines indicate indirect and direct interactions respectively. 
 
 
Valine degradation and ROCK2 signaling cascades 
By influencing the valine catabolic cascade through genetic disruption of HIBCH and 
HADHA it was possible to alter the CLN3 degenerative phenotype in Drosophila in vivo. 
Moreover, the further upstream in the catabolic cascade we intervened, the greater the 
resulting effect on neurodegenerative phenotype. The valine catabolism cascade has 
remained enigmatic mainly because only a few defects in the pathway have been described 
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(Wanders et al., 2012). In humans, both HIBCH and HADHA deficiency cause infantile 
onset diseases with neurological clinical scheme (Ferdinandusse et al., 2013, Peters et al., 
2015, Stiles et al., 2015).  Crucially, this could indicate that perturbations in valine catabolic 
pathways might be a shared event across multiple neurodegenerative conditions and 
therefore targets identified here may be transferable to other diseases. Importantly, the role 
of branched-chain amino acids such as valine as a source of glutamate has recently been 
suggested (Yudkoff, 2017). Therefore, defects in valine metabolism defects may be impacting 
on glutamate pathways which can affect neurotransmission. 
 
Interestingly, the upregulation of ROCK2 has been highlighted in a range of conditions by 
our laboratory and others (Wishart et al., 2012, Deyts et al., 2009, Herskowitz et al., 2011, 
Blaise et al., 2012). In this current study, I demonstrate for the first time that downregulation 
of ROCK2 also rescues the phenotype in a CLN3 model in vivo, when manipulated 
genetically, and to a lesser degree with available pharmacological agents (Fig. 5.12). Studies 
by others indicated that its genetic and/or pharmacological downregulation also ameliorated 
the phenotype of several conditions including SMA, another relatively early onset 
neurodegenerative disease (Bowerman et al., 2012, Coque et al., 2014). In general, ROCK2 
appears to be an attractive target for the development of new therapeutic strategies, not only 
for NCL, but also in a wide range of more common neurodegenerative diseases to potentially 
delay or halt disease progression (see Chapter 4). There are currently multiple ROCK 
inhibitors with different degrees of specificity available (Anastassiadis et al., 2011, Olson, 
2008). However, in order to avoid off-target effects in future studies (see Fig. 5.13), it will be 
necessary to examine complex -omic derived interaction/cascade data to utilised a 
compound that targets ROCK2 more specifically (see Fig. 5.13). 
 
Insulin-receptor signalling pathway and autophagy 
Interestingly, overexpression of InR/Igf1r increased the size of eyes in both CLN3 OE and 
WT background. In neurodegeneration background (CLN3 OE) the rescue was noticeable 
only in size as the structure of the eye showed a similar glazing effect from fused ommatidia 
similar to the CLN3 OE. The insulin receptor signalling (IRS) pathway is very conserved 
from Drosophila to mammals (Yamaguchi et al., 1995) and it has been extensively related in 
the regulation of cell growth (Brogiolo et al., 2001, Gu et al., 2014). Mutations in InR has 
been shown to affect nervous system development (Fernandez et al., 1995, Dutriaux et al., 
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2013), including synapse number and plasticity  (Chiu et al., 2008), neuronal pruning (Wong 
et al., 2013) or axonal guidance of photoreceptors during visual system development (Song et 
al., 2003). Insulin-related pathways alterations have been linked to a range of 
neurodegenerative diseases such as AD, HD or PD [reviewed in (Procaccini et al., 2016) ]. 
For instance, alterations in IGF1 signaling, contributed to progressive neuronal loss (Talbot 
et al., 2012, Procaccini et al., 2016) whereas the administration of insulin agonists (Bassil et 
al., 2014), showed positive effects in models of neurodegeneration. 
On the other hand, overexpression of Pten, which antagonizes InR signalling (Meléndez et 
al., 2008), was shown to enhance the CLN3-derived phenotype but also had an effect in a WT 
eye, producing a decrease in eye surface area (Fig. 5.16). Therefore, the phenotypic effects 
observed using both InR-OE and PTEN-OE constructs, confirms that promoting the insulin-
signaling pathway improves neuronal stability. 
 
The IRS pathway has not been reported to be altered in the NCLs so far, however using IGF 
treatment as a neurotrophic factor, proved to partially restore interneuron number and brain 
hypertrophy in CLN8 mouse models (Cooper et al., 1999). Since, in our data InR 
overexpression seemed to have an effect in both CLN3 OE and WT fly, it is unclear if there is 
an interaction between CLN3 and InR related pathyways. If CLN3 and the IRS pathway do 
interact, a possible connection could be autophagy. Autophagy has been a proposed 
neurodegenerative mechanism in CLN3 mouse models (Mitchison et al., 2004), and 
Tuxworth et al. (Tuxworth et al., 2009) already suggested that apoptosis was not a 
mechanism triggering cell death in the CLN3 OE Drosophila model. Therefore, since InR 
suppresses autophagy (Mohseni et al., 2014), this negative regulation of autophagy by the 
InR-OE will be a plausible hypothesis by which InR-OE rescues the eye size in CLN3-
degenerative eye. 
 
Notch signaling pathway 
Tuxworth et al. indicated that CLN3 blocks Notch signalling at the protein level (Tuxworth 
et al., 2009) and that it may be mediating cell death in the CLN3 OE fly. Therefore, the 
enhancement of the phenotype when knocking down Notch was not surprising to find (Fig. 
5.16). Paradoxically, knocking down notch caused 100% lethality of wild-type flies whereas it 
did not cause such high lethality in the CLN3 OE flies. A possible explanation for this, are the 
patterns of expression of the GMR-GAL4 driver (Freeman, 1996). We know that GMR-GAL4 
had been recently found to be expressed also in embryo and larval stages CNS (Ray et al., 
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2015), and therefore it might be driving CLN3-OE and Notch-RNAi in other organs during 
Drosophila development. Our results indicate that the downregulation of Notch without the 
presence of CLN3-OE (WT crosses) is lethal but not in the CLN3 OE fly. Therefore, CLN3-
OE might be “protecting” the Notch-RNAi effects in embryo and larval tissues, suggesting 
that CLN3 may have different roles depending on the Drosophila stage/organ. Further 
experiments raising the flies at different temperatures only at specific developmental stages 
will be necessary in order to shed light on these intriguing results.  
Nervertheless, our experiments clearly support the interaction between Notch and CLN3-
related pathways leading to neurodegeneration, as previously reported (Tuxworth et al., 
2009). We show that by knocking down Notch genetically we are able to enhance the CLN3-
OE-induced phenotype.  
 
 
Knocking-down the ATP synthase subunit ß suppresses CLN3-OE--induced phenotype 
An interesting suppressor found in this screen was the subunit ß of the ATP synthase 
(Atp5b), which forms the F1 (hydrophilic) portion of the complex V of the mitochondrial 
respiratory chain. Improvement of the eye surface area by almost 60% was accomplished by 
knocking down Atp5b expression via RNAi. Interestingly, the subunit C of the ATP synthase 
is the main storage protein which accumulates in most forms of NCL including CLN3, but 
not CLN1, CLN4 and CLN10 (Palmer et al., 2013). Despite the efforts of the NCL research 
community, the mechanisms that explain why the subunit C accumulates in the lysosome in 
various forms of NCL is still to be clarified. Importantly, no other subunits have been found 
in the storage material composition, indicating that the subunit C may be following a specific 
turnover pathway (Fearnley et al., 1990). Disregulation in ATP synthase activity has been 
reported in CLN3 and CLN2 patient fibroblasts (Das et al., 1996), but also in CLN1 patients 
(Das et al., 1999), indicating that these abnormalities are independent from the storage 
material composition of the different NCLs forms. More recently, other authors reported the 
interaction between Atp5b and Ppt1 protein (Lyly et al., 2008, Scifo et al., 2015). 
Interestingly, Lyly et al. showed that Ppt1-deficiency results in alterations in the amount of 
F1-ATP synthase on the plasma membrane, but not in mitochondria by 
immunohistochemistry studies (Lyly et al., 2008). Recent reports are starting to highlight the 
extra-mitochondrial expression of F1-ATP in plasma membrane and lipid rafts where it may 
have unknown functions [reviewed in (Champagne et al., 2006)]. Moreover, alterations were 
 171 
also shown in Atp5b expression in whole thalamus extracts at symptomatic stages in Ppt1∆ex4 
mouse model by proteomic studies (Tikka et al., 2016). 
 
Altogether, our data is consistent with previous reports where abnormalities in ATP 
synthase, and more specifically, Atp5b is perturbed in CLN1 and CLN3 disease (Das et al., 
1996, Das et al., 1999, Lyly et al., 2008, Scifo et al., 2015, Tikka et al., 2016). However, it is not 
clear whether these abnormalities reside in the mitochondria and/or elsewhere (Lyly et al., 
2008). In our Ppt1 time-course proteomic study (Chapter 4), we showed that Atp5b was 
down at 3-T & 5-C and up in 5-T &7-C synapses indicating that it could be accumulating 
towards late stages of the disease. Knocking down Atp5b in Drosophila CLN3 OE model, 
partially rescues the CLN3-derived neurodegeneration of the external and internal structure 
of the eye. Thus, our in vivo results, suggests that a potential accumulation/upregulation of 
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Investigations into the genetic underpinnings of the different NCL forms is leading to a 
growing number of gene repair and gene product replacement trials at the pre-clinical and 
clinical level including gene therapies and enzyme replacement trials respectively (Neverman 
et al., 2015). Thus, methodologies for determining disease progression and the effectiveness 
of therapeutic intervention become critical in the clinical setting.  
 
Behavioral and morphological markers are currently being developed and used in this 
context. For example, unified rating scales are currently being developed to quantify 
physical, behavioral and functional aspects for juvenile NCL (JNCL) (Adams et al., 2006, 
Marshall et al., 2005, Ragbeer et al., 2016, Kwon et al., 2011). Additionally, quantitative MR 
diffusion-weighted imaging has also been used to assess disease severity in late infantile NCL 
(LINCL) (Dyke et al., 2007). Although these studies are contributing to the evaluation of 
neurological form and function in patients, the development of standardized scales are 
necessary for all the NCL forms. However, such behavioral scales may be subjective, not 




sufficient information reflecting very subtle pathological alterations. Thus, an ideal 
biomarker would be a detectable objectively quantifiable molecular factor – alterations in 
which correlate to disease progression in a trackable and predictable manner for a specific 
form(s) of NCL (Biomarkers Definition Working Group, 2001) irrespective of a patients 
ability to perform behavioural tasks.  
 
NCL pathology in extra-neuronal tissues in patients have been extensively characterized and 
proved to be valuable for diagnostic purposes, which include blood, skin and muscle samples 
(Goebel et al., 1975, Rapola et al., 1973, Licchetta et al., 2015, Jadav et al., 2014, Anderson et 
al., 2013, Hersheson  et al., 2014). Therefore, we can also foresee molecular perturbances in 
such peripherally accessible tissues. Some studies in the NCLs have attempted to identify 
molecular biomarkers in cerebrospinal fluid (CSF) (Kay et al., 2009). CSF can be a source of 
detectable molecular alterations likely to be a consequence of the ongoing neurodegeneration 
in the brain. However, sampling CSF is a very invasive method and can be very stressful, 
especially to small infants.  Additionally, quantification of such factors from CSF is 
complicated by high levels of albumin. Other researchers have conducted preliminary 
examinations on more accessible tissues such as blood fractions including plasma (Hersrud 
et al., 2016) and lymphocytes (Lebrun et al., 2011) demonstrating that it is possible to find 
potential biomarkers in such tissues. Nonetheless, none of the studies to date have provided a 
correlation between potential biomarker expression data and the time-course of NCL disease 
progression. 
 
We and others have demonstrated that perturbations in ubiquitously expressed genes 
resulting in a disorder with a predominantly neurological presentation (such as the NCLs or 
Spinal Muscular Atrophy (SMA), also result in molecular pathology which is detectable in 
non-neuronal tissues (Hersrud et al., 2016, Lebrun et al., 2011, Kielar et al., 2009, Mutsaers et 
al., 2013). Multiple platforms can be used for the discovery of molecular biomarkers 
including genomics, transcriptomics or metabolomics. However, most biomarkers used in 
clinical trials have their origin in proteomic studies due to the fact that most developed drugs 
target proteins (Guest et al., 2013, Overington et al., 2006). In fact, applying proteomic 
techniques in an unbiased manner to the analysis of muscle, our laboratory has previously 
identified novel protein-based biomarkers which track with disease progression, and report 
on therapeutic efficacy in SMA (Mutsaers et al., 2013). Due to the disease causing mutation 




from analysis of tissue samples with a complex molecular composition such as muscle as a 
starting point can then be scaled down into less complex but more easily accessible samples 
such as skin and blood (Mutsaers et al., 2013) 
 
Studies by our laboratory have previously detected perturbations in protein expression in 
muscle extracts at early time-points of disease progression in the Ppt1-/- mouse model using 
quantitative western blotting techniques (QWB) (Kielar et al., 2009). Therefore, we are 
confident that by applying similar proteomic approaches as those used with brain derived 
isolates in Chapters 3 and 4, to peripherally accessible tissue such as muscle, we can identify 
multiple differentially expressed proteins, which after adequate filtering and processing 
could represent putative biomarkers for disease progression in the NCLs. 
 
Thus, in this study we begin by confirming that molecular pathology is detectable even at 
early time-points preceding morphological alterations in Cln3-/-mice.  Interestingly, we show 
that the molecular signature identified in muscle may also report on perturbations in the 
CNS including specific canonical cascades. These pathways included mitochondrial function 
and ubiquitin proteasome system regulation which are detectable in both infantile and 
juvenile NCL patient samples. Secondly, label free proteomics throughout the time-course of 
disease progression in Ppt1-/- murine samples, followed by a complex filtering strategy, 
identified a list of 40 putative biomarkers whose expression correlates with disease 
progression in Ppt1-/-. Additionally, a subset of these candidates also correlated with 
equivalent disease staging in Cln3-/-and therefore could represent potential biomarkers for 
both infantile and juvenile NCL. Finally, I demonstrate that specific candidates identified in 
muscle (i.e. Ndufs3), report the same molecular trends at the same time-points in blood and 













6.2 Materials and methods 
6.2.1 Animals and tissue harvesting 
Hind limb muscle tissues from six Cln3-/- mice at 13 months and four Ppt1-/- at 1, 3, 5 and 7 
months with each corresponding C57BL/6 age-matched control mice were dissected by Dr. 
Thomas Wishart and used for iTRAQ and label-free proteomics respectively (See Chapter 2. 
General materials and methods). Blood from four Ppt1-/- and C57BL/6 age-matched control 
at 3 and 7 months was collected by Dr Hemanth Navelgal from Prof. Jonathan Cooper’s 
laboratory (KCL) and sent to the Roslin Institute for its processing. For QWB, Cln3-/- muscle 
extracts at 13 months and Ppt1-/- muscle and blood were used at 3, and 7 months. 
Human cortical post mortem samples were used to examine the relevance of specific protein 
candidates to the human disease by QWB. Please refer to General materials and methods 
(Chapter 2) for more details.  
 
6.2.2 Synaptosome preparation 
Post mortem human patient and control frozen cortex were processed for synaptosome 
production as previously described (Wishart et al., 2007, Wishart et al., 2012). Please refer to 
General materials and methods (Chapter 2) for more details.  
 
6.2.3 Protein extraction 
For iTRAQ proteomics: Cln3-/- and WT controls hind limb muscles were homogenised in 4 
volumes (w/v) of 6M Urea, 2M thiourea, 2% CHAPS, 0.5% SDS and 5% protease inhibitor 
cocktail (Roche) using a pellet pestle (50 strokes with the pestle, left on ice for 10mins, 
followed by another 50 strokes with the pestle). The extracts were sonicated briefly and left 
on ice for 10 minutes, followed by centrifugation at 13,000 x g for 10 minutes at 4°C to pellet 
any insoluble material. For mass spectrometry analysis, an aliquot of extracted proteins from 
each mouse (n=6) and each brain region was pooled and precipitated in 6 volumes of ice cold 
acetone overnight at -20°C. The remaining extracts were stored (un-pooled) at -80°C for 
quantitative Western blotting validation. The acetone precipitates were pelleted by 
centrifugation at 13,000 x g for 10 minutes at 4°C and the supernatant was carefully remove 
and discarded. The pellets were resuspended in 6M Urea in 50mM TEAB. The protein 





For label-free proteomics: a section from forelimb muscle (predominantly gastroctemius) 
from 4 Ppt1-/- and 4 WT controls at 1, 3, 5 and 7 months were cut. Each corresponding 
genotype and time-point were pooled and masserated using a pestle and morter in SDT lysis 
buffer containing 100 mM Tris-HCl (pH 7.6), 4% (W/V). Please refer to General materials 
and methods (Chapter 2) for more details. 
 
For QWB: a section from hind limb muscle from 4 Cln3-/-, 4 Ppt1-/- mice and corresponding 
WT controls (4 for each) were homogenized individually in RIPA buffer and 1% protease 
inhibitor cocktail (Roche) using the Gentle Macs dissociator (Miltenyl Biotech Inc) and M 
tubes (Miltenyl Biotech Inc 130-093-236).  
Human patient and control brain homogenates and synaptosome fractions were 
homogenized in a solution containing 100mM Tris-HCl, 4% (w/v) SDS and 1% protease 
inhibitor cocktail (Roche). Please refer to General materials and methods (Chapter 2) for 
more details. 
 
6.2.4 iTRAQ Proteomic processing 
Cln3-/- and WT controls muscle extracts were processed for iTRAQ proteomics by Dr Heidi 
Fuller (Keele University). Please refer to General materials and methods (Chapter 2) for 
more details. 
 
6.2.5 Label-free proteomic processing 
Ppt1-/- and WT controls time-course muscle extracts (1, 3, 5 and 7 months) were processed 
for label-free proteomics by Abdel Atrih (Fingerprints proteomics facility, University of 
Dundee). Please refer to General materials and methods (Chapter 2) for more details. 
 
6.2.6 Quantitative fluorescent western blotting (QWB) 
15-60 µg of protein loaded for western blotting examination. Please refer to General 





6.2.7 In silico proteomic analysis 
6.2.7.1 Ingenuity Pathway analysis (IPA) 
IPA application (Ingenuity Systems) was used to obtain further insight into potential cellular 
pathways that may be perturbed in the iTRAQ proteomics data in Cln3-/- compared to 
control mice. Please refer to General materials and methods (Chapter 2) for more details. 
 
6.2.7.2 Progenesis 
Label-free proteomic raw data was imported into Progenesis LCMS for differential analysis 
and identification of peptides followed by quantification of relative ion abundance of 
peptides and corresponding proteins.  Samples were processed similarly to section 4.2.6.1 in 
Chapter 4. Only features contained between 8.84-93 min retention times with a limit of 5 ion 
charges were considered in the analyses. For this analyses we applied all the standard peptide 
filters except fold change filter that was not applied. Muscle is supposed to not be severely 
affected at early stage of the disease and potential biomarkers might not be differentially 
expressed in th early time-points. Please refer to General materials and methods (Chapter 2) 
for more details.  
 
6.2.7.3 BioLayout Express 
BioLayout software was used firstly, to analyse Ppt1-/- and WT time-course proteomic 
samples to examine the similarity between sample groups. Data was clustered by sample type 
and each sphere represents an individual sample and the closer they are, the more similar the 
samples are (Fig. 6.4B). Secondly, BioLayout was also used for clustering by co-expressed 
proteins in order to correlate their expression profile to the progression of the disease. In this 
display each sphere represents an individual protein and its colour and proximity to its 
neighbour indicates the similarity in protein expression (Fig. 6.5A&B). Please refer to 
General material and methods (Chapter 2) for more details. 
 
6.2.8 Data analysis and figure production 






6.3.1 iTRAQ proteomics identifies molecular pathology at early stages of Cln3-
/- mice 
To confirm that the causative mutation is affecting the molecular constituents of peripherally 
accessible tissue samples, we examined the proteome of limb muscle extracts of the Cln3-/- 
murine model of JNCL (relative to littermate controls) at 13 months old.  
 
Using iTRAQ proteomics a total of 598 individual proteins were identified. After filtering of 
proteins which were identified by less than 2 peptides and those whose expression differed 
from controls by less than 20%, 106 proteins remained for further analyses (Fig. 6.1A, 
Appendix I- Table A9) (Wishart et al., 2007, Wishart et al., 2012). Distribution of filtered 
proteins can be seen in Fig. 6.1A&B. 
Quantitative fluorescent western blotting (QWB) was used for the validation of the 
proteomic data confirming that proteins such Ndufs3, P4hb and Anxa5 (examples of sub-
threshold upregulation, upregulation and downregulation respectively) followed the same 
trends indicated by the proteomic analysis (Fig. 6.1C&D). After determining the veracity of 
the proteomic data and finding that so many proteins were indeed differentially expressed in 
muscle tissue, we sought to determine if any specific pathways or processes are perturbed. 
This was assessed with Ingenuity Pathway Analysis (IPA) software (see methods).  
 
Fig. 6.1. iTRAQ proteomics identified perturbations in muscle proteome from Cln3-/- mice 




(RHS) identified proteins (>1.2 Fold-Change, identified by ≥2 peptides). B. Representation of 
filtered proteins showing 60 upegulated and 31 downreguated proteins. C. QWB representative 
bands of total protein instant blue staining, NDUFS3, P4HB and ANXA5 validating the iTRAQ 
proteomics. D. Corresponding quantification of arbitrary fluorescent unit ratio of NDUFS3, 
P4HB and ANXA5. Mean ± SEM; * p -value<0.05, *** p-value<0.001, ns p-value>0.05 (Student T 
test, n=3-4 mice per genotype).  
 
 
IPA highlighted that the pathways which are likely to be the most affected by the alterations 
identified at this point are related to metabolic cascades associated with mitochondria such 
as “oxidative phosphorylation” and “TCA cycle”. This is perhaps unsurprising given the role 
of the causative mutation being examined here. Interestingly, other pathways related to cell-
junction and axonal guidance signaling were also altered suggesting either a potential 
perturbation in neuromuscular constituents or general machinery associated with neuronal 
formation and maintenance (Fig. 6.2A). Mitochondrial components have the potential to be 
useful biomarkers because of their presence in multiple cell types and the responsive nature 
of their biochemistry in relation the local envrironment (Raefsky et al., 2017, Chen et al., 
2007) (Krasnianski et al., 2005). Furthermore, mitochondrial dysfunction has been related to 
the pathogenesis of  the NCLs as well as in other lysosomal storage disorders (de la Mata et 
al., 2016) (Plotegher et al., 2017). In the Cln3-/- murine muscle proteome, specific 
upregulation of enzymes within complexes I & II of the mitochondria respiratory chain were 
identified, along with a decrease in complexes IV and V. This indicates, that this is likely a 
mitochondrial intrinsic response rather than an error in sample processing (Fig. 6.2B). 
Moreover, the data suggests a predicted activation of cascades leading to the synthesis and 
metabolism of reactive oxygen species (ROS), in this case regulated by PPARG, which is 
associated with lysosomal biogenesis (Song et al., 2011) (Fig. 6.2C&D). 
 
Here we confirm that individual differentially expressed proteins can be detected in the 
muscle proteome even at early disease stages in Cln3-/- mice. This analysis also demonstrates  
that perturbations in mitochondrial pathways and processes are highly represented in these 
peripheral samples suggesting mitochondrial proteins may be a potential source of molecular 








Fig. 6.2. IPA analysis reveals alterations in mitochondria-related pathways. A. Canonical 
pathway bar chart representing the most significant pathways linked to the Cln3-/- differentially 
expressed proteins identified by iTRAQ proteomics. B. Oxidative phosphorylation pathway 
representation showing the upregulation of enzymatic complexes I and II and the 
downregulation of complexes IV and V within the respiratory chain. C. IPA predicts the 
activation of the metabolism and synthesis of reactive oxygen species (ROS). D. PPARG is 
upstream of the proteins involved in the metabolism of ROS and it is predicted to be activated by 
IPA. Nodes in red, green, grey and white represent upregulated, downregulated, changed less 
than 20% and proteins not present in the analysed dataset respectively. Nodes in orange represent 






6.3.2 Proteomic analyses of Cln3-/- mouse muscle correctly predicts disruption 
of ubiquitination-related pathway perturbations in patient post mortem 
brain  
Given that the disease causing protein is expressed in all tissues, it is likely that a subset of its 
potential of the resulting downstream cascades will be affected in many sample types. As this 
disease presents primarily as a neurological condition, we used IPA to determine if the 106 
filtered detectable molecular perturbations in muscle isolates would cluster under any known 
neuronal designations.  Interestingly, of the five “disease and disorder” top clusters identified 
by IPA, three have clear neuronal associations (Table 6.1). These included “neurological 
disease” (the most significant), psychological disorders and skeletal and muscular disorders. 
This suggests that (as suspected) many of the protein pathways downstream of Cln3 loss, 
whose manipulation results in a disease with a predominantly neurological presentation, are 
likely to be perturbed in other neurological conditions. Thus, these proteins also reside in 
other tissues such as muscle, but may have subtly different functional consequences in 
alternative biological systems (Table 6.1). 
 
Table 6.1. Top Diseases and Disorders identified using IPA in Cln3-/- muscle extracts 
Name  p-value #Molecules  
Neurological Disease 2.99E-03 - 1.26E-19  58 
Organismal Injury and Abnormalities 3.09E-03 - 5.62E-18  90 
Psychological Disorders 2.99E-03 - 5.62E-18  47 
Skeletal and Muscular Disorders  2.99E-03 - 3.37E-15  56 
Hereditary Disorder  2.99E-03 - 3.92E-15  51 
 
 
Having determined that alterations reported in the literature as being primarily neuronal in 
association, are being detected in pre-symptomatic muscle, we next sought to assess if this 
data could be used to identify/predict biologically relevant alterations in brain samples from 
human patients. A closer examination of the IPA based clustering shows a predicted 
perturbation of ubiquitin as a potential master regulator of multiple alterations identified in 
the Cln3-/- muscle proteome (Fig. 6.3A). These candidates, which include mitochondrial 
proteins such as SOD1 and CS, are linked to ubiquitin through multiple molecular 
intermediate regulators. Some of these intermediate proteins, have previously been reported 
in relation to models of altered neuronal stability/vulnerability (i.e. Wlds) such as PTTG1 




the literature with adult-onset neurodegenerative diseases such as Alzheimer’s, Parkinson’s 
and Huntington’s diseases (Zheng et al., 2016). Interestingly, the disruption of ubiquitination 
pathways has also been implicated in other childhood neurodegenerative diseases (with a 
ubiquitously expressed causative monogenetic mutation) such as spinal muscular atrophy 
(SMA) (Wishart et al., 2014) .In the case of SMA, studies targeting elements of the ubiquitin 
proteasome system were able to rescue the neuromuscular system (Wishart et al., 2014) and 
provide systemic beneficial effects in animal models (Powis et al., 2016). Perturbations in the 
UPS have also been reported in animal models of NCLs (Cao et al., 2006, McCue et al., 2015) 
and in a human subtype of infantile onset NCL caused by mutations in the KCTD7 gene 
(Staropoli et al., 2012).  
 
In order to confirm that the identification of ubiquitin alteration was accurate as a predicted 
cascade in muscle, we began by showing with QWB that mono-ubiquitin was indeed 
downregulated in the Cln3-/- murine muscle extracts (Fig. 6.3B). To determine if the muscle 
proteome could be used to report on/or predict molecular pathology in human disease 
relevant tissue samples, we proceeded to examine different components of the UPS pathway 
by QWB in post mortem cortical extracts from JNCL and INCL patients. An antibody 
directed against ubiquitin protein was used for the detection of the different ubiquitin forms 
(Fig. 6.3C-F). As in the Cln3-/- mice, monomeric ubiquitin (mono-ubiquitin) was detected to 
be downregulated in both INCL and JNCL patients. However, an upregulation of tri – and 
multimeric ubiquitin (poli-ubiquitin) was also detected, suggesting a deregulation in 
ubiquitin homeostasis. To address this, we asked if other elements of the UPS are also 
altered. QWB of UchL1 and Uba1 showed differential expression in both juvenile and 
infantile patient samples (Fig. 6.3G-H), indicating disruption of the UPS pathway at end 
stage of disease in both INCL and JNCL. Interestingly, Uba1 and UchL1 alterations were also 
seen in SMA mouse models,  although not to the same magnitude, which could be a 
consequence of the differential time-course and regional specific severity of each condition 
(Wishart et al., 2014). 
 
Thus we confirm that by examining molecular pathology in muscle samples we are able to 
predict pathway disruption in disease relevant post mortem human neural NCL tissue from 
infantile and juvenile pateints. Muscle may therefore be a source of potential molecular 





Fig. 6.3. Cln3-/- mice muscle proteomics predicts perturbations in ubiquitin homeostasis 
confirmed by QWB in post mortem cortical extracts from INCL and JNCL patients. A. Murine 
proteomics: Mono-ubiquitin (Ubiquitin) is upstream some of the differentially expressed 
proteins in the Cln3-/- muscle proteome and it is predicted by IPA to be inhibited. Nodes in red, 
green, grey and white represent upregulated, downregulated, changed less than 20% and proteins 
not present in the analysed dataset, respectively. Nodes in orange and blue represent activation 
and inhibition respectively of predicted functions/molecules related to the proteins input in the 
analyses. B. Murine muscle protein: QWB representative bands and quantification bar chart of 
fluorescent intensity ratio of Cln3-/- vs. WT mice confirming the downregulation on ubiquitin 
predicted by IPA. C-H. Human post mortem brain protein: C-F. Poly-ubiquitin (Poly-Ub), Tri-
ubiquitin (Tri-Ub) and mono-ubiquitin (Mono-Ub) representative bands of Controls (C), INCL 
(I) and JNCL (J) patient cortical samples and corresponding quantification bar chart of their 
arbitrary fluorescent units (AFU). Mono-ub was shown to be downregulated in both INCL and 
JNCL with respect controls whereas Tri and poli-ub showed to be upregulated. G&H. 




ubiquitin-proteasome system such as Uba1 and UchL1 showing a trend towards downregulation 
in both INCL and JNCL samples. Mean ± SEM; * p-value<0.05, ** p -value<0.01, *** p-
value<0.001, ns p-value>0.05 (Student T test, Controls n=4, INCL n=2, JNCL n=3). 
 
 
6.3.3 Label-free proteomics throughout the whole time-couse of disease 
identifies proteins whose expression profile correlates with progression 
Having demonstrated (with iTRAQ proteomics of the Cln3-/- disease model) that muscle will 
likely prove to be a useful source of biomarkers, we next sought to identify and track 
molecular alterations taking place throughout the time-course of disease progression in a 
traceable and predictable manner (Biomarkers Definition Working Group, 2001).  
However, the Cln3-/- model is not necessarily the most appropriate for this type of temporal 
investigation. Reasons for this include but are not limited to the time-course length 
(approximately 23 months) (Pontikis et al., 2004) and increasing potential molecular noise 
through protracted systemic and chronic disease. Moreover, the morphological profiling of 
the the Cln3-/-  model is not as detailed in the later time-points as other shorter lived models. 
Ppt1-/- murine models of Infantile (I)NCL and have a shorter lifespan only reaching 8-8.5 
months of age (Gupta et al., 2001) and have been characterised in more detail at the 
pathological level (Kielar et al., 2007, Kielar et al., 2009). We therefore carried out a 
proteomic analysis of limb muscle extracts from Ppt1-/- and WT control mice. Given the 
more manageable time-course of the disease and our characterization of the model according 
to the degree of neuronal alterations we identified four disease stages which from this point 
on will be referred to as pre-, early-, mid- and late symptomatic stages at 1, 3, 5 and 7 months 
of age respectively (Kielar et al., 2007, Kielar et al., 2009). For future reference the 3 month 
early-symptomatic disease stage in Ppt1-/- is equivalent to 13 months in the Cln3-/- model 
(Kielar et al., 2009) and (Llavero Hurtado et al., 2017) This type of temporal investigation 
also warrants a shift from iTRAQ to label-free proteomic techniques as it offers a higher 
protein coverage with less starting material (Craft et al., 2013, Patel et al., 2009, Bantscheff et 
al., 2007), greater sample processing and data analysis flexibility without the need for 
multiple label incorporation (Xie et al., 2011). 
 
After protein extraction and label-free proteomic analysis, Progenesis software was used to 
process and analyse the raw proteomic data (see methods). A total of 985 proteins were 




protein level (unique peptides >2) as previously described (Aghamaleky Sarvestany et al., 
2014) No fold-change filter was used at this level as we would expect to identify proteins 
which are not differentially expressed at all time points throughout the time course. After 
filtering, 427 proteins remain for further analysis. Principal component analysis (PCA) 
carried out in Progenesis illustrated a normal distribution of identified protein abundances 
with no clear outliers within each sample group (Fig. 6.4A). In order to further confirm the 
reproducibility of the proteomic replicates we used BioLayout. BioLayout is a complex 
pattern recognition software which can be used to cluster sample or proteins according to 
their molecular expression trend (Theocharidis et al., 2009, Carpanini et al., 2017, Enright et 
al., 2002) (see methods). Confirming the PCA results, each replicate clustered together 
indicating consistency of the proteomic results (Fig. 6.4B). 
 
As we presumed, multiple differentially expressed proteins were detected across the Ppt1-/- 
mice time-course when compared to WT control as shown in the heat-map in Fig. 6.4C. A 
higher number of upregulated proteins were detectable at early stages (1 & 3 months) with a 
shift towards the downregulation at end stage (5 & 7 months) (Fig. 6.4C&D).  
However, the numbers shown only represent the proteins whose expression changes meet 
the filters at each time-point (Fig. 6.4D). Thus, in order to identify which of the 427 proteins 
were more likely to represent effective biomarkers, we next sought to track individual 
proteins throughout the time-course of disease progression in Ppt1-/- mice. To do so we turn 
again to BioLayout software, with the objective to identify proteins demonstrating a steady 
up or downregulation. Proteins showing a change of more than 20% at 7 months were input 
into BioLayout for molecular profiling clustering. A total of 40 individual proteins were 
clustered into specific up/downregulated clusters with a useful trend (Fig. 6.5, Table 2). 
Interesting examples of upregulated proteins are Cand2 and CtsD (Fig. 6.5C). CtsD shows no 
change at 1 month and progressively increases with disease progression until changing by 
more than 3 fold- by end-stage. Interesting examples of downregulated proteins are Ces1d 
and Clec3b. Ces1d is highly upregulated at 1 month (4.72 Fold-Change) but then quickly 
declines in abundance with disease progression. So in addition to correlating with 
neurodegenerative progression in the brain, Ces1d expression may also represent a useful 
biomarker for the early detection of infantile NCL. 
 
Here we demonstrate that we are able to track individual proteins throughout the time-




bioinformatic molecular profiling. We identify a list of 40 proteins whose changes track with 
the time course of disease progression in Ppt1-/- mice (Kielar et al., 2009, Kielar et al., 2007). 
Fig. 6.4. Label-free proteomics reveals perturbations in muscle proteome throughout the time-
course of disease progression in Ppt1-/- mice. A. Principal component analysis (PCA) generated 
in Progenesis based on protein abundance corresponding to each genotype and time-point. 
Proteins are represented by accession number (in grey) and followed a normal distribution 
(ellipse shape). PC1 represents the differences between genotypes (WT & Ppt1-/-) and PC2 
indicates the differences between technical replicates (technical error). All the technical replicates 
within each group clustered together indicating the absence of outliers in the analysis. B. 
BioLayout representation of the proteomic data clustered by sample similarity indicating, again, 
the clustering of technical replicates corresponding to the same genotype and time-point. Each 
sphere represents a sample and the closer they are, the more similar they are. C. Heat-map 
representing protein expression ratios of Ppt1-/- vs. WT showing the differentially expressed 
proteins identified across the 4 time-points. Red and green represents upregulated and 
downregulated proteins respectively. D. Proteins filtered by those identified by >2 peptides, >1.2 




proteins (blue lines, 3 technical replicate per group) in WT (background in pink) and Ppt1-/- 
(background in blue) across time-course (1, 3, 5 and 7 months). The number of 
up/downregulated proteins is shown to the right of each graph. C&D. Note the higher number of 






Fig. 6.5. BioLayout clustering by protein expression trend allows the identification of 40 
individual biomarker candidates whose expression correlates to disease progression in Ppt1-/- 
vs. WT. A. BioLayout clustering 3D representation of proteomic expression data across the time-
course of disease progression of Ppt1-/- vs. WT. Each sphere represents a single protein and the 
edge represents how similar their expression trend is towards the other proteins in the dataset. 
The closer the spheres are the more similar expression trend they have. The colours represent the 
different clusters of co-expressed proteins. B. Up and downregulated clusters identified with the 
Marckov clustering algorithm. 10 proteins showed a steady upregulation whereas 30 proteins 
were steady downregulated. Each dashed line is representing the average expression ratio in log 
scale of the proteins within each selected cluster. C. Line graphs showing the expression ratio 
Ppt1-/- vs. WT across time-course of example of individual protein candidates within the 







Table 6.2. Proteins identified by label-free proteomics showing steady up/downregulated profile 
throughout the time-course of disease progression in Ppt1-/-/WT 
  Ratio  Ppt1
-/-/WT 
Gene 
Symbol Protein name 1 m 3 m 5 m 7 m 
ACAA2 3-ketoacyl-CoA thiolase, mitochondrial 1.74 0.87 0.81 0.81 
ACADL Long-chain specific acyl-CoA dehydrogenase, mit. 1.78 0.95 0.75 0.71 
ACADV Very long-chain specific acyl-CoA dehydrogenase, mitochondrial 1.49 0.96 0.78 0.83 
APOA1 Apolipoprotein A-I 1.08 0.93 0.79 0.76 
ATP5B ATP synthase subunit b, mitochondrial 1.53 1.28 0.80 0.62 
ATP5O ATP synthase subunit O, mitochondrial 1.28 1.20 0.95 0.80 
ATPA ATP synthase subunit alpha, mitochondrial 1.21 1.14 0.88 0.75 
CALR Calreticulin 0.86 0.77 1.09 1.43 
CAND2 Cullin-associated NEDD8-dissociated protein 2 0.65 0.95 1.19 1.49 
CES1D Carboxylesterase 1D 4.72 0.68 0.72 0.33 
CILP2 Protein Cilp2 1.85 1.56 1.18 0.70 
CLEC3B C-type lectin domain family 3, member b 0.96 0.96 0.79 0.61 
COL6A2 Collagen type VI alpha 2 subunit 1.48 1.07 0.80 0.76 
COX5A Cytochrome c oxidase subunit 5A, mitochondrial 1.48 1.38 0.87 0.64 
CTSD Cathepsin D 1.04 1.66 2.13 3.41 
ETFDH Electron transfer flavoprotein-ubiquinone oxidored., mit. 1.70 0.93 0.87 0.69 
GBAS Guanine nucleotide-binding protein G(s) subunit alpha 1.55 0.86 0.74 0.73 
HADHA Trifunctional enzyme subunit alpha, mit. 1.47 1.19 0.86 0.65 
HADHB Trifunctional enzyme subunit beta, mitochondrial 1.49 0.98 0.79 0.83 
KRT84 Keratin, type II cuticular Hb4 0.16 0.32 0.42 0.48 
LOC10090
9612 
Protein LOC100909612 15.3 0.15 0.60 0.76 
MTCH2 Mitochondrial carrier homolog 2 1.72 0.98 0.93 0.76 
NDUFA10 NADH dehydrogenase 1 alpha subcomplex subunit 10, mitochondrial 1.37 1.16 0.81 0.81 
NDUFA6 NADH dehydrogenase [ubiquinone] 1 α subcomplex subunit 6 1.36 1.12 0.83 0.79 
NDUFA9 NADH dehydrogenase [ubiquinone] 1 α subcomplex subunit 9, mit. 1.26 1.14 0.91 0.79 
NDUFS3 NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mit. 1.45 1.08 0.94 0.81 
NEFH MKIAA0845 protein (Fragment) 0.59 0.57 0.97 1.37 
PDHX Pdhx protein (Fragment) 1.50 0.81 0.80 0.81 
PGK1 Phosphoglycerate kinase 1 0.79 0.67 0.95 1.39 
PHB2 Prohibitin-2 1.39 1.10 0.99 0.75 
PPIC Peptidyl-prolyl cis-trans isomerase 0.60 1.06 1.12 1.49 
PRDX5 Peroxiredoxin-6 1.47 0.99 0.77 0.81 
RNH1 Ribonuclease H1 0.72 0.91 0.99 2.02 
RPL4 60S ribosomal protein L4 0.78 1.07 1.24 1.33 
S100A1 Protein S100-A1 1.46 1.29 0.70 0.57 
SPTBN1 Protein Sptbn1 0.90 0.62 1.23 1.69 
TKT Transketolase 2.21 0.53 0.74 0.66 
TNNC2 Troponin C, skeletal muscle 1.27 0.81 0.84 0.71 




6.3.4 Ndufs3 and Calreticulin represent putative biomarkers for disease 
progression relevant to human NCL, and are detectable in muscle and 
blood samples in Ppt1-/- mice  
To strengthen the confidence in the proteins identified thus far and their utility as putative 
biomarkers, we next wanted to identify those candidates whose expression is “conserved” at 
equivalent disease stages in both the infantile and juvenile forms of the disease. Interestingly, 
we could find 181 overlapping proteins in both Cln3-/- iTRAQ and Ppt1-/- label-free datasets 
(Fig. 6.6A). From these common proteins, 8 had a relatively steady in-/de-creasing profile in 
the Ppt1-/- time-course, and also presented similar fold-change at equivalent disease stage in 
Cln3-/- (Fig. 6.6B). This suggests that these 8 proteins may be putative biomarkers for both 
juvenile and infantile NCL. 
 
Using QWB we then successfully validated the only example of an upregulated protein 
within the list, calreticulin (Calr) (Fig. 6.7A&E). Interestingly, calreticulin has also been 
shown to be a muscle and skin biomarker of disease progression in SMA with a very similar 
expression trend profile to that seen in the Ppt1-/- mice (Fig. 6.8) (Mutsaers et al., 2013). We 
also validated an example of a downregulated protein, Ndufs3, which is an enzyme from the 
complex I mitochondrial respiratory chain and was also altered in the Cln3-/- proteomic data 
(Fig. 6.2B, Fig. 6.7B&D). Thus, we can demonstrate that proteins identified with a 
predictable trend in expression alteration correlating with disease progression in PPT1 and 
exhibiting similar expression alterations at equivalent disease stages in CLN3 are also 
detectable by western blotting. 
 
Although muscle sampling yields a much more complex protein isolate of a greater yeild 
than CSF, it is very painful. A much less invasive method to obtain a sample is blood 
extraction. For this reason, we attempted to detect Calr and Ndufs3 in blood protein extracts 
from Ppt1-/- and WT controls. Here, we quantified Calr and Ndufs3 expression at early and 
late disease stages (3&7 months respectively) by QWB in order to determine if these proteins 
followed the same trend as in muscle. Our results confirm that both candidates followed the 
same trend as in muscle, with Calr was being upregulated and Ndufs3 downregulated as the 
disease progresses (Fig. 6.7). Moreover, the consistent strong upregulation of Ndufs3 at 1 






Fig. 6.6. Eight identified biomarker candidates from the Ppt1-/- analyses have a conserved 
change in the Cln3-/- mice at equivalent disease stage. A. Venn diagram showing 181 
overlapping proteins identified in both iTRAQ Cln3-/- and Ppt1-/- label-free proteomics. B. Line 
graphs showing the expression ratio Ppt1-/- vs. WT across time-course of the 8 individual 
candidate biomarkers which expression correlates to disease progression in Ppt1-/- mice and is 
conserved between Cln3-/- (green) and Ppt1-/- (blue) at equivalent disease stage (13 months in 









Fig. 6.7. Calreticulin and Ndufs3 represent putative biomarkers of disease progression 
detectable in muscle and blood in Ppt1-/- mice. A&B. Line graphs representing calreticulin (Calr) 
and Ndufs3 expression ratio Ppt1-/- vs. WT across time-course in muscle proteomics, muscle 
QWB and blood QWB respectively. QWB in muscle validated the upregulation of Calr and 
downregulation of Ndufs3 throughout the time-course of disease progression in Ppt1-/-mice. 
Expression ratio was also validated in Cln3-/- mice at 13 months. The same expression trends were 
detected in blood extracts at the same time-points in Ppt1-/-mice. C. Instant blue total protein 
staining representative bands showing equal loading for both Ppt1-/- and Cln3-/- and 
corresponding WT controls. D&E. Representative QWB bands of Calr and Ndufs3 in muscle and 
blood in Ppt1-/- and WT mice at 3 and 7 months and in Cln3-/- and WT mice at 13 months. Mean 









Fig. 6.8. Calreticulin and expression levels in SMA mice skin biopsies and NCL mice muscle 
extractions. A&B. In both mice models Calreticulin increases only after the onset of symptoms 
(in SMA) and synaptic pathology (in NCL). Therefore, calreticulin may be a potential conserved 
biomarker in two conditions where synapses are an early pathological target. Panel A is adapted 
from Fig. 4 in (Mutsaers et al., 2013). 
 
 
Finally, we wanted to determine if these changes identified and validated in muscle and 
blood from mouse models of NCL, are actually relevant to the molecular pathology 
occurring in brain in NCL patients. Being aware of the limitations of using post-mortem end 
stage samples, we proceeded to examine Calr and Ndufs3 by QWB. We can show that 
Ndufs3 had the same trend in cortical protein extracts from both INCL and JNCL patients as 
in the muscle and blood from mouse models at equivalent disease stage. Although Calr did 
not reach significance, Ndufs3 showed a deep consistent downregulation (Fig. 6.9). 
 
Overall, we demonstrate that we can identify biomarkers of disease progression in Ppt1-/-  
mice, some of which may be conserved in both INCL and JNCL. Muscle is a rich source of 
peripherally accessible biomarkers, and we can identify differentially expressed proteins in 
blood that follow the same molecular expression trend as muscle. Finally, we confirm that 
changes detected in muscle and blood which correlate to the time-course of disease 
progression in Cln3-/- and Ppt1-/- are likely to be physiologically relevant to the human disease 
as they are also changed in the same direction in post mortem cortical protein extracts from 






Fig. 6.9. Ndufs3 changes detected in muscle and blood from mice models are relevant to 
infantile and juvenile NCL in humans. A. Instant blue total protein staining scanned image and 
corresponding bar chart quantification of fluorescence abundance indicating equal loading across 
samples. B&C. Calreticulin (Calr) did not show a consistent or significant change in post mortem 
brain samples, but Ndufs3 shows the same expression trend in post mortem cortical extracts 
from INCL and JNCL patients compared to controls (C) as predicted from muscle and blood 
from Ppt1-/- and Cln3-/- murine models. Mean ± SEM; * p-value<0.05, ns p-value>0.05 (Student T 





In this chapter we demonstrate that muscle protein extracts are a rich source of biomarkers 
of disease progression in the NCLs mice models, predicting molecular perturbation at the 
neuronal level in humans. We are able to track individual protein candidates throughout the 
time-course of disease progression in mice models of NCL by means of state-of-the art label-
free proteomics followed by bioinformatics analyses. We have identified calreticulin and 
Ndufs3 as putative biomarkers of disease progression in muscle and blood extracts in Ppt1-/- 
mice and demonstrated that Ndufs3 expression in human post mortem tissue from both 
INCL and JNCL patients follows the alterations predicted from analysis of murine peripheral 
samples. 
 
iTRAQ proteomics carried out in muscle extracts from the Cln3-/- mouse model of JNCL at 
an early stage (13 months), identified multiple molecular perturbations related primarily to 
mitochondrial pathways (Fig. 6.1 & Fig. 6.2). Disrupted cascades predicted by the mice 
proteomics followed by IPA analysis were validated in post mortem cortical extracts from 
NCL patients highlighting the relevance of these changes to the human condition (Fig. 6.3). 
Therefore, we confirmed that muscle proteome is a potential source of biomarkers in the 
NCLs. 
 
In order to track specific candidates throughout disease progression, a time-course 
proteomic study was carried out in Ppt1-/- mice model of INCL. Label-free proteomics 
followed by hierarchical clustering bioinformatic methods; identified 40 individual 
candidates with correlated to the disease progression of Ppt1-/- mice (Table 6.2) (Kielar et al., 
2009, Kielar et al., 2007). From these 40 proteins, a subset of 8 candidates presented a 
conserved change between Cln3-/- and Ppt1-/- at equivalent disease stage (Fig. 6.6). This 
highlights the possibility of identifying common biomarkers across multiple NCL conditions 
but also specific ones for each form of NCL (Fig. 6.5).  
 
Importantly, Calreticulin and Ndufs3 expression trend was conserved in blood samples at 
the same time-points in Ppt1-/- mice, suggesting that changes in specific proteins might be 
conserved across less invasive peripherally accessible tissues. Examination of post mortem 
cortical protein extracts from INCL and JNCL patients identified the same expression trend 




Interestingly, previous studies in our laboratory detected Calreticulin to be also upregulated 
with disease progression in muscle and skin in SMA animal models and patients (Fig. 6.8) 
(Mutsaers et al., 2013). Both SMA and NCL are neurodegenerative diseases of childhood 
where synapses are an early pathological target (Kielar et al., 2009, Partanen et al., 2008, 
Murray et al., 2008, Wishart et al., 2006). Some commonalities at the molecular level in 
neurons between these two conditions were already highlighted in this chapter such as the 
defects in ubiquitin homeostasis and some of the enzymes within the UPS (Fig. 6.3) (Wishart 
et al., 2014). Therefore, common perturbations between NCL and SMA might be also 
occuring in muscle, suggesting the possibility to identify accessible biomarkers of disease 
progression in multiple conditions where some pathological events might be shared [ie. early 
synaptic loss (Wishart et al., 2006)]. The discovery of common biomarkers across multiple 
neurodegenerative diseases could provide a more efficient way to develop new platforms for 
the detection of specific predictive alterations, or it can even allow us to repurpose tools 
available for existing reagents. 
 
Nevertheless, due to the inter-species differences, a complete mapping of the molecular 
fingerprint of peripherally accessible tissues in humans will be required in order to 
determine the validity of candidates such as Calreticulin and Ndufs3 as peripherally 
accessible biomarkers for NCL patients. Moreover, it will be important to consider that 
blood and muscle proteomic composition is very different and further proteomic studies 
focused solely in blood would provide more insight for the discovery of specific blood 
biomarkers. 
 
Altogether, this chapter offers a proof of concept that such techniques and such tissues are a 
reliable source of biomarkers in the mouse models of NCL. The exponential improvements 
in proteomic technologies combined with carefully planned experimental design (Fuller et 
al., 2016), allows the reliable characterization of molecular changes taking place in complex 
protein extracts from multiple tissue types i.e. dried blood spots (Ozcan et al., 2017), CSF 
(Heywood et al., 2015), nerve (Catenaccio et al., 2017, McGorum et al., 2015), muscle 
(Mutsaers et al., 2013) and even subcellular fractions (Wishart et al., 2014, Graham et al., 
2017). Here we demonstrate, that using such technologies we can successfully track specific 
proteins through disease progression in animal models. Follow up for this particular line of 




more effectively enable the application of similar workflows and techniques to translate these 



















7.1 Overview of results 
In this project, we demonstrated that: 
1 We can use proteomic technologies to underpin a data-driven target discovery 
approach. We mapped the molecular changes correlating to the synaptic vulnerability 
patterns across various brain regions and throughout the time-course of disease 
progression in two distinct neurodegenerative mouse models of NCL (Ppt1-/- and Cln3-/-
). The combination of multiple in silico tools allows interpretation and characterization 
of these molecular changes, and identifies specific pathways which are perturbed at 
different stages of disease progression.  
2 We showed that some of these changes are conserved across both the Ppt1-/- and Cln3-/- 
mouse models as well as other neurodegenerative diseases where synapses are an early 
pathological target. Such candidates may therefore be conserved regulators across 
multiple conditions. Importantly, a subset of these candidates presented similar 
perturbations in post mortem infantile and juvenile NCL patient samples. This 
highlights the relevance of these findings to human disease. 
3 Ultimately, we generated a list of protein candidates which were targeted using 
Drosophila models of NCL. We showed that many of these candidates do indeed have 
the ability to modulate neuronal stability in vivo. 
4 We also combined the use of proteomics and in silico analysis for the discovery of 
putative biomarkers of disease progression, detectable in muscle and blood. Protein 
changes detected in peripherally accessible tissues were able to predict molecular 
changes at the neuronal level in NCL patient samples. A subset of these candidates 
presented similar alterations at equivalent disease stages in both Ppt1-/- and Cln3-/- mice, 





Overall, we showed that refining experimental design to take into account regional 
vulnerability for tissue sampling, using state-of-the-art proteomics and in silico analyses in 
murine models of neurodegeneration, and combined with rapid phenotypic assessment in 
lower order animal organisms is a robust approach for the elucidation of regulators of 
neuronal stability in vivo. 
 
 
7.2 The importance of target and biomarker discovery 
In the past decade, there has been a dramatic decline in new entities approved by the Food 
and Drug Administration (FDA) (Munos, 2009), as a result, there are no effective disease 
modifying drugs available for any neurodegenerative disease. Target identification is a key 
step in the drug discovery pipeline, which generally occurs 10-15 years before a drug gets 
approval. The cost of drug development has also increased in the last few years, highlighting 
the importance and the need of target validation approaches during pre-clinical 
investigations. Along with drug target discovery, the importance of molecular biomarkers 
should not be overlooked. Biomarkers allow the monitoring of disease progression and are 
essential to the drug discovery pipeline. This is because they are also used to evaluate the 
efficacy of novel therapies in pre- and clinical trials (Paul et al., 2010). 
 
Importantly, it has been pointed out by many investigators that the activity of a single drug 
or target is unlikely to regulate the whole process of neurodegeneration (Prior et al., 2014). 
Thus, omics approaches such as proteomic technologies combined with phenotypic 
assessment experiments as target validation, offer the possibility to shed light into the 
complex mechanistic pathways underlying neurodegeneration (see section 1.7).  
The results outlined in this thesis support the notion that multiple cascades may be 
regulating neuronal stability. The identification of protein candidates, based on their 
expression profile correlating to synaptic pathology in mouse models of NCL (Chapter 3 
&4), gave rise to interesting and promising results which were assessed in Drosophila models 
(Chapter 5). The misexpression of many of the identified candidates were able to regulate 




Moreover, the modifier effect observed by each one of the candidates yielded different 
phenotypes indicating that these proteins may participate in different pathways (See section 
5.4) (Oortveld et al., 2013). 
Importantly, some of the changes detected in the mouse models were conserved in patients 
and are therefore relevant to the human disease. Further experiments would be needed in 
order to establish the cascade initiator and which pathway(s) is/are downstream, or whether 
or not candidate-related pathways converge to a common hub, triggering neuronal loss. 
 
However, we should also consider that although Drosophila are excellent “simple” organisms 
and an attractive platform to do in vivo studies, further steps are needed to translate these 
results to patients. The use of human-derived neuronal cultures would be a valuable platform 
to validate genetically and pharmacologically some of our proposed targets such a ROCK2 or 
ATP5B, for which compounds exist (Vargas-Caballero et al., 2016, Olson, 2008, Ivanes et al., 
2014). Large animal models also offer multiple advantages over rodents and interestingly, 
some neurodegenerative diseases naturally occur in these animals (Eaton et al., 2017). This is 
the case for some of the NCLs, including the existence of; ovine (Palmer et al., 2015), porcine 
(Cesta et al., 2006) and dog models (Jolly et al., 1997). Interestingly, Amorim et al., reported 
that multiple protein perturbations were conserved across different model systems such as 
Drosophila, mice, and CLN5 sheep synaptic compartments (Amorim et al., 2015). Therefore, 
ovine models of NCL represent valuable systems to bridge the gap between the findings 
highlighted here and patients. 
 
Nonetheless, the results shown in this thesis give some clues regarding specific protein and 
pathways that may be involved in regulating the process of neurodegeneration. 
 
 
7.3 Conserved modulators of neurodegeneration across 
multiple conditions 
In this project, we aimed to identify novel regulators of synaptic stability. Thus, it is 
important to highlight that all of the protein candidates in this thesis were identified based 
solely on how their expression profiles correlated to synaptic vulnerability and/or disease 
progression. We therefore avoided biasing our candidate list with recurrent proteins popular 




Nevertheless, when it came to unravelling the functions and pathways in which these 
proteins interact, many have shown to be perturbed in other neurodegenerative diseases. For 
instance, the valine degradation cascade was identified in two independent proteomic 
studies. The first one, carried out in Cln3-/- mice (Chapter 3), where there was shown to have 
a progressive disruption correlating to synaptic vulnerability across brain areas (Llavero 
Hurtado et al., 2017). The second in the Ppt1-/- time-course study (Chapter 4), the valine 
degradation pathway was identified in IPA to be the top most significant pathway perturbed 
among all the candidates identified. Several enzymes catalyzing the catabolism of valine seem 
to be disrupted in both NCL mouse models. HIBCH and HADHA, two of the perturbed 
enzymes in the pathway, were also changed in the same direction in cortical synaptic 
fractions from post mortem NCL patients. Thus, these changes are relevant to the human 
disease. Knocking down these two enzymes in Drosophila enhanced the CLN3-OE-induced 
degenerative phenotype but did not cause any phenotypic change in a WT fly when knocking 
them down under the same conditions. This indicates that these two enzymes have the ability 
to change neuronal stability in a CLN3-dependent manner. Importantly, HADHA and 
HIBCH deficiencies have been reported to cause neurological disease in humans (Loupatty et 
al., 2007, Ibdah et al., 2001). Interestingly, mutations in HADHA cause retinopathy leading 
to vision loss (Fletcher et al., 2012). Vision loss is generally the first symptom detected in 
CLN3 patients. Moreover, previous studies in our laboratory highlighted that HIBCH was 
also disrupted in synapses following injury in mice (Wishart et al., 2012). 
 
Taken together, there is strong evidence to indicate that enzymes within the valine 
degradation cascade are affected by CLN3 perturbations contributing to neurodegeneration. 
Importantly, metabolomic studies by Pears et al. in Cln6 sheep brain detected increased 
levels of valine at both early and late clinical stages, which correlate to our results in mice, 
suggesting a deficiency in the degradation of this amino acid (Pears et al., 2007). 
But why is disruption of valine degradation affecting neuronal stability? Some studies have 
indicated that branched-chain amino acids such as valine are important to maintain 
synthesis of the neurotransmitter, glutamate (Yudkoff, 2017). More specifically, Bak et al. 
showed that valine amino acid was needed for the synthesis of vesicular glutamate 
neurotransmitter during synaptic activity in cultured cerebellar neurons (Bak et al., 2012). 
The correct homeostasis of amino acids in neurons and especially in synapses is crucial for 
synaptic function (see 1.5.3). Metabolomic studies have indicated a dysregulation of 




2007), which have been related to excitotoxicity (Chattopadhyay et al., 2002). Interestingly, it 
has also been reported that there are alterations in glutamate receptor function in both Ppt1-/- 
and Cln3-/- mutant mice (Finn et al., 2012, Finn et al., 2011).  
 
We show that the knock-down of valine degradation enzymes enhances the CLN3-OE-
induced phenotype in Drosophila. A plausible hypothesis of why this is happening may be a 
disruption in amino acid balance, and more specifically valine and glutamate perturbations. 
Importantly, this could to be conserved from lower model organisms (yeast) up to higher 
organisms such as Drosophila, through to mice and sheep. 
 
Conversely, in this study we also detected the upregulation of ROCK2 in Cln3-/-, correlating 
to synaptic vulnerability across brain areas (Chapter 3). By suppressing ROCK2 expression 
(genetic manipulation) or inhibiting its function (ROCK2 inhibitor compound), we showed 
a rescue of the CLN3-induced phenotype in Drosophila.  
 
Upregulation of ROCK2 has been implicated in several adult-onset neurodegenerative 
conditions where synaptic pathology is present, such as HD, AD, ataxia, and in Purkinje cell 
degeneration (Deyts et al., 2009, Herskowitz et al., 2011, Zhou et al., 2003, Blaise et al., 2012, 
Wishart et al., 2012). Moreover, pharmacological inhibition of ROCK2 partially rescued 
symptoms and increases lifespan in an SMA mouse model (Bowerman et al., 2012, Coque et 
al., 2014). ROCK2 also was reported to influence axonal degeneration following injury 
(Wishart et al., 2012). Thus, ROCK2 is an attractive target for NCL but also for many other 
neurodegenerative diseases where synapses are an early pathological target (Llavero Hurtado 
et al., 2017). 
 
Importantly, more intriguing commonalities between NCL and SMA have been highlighted 
throughout this thesis. In Chapter 6, we aimed to identify molecular biomarkers in 
peripherally accessible tissues, which correlated to synaptic pathology/neuronal loss. 
Proteomics carried out at an early stage in Cln3-/- muscle extracts were followed by in silico 
analysis which helped identify mono-ubiquitin as a predicted master regulator, estimated to 
be inhibited/downregulated. After confirming mono-ubiquitin downregulation in mouse 
muscle tissue, by examining post mortem brain samples of NCL patients we identified the 
dysregulation of ubiquitin-related proteins including Uba1 and UchL1 proteins. 




this pathway allowed the rescue of the neuromuscular system and the whole organism in 
animal models of the disease (Wishart et al., 2014, Powis et al., 2016). Therefore, it will be 
interesting to further investigate the role of this pathway in the NCLs as it also indicates that 
ubiquitin-related proteins may be common regulators of neuronal stability across multiple 
conditions (Zheng et al., 2016). 
 
Moreover, the unbiased study of molecular biomarkers correlating to disease progression, 
using a pattern recognition software, Biolayout, identified that calreticulin steadily increases 
with disease progression in muscle and blood extracts from Ppt1-/- mice. Surprisingly, 
calreticulin was reported by our laboratory to display a very similar expression profile in skin 
samples in SMA mouse models (Fig 6.8) (Mutsaers et al., 2013). Therefore, conserved 
biomarkers may exist across multiple neurodegenerative disease sharing common aspects, 
such as early synaptic vulnerability. This will allow the utilization of the same methods for 
biomarker detection or perhaps they can even be used on already existing platforms. 
 
Overall, the identification of common molecular regulators and biomarkers of 
neurodegeneration across multiple diseases will facilitate the development of therapeutic 
strategies to halt or delay the progression of all these conditions. 
 
 
7.4 The NCLs as model of neurodegeneration 
As highlighted in the previous section, we suggest that common mechanisms regulating the 
process of neurodegeneration and/or vulnerability of synapses may occur across a range of 
neurodegenerative conditions triggered by different genetic insults. In fact, other 
investigators already reported similarities between the NCLs and one of the most common 
adult-onset neurodegenerative diseases such as Parkinsons’s disease. In the CLN3 disease, 
motor difficulties start with epilepsy and extrapyramidal/parkinsonian signs that include 
rigidity, hypokinesia and impaired balance, leading to complete immobility (Gardiner, 2002, 
Haltia, 2003, Nita et al., 2016). This highlights the potential mechanistic connections 
between these two conditions. 
We then should consider that most of the more common adult-onset neurodegenerative 




understood (potentially multifactorial) aetiology for which the genetic insult triggering 
neuronal loss is not well understood. Therefore, the availability of animal models that fully 
replicate the disease in humans are limited (Escott-Price et al., 2015, La Cognata et al., 2017). 
In contrast, the NCLs are monogenetic diseases for which there are available many well-
characterized mice models that more accurately replicate the human disease (Mitchison et 
al., 1999, Pontikis et al., 2004, Cotman et al., 2002, Gupta et al., 2001, Kielar et al., 2007, 
Partanen et al., 2008). In this project, we demonstrated that we can use the NCLs as a model 
to study a specific neurodegenerative process (i.e. synaptic loss) which is likely to be 
governed by mechanisms which may indeed be conserved across multiple conditions ranging 
from injury through to chronic neurodegenerative conditions (i.e. Huntington disease and 
spinocerebellar ataxia) and diseases of childhood (i.e. SMA & the NCLs) (Wishart et al., 
2012) (Llavero Hurtado et al., 2017). 
 
The connection between the NCLs and more common ageing-related diseases such as 
Alzheimer’s will benefit academia, the pharmaceutical and biotechnology industries. This is 
because these shared common pathophysiological pathways will open up funding and 




In this work, we identified regulators of neuronal stability which may serve as drug targets 
for the development of novel therapies, not only for the NCLs, but also for other 
neurodegenerative conditions where synapses are an early pathological target. The workflows 
highlighted in this project should not be viewed as a mass screening “stamp collecting” 
exercise. Instead it should be clear that combining mammalian models with “–omic” 
screening of differentially vulnerable tissues with in silico candidate identification and in vivo 
phenotypic assessment in Drosophila is an efficient pipeline for elucidating the mechanistic 
cascades governing neurodegenerative processes. Ultimately, we have developed “target-
rich” and data-driven pipelines for identifying factors which are capable of modulating 
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Appendix. Data tables 
 
Table A1. BioLayout analysis of cortical, hippocampal and thalamic samples in Cln3-/-: Cluster 3 (Chapter 3) Ratio Cln3/WT 
ID Gene Symbol Description Cortex Hippocampus Thalamus 
91130  neural cell adhesion molecule - mouse (fragments) 1.160 1.039 1.036 200022 TMEM154 transmembrane protein 154 1.438 1.123 1.095 
347839 CCT3 chaperonin containing TCP1 subunit 3 1.261 0.944 0.726 
400269 ALDH6A1 aldehyde dehydrogenase 6 family member A1 1.085 1.012 0.950 
417489 Pcmt1 protein-L-isoaspartate (D-aspartate) O-methyltransferase 1 1.079 0.740 0.687 
790470 PA2G4 proliferation-associated 2G4 1.160 0.989 0.934 
1170970 MYL12A myosin light chain 12A 1.064 0.904 0.742 
1769577 TWF1 twinfilin actin binding protein 1 1.133 0.798 0.553 
1902905 HSPA4L heat shock protein family A (Hsp70) member 4 like 0.922 0.824 0.759 
2078522 DLD dihydrolipoamide dehydrogenase 1.132 1.061 1.049 
3318958 OR2AG1 olfactory receptor family 2 subfamily AG member 1 (gene/pseudogene)(OR2AG1) 1.236 0.940 0.760 
3329498 HNRNPA2B1 heterogeneous nuclear ribonucleoprotein A2/B1 1.415 1.314 1.311 
3766201 SUCLA2 succinate-CoA ligase ADP-forming beta subunit 1.013 0.935 0.917 
6671549 PRDX6 peroxiredoxin 6 1.038 0.957 0.890 
6679439 PPIA peptidylprolyl isomerase A 1.050 0.941 0.939 
6681069 CSRP1 cysteine and glycine rich protein 1 1.054 0.834 0.683 
6681079 CTSB cathepsin B 0.815 0.735 0.720 
6746357 PRDX5 peroxiredoxin 5 1.130 0.967 0.821 
6754976 PRDX1 peroxiredoxin 1 0.971 0.794 0.768 
6981600 STX1B syntaxin 1B 1.047 0.911 0.816 
8393866 OAT ornithine aminotransferase 1.132 1.005 0.864 
9483736 SUCLG1 succinate-CoA ligase alpha subunit 1.044 0.842 0.782 
9489054  G protein Gi2 alpha, partial 1.055 0.960 0.900 11693172 CALR calreticulin 0.950 0.909 0.865 
12805413 ECHS1 enoyl-CoA hydratase, short chain 1 1.190 0.971 0.849 
12833936 CYB5B cytochrome b5 type B 1.162 0.969 0.765 




13385968 TPPP3 tubulin polymerization promoting protein family member 3 1.031 0.751 0.651 
13543186 NDUFA9 NADH:ubiquinone oxidoreductase subunit A9 1.132 0.913 0.813 
13592051 RPL5 ribosomal protein L5 0.937 0.926 0.916 
14193690 GFAP glial fibrillary acidic protein 1.555 1.027 0.798 
15029655 BPNT1 3'(2'), 5'-bisphosphate nucleotidase 1 1.005 0.851 0.840 
15042971 HAPLN2 hyaluronan and proteoglycan link protein 2 0.884 0.538 0.427 
16307381 DNM2 dynamin 2 0.909 0.793 0.753 
16758748 DNAH10 dynein axonemal heavy chain 10(DNAH10) 1.011 0.875 0.773 
16930823 PROSC proline synthetase cotranscribed homolog (bacterial) 1.229 0.862 0.849 
18152793 PDHB pyruvate dehydrogenase (lipoamide) beta 1.112 1.004 0.982 
18700024 IDH3B isocitrate dehydrogenase 3 (NAD(+)) beta 1.041 0.877 0.815 
21314826 NDUFB4 NADH:ubiquinone oxidoreductase subunit B4 1.097 0.882 0.800 
26328615 ETFA electron transfer flavoprotein alpha subunit 0.934 0.846 0.755 
26329027 PCYOX1 prenylcysteine oxidase 1 1.250 0.899 0.750 
26329893 GPD2 glycerol-3-phosphate dehydrogenase 2 1.102 1.043 1.029 
26337977 NDUFA10 NADH:ubiquinone oxidoreductase subunit A10 1.070 0.924 0.846 
26342124 Nefm neurofilament, medium polypeptide 1.828 1.016 1.061 
26347027 HIBADH 3-hydroxyisobutyrate dehydrogenase 1.171 0.794 0.665 
26348195 ENDOD1 endonuclease domain containing 1 1.065 0.926 0.783 
26352474 TWF2 twinfilin actin binding protein 2 1.024 0.892 0.874 
26352986 NDUFB5 NADH:ubiquinone oxidoreductase subunit B5 1.091 0.941 0.903 
26361821 ARPC2 actin related protein 2/3 complex subunit 2 1.181 1.071 1.066 
27465523 KCNA1 potassium voltage-gated channel subfamily A member 1 0.930 0.834 0.790 
28200903 PLXNA4 plexin A4 1.281 1.095 0.912 
29420429 AKAP12 A-kinase anchoring protein 12 1.364 0.981 0.861 
29789148 NDUFB9 NADH:ubiquinone oxidoreductase subunit B9 0.968 0.623 0.565 
31543797 SYT2 synaptotagmin 2 0.968 0.843 0.768 
31982273 HSD17B4 hydroxysteroid 17-beta dehydrogenase 4 0.877 0.830 0.789 
31982332 GLUL glutamate-ammonia ligase 1.079 0.916 0.749 
33469051 TPPP tubulin polymerization promoting protein 1.065 0.998 0.964 
33667095 VAT1L vesicle amine transport 1-like 1.286 1.057 0.896 
34610235 RTN4 reticulon 4 1.123 0.992 0.882 
39204499 NEFL neurofilament, light polypeptide 2.090 1.289 1.229 
51773592 IDH3G isocitrate dehydrogenase 3 (NAD(+)) gamma 1.150 0.937 0.924 
56541260 RPL10 ribosomal protein L10 1.645 0.918 0.850 




57164133 NDUFC2 NADH:ubiquinone oxidoreductase subunit C2 1.006 0.893 0.877 
78214312 ATP5F1 ATP synthase, H+ transporting, mitochondrial Fo complex subunit B1 1.088 0.995 0.941 
126723393 ENO3 enolase 3 1.098 0.930 0.875 
188035915 ALDH7A1 aldehyde dehydrogenase 7 family member A1 0.979 0.920 0.914 
226694171 PLS3 plastin 3(Pls3) 1.000 0.910 0.855 
312032384 DPP6 dipeptidyl peptidase like 6 1.069 0.940 0.871 
 
Table A2. BioLayout analysis of cortical, hippocampal and thalamic samples in Cln3-/-: Cluster 4 (Chapter3) Ratio Cln3/WT 
ID Gene Symbol Description Cortex Hippocampus Thalamus 
49868 ACTB actin beta 1.044 1.060 1.210 
203276 CLTA clathrin light chain A 0.919 1.038 1.264 
206440 EEF1A2 eukaryotic translation elongation factor 1 alpha 2 0.997 1.012 1.067 
288120 PRKACB protein kinase cAMP-activated catalytic subunit beta 0.905 1.095 1.470 
1001011 HSPH1 heat shock protein family H (Hsp110) member 1 0.868 0.943 1.135 
1167982 ABCB7 ATP binding cassette subfamily B member 7 0.817 1.015 1.268 
1527199 USP9X ubiquitin specific peptidase 9, X-linked 0.701 0.756 1.149 
1809320 AP2S1 adaptor related protein complex 2 sigma 1 subunit 1.106 1.145 1.327 
2769587 MAP6 microtubule associated protein 6 0.999 1.038 1.215 
3171934 MAP6 microtubule associated protein 6 1.025 1.076 1.191 
4506005 PPP1CB protein phosphatase 1 catalytic subunit beta 0.704 0.862 1.175 
4584820 PPP3CA protein phosphatase 3 catalytic subunit alpha 1.131 1.173 1.321 
5901688 GPRIN1 G protein regulated inducer of neurite outgrowth 1 1.168 1.278 1.899 
6636119 ACTN4 actinin alpha 4 1.106 1.187 1.582 
6671561 AP2A1 adaptor related protein complex 2 alpha 1 subunit 0.836 0.940 1.127 
6679593 RAB3A RAB3A, member RAS oncogene family 0.952 0.964 1.102 
6729920  
Chain A, Mu2 Adaptin Subunit (Ap50) Of Ap2 Adaptor (Second Domain), 
Complexed With Egfr Internaliza 0.937 1.032 1.250 
6754240 HPCA hippocalcin 0.842 1.065 1.566 
6755080 PRKCG protein kinase C gamma 1.032 1.238 1.915 
7305485 SH3GL1 SH3 domain containing GRB2 like 1, endophilin A2 1.011 1.223 1.698 
7670399 MAP2K1 mitogen-activated protein kinase kinase 1 0.904 0.989 1.161 
7949055 HPCAL1 hippocalcin like 1 1.106 1.188 1.618 
8393496 GSK3A glycogen synthase kinase 3 alpha 1.007 1.072 1.263 
9790285 VPS29 VPS29, retromer complex component 0.826 1.014 1.548 
11177910 HSPA2 heat shock protein family A (Hsp70) member 2 0.899 0.985 1.194 




12408324 CPLX1 complexin 1 0.954 1.012 1.096 
12835802 ACTR3 ARP3 actin related protein 3 homolog 0.955 1.082 1.661 
13470090 RAB3C RAB3C, member RAS oncogene family 0.942 0.979 1.234 
14250186 AP1B1 adaptor related protein complex 1 beta 1 subunit 0.983 0.995 1.046 
14719578  
Chain E, Crystal Structure Of The Catalytic Subunit Of Camp- Dependent Protein 
Kinase Complexed Wit 0.971 1.048 1.250 
16758726 SLC17A7 solute carrier family 17 member 7 0.896 1.176 4.311 
16758742 CAP2 CAP, adenylate cyclase-associated protein, 2 (yeast) 0.994 1.095 1.346 
17105370 ATP6V1B2 ATPase H+ transporting V1 subunit B2 0.990 1.101 1.544 
19424194 RAB3C RAB3C, member RAS oncogene family 0.925 0.976 1.260 
19526936 LANCL2 LanC like 2 0.968 1.091 1.922 
20138800  RecName: Full=Intersectin-1; AltName: Full=EH and SH3 domains protein 1 0.843 1.006 1.284 
20141804  
RecName: Full=Catenin delta-2; AltName: Full=Neural plakophilin-related ARM-
repeat protein; Short=N 0.926 0.986 1.307 
21594625 PGM2L1 phosphoglucomutase 2 like 1 0.829 0.870 1.183 
26329629 NCALD neurocalcin delta 0.921 1.099 1.526 
26337253 SLC2A3 solute carrier family 2 member 3 1.042 1.073 1.369 
26355647 NAPG NSF attachment protein gamma 0.940 0.966 1.091 
26667199 CAMK2G calcium/calmodulin dependent protein kinase II gamma 1.046 1.248 1.917 
27372319 PCLO piccolo presynaptic cytomatrix protein 0.951 1.018 1.168 
27574127  Chain A, High Resolution Structure Of A Truncated Neuronal Snare Complex 1.132 1.277 1.897 28972065 CKAP5 cytoskeleton associated protein 5 0.780 0.901 1.259 
31560792 SH3GL2 SH3 domain containing GRB2 like 2, endophilin A1 1.013 1.146 1.351 
31791059 ALCAM activated leukocyte cell adhesion molecule 0.935 0.975 1.275 
37360508 SRCIN1 SRC kinase signaling inhibitor 1 0.943 1.025 1.379 
38454230 ATP6V1E1 ATPase H+ transporting V1 subunit E1 0.951 1.030 1.250 
39104547 SH3GLB2 SH3 domain containing GRB2 like endophilin B2 0.927 0.996 1.143 
41018346 SYNJ1 synaptojanin 1 0.905 1.017 1.158 
47059104 ATP6V1G2 ATPase H+ transporting V1 subunit G2 0.860 0.966 1.283 
47605990 ROCK2 Rho associated coiled-coil containing protein kinase 2 0.878 1.013 1.314 
50510671 DMXL2 Dmx like 2 0.980 1.013 1.074 
52345394 ACTR3B ARP3 actin related protein 3 homolog B 0.930 1.083 2.051 
54291704 PACS1 phosphofurin acidic cluster sorting protein 1 1.028 1.036 1.056 
56205559 Myh10 myosin, heavy polypeptide 10, non-muscle [Mus musculus] 0.944 0.994 1.072 
60360046 TRIM2 tripartite motif containing 2 0.865 0.893 1.113 




77416393 CLASP2 cytoplasmic linker associated protein 2 0.920 0.943 1.014 
78711838 Ap2b1 adaptor-related protein complex 2, beta 1 subunit 1.006 1.090 1.210 
114520592 MAP6 microtubule associated protein 6 1.016 1.068 1.287 
117647240 MADD MAP kinase activating death domain 0.987 1.006 1.227 
158749626 SCAMP1 secretory carrier membrane protein 1 0.922 1.000 1.122 
161086898 CACNA2D1 calcium voltage-gated channel auxiliary subunit alpha2delta 1 1.038 1.147 1.440 
164565391 CNKSR2 connector enhancer of kinase suppressor of Ras 2 0.942 1.104 1.420 
347360906 ACTB actin, cytoplasmic 1 1.024 1.055 1.230 
 
 
Table A3. BioLayout analysis of cortical, hippocampal and thalamic samples in Cln3-/-: Cluster 6 (Chapter 3) Ratio Cln3/WT 
ID Gene Symbol Description Cortex Hippocampus Thalamus 
57657 PDHA1 pyruvate dehydrogenase (lipoamide) alpha 1 1.049 0.946 0.770 
114400 ATP1B2 ATPase Na+/K+ transporting subunit beta 2 0.882 0.823 0.719 
198884 LTA4H leukotriene A4 hydrolase 1.027 0.974 0.832 
226486 RAB1B rab1B protein 1.004 0.961 0.900 
832851  manganese superoxide dismutase 0.917 0.911 0.876 930145 SPTAN1 spectrin alpha, non-erythrocytic 1 1.106 1.068 1.007 
1730559 PYGB phosphorylase, glycogen; brain 1.124 1.013 0.767 
1747304 Nptn neuroplastin 1.055 1.047 0.974 
1942391  
Chain A, G Protein Heterotrimer Mutant Gi_alpha_1(G203a) Beta_1 Gamma_2 
With Gdp Bound 1.064 1.062 1.040 
2118463  GTP-binding protein MEL - mouse 1.142 1.018 0.862 4506713 RPS27A ribosomal protein S27a 1.172 1.052 0.855 
6671664 CANX calnexin 0.964 0.938 0.898 
6680027 GLUD1 glutamate dehydrogenase 1 1.099 0.986 0.831 
6680748 ATP5A1 ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, cardiac muscle 0.993 0.952 0.867 
6753498 COX4IL cytochrome c oxidase subunit 4 isoform 1, mitochondrial precursor 0.975 0.966 0.920 
6753992 GJA1 gap junction protein alpha 1 1.186 1.070 0.852 
6754974 PACSIN1 protein kinase C and casein kinase substrate in neurons 1 0.998 0.980 0.916 
7949005 ATP5J ATP synthase, H+ transporting, mitochondrial Fo complex subunit F6 0.998 0.982 0.899 
12833077 CYC1 cytochrome c1 1.139 1.070 0.854 
12839092 ASRGL1 asparaginase like 1 1.164 1.131 0.904 
13385854 PPID peptidylprolyl isomerase D 1.024 0.997 0.898 




15030102 SDHA succinate dehydrogenase complex flavoprotein subunit A 1.053 1.024 0.805 
16758642 DARS aspartyl-tRNA synthetase 0.966 0.873 0.688 
19527228 CISD1 CDGSH iron sulfur domain 1 1.020 1.010 0.974 
20070420 C21orf33/LOC102724023 chromosome 21 open reading frame 33 1.047 1.029 0.990 
20072543 FBXO2 F-box protein 2 1.175 1.042 0.654 
21312520 QDPR quinoid dihydropteridine reductase 1.230 1.118 0.650 
23271467 ALDH1L1 aldehyde dehydrogenase 1 family member L1 1.020 0.984 0.814 
26328021 ME3 malic enzyme 3 1.162 1.090 0.830 
26336659 Ank2 ankyrin 2, brain 1.151 1.012 0.711 
26344409 Nptn neuroplastin 1.032 1.026 0.966 
26346450 UQCRC2 ubiquinol-cytochrome c reductase core protein II 1.018 0.965 0.816 
26354805 SFXN3 sideroflexin 3 1.165 1.095 1.000 
27369581 SLC25A12 solute carrier family 25 member 12 0.970 0.949 0.852 
27503563 MAP4 microtubule associated protein 4 1.037 0.993 0.683 
28893409 ENPP6 ectonucleotide pyrophosphatase/phosphodiesterase 6 1.174 1.048 0.477 
29293809 ACLY ATP citrate lyase 1.093 0.891 0.561 
31981515 RPL7 ribosomal protein L7 1.033 0.962 0.848 
33859482 EEF2 eukaryotic translation elongation factor 2 1.012 0.992 0.962 
54037163 GANAB glucosidase II alpha subunit 0.899 0.869 0.791 
54887356 HADHA hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), alpha subunit 1.072 0.995 0.687 
59808764 NIPSNAP1 nipsnap homolog 1 (C. elegans) 0.950 0.854 0.621 
60360580 OGDH oxoglutarate dehydrogenase 0.983 0.927 0.804 
61556993 HIBCH 3-hydroxyisobutyryl-CoA hydrolase 0.892 0.839 0.767 
83921618 EZR ezrin 1.012 1.009 0.999 
89001109 GNA13 G protein subunit alpha 13 0.959 0.916 0.724 
125987842 MYO18A myosin XVIIIA 1.067 1.026 0.561 
162138936 HAPLN1 hyaluronan and proteoglycan link protein 1 1.150 0.963 0.611 
228480241 MTX2 metaxin 2 1.056 0.995 0.863 
254587947 PTPA protein phosphatase 2 phosphatase activator 1.376 1.324 0.735 
 
 
Table A4. BioLayout analysis of cortical, hippocampal and thalamic samples in Cln3-/-: Cluster 7 (Chapter 3) Ratio Cln3/WT 
ID Gene Symbol Description Cortex Hippocampus Thalamus 




192912 MAPT microtubule associated protein tau 0.663 1.001 1.256 
199023 MAP2 microtubule associated protein 2 0.995 1.046 1.092 
464506 PC pyruvate carboxylase 0.888 0.933 0.952 
557967 PSAP prosaposin 0.766 1.052 1.246 
557967 PSAP prosaposin 0.803 1.052 1.246 
817984 NCAM1 neural cell adhesion molecule 1 1.107 1.169 1.180 
1054878 ATP2B4 ATPase plasma membrane Ca2+ transporting 4 0.939 1.008 1.066 
1346311  
RecName: Full=Hypoxanthine-guanine phosphoribosyltransferase; 
Short=HGPRT; Short=HGPRTase 1.028 1.061 1.078 
1517864 PEBP1 phosphatidylethanolamine binding protein 1 1.050 1.146 1.168 
1708161 HTT huntingtin 0.839 1.032 1.196 
1840399 SYT3 synaptotagmin 3 0.992 1.076 1.092 
2062607 KIF5B kinesin family member 5B 0.870 1.039 1.073 
3046247  aldose reductase [Mus musculus] 0.920 1.010 1.016 3955098 ATP6V1C1 ATPase H+ transporting V1 subunit C1 0.841 1.026 1.143 
4506025 PPP3R1 protein phosphatase 3 regulatory subunit B, alpha 0.984 1.090 1.186 
4507729 TUBB2A tubulin beta 2A class IIa 0.961 1.072 1.128 
4507789 UBE2L3 ubiquitin conjugating enzyme E2 L3 0.814 0.966 1.043 
6693834 SRCIN1 SRC kinase signaling inhibitor 1 0.890 1.114 1.200 
7106439 TUBB tubulin beta class I 0.907 1.028 1.062 
7657031 NT5C 5', 3'-nucleotidase, cytosolic 0.917 1.140 1.264 
8394027 PPP2R1A protein phosphatase 2 scaffold subunit Aalpha 0.813 1.111 1.211 
9790219 DSTN destrin, actin depolymerizing factor 0.841 1.116 1.204 
12844989 PGAM1 phosphoglycerate mutase 1 0.934 1.022 1.074 
12851187 TUBB4A tubulin beta 4A class IVa 0.915 0.973 0.995 
13542680 TUBB4B tubulin beta 4B class IVb 0.893 1.029 1.081 
17865351 VCP valosin containing protein 0.961 1.042 1.093 
20072952 AUH AU RNA binding protein/enoyl-CoA hydratase 0.868 0.943 1.033 
21165514 LETM1 leucine zipper and EF-hand containing transmembrane protein 1 0.816 0.951 0.991 
21311871 Nebl nebulette 0.857 1.058 1.139 
21746161 TUBB2B tubulin beta 2B class IIb 0.956 1.057 1.159 
24817674 UBE2V2 ubiquitin conjugating enzyme E2 V2 0.847 0.921 0.945 
26327655 MAOB monoamine oxidase B 1.080 1.150 1.229 
26345590 EEF1A1 eukaryotic translation elongation factor 1 alpha 1 0.909 1.026 1.102 
26353710 RPS8 ribosomal protein S8 0.823 0.849 0.865 




27754056 TUBB6 tubulin beta 6 class V 0.930 1.043 1.115 
34996495 RPN2 ribophorin II 0.885 1.034 1.052 
37812499 OPA1 OPA1, mitochondrial dynamin like GTPase 0.879 0.954 1.022 
38259194 DNAJC6 DnaJ heat shock protein family (Hsp40) member C6 0.777 0.996 1.073 
41281852 AMPH amphiphysin 0.882 1.105 1.292 
45598372 BASP1 brain abundant membrane attached signal protein 1 0.972 1.061 1.113 
56744242 AP1G1 adaptor related protein complex 1 gamma 1 subunit 0.887 1.182 1.491 
57164143 ACTR2 ARP2 actin related protein 2 homolog 0.983 1.033 1.087 
57527421 Sh3glb2 SH3 domain-containing GRB2-like endophilin B2 1.018 1.278 1.403 
81867523 LRP1 LDL receptor related protein 1 0.812 0.932 0.978 
112807195 Cox5b cytochrome c oxidase subunit Vb 0.852 0.908 0.920 
148491097 DYNC1H1 dynein cytoplasmic 1 heavy chain 1 0.863 0.954 0.981 
157787064 GRM2 glutamate metabotropic receptor 2 0.817 0.992 1.018 
172072590 NCDN neurochondrin 0.727 1.078 1.140 
 
 
Table A5. Cln3-/- thalamic filtered proteins upregulated more than 20% (Chapter 3) 







solute carrier family 17 (vesicular glutamate transporter), member 
7 16758726 SLC17A7 4.311 10.117 85.29 5 
calcium/calmodulin-dependent protein kinase II alpha 39104626 CAMK2A 2.537 0.841 130.09 14 
actinin, alpha 1 61097906 ACTN1 2.447 1.829 80.05 9 
CaM kinase-like vesicle-associated 21704242 CAMKV 2.340 1.716 112.93 10 
ankyrin repeat and sterile alpha motif domain containing 1B 31088914 ANKS1B 2.305 4.244 52.48 4 
inositol-trisphosphate 3-kinase A 124808 ITPKA 2.231 2.298 99.10 2 
glutamate receptor, metabotropic 5 8393490 GRM5 2.149 1.194 55.86 2 
lectin, galactoside-binding-like 26349211 LGALSL 2.146 2.737 54.71 2 
ARP3 actin-related protein 3 homolog B (yeast) 52345394 ACTR3B 2.051 1.069 66.33 4 
calcium/calmodulin-dependent protein kinase II delta 26667180 CAMK2D 1.992 0.993 130.09 6 
syntaxin 1A (brain) 220777 STX1A 1.983 0.737 101.88 10 
synaptic vesicle glycoprotein 2B 27261824 SV2B 1.979 0.945 77.38 8 
Dmx-like 2 26327915 DMXL2 1.959 0.397 73.26 3 
seryl-tRNA synthetase 2, mitochondrial 228008415 SARS2 1.950 1.089 44.17 2 
LanC lantibiotic synthetase component C-like 2 (bacterial) 19526936 LANCL2 1.922 0.586 99.94 4 
calcium/calmodulin-dependent protein kinase II gamma 26667199 CAMK2G 1.917 0.988 130.09 5 




crystallin, mu 7710012 CRYM 1.911 0.379 73.61 4 
G protein regulated inducer of neurite outgrowth 1 5901688 GPRIN1 1.899 4.100 60.52 3 
synaptic Ras GTPase activating protein 1 2935448 SYNGAP1 1.864 1.271 74.69 9 
synaptotagmin VII 41281824 SYT7 1.858 1.339 54.01 4 
drebrin 1 19909851 DBN1 1.820 1.783 60.28 5 
keratin 1, type II 81891716 KRT1 1.818 0.413 66.06 2 
phospholipase C, eta 2 30354507 PLCH2 1.802 0.392 67.98 2 
histone cluster 2, H4a 51311 HIST2H4A 1.781 0.231 65.47 4 
calcium channel, voltage-dependent, gamma subunit 8 21687018 CACNG8 1.764 0.708 62.10 2 
KIAA1211-like 12842691 KIAA1211L 1.761 1.117 62.50 2 
solute carrier family 1 (glial high affinity glutamate transporter), 
member 3 232176 SLC1A3 1.757 0.955 113.68 5 
glutamate receptor, ionotropic, AMPA 2 22096313 GRIA2 1.734 1.478 102.27 11 
Rho GTPase activating protein 1 13879250 ARHGAP1 1.727 0.674 44.90 2 
glycoprotein M6B 30316333 GPM6B 1.725 0.471 62.72 6 
NCK-associated protein 1 28395023 NCKAP1 1.701 0.575 79.30 8 
SH3-domain GRB2-like 1 7305485 SH3GL1 1.698 0.462 61.56 3 
catenin (cadherin-associated protein), delta 2 20177853 CTNND2 1.673 2.479 54.59 4 
mitogen-activated protein kinase 1 6754632 MAPK1 1.669 0.381 86.05 4 
ARP3 actin-related protein 3 homolog (yeast) 12835802 ACTR3 1.661 0.875 58.56 8 
bassoon presynaptic cytomatrix protein 3413810 BSN 1.643 0.637 118.55 15 
thioredoxin-related transmembrane protein 2 56090369 TMX2 1.641 2.331 39.21 2 
PHD finger protein 24 27369996 PHF24 1.621 0.379 59.41 2 
hippocalcin-like 1 7949055 HPCAL1 1.618 0.657 68.83 5 
synaptotagmin I 148356226 SYT1 1.617 0.780 110.97 16 
complexin 2 5729783 CPLX2 1.609 0.154 72.91 3 
CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 
2 37589410 CDS2 1.608 0.767 57.79 2 
lymphocyte antigen 6 complex, locus H 6754586 LY6H 1.583 0.216 58.43 3 
actinin, alpha 4 6636119 ACTN4 1.582 1.060 61.66 6 
catenin (cadherin-associated protein), alpha 2 475010 CTNNA2 1.571 0.350 146.07 3 
hippocalcin 6754240 HPCA 1.566 0.855 100.20 4 
thymosin beta 10 207318 TMSB10/TMSB4X 1.565 0.157 88.25 3 
flotillin 1 158636004 FLOT1 1.559 0.501 77.71 4 
dihydropyrimidinase-like 4 3122044 DPYSL4 1.557 0.177 70.41 3 
VPS29 retromer complex component 9790285 VPS29 1.548 1.581 48.18 3 
ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B2 17105370 ATP6V1B2 1.544 0.595 68.59 8 




epsin 1 16923990 EPN1 1.537 0.253 87.72 2 
flotillin 2 13929186 FLOT2 1.529 0.720 111.15 5 
neurocalcin delta 26329629 NCALD 1.526 0.636 67.10 5 
synapsin II 77404242 SYN2 1.512 0.654 102.12 11 
calcium/calmodulin-dependent protein kinase ID 79750129 CAMK1D 1.508 0.984 54.11 2 
adaptor-related protein complex 1, gamma 1 subunit 56744242 AP1G1 1.491 0.230 43.55 2 
actin related protein 2/3 complex, subunit 3, 21kDa 9790141 ARPC3 1.490 0.033 62.78 3 
calcium/calmodulin-dependent protein kinase II beta 125287 CAMK2B 1.488 0.827 130.09 9 
protein kinase, cAMP-dependent, catalytic, beta 288120 PRKACB 1.470 0.479 54.31 2 
glutaminase 121447 GLS 1.463 0.571 85.77 8 
clathrin, light chain B 12844891 CLTB 1.462 0.548 96.68 3 
cytochrome b5 reductase 3 19745150 Cyb5r3 1.459 0.263 85.50 3 
adducin 2 (beta) 26325436 ADD2 1.458 0.511 60.35 4 
dynein, cytoplasmic 1, light intermediate chain 1 22122795 DYNC1LI1 1.455 1.295 37.64 3 
CD47 molecule 6754382 CD47 1.444 0.183 84.63 3 
calcium channel, voltage-dependent, alpha 2/delta subunit 1 161086898 CACNA2D1 1.440 0.319 69.46 5 
mitochondrial carrier 1 6453809 MTCH1 1.437 0.854 49.64 2 
mercaptopyruvate sulfurtransferase 90110410 MPST 1.435 0.477 36.88 2 
reticulon 1 31982561 RTN1 1.424 0.341 87.99 9 
connector enhancer of kinase suppressor of Ras 2 164565391 CNKSR2 1.420 0.126 65.51 2 
protein kinase, cAMP-dependent, regulatory, type II, beta 45598396 PRKAR2B 1.415 0.454 130.95 6 
septin 9 164698479 SEPT9 1.414 0.457 53.32 3 
potassium channel, calcium activated large conductance subfamily 
M alpha, member 1 1305547 KCNMA1 1.404 0.042 73.55 2 
early endosome antigen 1 26337923 EEA1 1.404 0.394 86.60 3 
SH3-domain GRB2-like endophilin B2 57527421 Sh3glb2 1.403 0.093 47.88 2 
prosaposin 298231229 PSAP 1.399 0.129 85.31 5 
synapsin I 160707903 SYN1 1.398 0.491 133.06 19 
signal-regulatory protein alpha 110626109 SIRPA 1.397 0.137 104.74 4 
copine IV 12852219 CPNE4 1.393 0.270 47.62 3 
ubiquitin specific peptidase 5 (isopeptidase T) 7305619 USP5 1.391 0.284 78.84 6 
chromosome 14 open reading frame 2 21312554 C14orf2 1.389 0.053 54.78 2 
receptor accessory protein 2 54261730 REEP2 1.388 0.498 44.75 2 
discs, large homolog 4 (Drosophila) 9665227 DLG4 1.387 0.392 97.64 5 
internexin neuronal intermediate filament protein, alpha 148539957 INA 1.387 0.346 79.73 10 
glycoprotein M6A 19483938 GPM6A 1.385 0.624 84.99 5 




SRC kinase signaling inhibitor 1 37360508 SRCIN1 1.379 0.838 53.91 4 
WD repeat domain 1 29144967 WDR1 1.375 0.316 51.49 3 
solute carrier family 2 (facilitated glucose transporter), member 3 26337253 SLC2A3 1.369 0.295 82.36 5 
NADH dehydrogenase (ubiquinone) complex I, assembly factor 2 188035926 NDUFAF2 1.368 1.334 55.23 3 
TBC1 domain family, member 10B 15076925 TBC1D10B 1.367 0.081 58.14 2 
solute carrier family 25 (mitochondrial carrier: glutamate), 
member 22 21311845 SLC25A22 1.366 0.581 73.57 4 
phosphoenolpyruvate carboxykinase 2 (mitochondrial) 28077029 PCK2 1.358 0.111 62.45 2 
monoglyceride lipase 6754690 MGLL 1.355 0.760 57.26 2 
guanine nucleotide binding protein (G protein), alpha 11 (Gq 
class) 6754004 GNA11 1.353 0.091 62.01 2 
plectin 40849920 PLEC 1.353 0.326 96.64 6 
SH3-domain GRB2-like 2 31560792 SH3GL2 1.351 0.389 112.49 12 
CAP, adenylate cyclase-associated protein, 2 (yeast) 16758742 CAP2 1.346 0.392 79.68 3 
L1 cell adhesion molecule 115558 L1CAM 1.344 0.212 56.44 3 
cytoplasmic FMR1 interacting protein 2 34784177 CYFIP2 1.328 0.665 108.76 8 
spectrin, beta, non-erythrocytic 2 55926127 SPTBN2 1.328 0.507 94.30 23 
dedicator of cytokinesis 4 62543571 DOCK4 1.328 0.061 36.76 2 
adaptor-related protein complex 2, sigma 1 subunit 1809320 AP2S1 1.327 0.273 79.59 2 
thioredoxin-related transmembrane protein 3 37360566 TMX3 1.327 0.154 79.98 2 
heterogeneous nuclear ribonucleoprotein A3 157277969 Hnrnpa3 1.325 0.252 49.13 2 
adaptor-related protein complex 2, alpha 2 subunit 49880 AP2A2 1.323 0.376 74.55 11 
ryanodine receptor 2 (cardiac) 11321166 RYR2 1.323 1.025 47.66 3 
septin 6 293597553 SEPT6 1.323 0.352 126.73 6 
protein phosphatase 1, regulatory subunit 7 57634526 PPP1R7 1.322 0.387 82.05 2 
protein phosphatase 3, catalytic subunit, alpha isozyme 4584820 PPP3CA 1.321 0.498 76.23 8 
BR serine/threonine kinase 1 47013801 BRSK1 1.319 0.130 44.87 2 
neurotrimin 31982044 NTM 1.314 0.148 81.05 3 
Rho-associated, coiled-coil containing protein kinase 2 47605990 ROCK2 1.314 0.194 66.68 2 
threonyl-tRNA synthetase 27229277 TARS 1.312 0.006 71.89 2 
heterogeneous nuclear ribonucleoprotein A2/B1 3329498 HNRNPA2B1 1.311 0.189 81.03 6 
actin related protein 2/3 complex, subunit 4, 20kDa 12857620 ARPC4 1.295 0.076 50.11 2 
amphiphysin 41281852 AMPH 1.292 0.944 136.98 14 
septin 11 57634518 SEPT11 1.292 0.424 82.12 6 
ATP synthase, H+ transporting, mitochondrial Fo complex, 
subunit G 31980744 ATP5L 1.291 0.205 64.34 2 
ankyrin 3, node of Ranvier (ankyrin G) 25121946 ANK3 1.290 1.209 50.58 4 




phosphodiesterase 2A, cGMP-stimulated 56606121 PDE2A 1.286 0.155 51.50 2 
LIM and SH3 protein 1 6754508 LASP1 1.284 0.083 47.54 2 
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, zeta 6756041 YWHAZ 1.283 0.399 152.20 27 
ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G2 47059104 ATP6V1G2 1.283 0.577 76.84 3 
glutamate receptor, ionotropic, N-methyl D-aspartate 2A 3915771 GRIN2A 1.280 0.206 48.49 2 
Thy-1 cell surface antigen 6678347 THY1 1.277 0.269 84.78 9 
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, eta 1526541 YWHAH 1.276 0.321 77.24 11 
activated leukocyte cell adhesion molecule 31791059 ALCAM 1.275 0.240 57.47 4 
protein kinase, cAMP-dependent, regulatory, type I, beta 6016420 PRKAR1B 1.269 0.423 45.75 2 
ATP-binding cassette, sub-family B (MDR/TAP), member 7 1167982 ABCB7 1.268 0.344 60.05 2 
secretory carrier membrane protein 5 13929020 SCAMP5 1.267 0.235 91.66 3 
eukaryotic translation initiation factor 4 gamma, 3 29126896 EIF4G3 1.266 0.420 46.33 2 
NSFL1 (p97) cofactor (p47) 41017503 NSFL1C 1.266 0.260 61.96 3 
calcium channel, voltage-dependent, gamma subunit 3 21687008 CACNG3 1.265 0.002 52.18 2 
clathrin, light chain A 203276 CLTA 1.264 0.770 54.73 6 
5', 3'-nucleotidase, cytosolic 7657031 NT5C 1.264 0.062 60.79 3 
glycogen synthase kinase 3 alpha 8393496 GSK3A 1.263 0.325 51.75 3 
protein phosphatase 1, regulatory subunit 9B 22535257 PPP1R9B 1.261 0.001 77.27 2 
doublecortin 59797481 DCX 1.261 0.457 56.06 2 
RAB3C, member RAS oncogene family 19424194 RAB3C 1.260 0.323 70.93 5 
cytoskeleton associated protein 5 28972065 CKAP5 1.259 0.202 58.02 5 
cystatin C 192912 CST3 1.256 0.175 82.15 3 
SH3-domain GRB2-like (endophilin) interacting protein 1 26335469 SGIP1 1.251 0.072 92.35 2 
coactosin-like F-actin binding protein 1 19482160 COTL1 1.250 0.347 71.02 3 
WW domain binding protein 2 20376818 WBP2 1.250 0.054 110.95 2 
ATPase, H+ transporting, lysosomal 31kDa, V1 subunit E1 38454230 ATP6V1E1 1.250 0.260 114.67 12 
p21 protein (Cdc42/Rac)-activated kinase 3 304307785 PAK3 1.248 0.445 70.00 2 
guanine nucleotide binding protein (G protein), alpha activating 
activity polypeptide O 164607137 GNAO1 1.245 0.304 112.24 24 
coronin, actin binding protein, 2B 38541878 CORO2B 1.237 0.123 66.10 2 
monoamine oxidase B 26327655 MAOB 1.229 0.014 56.95 2 
neurofilament, light polypeptide 39204499 NEFL 1.229 0.226 62.03 8 
MAP-kinase activating death domain 117647240 MADD 1.227 0.580 37.08 2 
ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 6806903 ATP2A2 1.224 0.297 125.07 8 
calbindin 1, 28kDa 6753242 CALB1 1.222 0.114 49.47 2 




neuroplastin 9507073 NPTN 1.216 0.800 104.78 8 
secernin 1 38044104 SCRN1 1.216 0.339 69.09 5 
phosphatidylinositol-5-phosphate 4-kinase, type II, gamma 81882183 PIP4K2C 1.216 0.343 80.01 3 
huntingtin interacting protein 1 related 12718814 HIP1R 1.212 0.054 70.49 2 
actin, beta-like 2 30425250 ACTBL2 1.212 0.141 87.32 14 
protein phosphatase 2, regulatory subunit A, alpha 26353870 PPP2R1A 1.211 0.222 72.75 6 
actin, beta 49868 ACTB 1.210 0.392 115.47 33 
G protein-coupled receptor 158 52350563 GPR158 1.210 0.167 51.25 2 
adaptor-related protein complex 2, beta 1 subunit 78711838 Ap2b1 1.210 0.431 124.94 24 
phosphofructokinase, platelet 8489537 PFKP 1.209 0.436 79.09 5 
importin 5 12057236 IPO5 1.209 0.625 61.49 3 
esterase D 13937355 ESD 1.205 0.440 66.89 2 
cortactin 2996044 CTTN 1.204 0.241 83.75 5 
destrin (actin depolymerizing factor) 9790219 DSTN 1.204 0.007 47.54 2 
UBX domain protein 6 16741117 UBXN6 1.204 0.098 53.48 2 
biphenyl hydrolase-like (serine hydrolase) 21624609 BPHL 1.204 0.105 77.95 2 
3-hydroxybutyrate dehydrogenase, type 1 20071589 BDH1 1.202 0.046 61.59 2 
 
 
Table A6. Cln3-/- thalamic filtered proteins downregulated more than 20% (Chapter 3) 







talin 2 26325762 TLN2 -1.201 0.101 84.01 2 
leukotriene A4 hydrolase 198884 LTA4H -1.202 0.129 78.46 3 
microtubule-associated protein, RP/EB family, member 1 78097100 MAPRE1 -1.202 0.208 70.97 4 
glutamate dehydrogenase 1 6680027 GLUD1 -1.204 0.316 92.27 18 
acetyl-CoA acetyltransferase 1 21450129 ACAT1 -1.205 0.374 100.64 4 
ADP-ribosylation factor-like 3 12083661 ARL3 -1.206 0.030 37.03 2 
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 
13 12963633 NDUFA13 -1.206 0.109 85.23 5 
malic enzyme 3, NADP(+)-dependent, mitochondrial 26328021 ME3 -1.206 0.197 58.25 3 
COP9 signalosome subunit 6 33563284 COPS6 -1.206 0.185 41.73 2 
Rho GDP dissociation inhibitor (GDI) alpha 26344461 ARHGDIA -1.207 0.353 75.31 5 
pyrophosphatase (inorganic) 1 26353394 PPA1 -1.207 0.173 51.29 2 
transferrin 17046471 TF -1.208 0.064 42.72 2 
neuronal calcium sensor 1 26347817 NCS1 -1.211 0.168 58.70 2 




NADH dehydrogenase (ubiquinone) flavoprotein 2, 24kDa 12850902 NDUFV2 -1.212 0.167 53.16 5 
solute carrier family 25 (mitochondrial carrier; adenine 
nucleotide translocator), member 5 32189350 SLC25A5 -1.212 0.207 88.94 22 
ATPase, Na+/K+ transporting, beta 1 polypeptide 6753138 ATP1B1 -1.213 0.187 88.36 19 
glucose-6-phosphate dehydrogenase 6996917 G6PD -1.213 0.054 83.94 3 
peptidylglycine alpha-amidating monooxygenase 1711199 PAM -1.214 0.322 39.82 2 
protein kinase C and casein kinase substrate in neurons 2 22256944 PACSIN2 -1.215 0.112 52.98 3 
Tu translation elongation factor, mitochondrial 254911131 TUFM -1.216 0.272 74.07 7 
transaldolase 1 12002054 TALDO1 -1.217 0.080 87.82 2 
glutamate decarboxylase 2 (pancreatic islets and brain, 
65kDa) 2558495 GAD2 -1.218 0.130 75.16 3 
peroxiredoxin 5 6746357 PRDX5 -1.218 0.208 101.70 9 
glutathione S-transferase, mu 6 2275019 Gstm6 -1.220 0.288 62.60 4 
dynein, cytoplasmic 1, light intermediate chain 2 2618478 DYNC1LI2 -1.223 0.089 108.96 2 
phosphatidylinositol-5-phosphate 4-kinase, type II, beta 33563294 PIP4K2B -1.224 0.192 109.32 2 
syntaxin 1B 6981600 STX1B -1.225 0.269 90.79 24 
ubiquinol-cytochrome c reductase core protein II 26346450 UQCRC2 -1.226 0.267 146.53 8 
heat shock 70kDa protein 5 (glucose-regulated protein, 
78kDa) 12835845 HSPA5 -1.227 0.783 103.16 15 
isocitrate dehydrogenase 3 (NAD+) beta 18700024 IDH3B -1.228 0.342 121.42 11 
aldehyde dehydrogenase 1 family, member L1 23271467 ALDH1L1 -1.229 0.101 63.73 2 
heat shock protein 90kDa alpha (cytosolic), class B member 
1 51859516 HSP90AB1 -1.229 0.350 93.20 19 
glutamic-oxaloacetic transaminase 2, mitochondrial 2690302 GOT2 -1.230 0.171 86.03 16 
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 9, 
39kDa 13543186 NDUFA9 -1.231 0.274 95.46 9 
RAP1B, member of RAS oncogene family 7661678 RAP1B -1.234 0.192 78.27 3 
mechanistic target of rapamycin (serine/threonine kinase) 8132058 MTOR -1.234 0.093 53.90 2 
electron-transfer-flavoprotein, beta polypeptide 12832367 ETFB -1.234 0.410 40.89 2 
phosphoserine aminotransferase 1 26354941 PSAT1 -1.234 0.060 60.75 3 
septin 4 6755120 SEPT4 -1.235 0.014 54.40 2 
heat shock protein 90kDa beta (Grp94), member 1 14714615 HSP90B1 -1.236 0.221 74.95 8 
lactate dehydrogenase B 6678674 LDHB -1.237 0.195 120.96 15 
dynactin 1 2104495 DCTN1 -1.238 0.307 96.43 7 
neurocan 40789268 NCAN -1.239 0.713 72.94 3 
ATP synthase, H+ transporting, mitochondrial F1 complex, 
O subunit 20070412 ATP5O -1.241 0.336 53.65 7 





immunoglobulin superfamily, member 8 32189434 IGSF8 -1.243 0.385 84.16 5 
junction plakoglobin 41529837 JUP -1.243 0.419 42.60 2 
oxoglutarate (alpha-ketoglutarate) dehydrogenase 
(lipoamide) 60360580 OGDH -1.244 0.212 88.55 17 
tumor protein D52 6678407 TPD52 -1.246 0.058 71.62 2 
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 4, 
15kDa 21314826 NDUFB4 -1.250 0.226 49.80 3 
synaptogyrin 3 4731936 SYNGR3 -1.252 0.108 41.91 2 
glial fibrillary acidic protein 14193690 GFAP -1.253 0.049 69.47 3 
leucine aminopeptidase 3 58865398 LAP3 -1.255 0.091 66.21 3 
adenylate kinase 4 6753022 AK4 -1.257 0.120 45.85 2 
proline dehydrogenase (oxidase) 1 6649587 LOC102724788/PRODH -1.259 0.185 43.28 2 
malic enzyme 1, NADP(+)-dependent, cytosolic 266504 ME1 -1.262 0.108 93.04 2 
pyruvate kinase, muscle 16757994 PKM -1.263 0.274 112.60 22 
glucosidase, alpha; neutral AB 54037163 GANAB -1.264 0.439 73.93 4 
ubiquinol-cytochrome c reductase hinge protein like 57164091 UQCRHL -1.265 0.187 49.02 4 
potassium channel, voltage gated shaker related subfamily 
A, member 1 27465523 KCNA1 -1.266 0.263 58.35 4 
solute carrier family 12 (potassium/chloride transporter), 
member 5 28972652 SLC12A5 -1.266 0.245 79.92 11 
hydroxysteroid (17-beta) dehydrogenase 4 31982273 HSD17B4 -1.268 0.331 41.33 2 
NADH dehydrogenase (ubiquinone) Fe-S protein 3, 30kDa 
(NADH-coenzyme Q reductase) 12832533 NDUFS3 -1.269 0.471 63.68 4 
ATPase, Na+/K+ transporting, alpha 1 polypeptide 21450277 ATP1A1 -1.270 0.346 167.03 43 
translocase of inner mitochondrial membrane 44 homolog 
(yeast) 2351410 TIMM44 -1.271 0.057 52.26 2 
bridging integrator 1 6753050 BIN1 -1.275 0.290 79.10 7 
succinate-CoA ligase, alpha subunit 9483736 SUCLG1 -1.278 0.203 129.75 7 
endonuclease domain containing 1 26348195 ENDOD1 -1.278 0.057 49.81 2 
sorbin and SH3 domain containing 1 39104628 SORBS1 -1.280 0.001 44.02 2 
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 7, 
18kDa 13385322 NDUFB7 -1.281 0.115 56.32 3 
potassium channel, voltage gated shaker related subfamily 
A, member 2 25742772 KCNA2 -1.284 0.164 58.35 3 
chaperonin containing TCP1, subunit 7 (eta) 26346713 CCT7 -1.284 0.189 53.07 3 
caldesmon 1 21704156 Cald1 -1.287 0.096 62.86 2 




serine/threonine kinase receptor associated protein 58865512 STRAP -1.290 0.387 51.35 3 
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 8, 
19kDa 13385558 NDUFB8 -1.291 0.271 76.19 4 
ATPase, Na+/K+ transporting, alpha 3 polypeptide 6978547 ATP1A3 -1.298 0.262 167.03 72 
exocyst complex component 4 213688367 EXOC4 -1.298 0.164 88.39 3 
pyruvate dehydrogenase (lipoamide) alpha 1 57657 PDHA1 -1.299 0.114 55.65 4 
peroxiredoxin 1 6754976 PRDX1 -1.301 0.340 76.38 13 
acyl-CoA dehydrogenase, long chain 31982520 ACADL -1.301 0.232 42.87 2 
glutathione peroxidase 4 90903233 GPX4 -1.301 0.006 44.27 2 
synaptotagmin II 31543797 SYT2 -1.302 0.512 110.97 7 
phosphorylase, glycogen; brain 1730559 PYGB -1.303 0.254 104.93 14 
3-hydroxyisobutyryl-CoA hydrolase 61556993 HIBCH -1.303 0.321 74.67 2 
ubiquinol-cytochrome c reductase, Rieske iron-sulfur 
polypeptide 1 13385168 UQCRFS1 -1.307 0.152 98.69 4 
ATP synthase, H+ transporting, mitochondrial Fo complex, 
subunit d 21313679 ATP5H -1.307 0.363 106.89 9 
palmitoyl-protein thioesterase 1 121674797 PPT1 -1.307 0.030 47.63 2 
cytochrome b5 type B (outer mitochondrial membrane) 12833936 CYB5B -1.308 0.283 47.18 2 
pyridoxal (pyridoxine, vitamin B6) kinase 26348803 PDXK -1.310 0.238 66.09 3 
heat shock 70kDa protein 4-like 1902905 HSPA4L -1.318 0.166 77.96 5 
COP9 signalosome subunit 2 4759264 COPS2 -1.325 0.070 57.75 2 
electron-transfer-flavoprotein, alpha polypeptide 26328615 ETFA -1.325 0.252 146.80 3 
dynamin 2 16307381 DNM2 -1.329 0.326 42.26 2 
ARP1 actin-related protein 1 homolog A, centractin alpha 
(yeast) 5031569 ACTR1A -1.331 0.435 72.62 4 
B-cell receptor-associated protein 31 12841984 BCAP31 -1.331 0.125 85.73 5 
prenylcysteine oxidase 1 26329027 PCYOX1 -1.332 0.215 85.96 3 
tweety family member 1 47496738 TTYH1 -1.332 0.037 62.23 2 
microtubule-associated protein 1A 6272692 MAP1A -1.335 0.292 64.80 5 
glutamate-ammonia ligase 31982332 GLUL -1.335 0.177 79.93 14 
ribophorin I 26325850 RPN1 -1.340 0.022 63.95 2 
cell adhesion molecule 4 23346547 CADM4 -1.341 0.178 64.74 3 
SAC1 suppressor of actin mutations 1-like (yeast) 28972437 SACM1L -1.343 0.156 45.82 3 
myosin, light chain 12A, regulatory, non-sarcomeric 1170970 MYL12A -1.348 0.456 40.51 3 
creatine kinase, brain 10946574 CKB -1.351 0.275 121.95 22 
malate dehydrogenase 1, NAD (soluble) 254540027 MDH1 -1.352 0.297 114.28 9 
solute carrier family 6 (neurotransmitter transporter), 




monoamine oxidase A 20810093 MAOA -1.358 0.132 56.77 2 
leucine rich repeat containing 7 16924000 LRRC7 -1.359 0.020 41.72 2 
N-myc downstream regulated 1 118150658 NDRG1 -1.359 0.201 107.99 5 
protein phosphatase 2A activator, regulatory subunit 4 254587947 PPP2R4 -1.360 0.015 55.32 2 
proteasome 26S subunit, non-ATPase 12 12841273 PSMD12 -1.370 0.033 78.98 2 
hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA 
thiolase/enoyl-CoA hydratase (trifunctional protein), beta 
subunit 
26350301 HADHB -1.370 0.496 46.09 2 
hemoglobin, beta 31982300 HBB -1.372 0.205 89.15 9 
semaphorin 7A, GPI membrane anchor (John Milton 
Hagen blood group) 3523117 SEMA7A -1.373 0.075 86.69 2 
peroxiredoxin 3 11968132 PRDX3 -1.375 0.045 40.64 2 
chaperonin containing TCP1, subunit 3 (gamma) 347839 CCT3 -1.378 0.124 80.66 2 
guanine nucleotide binding protein (G protein), alpha 13 89001109 GNA13 -1.382 0.213 75.64 5 
chaperonin containing TCP1, subunit 5 (epsilon) 37359776 CCT5 -1.388 0.928 74.83 5 
cathepsin B 6681079 CTSB -1.389 0.001 66.16 2 
ATPase, Na+/K+ transporting, beta 2 polypeptide 114400 ATP1B2 -1.391 0.180 78.58 6 
adenosylhomocysteinase-like 2 342307099 AHCYL2 -1.397 0.317 90.27 4 
ankyrin 2, brain 26336659 Ank2 -1.407 0.817 66.78 6 
AHA1, activator of heat shock 90kDa protein ATPase 
homolog 1 (yeast) 26345022 AHSA1 -1.415 0.269 56.52 4 
acyl-CoA synthetase long-chain family member 6 75992915 ACSL6 -1.423 0.164 59.40 6 
hemoglobin, alpha 1 145301549 HBA1/HBA2 -1.431 0.175 105.53 8 
BTB (POZ) domain containing 17 58037273 BTBD17 -1.432 0.080 74.35 2 
glyoxalase I 19354350 GLO1 -1.450 0.273 80.57 2 
aspartyl-tRNA synthetase 16758642 DARS -1.453 0.236 103.35 2 
ribosomal protein S15 40287237 RPS15 -1.454 0.026 49.83 2 
protein-L-isoaspartate (D-aspartate) O-methyltransferase 1 417489 Pcmt1 -1.456 0.106 59.88 2 
hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA 
thiolase/enoyl-CoA hydratase (trifunctional protein), alpha 
subunit 
54887356 HADHA -1.456 0.298 95.64 6 
fatty acid amide hydrolase 226443015 FAAH -1.457 0.011 37.86 2 
cysteine and glycine-rich protein 1 6681069 CSRP1 -1.465 0.208 92.69 6 
microtubule-associated protein 4 27503563 MAP4 -1.465 0.560 70.70 4 
hydroxysteroid (17-beta) dehydrogenase 12 9789991 HSD17B12 -1.476 0.195 56.78 2 
potassium channel, voltage gated subfamily A regulatory 
beta subunit 2 8393646 KCNAB2 -1.480 0.127 63.66 5 





carbonic anhydrase II 157951596 CA2 -1.491 0.182 72.37 7 
ATPase, Na+/K+ transporting, alpha 2 polypeptide 37360088 ATP1A2 -1.497 0.252 167.03 53 
aspartoacylase 12842492 ASPA -1.501 0.001 86.83 2 
ADP-ribosylarginine hydrolase 6680658 ADPRH -1.502 0.092 73.54 2 
3-hydroxyisobutyrate dehydrogenase 26347027 HIBADH -1.504 0.047 78.63 2 
RAB21, member RAS oncogene family 51948448 RAB21 -1.509 0.224 68.61 3 
adenosylhomocysteinase-like 1 21361647 AHCYL1 -1.513 0.163 90.27 7 
synuclein, gamma (breast cancer-specific protein 1) 122066261 SNCG -1.526 0.165 72.29 2 
F-box protein 2 20072543 FBXO2 -1.529 0.208 80.52 4 
acyl-CoA synthetase bubblegum family member 1 16716465 ACSBG1 -1.532 0.432 84.72 5 
CD9 molecule 6680894 CD9 -1.536 0.108 65.77 2 
tubulin polymerization-promoting protein family member 3 13385968 TPPP3 -1.537 0.038 80.73 2 
quinoid dihydropteridine reductase 21312520 QDPR -1.538 0.044 67.69 3 
transketolase 11066098 TKT -1.547 0.273 83.80 7 
ATP synthase, H+ transporting, mitochondrial Fo complex, 
subunit F2 10181184 ATP5J2 -1.562 0.071 67.34 3 
cytochrome c oxidase III 34538604 MT-CO3 -1.570 0.024 92.03 2 
ATPase, Ca++ transporting, plasma membrane 3 56699478 ATP2B3 -1.577 0.333 146.05 10 
nicalin 12859602 NCLN -1.598 0.122 89.99 2 
nipsnap homolog 1 (C. elegans) 59808764 NIPSNAP1 -1.610 0.181 61.94 2 
translocase of inner mitochondrial membrane 13 homolog 
(yeast) 7305581 TIMM13 -1.617 0.078 63.72 2 
guanine nucleotide binding protein (G protein), alpha z 
polypeptide 6980966 GNAZ -1.637 0.209 58.23 2 
hyaluronan and proteoglycan link protein 1 162138936 HAPLN1 -1.638 0.095 64.47 6 
up-regulated during skeletal muscle growth 5 homolog 
(mouse) 77404294 USMG5 -1.657 0.053 57.18 2 
sirtuin 2 170650632 SIRT2 -1.662 0.210 73.05 10 
glycerol-3-phosphate dehydrogenase 1 (soluble) 13543176 GPD1 -1.665 0.217 72.10 4 
ras homolog family member G 9625037 RHOG -1.699 0.211 63.39 3 
solute carrier family 12 (sodium/potassium/chloride 
transporter), member 2 13929130 SLC12A2 -1.703 0.033 60.92 3 
nucleobindin 1 12841873 NUCB1 -1.734 0.165 56.87 2 
gamma-aminobutyric acid (GABA) A receptor, alpha 1 6753936 GABRA1 -1.739 0.176 53.81 3 
versican 21431624 VCAN -1.761 0.155 79.33 3 
annexin A6 31981302 ANXA6 -1.767 0.183 95.36 4 





myosin XVIIIA 125987842 MYO18A -1.782 0.357 50.22 4 
ATP citrate lyase 29293809 ACLY -1.783 0.350 52.19 3 
N-acylsphingosine amidohydrolase (acid ceramidase) 1 9790019 ASAH1 -1.786 0.072 43.31 3 
RAB33B, member RAS oncogene family 8394133 RAB33B -1.806 0.314 69.46 2 
twinfilin actin binding protein 1 1769577 TWF1 -1.807 0.447 59.25 3 
2',3'-cyclic nucleotide 3' phosphodiesterase 2160434 CNP -1.856 0.199 116.30 40 
S100 calcium binding protein B 6981498 S100B -1.856 0.112 105.92 2 
hyaluronan and proteoglycan link protein 4 30349291 HAPLN4 -1.859 0.085 48.61 2 
proteolipid protein 1 200425 PLP1 -1.901 0.239 99.93 22 
claudin 11 6679186 CLDN11 -1.925 0.053 95.27 2 
phosphorylase, glycogen, muscle 6755256 PYGM -1.928 0.182 101.55 11 
myosin ID 56799396 MYO1D -1.935 0.287 62.80 4 
annexin A5 13277612 ANXA5 -1.944 0.079 72.81 6 
secretory carrier membrane protein 3 2232237 SCAMP3 -1.968 0.181 63.63 2 
solute carrier family 32 (GABA vesicular transporter), 
member 1 26665359 SLC32A1 -2.002 0.219 121.41 5 
myelin associated glycoprotein 8393742 MAG -2.063 0.105 71.70 4 
ectonucleotide pyrophosphatase/phosphodiesterase 6 28893409 ENPP6 -2.095 0.059 65.23 4 
acyl-CoA thioesterase 7 14587839 ACOT7 -2.110 0.246 64.59 3 
myelin basic protein 69885032 MBP -2.163 0.171 101.64 23 
S100 calcium binding protein A1 12856441 S100A1 -2.308 0.172 63.05 2 
myelin oligodendrocyte glycoprotein 399589 MOG -2.330 0.041 105.68 5 
hyaluronan and proteoglycan link protein 2 15042971 HAPLN2 -2.343 0.091 52.69 2 
glycolipid transfer protein 6959684 GLTP -2.452 0.074 62.92 2 
ATPase, Na+/K+ transporting, beta 3 polypeptide 6680744 ATP1B3 -2.565 0.237 52.43 2 
solute carrier family 16 (monocarboxylate transporter), 
member 1 26353846 SLC16A1 -3.344 0.050 100.49 2 
ermin, ERM-like protein 26346945 ERMN -3.381 0.134 76.64 2 






Table A7. Proteins identified by ≥ 2 peptide in Ppt1-/- thalamic 
synaptosomes (Chapter 4) Fold change Ppt1
-/-/WT 
ID Gene Symbol Entrez Gene Name 1 m 3 m 5 m 7 m 
P61922 ABAT 4-aminobutyrate aminotransferase 1.15 -3.22 2.59 -1.47 
Q61282 Acan aggrecan 3.08 2.17 1.18 -1.43 
Q99KI0 ACO2 aconitase 2 1.41 -2.42 2.21 -1.59 
Q3TSB7 ACTG1 actin gamma 1 -3.35 -1.37 -1.17 -1.13 
A1BN54 ACTN1 actinin alpha 1 -1.48 -1.73 -1.22 -1.08 
E9PY16 ADAP1 ArfGAP with dual PH domains 1 -1.38 -1.68 -1.14 -1.16 
P84309 ADCY5 adenylate cyclase 5 1.67 1.19 -1.88 -1.24 
Q3TF14 AHCY Adenosylhomocysteinase 1.48 -2.21 1.66 -1.07 
H3BKT5 AHCYL2 adenosylhomocysteinase like 2 -1.58 -3.28 1.90 1.28 
Q9R0Y5 AK1 adenylate kinase 1 -1.28 -2.45 1.83 1.19 
D3YVF0 AKAP5 A-kinase anchoring protein 5 -2.31 -2.47 -3.49 -1.52 
P07724 ALB albumin 2.03 1.27 1.22 1.83 
Q8R0Y6 ALDH1L1 aldehyde dehydrogenase 1 family member L1 1.20 3.52 -1.54 -1.05 
Q5FWB7 ALDOA aldolase, fructose-bisphosphate A -2.28 1.51 -1.17 1.02 
P05063 ALDOC aldolase, fructose-bisphosphate C 1.04 2.70 -1.57 1.19 
C6EQG9 AMPH ASL1/Amph fusion protein 1.29 -1.25 -1.09 -1.26 
Q8C8R3-2 Ank2 ankyrin 2, brain -1.86 -1.23 -1.09 1.13 
P48036 ANXA5 annexin A5 1.88 -1.61 2.15 1.74 
P17426 AP2A1 adaptor related protein complex 2 alpha 1 subunit -2.04 -4.24 1.37 1.15 
H3BKM0 Ap2b1 adaptor-related protein complex 2, beta 1 subunit -1.07 -3.35 1.43 1.09 
Q3TH69 AP2M1 adaptor related protein complex 2 mu 1 subunit -2.02 1.04 -1.31 1.35 
Q8BSL7 Arf2 ADP-ribosylation factor 2 -1.26 -4.24 1.66 -1.20 
Q3TGS9 ARFGAP1 ADP ribosylation factor GTPase activating protein 1 -1.18 1.44 -1.91 -1.15 
Q8R5J9 ARL6IP5 ADP ribosylation factor like GTPase 6 interacting protein 5 1.31 -4.84 2.49 -1.60 
H7BWZ3 ARPC3 actin related protein 2/3 complex subunit 3 -1.66 -4.68 1.40 -1.27 
Q7TPD9 ARPC4 actin related protein 2/3 complex subunit 4 -1.97 -1.94 1.35 1.28 
Q3TWT5 ASAH1 N-acylsphingosine amidohydrolase 1 2.17 -1.54 2.97 1.31 
Q3TXF9 ATP1A1 ATPase Na+/K+ transporting subunit alpha 1 -1.07 1.24 -1.58 1.90 
D3YYN7 ATP1A2 ATPase Na+/K+ transporting subunit alpha 2 1.71 -10.44 6.56 -1.18 
Q6PIC6 ATP1A3 ATPase Na+/K+ transporting subunit alpha 3 1.03 -4.18 3.43 -1.73 
J3KMM5 ATP2A2 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 -1.45 -4.87 1.73 -1.31 
G5E829 ATP2B1 ATPase plasma membrane Ca2+ transporting 1 -1.27 -1.06 -1.49 1.09 
Q3UHH0 ATP2B2 ATPase plasma membrane Ca2+ transporting 2 1.09 1.20 -1.82 1.19 
D3Z6F5 ATP5A1 
ATP synthase, H+ transporting, 
mitochondrial F1 complex, alpha 
subunit 1, cardiac muscle 
1.35 -2.73 2.18 -1.45 
P56480 ATP5B 
ATP synthase, H+ transporting, 
mitochondrial F1 complex, beta 
polypeptide 
1.00 -5.61 3.03 -1.55 




Q3TF25 ATP5O ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit 1.20 -11.18 2.66 -1.46 
K3W4T3 ATP6V0A1 ATPase H+ transporting V0 subunit a1 -1.20 -3.24 1.51 -1.75 
P51863 ATP6V0D1 ATPase H+ transporting V0 subunit d1 1.03 -12.14 2.80 -1.99 
P50516 ATP6V1A ATPase H+ transporting V1 subunit A -1.07 -5.32 1.86 -1.53 
P62814 ATP6V1B2 ATPase H+ transporting V1 subunit B2 -1.11 -3.71 2.41 -1.07 
Q3TG21 ATP6V1C1 ATPase H+ transporting V1 subunit C1 -1.83 -3.95 -1.26 1.33 
Q8BVE3 ATP6V1H ATPase H+ transporting V1 subunit H 1.06 -4.93 1.70 -1.46 
Q9JLZ3 AUH AU RNA binding methylglutaconyl-CoA hydratase 1.26 -27.70 3.23 -3.24 
B1AZ46 BAIAP2 BAI1 associated protein 2 -1.20 -1.01 -2.52 -1.09 
Q91XV3 BASP1 brain abundant membrane attached signal protein 1 -4.13 -3.40 -3.37 1.22 
Q61361 BCAN brevican 2.37 -2.69 2.71 -1.10 
A2AVX1 BCAS1 breast carcinoma amplified sequence 1 1.72 2.88 -1.06 1.48 
Q80XN0 BDH1 3-hydroxybutyrate dehydrogenase 1 1.05 -1.08 1.30 1.24 
Q6P1B9 BIN1 bridging integrator 1 -1.04 -1.51 1.21 -1.11 
O88737 BSN bassoon presynaptic cytomatrix protein -1.25 1.29 -3.43 -1.14 
Q9DB72 BTBD17 BTB domain containing 17 1.36 2.18 -1.52 -1.54 
P00920 CA2 carbonic anhydrase 2 1.54 1.43 -1.11 1.00 
F7CZ64 CACNG8 calcium voltage-gated channel auxiliary subunit gamma 8 -1.91 1.33 -2.38 -1.28 
Q80TN1 CAMK2A calcium/calmodulin dependent protein kinase II alpha -1.45 -1.17 -2.26 -1.30 
Q5SVI0 CAMK2B calcium/calmodulin dependent protein kinase II beta 1.01 -3.62 1.46 -1.64 
Q3UHL1 CAMKV CaM kinase like vesicle associated -2.08 -1.15 -2.87 -1.33 
P80316 CCT5 chaperonin containing TCP1 subunit 5 -1.14 -7.27 2.18 -1.82 
Q8BS79 CDH13 cadherin 13 -1.25 1.22 -2.35 -1.64 
F8WGL3 CFL1 cofilin 1 1.02 -5.06 2.55 -1.25 
Q04447 CKB creatine kinase B -1.06 -3.96 1.68 -1.68 
F7DCH5 CLASP2 cytoplasmic linker associated protein 2 -1.05 -2.37 1.48 -1.63 
Q60771 CLDN11 claudin 11 1.91 2.84 -1.52 1.13 
Q5SXR6 CLTC clathrin heavy chain 1.27 -4.24 2.91 -1.09 
Q3TYL9 CNP 2',3'-cyclic nucleotide 3' phosphodiesterase 3.81 -1.02 1.72 -1.19 
Q5M8N0 CNRIP1 cannabinoid receptor interacting protein 1 -1.17 -13.12 1.81 -2.46 
P12960 CNTN1 contactin 1 -1.67 -2.75 1.20 1.19 
Q3U1N0 CORO1A coronin 1A -1.10 -1.99 -1.19 -1.48 
B2L0P0 COX2 Cytochrome c oxidase subunit 2 -1.34 -2.51 1.71 -1.42 
A2RSV8 COX4I1 cytochrome c oxidase subunit 4I1 -1.07 2.53 -1.73 1.09 
P36552 CPOX coproporphyrinogen oxidase -1.06 -1.94 1.46 -1.19 
Q3TXY0 CRMP1 collapsin response mediator protein 1 -1.22 -1.30 -1.09 -1.06 
Q52L78 CRYAB crystallin alpha B 1.49 1.06 -1.12 1.32 
Q3UPX0 CRYM crystallin mu -1.29 -1.14 -2.32 -1.22 
Q0QEL9 CS citrate synthase 1.38 2.61 -1.70 1.21 
Q71M36-2 CSPG5 chondroitin sulfate proteoglycan 5 -1.51 1.13 -1.71 1.12 
G3UZG6 CYB5R1 cytochrome b5 reductase 1 1.18 -1.24 1.57 -1.09 




Q3UGP0 DCLK1 doublecortin like kinase 1 -1.32 1.01 -1.38 1.04 
G3UZR0 DDAH2 dimethylarginine dimethylaminohydrolase 2 1.03 1.31 1.33 1.76 
Q3TQX5 DDX3X DEAD-box helicase 3, X-linked 1.71 -3.23 3.31 -1.32 
Q8BMF4 DLAT dihydrolipoamide S-acetyltransferase 1.14 1.45 -1.26 -1.14 
Q3TIE8 DLD dihydrolipoamide dehydrogenase 1.40 -4.67 2.39 -2.19 
B0V2P5 DMXL2 Dmx like 2 -1.16 -1.26 1.06 1.05 
P39053 DNM1 dynamin 1 1.28 -7.33 2.20 -2.34 
Q3TT92 DPYSL3 dihydropyrimidinase like 3 -1.27 1.34 -1.09 1.05 
Q3TMU8 DPYSL4 dihydropyrimidinase like 4 -1.16 1.24 -1.51 1.07 
Q9EQF6 DPYSL5 dihydropyrimidinase like 5 -1.34 -1.29 1.03 -1.08 
Q9JHU4 DYNC1H1 dynein cytoplasmic 1 heavy chain 1 1.71 -3.83 2.58 -1.47 
P62631 EEF1A2 eukaryotic translation elongation factor 1 alpha 2 -1.07 -4.88 3.05 -2.19 
Q3TJZ1 EEF2 eukaryotic translation elongation factor 2 1.07 -8.90 3.62 1.08 
Q5FW97 ENO1 Enolase 1, alpha non-neuron -1.22 1.67 -1.38 1.30 
Q3UJ20 ENO2 enolase 2 1.26 -1.58 2.28 -1.09 
A2AUK5 EPB41L1 erythrocyte membrane protein band 4.1 like 1 -1.76 1.11 -1.41 1.41 
D0VYV6 EPB41L3 erythrocyte membrane protein band 4.1 like 3 -1.01 -7.66 2.56 -1.64 
Q5NDA4 FABP7 fatty acid binding protein 7 -1.36 1.70 1.02 1.90 
P97807 FH fumarate hydratase -1.05 -8.32 3.77 -1.60 
Q9CQ92 FIS1 fission, mitochondrial 1 1.36 -3.15 2.35 -1.77 
P26883 FKBP1A FK506 binding protein 1A -1.21 1.35 -1.66 1.27 
Q61553 FSCN1 fascin actin-bundling protein 1 -1.09 -1.72 1.03 1.01 
P48318 GAD1 glutamate decarboxylase 1 -1.55 -2.81 1.80 -1.04 
P06837 GAP43 growth associated protein 43 -1.39 1.28 -1.78 -1.01 
M0QWZ0 GAPDH Uncharacterized protein -1.97 -3.36 1.29 1.08 
Q3U0C4 GDA guanine deaminase -1.62 -1.83 -1.38 1.11 
Q3TSQ7 GLUD1 glutamate dehydrogenase 1 -1.01 -7.15 3.91 -1.11 
P15105 GLUL glutamate-ammonia ligase -2.21 2.21 -1.82 1.12 
G3UWG1 GM10108 MCG115977 -1.43 -4.98 2.19 -1.24 
P18872 GNAO1 G protein subunit alpha o1 -1.03 -2.77 1.36 -1.12 
D3YZX3 GNB2 G protein subunit beta 2 -1.00 -13.54 7.44 1.36 
Q3THF3 GNB4 G protein subunit beta 4 1.01 1.77 -1.66 1.88 
P05201 GOT1 glutamic-oxaloacetic transaminase 1 1.27 -9.51 2.27 -2.30 
A2AQR0 GPD2 glycerol-3-phosphate dehydrogenase 2 1.61 -15.14 6.35 -1.10 
P06745 GPI glucose-6-phosphate isomerase 1.08 -5.82 2.13 -1.07 
P35802 GPM6A glycoprotein M6A -1.15 -1.30 -2.83 1.25 
A2AEG6 GPM6B glycoprotein M6B 1.21 -1.06 -3.27 1.21 
Q3UNH4 GPRIN1 G protein regulated inducer of neurite outgrowth 1 -1.65 1.54 -2.44 -1.00 




hydratase (trifunctional protein), 
alpha subunit 
1.26 -2.39 3.36 1.50 
Q9QUP5 HAPLN1 hyaluronan and proteoglycan link protein 1 1.27 -1.14 1.30 -1.17 
Q3U890 HARS histidyl-tRNA synthetase 2.14 -2.58 3.51 -1.11 
Q8BPF4 HBA1/HBA2 hemoglobin subunit alpha 2 2.73 -1.30 1.05 1.80 
D0U281 HBBT1 Beta-globin 2.62 -1.17 1.11 1.71 
B2RSY3 HEPACAM hepatic and glial cell adhesion molecule 1.08 -4.71 2.52 1.12 




G3UVV4 HK1 hexokinase 1 1.38 -2.02 1.55 -1.27 
Q3UJ70 HMGCS1 3-hydroxy-3-methylglutaryl-CoA synthase 1 -1.04 1.65 -1.41 -1.07 
B2RRY8 HPCAL4 hippocalcin like 4 -1.59 -1.90 -1.52 -1.03 
Q3UIF3 HSP90AA1 heat shock protein 90 alpha family class A member 1 -1.36 1.53 -1.13 1.41 
Q3TI47 HSPA5 heat shock protein family A (Hsp70) member 5 -1.39 -15.59 3.89 -1.56 
Q3TEK2 HSPA8 heat shock protein family A (Hsp70) member 8 -1.98 -1.05 1.10 -1.15 
P63038 HSPD1 heat shock protein family D (Hsp60) member 1 -1.21 -1.20 1.47 1.14 
Q5HZJ8 IDH1 isocitrate dehydrogenase (NADP(+)) 1, cytosolic -1.95 -2.35 1.27 1.09 
Q9D6R2 IDH3A isocitrate dehydrogenase 3 (NAD(+)) alpha -1.32 -1.03 -1.34 -1.56 
G3UYZ1 IGSF8 immunoglobulin superfamily member 8 1.89 1.22 -1.35 -1.55 
Q3UMG4 INA internexin neuronal intermediate filament protein alpha 1.87 2.50 -1.51 -1.29 
P85094 ISOC2 isochorismatase domain containing 2 1.68 -1.49 2.21 -1.06 
Q8C7Z5 KCNJ10 potassium voltage-gated channel subfamily J member 10 -1.15 1.19 -1.53 -1.47 
G3X9J4 KIAA1468 KIAA1468 -1.10 1.16 -1.27 1.26 
A2AFG7 L1CAM L1 cell adhesion molecule -1.21 1.12 -1.29 1.01 
Q3TCI7 LDHA lactate dehydrogenase A -1.50 -1.85 1.20 1.10 
Q9Z2I0 LETM1 leucine zipper and EF-hand containing transmembrane protein 1 1.37 -5.21 2.80 -1.89 
Q6PB66 LRPPRC leucine rich pentatricopeptide repeat containing 1.21 -3.77 2.63 -1.36 
P20917 MAG myelin associated glycoprotein 1.96 1.00 1.85 1.18 
B2RQQ5 MAP1B microtubule associated protein 1B 1.45 -5.42 1.67 -2.50 
Q3U4H0 MAPRE1 microtubule associated protein RP/EB family member 1 -1.11 1.64 -1.30 1.41 
P26645 Marcks myristoylated alanine rich protein kinase C substrate -1.46 -1.02 -1.54 1.32 
P28667 MARCKSL1 MARCKS like 1 -1.09 1.42 1.04 3.51 
F6RT34 MBP myelin basic protein 2.96 1.70 -1.01 -1.39 
P14152 MDH1 malate dehydrogenase 1 -1.57 -1.45 1.50 1.39 
P08249 MDH2 malate dehydrogenase 2 1.34 -1.12 1.35 -1.48 
Q3UY21 MOG myelin oligodendrocyte glycoprotein 1.73 1.30 -1.70 -1.12 
Q3UH59 MYH10 myosin heavy chain 10 1.18 -1.73 1.27 1.17 
B2RRE2 MYO18A myosin XVIIIA 1.58 -4.14 2.94 -1.60 
D3YZ62 MYO5A myosin VA 1.40 -9.54 2.87 -2.36 
Q9DB05 NAPA NSF attachment protein alpha 1.14 -4.42 1.56 -1.34 
D3YVA2 NCALD neurocalcin delta -2.28 -2.69 -1.49 1.08 
P13595 NCAM1 neural cell adhesion molecule 1 -1.58 -1.02 -1.73 1.25 
O35136 NCAM2 neural cell adhesion molecule 2 -1.92 -1.58 -1.53 1.51 
Q9Z0E0 NCDN neurochondrin -1.18 -8.41 2.93 -1.18 
Q9QYG0 NDRG2 NDRG family member 2 1.05 -7.61 2.25 -1.20 
Q99LC3 NDUFA10 NADH:ubiquinone oxidoreductase subunit A10 1.68 -4.66 2.65 -1.76 
G5E814 NDUFA11 NADH:ubiquinone oxidoreductase subunit A11 1.06 -1.89 2.13 -1.24 
Q9ERS2 NDUFA13 NADH:ubiquinone oxidoreductase subunit A13 -1.44 -3.49 2.52 1.07 
Q9DC69 NDUFA9 NADH:ubiquinone oxidoreductase subunit A9 1.11 -4.96 2.54 -1.40 




Q3UIQ2 NDUFS1 NADH:ubiquinone oxidoreductase core subunit S1 -1.21 -4.42 2.32 -1.98 
F6RJ83 NDUFS2 
NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 2, mitochondrial 
(Fragment) 
1.83 -14.46 10.24 -2.01 
D3YW32 NDUFS6 NADH dehydrogenase [ubiquinone] iron-sulfur protein 6, mitochondrial 1.29 -1.57 1.80 1.05 
D3YUM1 NDUFV1 NADH:ubiquinone oxidoreductase core subunit V1 1.07 -6.23 1.82 -2.44 
Q80TQ3 NEFH neurofilament heavy 2.79 3.62 -1.23 -1.13 
Q05DD2 NEFL neurofilament light 1.83 1.81 -1.35 -1.26 
P08553 Nefm neurofilament, medium polypeptide 2.60 2.46 -1.31 -1.46 
A0A4W9 NEGR1 neuronal growth regulator 1 -1.31 1.44 -1.87 -1.03 
Q3U536 NPM1 nucleophosmin 2.03 -1.33 1.84 1.45 
P97300 Nptn neuroplastin -1.38 1.07 -2.84 -1.01 
P46460 NSF N-ethylmaleimide sensitive factor, vesicle fusing ATPase -1.17 -12.66 2.04 -2.04 
Q8VCE6 NT5M 5',3'-nucleotidase, mitochondrial 1.19 -2.56 2.15 -1.58 
Q8BRD3 NUCB1 nucleobindin 1 1.15 1.07 1.83 -1.13 
Q60597-3 OGDH oxoglutarate dehydrogenase 1.24 -2.55 2.10 -1.40 
B2RXT3 OGDHL oxoglutarate dehydrogenase-like 1.29 -1.59 1.78 -1.08 
E0CXD1 OPA1 OPA1, mitochondrial dynamin like GTPase 1.43 -2.51 2.35 -1.16 
Q3UJQ9 OXCT1 3-oxoacid CoA-transferase 1 -1.24 1.14 1.10 1.14 
Q4KMM3 OXR1 oxidation resistance 1 -1.47 1.20 -2.02 1.13 
Q3TBF1 PADI2 peptidyl arginine deiminase 2 3.67 3.18 2.88 5.32 
Q8BP54 PC pyruvate carboxylase 1.19 -4.31 2.10 -1.33 
Q7TPG1 PDE10A phosphodiesterase 10A 2.04 -1.17 -1.08 1.13 
Q3UFJ3 PDHA1 pyruvate dehydrogenase (lipoamide) alpha 1 1.10 -4.85 2.23 -2.46 
Q9D051 PDHB pyruvate dehydrogenase (lipoamide) beta -1.60 -1.57 -1.40 1.12 
Q8C605 PFKP phosphofructokinase, platelet -1.31 -3.17 1.90 1.23 
Q3U7Z6 PGAM1 phosphoglycerate mutase 1 -1.25 -1.27 -1.57 -1.34 
A1A4A7 PGAM5 
PGAM family member 5, 
mitochondrial serine/threonine 
protein phosphatase 
-1.08 1.30 -1.31 -1.19 
P09411 PGK1 phosphoglycerate kinase 1 -1.31 -7.18 1.70 -1.93 
Q3V235 PHB2 prohibitin 2 -1.05 -7.16 2.23 -1.70 
P52480-2 PKM pyruvate kinase, muscle -1.55 -11.70 3.62 -1.13 
Q2M4J2 PLCB1 phospholipase C beta 1 1.04 -6.35 2.01 -1.38 
Q9DBG5 PLIN3 perilipin 3 1.92 -3.56 1.61 -1.01 
Q5DTP6 PLPPR3 phospholipid phosphatase related 3 -1.56 1.24 -1.54 -1.23 
Q3U7K1 Ppp1cc protein phosphatase 1, catalytic subunit, gamma isoform 1.79 -9.40 2.50 -2.00 
Q3UM45 PPP1R7 protein phosphatase 1 regulatory subunit 7 1.29 -1.14 -1.28 1.10 
Q7TMX2 PPP2R1A protein phosphatase 2 scaffold subunit Aalpha -1.14 -3.73 1.93 -1.02 
B2RRX2 PPP3CA protein phosphatase 3 catalytic subunit alpha -1.01 -9.51 1.48 -1.70 
P31324 PRKAR2B protein kinase cAMP-dependent type II regulatory subunit beta -1.18 -1.03 -1.59 -1.29 
P68404 PRKCB protein kinase C beta -1.36 -1.19 -1.11 1.60 
Q3UN66 PRKCG protein kinase C gamma -1.11 -1.16 -2.05 1.65 
B2RUD7 PSAP prosaposin 3.58 -1.04 3.01 2.22 
Q3UWT6 PSMA2 proteasome subunit alpha 2 1.13 -6.16 3.12 -1.31 
Q9WUB3 PYGM glycogen phosphorylase, muscle associated 1.66 -2.83 2.10 -1.41 




Q0PD66 RAB1B RAB1B, member RAS oncogene family -2.08 -1.71 1.32 1.51 
Q0PD63 RAB3A RAB3A, member RAS oncogene family -1.91 -3.35 1.71 -1.32 
C5H0E9 RAP1A RAP1A, member of RAS oncogene family 1.14 -5.68 2.45 -1.09 
Q80ZJ1 RAP2A RAP2A, member of RAS oncogene family -1.19 -3.67 1.32 -1.09 
P52760 RIDA reactive intermediate imine deaminase A homolog 1.55 2.34 1.24 2.04 
A2ACG7 RPN2 ribophorin II 1.34 -6.79 2.94 -1.70 
Q9CTF6 RRAS2 related RAS viral (r-ras) oncogene homolog 2 1.44 1.23 1.09 1.35 
A3QM89 RTN1 reticulon 1 -1.81 -3.25 1.14 1.15 
Q99P72 RTN4 reticulon 4 -2.16 -1.58 1.22 2.21 
Q9D3M4 S100A1 S100 calcium binding protein A1 1.53 -1.66 4.68 2.20 
Q9EP69 SACM1L SAC1 suppressor of actin mutations 1 like (yeast) 1.25 -4.75 2.85 -1.29 
Q8K2B3 SDHA succinate dehydrogenase complex flavoprotein subunit A 1.56 -7.36 5.21 -2.29 
Q8BK60 SERPINB1 serpin family B member 1 4.27 1.43 1.07 -1.05 
Q8VD37 SGIP1 SH3 domain GRB2 like endophilin interacting protein 1 1.38 -1.24 -1.46 -1.44 
Q91VW3 SH3BGRL3 SH3 domain binding glutamate rich protein like 3 -1.17 -1.66 1.24 -1.06 
E0CYM8 SIRPA signal regulatory protein alpha 1.04 -5.82 1.18 -1.51 
Q91V14 SLC12A5 solute carrier family 12 member 5 1.38 -9.53 2.61 -2.14 
Q3TXX4 SLC17A7 solute carrier family 17 member 7 -1.20 -1.60 -2.18 -1.47 
A2APL5 SLC1A2 solute carrier family 1 member 2 -1.34 -3.56 1.33 -1.01 
Q8C3T7 SLC1A3 solute carrier family 1 member 3 -1.56 -1.41 -1.30 1.78 
Q5SX53 SLC25A11 solute carrier family 25 member 11 -1.22 -3.22 2.43 -1.39 
Q8BH59 SLC25A12 solute carrier family 25 member 12 -1.02 -4.10 2.45 -1.63 
Q3THU8 SLC25A3 solute carrier family 25 member 3 1.60 -4.77 2.42 -1.47 
P51881 SLC25A5 solute carrier family 25 member 5 -1.29 -6.03 1.72 -1.19 
Q3TPL8 SLC2A3 solute carrier family 2 member 3 -1.28 -1.38 1.07 -1.26 
Q49S98 SLC32A1 solute carrier family 32 member 1 -1.99 -8.80 2.28 -1.58 
A2AMH3 SLC44A1 solute carrier family 44 member 1 2.57 -1.08 1.01 1.41 
B2RQX9 SLC6A5 solute carrier family 6 member 5 3.18 2.25 1.55 1.02 
Q6ZPY3 SLC8A2 MKIAA1087 protein (Fragment) -1.11 -1.06 -2.19 1.02 
P60879 SNAP25 synaptosome associated protein 25 1.01 -1.25 -1.32 1.99 
O55042 SNCA synuclein alpha -1.15 -1.01 -2.20 -1.11 
P08228 SOD1 superoxide dismutase 1 -1.11 3.09 -1.59 1.64 
A3KGU5 SPTAN1 spectrin alpha, non-erythrocytic 1 -1.27 -8.12 1.28 -1.19 
Q62261 SPTBN1 spectrin beta, non-erythrocytic 1 -1.02 -2.11 1.25 -1.45 
B1AQX9 SRCIN1 SRC kinase signaling inhibitor 1 -1.36 1.24 -2.36 1.27 
Q9QZX7 SRR serine racemase -1.43 -1.21 -2.27 1.03 
Q5D0A4 STX1A syntaxin 1A -1.67 -2.33 -1.85 -1.09 
P61264 STX1B syntaxin 1B 1.22 1.66 -1.41 1.10 
O08599 STXBP1 syntaxin binding protein 1 1.20 -1.17 -1.02 -1.61 
Q8BG39 SV2B synaptic vesicle glycoprotein 2B -1.37 -1.55 -2.69 -1.25 
O88935 SYN1 synapsin I -1.30 -2.84 1.49 -2.39 
Q64332 SYN2 synapsin II -1.49 -8.46 2.00 -1.66 
J3QQ18 SYNGAP1 synaptic Ras GTPase activating protein 1 -1.64 -1.06 -3.75 -1.28 
Q3TPT3 SYT1 synaptotagmin 1 1.13 -1.98 1.16 -1.06 
P11983 TCP1 t-complex 1 -1.04 -2.60 1.91 -1.25 
Q8C872 TFRC transferrin receptor -1.60 1.07 -1.28 1.17 
P40142 TKT transketolase 1.52 -7.51 2.97 -2.81 





Q8BYI9 TNR tenascin R 1.36 -2.26 1.68 -1.25 
Q3UQD0 TOMM40 translocase of outer mitochondrial membrane 40 1.08 -2.27 1.81 -1.30 
Q3URG1 TPPP tubulin polymerization promoting protein 1.37 -1.88 1.13 -1.32 
P68368 TUBA4A tubulin alpha 4a 1.24 1.47 -1.15 1.12 
P99024 TUBB tubulin beta class I -1.69 -7.08 3.55 1.02 
B2RSN3 TUBB2B tubulin beta 2B class IIb -1.34 1.03 1.04 1.29 
Q9D6F9 TUBB4A tubulin beta 4A class IVa 1.53 -9.54 3.68 -1.02 
B9EHN0 UBA1 ubiquitin like modifier activating enzyme 1 1.19 -1.90 2.27 1.38 
Q3TCH2 UCHL1 ubiquitin C-terminal hydrolase L1 -1.09 2.47 -2.07 1.26 
Q3THM1 UQCRC1 ubiquinol-cytochrome c reductase core protein I -1.33 -6.84 2.08 -1.94 
Q9DB77 UQCRC2 ubiquinol-cytochrome c reductase core protein II 1.02 -6.06 2.45 -1.98 
Q80TB8 VAT1L vesicle amine transport 1 like -1.26 -3.94 1.82 -1.66 
G3XA35 VCAN versican 1.10 1.30 -1.14 1.31 
Q8BNF8 VCP valosin containing protein -2.22 -3.94 -1.21 1.28 
Q3TJ43 VPS35 VPS35, retromer complex component -1.74 -3.40 3.32 1.71 




monooxygenase activation protein 
epsilon 




monooxygenase activation protein eta 




monooxygenase activation protein 
theta 




Table A8. Proteins identified by ≥ 2 peptide in Ppt1-/- cortical 
synaptosomes (Chapter 4) Fold change Ppt1
-/-/WT 
ID Gene Symbol Entrez Gene Name 1m 3m 5m 7m 
Q3V1S0 ABAT 4-aminobutyrate aminotransferase -1.53 -1.87 1.04 2.86 
Q99LR1 ABHD12 abhydrolase domain containing 12 -1.07 1.68 -1.74 -1.38 
Q8R2Y0 ABHD6 abhydrolase domain containing 6 -2.55 -1.70 -1.31 2.32 
H3BJZ9 ACAA1 acetyl-CoA acyltransferase 1 1.05 1.18 -2.50 -2.19 
Q8BWT1 ACAA2 acetyl-CoA acyltransferase 2 1.15 1.13 -2.60 -1.23 
Q9D7B6 ACAD8 acyl-CoA dehydrogenase family member 8 -1.37 1.33 -2.08 -2.05 
P51174 ACADL acyl-CoA dehydrogenase, long chain 1.45 1.02 -2.48 1.17 
Q07417 ACADS acyl-CoA dehydrogenase, C-2 to C-3 short chain 1.23 1.21 -2.73 -1.46 
Q7TMY2 ACADSB acyl-CoA dehydrogenase, short/branched chain 1.05 1.22 -4.10 -1.70 
P50544 ACADVL acyl-CoA dehydrogenase, very long chain -1.07 -1.07 -2.16 -1.24 
Q3TQP7 ACAT1 acetyl-CoA acetyltransferase 1 -1.74 1.24 -1.16 -1.55 
Q3TED3 ACLY ATP citrate lyase -1.06 -1.14 -1.32 1.91 
Q99KI0 ACO2 aconitase 2 -1.67 -1.33 -1.06 2.52 
Q4VA32 ACOT13 acyl-CoA thioesterase 13 1.60 1.86 -1.81 1.62 
Q6P2K2 ACOT2 acyl-CoA thioesterase 2 1.53 1.01 -2.03 1.10 




Q5F2C5 ACSL6 acyl-CoA synthetase long-chain family member 6 -1.23 -1.09 -1.60 1.57 
A1BN54 ACTN1 actinin alpha 1 -1.76 -2.05 -1.97 1.19 
Q3ULT2 ACTN4 actinin alpha 4 -1.23 -1.15 1.44 -1.45 
Q8R5C5 ACTR1B ARP1 actin-related protein 1 homolog B, centractin beta -2.06 -2.59 1.02 1.91 
Q3TGE1 ACTR3 ARP3 actin related protein 3 homolog -1.43 -1.79 1.36 1.30 
D3YUP9 ADAM22 ADAM metallopeptidase domain 22 -1.37 -1.48 1.03 3.24 
E9PY16 ADAP1 ArfGAP with dual PH domains 1 -2.53 -2.71 2.11 2.26 
E9Q706 ADCY9 adenylate cyclase 9 -1.93 -1.63 -1.16 3.19 
F8WGR0 ADD1 adducin 1 -1.85 -2.21 1.04 2.48 
J3QN31 ADSSL1 adenylosuccinate synthase like 1 1.51 -1.25 -1.52 3.89 
Q91VJ9 AGPAT1 1-acylglycerol-3-phosphate O-acyltransferase 1 -1.01 1.34 -1.31 -1.37 
Q80SW1 AHCYL1 adenosylhomocysteinase like 1 -1.20 -1.61 -1.17 1.63 
Q9R0Y5 AK1 adenylate kinase 1 -2.46 -2.49 1.41 3.50 
Q9WTP7 AK3 adenylate kinase 3 1.11 1.34 -2.11 1.05 
P07724 ALB albumin 1.91 -1.34 -1.72 1.60 
P24549 ALDH1A1 aldehyde dehydrogenase 1 family member A1 -1.20 -2.44 -1.40 1.94 
Q9CZS1 ALDH1B1 aldehyde dehydrogenase 1 family member B1 -3.26 -1.60 1.21 -1.71 
Q8R0Y6 ALDH1L1 aldehyde dehydrogenase 1 family member L1 1.50 1.60 -1.76 -1.10 
Q3TVM2 ALDH2 aldehyde dehydrogenase 2 family (mitochondrial) -1.03 1.19 -2.01 1.19 
B2RS41 ALDH5A1 aldehyde dehydrogenase 5 family member A1 -1.57 1.07 -1.69 1.31 
Q9EQ20 ALDH6A1 aldehyde dehydrogenase 6 family member A1 1.42 1.29 -1.92 1.16 
Q9DBF1 ALDH7A1 aldehyde dehydrogenase 7 family member A1 1.91 1.24 -1.85 -1.13 
Q5FWB7 ALDOA aldolase, fructose-bisphosphate A -1.15 -1.52 1.43 2.15 
P05063 ALDOC aldolase, fructose-bisphosphate C 1.58 1.35 -1.38 -1.10 
Q9DBE8 ALG2 ALG2, alpha-1,3/1,6-mannosyltransferase -1.38 -1.21 -1.15 1.66 
C6EQG9 Amph ASL1/Amph fusion protein -1.27 -2.16 1.50 2.93 
Q8C8R3 Ank2 ankyrin 2, brain -1.31 -1.05 1.23 -1.20 
P48036 ANXA5 annexin A5 2.50 1.01 -2.25 1.74 
Q3TJ49 ANXA7 annexin A7 2.24 1.64 -1.06 1.44 
Q3TVN4 AP1B1 adaptor related protein complex 1 beta 1 subunit -1.07 -1.45 1.04 1.91 
P17426 AP2A1 adaptor related protein complex 2 alpha 1 subunit -1.11 -2.91 2.07 2.00 
Q3U7X9 AP2A2 adaptor related protein complex 2 alpha 2 subunit -1.40 -2.15 1.37 2.52 
Q5SWR1 Ap2b1 adaptor-related protein complex 2, beta 1 subunit -1.21 -2.71 1.71 2.93 
Q3TH69 AP2M1 adaptor related protein complex 2 mu 1 subunit 1.88 -4.50 3.35 3.91 
Q9JME5 AP3B2 adaptor related protein complex 3 beta 2 subunit -1.23 -1.64 1.65 1.36 
Q3TXU4 APOE apolipoprotein E 3.44 1.06 -2.13 1.07 
B1AV14 APOOL apolipoprotein O like -1.37 1.41 -2.16 1.35 
Q3TGS9 ARFGAP1 ADP ribosylation factor GTPase activating protein 1 -1.21 1.60 1.15 -1.87 
Q8R5J9 ARL6IP5 ADP ribosylation factor like GTPase 6 interacting protein 5 -2.53 -2.11 1.46 3.01 




Q9R0Q6 ARPC1A actin related protein 2/3 complex subunit 1A -1.77 -1.45 1.54 1.62 
H7BWZ3 ARPC3 actin related protein 2/3 complex subunit 3 1.04 -1.40 1.93 1.30 
Q3U646 ASAH1 N-acylsphingosine amidohydrolase 1 1.17 -1.35 -2.84 2.74 
Q3UHD7 ASTN1 astrotactin 1 -3.00 -1.68 1.05 -1.38 
Q8BH66 ATL1 atlastin GTPase 1 -1.94 -1.75 1.40 1.25 
Q3TXF9 ATP1A1 ATPase Na+/K+ transporting subunit alpha 1 -1.46 -1.51 -1.37 1.30 
D3YYN7 ATP1A2 ATPase Na+/K+ transporting subunit alpha 2 1.60 1.67 -1.39 1.03 
Q6PIC6 ATP1A3 ATPase Na+/K+ transporting subunit alpha 3 1.06 -1.49 1.94 1.71 
Q3UR55 ATP1B2 ATPase Na+/K+ transporting subunit beta 2 1.57 1.72 -1.47 -1.13 
J3KMM5 Atp2a2 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 -1.39 -3.22 1.47 1.83 
G5E829 ATP2B1 ATPase plasma membrane Ca2+ transporting 1 -1.85 -2.26 1.39 2.05 
Q0VF54 ATP2B3 ATPase plasma membrane Ca2+ transporting 3 1.11 -1.65 1.80 2.45 
D1FNM8 ATP2B4 ATPase plasma membrane Ca2+ transporting 4 -1.14 1.18 1.53 1.03 
D3Z6F5 ATP5A1 
ATP synthase, H+ transporting, 
mitochondrial F1 complex, alpha 
subunit 1, cardiac muscle 
-1.75 -1.22 -1.20 1.83 
P56480 ATP5B 
ATP synthase, H+ transporting, 
mitochondrial F1 complex, beta 
polypeptide 
-1.57 1.19 -1.64 1.02 
A2AKU9 ATP5C1 
ATP synthase, H+ transporting, 
mitochondrial F1 complex, gamma 
polypeptide 1 
-1.61 1.36 1.01 1.84 
Q3TJD4 ATP5F1 ATP synthase, H+ transporting, mitochondrial Fo complex subunit B1 -1.80 -1.83 -1.07 3.78 
Q9CPQ8 ATP5L ATP synthase, H+ transporting, mitochondrial Fo complex subunit G -1.89 -1.32 -1.94 1.49 
Q3TF25 ATP5O ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit -2.38 -1.75 -1.25 1.74 
K3W4T3 ATP6V0A1 ATPase H+ transporting V0 subunit a1 -1.44 -1.51 1.71 2.41 
A3KML5 ATP6V0C ATPase H+ transporting V0 subunit c 1.21 -1.49 1.35 2.61 
P51863 ATP6V0D1 ATPase H+ transporting V0 subunit d1 -1.49 -2.21 2.09 3.60 
P50516 ATP6V1A ATPase H+ transporting V1 subunit A -1.39 -1.67 1.20 1.76 
P62814 ATP6V1B2 ATPase H+ transporting V1 subunit B2 -1.27 -1.47 1.35 2.22 
Q3TG21 ATP6V1C1 ATPase H+ transporting V1 subunit C1 -1.30 -1.89 1.41 2.32 
P50518 ATP6V1E1 ATPase H+ transporting V1 subunit E1 -1.09 -2.11 1.79 2.87 
Q5HZY7 ATP6V1G1 ATPase H+ transporting V1 subunit G1 -1.06 1.16 -1.75 -1.66 
B0V2H4 ATP6V1G2 ATPase H+ transporting V1 subunit G2 -1.55 -1.39 1.03 -1.26 
Q8BVE3 ATP6V1H ATPase H+ transporting V1 subunit H -1.31 -1.42 1.69 1.69 
Q91XV3 BASP1 brain abundant membrane attached signal protein 1 1.56 -1.04 2.43 -1.15 




Q80YN3 BCAS1 breast carcinoma amplified sequence 1 -1.08 2.72 -1.33 -3.14 
Q3TNR7 BCL2L13 BCL2 like 13 -1.67 1.03 -1.25 -1.67 
Q80XN0 BDH1 3-hydroxybutyrate dehydrogenase 1 -3.40 -1.26 -1.34 -2.98 
Q6P1B9 BIN1 bridging integrator 1 -1.22 -1.19 -1.02 2.87 
O88737-2 BSN bassoon presynaptic cytomatrix protein -1.03 2.13 -1.18 -1.74 
Q3TXB1 C1QA complement C1q A chain 6.93 1.46 -4.05 1.68 





chromosome 21 open reading frame 
33 -1.32 -1.06 -1.43 1.52 
Q3U590 C2CD2L C2CD2 like 1.01 1.66 1.00 -2.09 
B2RWX2 C4A/C4B complement C4B (Chido blood group) 10.70 1.13 -12.87 1.04 
P00920 CA2 carbonic anhydrase 2 2.66 1.64 -1.59 3.46 
P28651 CA8 carbonic anhydrase 8 -1.20 -8.91 2.17 -1.72 
Q14BH8 CACNA2D1 calcium voltage-gated channel auxiliary subunit alpha2delta 1 -1.07 1.19 1.26 -1.65 
Q9Z1L5 CACNA2D3 calcium voltage-gated channel auxiliary subunit alpha2delta 3 -3.20 -1.39 -1.37 -2.26 
F7CZ64 CACNG8 calcium voltage-gated channel auxiliary subunit gamma 8 -1.14 1.38 1.11 -2.04 
G3UZM4 CADM2 cell adhesion molecule 2 -3.02 -3.79 1.45 4.98 
K4DI58 CADM3 cell adhesion molecule 3 1.14 -1.01 1.53 1.59 
J3QJW3 CADPS calcium dependent secretion activator -1.63 -6.26 2.16 7.88 
Q8C5H2 CALB1 calbindin 1 -1.06 -2.92 2.06 1.04 
Q8CCS7 CALB2 calbindin 2 1.29 -1.92 2.21 -1.75 
P62204 Calm1 Calmodulin -3.01 -1.89 -1.30 -1.45 
B2MWM9 CALR calreticulin 1.02 -1.01 1.07 -1.86 
F8WHB5 CAMK2A calcium/calmodulin dependent protein kinase II alpha -2.63 -6.27 2.46 10.11 
Q3TY93 CAMK2B calcium/calmodulin dependent protein kinase II beta -1.52 -1.67 1.55 1.54 
Q6PHZ2 CAMK2D calcium/calmodulin dependent protein kinase II delta -1.70 -2.41 1.92 2.70 
Q8BGR3 CAMK4 calcium/calmodulin dependent protein kinase IV -1.68 -1.65 1.36 -1.42 
Q3UHL1 CAMKV CaM kinase like vesicle associated -1.05 1.10 1.26 -1.84 
Q6ZQ38 CAND1 cullin associated and neddylation dissociated 1 -1.46 -2.45 1.10 2.66 
Q3TXE5 CANX calnexin 1.12 -2.70 1.63 2.29 
Q3U3A8 CAPN2 calpain 2 2.28 1.10 -1.21 2.29 
D3YW48 CAPNS1 calpain small subunit 1 1.33 -1.40 -1.36 1.40 
Q3UBZ3 CAPZA2 capping actin protein of muscle Z-line alpha subunit 2 -1.58 1.26 1.29 -1.55 
Q6P9K8 CASKIN1 CASK interacting protein 1 -1.02 1.77 -1.26 -2.21 
Q0VBU4 CCDC47 coiled-coil domain containing 47 -1.20 1.17 -1.22 -2.13 
Q3U0I3 CCT3 chaperonin containing TCP1 subunit 3 -1.19 -1.35 -1.15 1.26 
P80316 CCT5 chaperonin containing TCP1 subunit 5 -2.17 -2.79 -1.09 1.54 
Q3TIJ7 CCT7 chaperonin containing TCP1 subunit 7 -1.99 -1.32 1.01 1.29 
Q3UKQ2 CCT8 chaperonin containing TCP1 subunit 8 1.17 1.14 1.01 -1.19 
Q61735-2 CD47 CD47 molecule -1.46 -1.51 1.16 1.39 
Q3UWG5 CD81 CD81 molecule 1.02 -1.32 -1.75 1.27 
Q8CE18 CDH13 cadherin 13 -1.74 1.29 1.42 -3.39 




Q9JKC6 CEND1 cell cycle exit and neuronal differentiation 1 1.42 -2.00 2.74 1.78 
Q9R1K9 CETN2 centrin 2 -2.12 -3.65 2.36 3.89 
Q8BMK4 CKAP4 cytoskeleton associated protein 4 -1.59 1.15 -1.07 -2.68 
Q04447 CKB creatine kinase B -1.08 -1.68 1.01 2.25 
B0R0E9 CKMT1A/CKMT1B creatine kinase, mitochondrial 1B -1.99 -1.17 -3.54 -1.51 
F7DCH5 CLASP2 cytoplasmic linker associated protein 2 -1.63 1.16 -1.00 -1.54 
Q60771 CLDN11 claudin 11 2.73 1.90 -1.36 3.61 
Q9QYB1 CLIC4 chloride intracellular channel 4 1.10 -1.05 -1.60 1.10 
Q5SXR6 CLTC clathrin heavy chain -1.27 -2.28 1.42 2.95 
Q06890 CLU clusterin 1.85 1.47 -2.53 -1.74 
Q9DBP5 CMPK1 cytidine/uridine monophosphate kinase 1 -1.84 -2.76 2.09 3.26 
Q9DAW9 CNN3 calponin 3 2.51 1.52 -3.81 -1.47 
Q3TYL9 CNP 2',3'-cyclic nucleotide 3' phosphodiesterase 1.35 1.34 1.20 2.07 
P12960 CNTN1 contactin 1 -1.01 1.58 1.08 -1.60 
O54991 CNTNAP1 contactin associated protein 1 -1.03 1.19 1.06 1.93 
Q9DBL7 COASY Coenzyme A synthase -3.73 -2.90 -7.12 -2.63 
Q8CIE6 COPA coatomer protein complex subunit alpha 1.34 1.17 -1.83 -2.25 
Q3UQL2 COPS3 COP9 signalosome subunit 3 -1.26 -2.39 1.19 2.30 
Q3U1N0 CORO1A coronin 1A -1.82 -1.43 1.96 1.61 
Q3TEU8 CORO1C coronin 1C -2.52 -1.90 1.29 1.65 
B2L0P0 COX2 Cytochrome c oxidase subunit 2 -2.13 -2.51 -1.48 2.70 
P56391 COX6B1 cytochrome c oxidase subunit 6B1 -1.83 -1.69 -1.11 2.08 
Q00493 CPE carboxypeptidase E 1.22 1.43 -1.24 -2.01 
Q3UN71 CPNE6 copine 6 1.44 1.34 1.21 -2.21 
Q6P1J1 CRMP1 collapsin response mediator protein 1 -1.79 -1.22 1.34 -1.70 
Q52L78 CRYAB crystallin alpha B 3.57 1.59 -2.11 6.12 
Q3UPX0 CRYM crystallin mu 1.15 -1.38 1.82 -1.31 
Q3UYY0 CRYZ crystallin zeta 2.52 2.07 -1.58 -1.08 
Q9CZU6 CS citrate synthase -1.11 2.05 -2.14 -1.66 
Q71M36-2 CSPG5 chondroitin sulfate proteoglycan 5 -1.05 -1.38 -1.05 -1.52 
Q4FJX4 CSRP1 cysteine and glycine rich protein 1 1.60 1.69 -1.94 1.26 
O88712 CTBP1 C-terminal binding protein 1 -2.60 -2.38 1.28 4.72 
Q61301-3 CTNNA2 catenin alpha 2 -2.12 -1.48 -1.07 -1.41 
Q3UZT7 CTNNB1 catenin beta 1 -2.88 -1.03 -1.70 -2.49 
B7ZNF6 CTNND2 catenin delta 2 -1.37 1.35 -1.09 -2.09 
Q3TVS6 CTSB cathepsin B 1.04 -1.48 -1.42 3.02 
Q3TWD0 CTSD cathepsin D 1.49 1.31 -3.48 1.11 
Q8BNA5 CTTN cortactin 1.11 -1.36 1.66 -1.44 
B9EJA2 CTTNBP2 cortactin binding protein 2 -1.47 -1.19 1.38 -1.82 
Q6ZQ84 CUL3 cullin 3 1.06 -5.15 1.99 3.87 
Q3TH64 CYB5B cytochrome b5 type B -1.68 -3.16 -1.19 2.40 
Q9D0M3 CYC1 cytochrome c1 -1.08 1.14 -1.22 2.90 
Q3US73 CYP46A1 cytochrome P450 family 46 subfamily A member 1 1.67 2.09 1.76 1.15 
Q548W7 DBI diazepam binding inhibitor, acyl-CoA binding protein 1.85 1.07 -1.56 -1.50 
Q9QXS6 DBN1 drebrin 1 -1.75 -1.28 1.24 -2.59 
A3KN70 DCLK1 doublecortin like kinase 1 -1.84 -1.02 1.16 -2.26 
D3YX34 DCTN1 dynactin subunit 1 -1.31 -2.46 1.49 4.92 
D3YU15 DDAH1 dimethylarginine dimethylaminohydrolase 1 1.39 1.09 -1.54 1.07 
Q3TQX5 DDX3X DEAD-box helicase 3, X-linked 1.06 1.21 -1.21 -1.42 




Q3TVU9 DHRS1 dehydrogenase/reductase 1 1.88 1.76 -4.01 -1.82 
Q3UWU7 DIRAS2 DIRAS family GTPase 2 -1.84 -2.09 1.66 1.88 
Q8BMF4 DLAT dihydrolipoamide S-acetyltransferase -1.11 1.11 -1.80 2.16 
O08749 DLD dihydrolipoamide dehydrogenase -1.62 -1.76 1.17 4.16 
Q62108 DLG4 discs large MAGUK scaffold protein 4 -1.56 -2.44 1.51 2.09 
Q9D2G2 DLST dihydrolipoamide S-succinyltransferase -1.08 1.36 -2.51 1.05 
B0V2P5 DMXL2 Dmx like 2 -2.36 -1.50 -1.06 -1.22 
G3X8S5 DNAJB6 DnaJ heat shock protein family (Hsp40) member B6 2.25 -3.03 2.91 3.32 
P39053 DNM1 dynamin 1 -1.67 -2.41 2.42 7.67 
Q8K1M6 DNM1L dynamin 1 like -2.02 -2.40 1.30 2.66 
Q8BZ98 DNM3 dynamin 3 -1.41 -1.95 1.13 2.63 
D3Z5I7 DPP10 dipeptidyl peptidase like 10 -1.67 -2.51 2.09 4.92 
Q3TY19 DPP6 dipeptidyl peptidase like 6 -1.04 -1.20 1.56 1.00 
O08553 DPYSL2 dihydropyrimidinase like 2 -1.15 -2.30 1.92 6.56 
Q3TT92 DPYSL3 dihydropyrimidinase like 3 -3.74 -1.47 2.02 -5.05 
Q3TMU8 DPYSL4 dihydropyrimidinase like 4 -1.72 -1.07 1.46 -2.45 
Q9EQF6 DPYSL5 dihydropyrimidinase like 5 -3.53 -2.10 2.81 -3.56 
Q9JHU4 DYNC1H1 dynein cytoplasmic 1 heavy chain 1 -1.21 -1.70 1.31 2.04 
Q3TWG5 DYNC1LI1 dynein cytoplasmic 1 light intermediate chain 1 -1.34 -4.23 2.17 3.60 
O35459 ECH1 enoyl-CoA hydratase 1 1.10 -1.01 -3.75 1.43 
Q9DBN7 ECI1 enoyl-CoA delta isomerase 1 1.74 1.17 -2.69 1.31 
Q3TCD4 ECI2 enoyl-CoA delta isomerase 2 1.08 1.04 -2.59 -1.53 
Q8BL66 EEA1 early endosome antigen 1 -1.74 1.55 -1.36 -2.91 
D3YZ68 EEF1A1 eukaryotic translation elongation factor 1 alpha 1 -1.90 -6.36 1.68 4.27 
P62631 EEF1A2 eukaryotic translation elongation factor 1 alpha 2 -1.50 -1.60 1.56 2.31 
O70251 EEF1B2 eukaryotic translation elongation factor 1 beta 2 -1.40 -1.38 1.14 1.21 
Q80T06 EEF1D eukaryotic translation elongation factor 1 delta 1.23 1.21 -1.41 -2.07 
Q4FZK2 EEF1G eukaryotic translation elongation factor 1 gamma -1.11 -1.06 1.04 -1.43 
Q3TJZ1 EEF2 eukaryotic translation elongation factor 2 -1.27 -2.20 1.28 2.33 
Q8BTU6 EIF4A2 eukaryotic translation initiation factor 4A2 -1.13 -1.18 1.15 -1.09 
Q3TDD8 EIF4B eukaryotic translation initiation factor 4B -1.12 1.56 1.09 -1.93 
Q3TG58 EIF4H eukaryotic translation initiation factor 4H -1.90 1.12 -1.46 -1.03 
Q5FW97 Eno1 Enolase 1, alpha non-neuron -1.44 -1.67 1.12 2.03 
Q3UJ20 ENO2 enolase 2 -1.53 -3.22 1.68 4.73 
D3YU63 ENPP6 ectonucleotide pyrophosphatase/phosphodiesterase 6 -1.13 -1.89 -1.16 1.55 
Q3T9U8 ENTPD2 ectonucleoside triphosphate diphosphohydrolase 2 1.46 1.58 -2.13 -1.18 
A2AUK5 EPB41L1 erythrocyte membrane protein band 4.1 like 1 -1.00 -1.20 1.34 -1.56 
B6ZHC5 EPB41L2 erythrocyte membrane protein band 4.1 like 2 1.37 1.25 -1.68 -1.37 
D0VYV6 EPB41L3 erythrocyte membrane protein band 4.1 like 3 -1.36 -2.86 1.88 4.58 
Q3UQ71 EPHX2 epoxide hydrolase 2 3.17 1.27 -1.43 1.23 
Q80VP1 EPN1 epsin 1 -1.34 -3.00 2.07 4.43 
Q8BFZ9 ERLIN2 ER lipid raft associated 2 1.34 1.54 -1.34 -1.76 




Q3URM4 ERP44 endoplasmic reticulum protein 44 -2.90 -1.15 -1.22 -2.06 
H3BJL6 ESD esterase D -1.21 1.01 -1.12 -1.24 
Q99LC5 ETFA electron transfer flavoprotein alpha subunit -1.26 -1.71 -2.12 1.06 
Q9DCW4 ETFB electron transfer flavoprotein beta subunit 1.07 1.03 -1.77 -1.01 
Q3TCP5 EZR ezrin 1.07 1.10 -2.10 -1.04 
Q3UUF0 FAAH fatty acid amide hydrolase -1.86 -2.06 1.39 1.83 
Q5NDA4 FABP7 fatty acid binding protein 7 -1.93 -1.33 -1.58 -10.81 
Q8C729 FAM126B family with sequence similarity 126 member B -1.49 -1.78 1.07 2.51 
Q921M7 FAM49B family with sequence similarity 49 member B -1.26 -1.59 1.15 1.37 
F8VPU2 FARP1 FERM, ARH/RhoGEF and pleckstrin domain protein 1 1.77 1.62 -1.75 -1.86 
Q3UHT6 FASN fatty acid synthase -1.76 -2.10 -1.22 1.86 
A2RT62 FBXL16 F-box and leucine rich repeat protein 16 -1.17 -1.35 1.30 -1.42 
Q3USR5 FBXO2 F-box protein 2 1.06 -1.82 1.02 2.81 
P97807 FH fumarate hydratase -2.69 -2.77 -1.42 4.41 
Q540I4 FLOT1 flotillin 1 1.04 1.62 -1.47 -1.47 
Q61553 FSCN1 fascin actin-bundling protein 1 -2.13 -1.96 1.63 1.55 
Q7TPM6 FSD1 fibronectin type III and SPRY domain containing 1 -1.33 -1.73 1.06 1.16 
Q3USY4 Fus fused in sarcoma -1.88 -2.46 -1.12 1.78 
Q3UVW2 GABRG2 gamma-aminobutyric acid type A receptor gamma2 subunit -1.91 -1.32 1.64 1.69 
M0QWZ0 GADPH Uncharacterized protein -1.26 -1.61 -1.22 1.71 
A1A4T2 GANAB glucosidase II alpha subunit 1.15 -2.83 1.82 2.06 
P06837 GAP43 growth associated protein 43 -1.47 1.15 2.17 -2.78 
D3YU09 GDA guanine deaminase -1.47 -1.29 -1.05 -1.31 
A2A5H8 GDAP1L1 ganglioside induced differentiation associated protein 1 like 1 -1.66 -1.63 1.15 1.26 
P50396 GDI1 GDP dissociation inhibitor 1 -1.49 -2.31 1.26 1.73 
P03995 GFAP glial fibrillary acidic protein 4.86 1.58 -7.90 -1.19 
Q7TMQ1 GJA1 gap junction protein alpha 1 2.99 1.83 -2.98 -1.10 
F8WHM5 GLG1 golgi glycoprotein 1 -1.66 1.02 1.49 -1.10 
Q9CPV4 GLOD4 glyoxalase domain containing 4 1.14 -1.45 -1.04 2.82 
D3Z7P3 GLS glutaminase -1.71 -1.45 -1.07 1.55 
P26443 GLUD1 glutamate dehydrogenase 1 1.38 1.12 -1.98 1.12 
P15105 GLUL glutamate-ammonia ligase 1.47 1.61 -1.46 -1.12 
G3UWG1 Gm10108 MCG115977 -1.78 -1.98 1.06 2.42 
G3X9L6 Gm10250 
ATP synthase, H+ transporting, 
mitochondrial F0 complex, subunit d 
pseudogene 
-1.74 -1.70 1.02 2.23 
B2RTM0 Gm11275 Histone H4 -1.14 1.01 -1.22 4.12 
E9PZF0 Gm20390 Nucleoside diphosphate kinase 1.34 -3.61 2.44 1.82 
E9Q035 Gm20425 Protein Gm20425 1.46 -1.00 -2.22 -1.46 
Q3UE40 GNA13 G protein subunit alpha 13 1.51 1.97 -1.26 1.34 
P08752 GNAI2 G protein subunit alpha i2 1.45 1.64 -1.52 -1.22 
P18872 GNAO1 G protein subunit alpha o1 -2.64 -2.71 1.03 2.50 
Q6R0H7 GNAS GNAS complex locus -1.47 -1.02 1.56 2.39 
Q3TQ70 GNB1 G protein subunit beta 1 1.06 1.23 -1.28 -1.29 
D3YZX3 GNB2 G protein subunit beta 2 1.03 -1.68 1.63 3.57 
Q3THF3 GNB4 G protein subunit beta 4 -1.91 1.02 2.00 -2.13 
Q9DAS9 GNG12 G protein subunit gamma 12 1.96 1.69 -1.33 1.15 
Q3UGN1 GNG7 G protein subunit gamma 7 2.16 -2.19 2.84 2.11 
P05201 GOT1 glutamic-oxaloacetic transaminase 1 -1.56 -3.74 3.23 11.31 




E0CXN5 GPD1 glycerol-3-phosphate dehydrogenase 1 -1.07 -1.29 1.09 2.36 
A2AQR0 GPD2 glycerol-3-phosphate dehydrogenase 2 -2.06 -1.95 -1.86 1.11 
A0JNY3 GPHN gephyrin -1.03 -2.04 2.83 -1.19 
P06745 GPI glucose-6-phosphate isomerase -1.17 -1.82 1.24 2.33 
P35802 GPM6A glycoprotein M6A -1.06 -1.76 2.68 1.64 
A2AEG6 GPM6B glycoprotein M6B -1.56 1.10 1.27 -1.79 
Q3UNH4 GPRIN1 G protein regulated inducer of neurite outgrowth 1 -1.18 1.57 1.34 -2.45 
Q4LG64 GRIA2 glutamate ionotropic receptor AMPA type subunit 2 -1.78 -3.44 1.11 1.80 
G3X9V4 GRIN2B glutamate ionotropic receptor NMDA type subunit 2B -2.30 -3.23 -1.19 1.16 
Q3TGJ9 GSN gelsolin 1.91 1.14 -2.93 -1.37 
E9PVM7 GSTM3 glutathione S-transferase mu 3 -1.02 -1.48 1.70 2.61 
P10649 GSTM5 glutathione S-transferase mu 5 2.12 1.36 -1.29 1.77 
P19157 GSTP1 glutathione S-transferase pi 1 1.57 1.11 -1.16 2.45 




hydratase (trifunctional protein), 
alpha subunit 




hydratase (trifunctional protein), beta 
subunit 
1.32 1.21 -2.43 -1.30 
Q9QUP5 HAPLN1 hyaluronan and proteoglycan link protein 1 1.84 1.28 -1.86 1.61 
Q8BPF4 HBA1/HBA2 hemoglobin subunit alpha 2 1.96 -1.06 -1.59 1.87 
D0U281 Hbbt1 Beta-globin 2.05 -1.14 -1.90 2.24 
Q3UGR5 HDHD2 haloacid dehalogenase like hydrolase domain containing 2 -1.25 -1.91 1.14 2.65 
Q3U4Z7 HDLBP high density lipoprotein binding protein 1.28 1.41 -1.82 -2.50 
B2RSY3 HEPACAM hepatic and glial cell adhesion molecule 1.59 1.57 -1.56 -1.14 
Q3TXR9 HEXB hexosaminidase subunit beta 1.26 1.30 -4.17 -1.26 
A0ZNJ2 HIBADH 3-hydroxyisobutyrate dehydrogenase 1.26 1.22 -1.91 1.11 
A0JLV3 HIST1H2BL histone cluster 1 H2B family member l -1.41 1.17 1.21 4.15 
G3UVV4 HK1 hexokinase 1 -1.46 -1.52 -1.20 2.47 
B7ZP22 HNRNPA2B1 
heterogeneous nuclear 
ribonucleoprotein A2/B1 -1.31 -1.80 1.42 1.70 
Q9Z2Y3 HOMER1 homer scaffolding protein 1 -1.17 -1.96 1.80 1.30 
P62748 HPCAL1 hippocalcin like 1 1.62 -1.47 1.71 1.25 
B2RRY8 HPCAL4 hippocalcin like 4 -1.91 -2.84 1.23 -1.10 
C0H5X4 HRAS HRas proto-oncogene, GTPase -3.05 -3.44 -1.16 2.30 
A2AFQ2 HSD17B10 hydroxysteroid 17-beta dehydrogenase 10 -1.05 1.56 -2.47 -1.69 
Q3TT11 HSD17B4 hydroxysteroid 17-beta dehydrogenase 4 1.05 1.48 -1.46 -1.67 
Q3UIF3 HSP90AA1 heat shock protein 90 alpha family class A member 1 -1.05 -2.19 2.39 2.94 
Q80YC2 HSP90AB1 heat shock protein 90 alpha family class B member 1 -1.78 -3.48 1.41 3.18 
Q3UAD6 HSP90B1 heat shock protein 90 beta family member 1 -1.04 -1.40 1.04 -1.54 





Q3U2G2 HSPA4 heat shock protein family A (Hsp70) member 4 -1.34 -1.63 1.22 1.78 
E0CY23 HSPA4L heat shock protein family A (Hsp70) member 4 like -1.23 -1.46 1.25 2.75 
Q3TI47 HSPA5 heat shock protein family A (Hsp70) member 5 -1.04 1.32 -1.61 -2.16 
Q3KQJ4 HSPA8 heat shock protein family A (Hsp70) member 8 1.23 -5.04 3.21 1.99 
P38647 HSPA9 heat shock protein family A (Hsp70) member 9 -1.27 1.25 -1.76 -1.04 
P63038 HSPD1 heat shock protein family D (Hsp60) member 1 -1.63 -1.44 -1.38 1.62 
Q8C6H1 HSPH1 heat shock protein family H (Hsp110) member 1 -1.94 -2.42 1.19 2.63 
Q8R2M5 IARS2 isoleucyl-tRNA synthetase 2, mitochondrial -1.20 -1.33 -1.35 2.20 
Q2KHL7 ICAM5 intercellular adhesion molecule 5 -1.08 -1.54 1.64 -1.69 
P54071 IDH2 isocitrate dehydrogenase (NADP(+)) 2, mitochondrial 1.32 1.11 -2.04 1.09 
Q9D6R2 IDH3A isocitrate dehydrogenase 3 (NAD(+)) alpha -1.53 -1.12 -1.25 1.72 
Q91VA7 IDH3B isocitrate dehydrogenase 3 (NAD(+)) beta -1.34 -1.00 -1.24 1.93 
Q3TGZ3 IDH3G isocitrate dehydrogenase 3 (NAD(+)) gamma -1.71 -1.66 -1.61 1.25 
G3UYZ1 IGSF8 immunoglobulin superfamily member 8 1.59 1.71 -1.06 1.89 
Q3TEY5 IMMT inner membrane mitochondrial protein -1.35 1.07 -1.46 1.54 
B2RY90 ISOC2 isochorismatase domain containing 2 -1.28 -2.72 -2.13 3.88 
M0QWA7 ITGB2 integrin subunit beta 2 2.54 1.62 -1.74 1.21 
P11881 ITPR1 inositol 1,4,5-trisphosphate receptor type 1 1.06 -1.87 1.06 1.19 
E0CXZ9 KCNAB2 potassium voltage-gated channel subfamily A regulatory beta subunit 2 -1.26 1.02 -1.29 1.55 
G3X9J4 KIAA1468 KIAA1468 -2.70 -3.57 1.11 1.46 
Q61768 KIF5B kinesin family member 5B -1.63 -1.56 -1.35 -1.31 
Q3TFE8 KPNB1 karyopherin subunit beta 1 -1.60 -2.79 1.21 1.93 
Q61765 KRT31 keratin 31 -4.24 -1.49 1.22 1.19 
Q61595-12 Ktn1 kinectin 1 -1.99 -1.26 -1.73 -1.82 
A2AFG7 L1CAM L1 cell adhesion molecule -2.05 -1.18 1.10 -2.16 
Q3TA96 LAMP1 lysosomal associated membrane protein 1 1.76 1.44 -1.69 1.28 
Q9CPY7 LAP3 leucine aminopeptidase 3 1.79 1.46 -1.69 1.12 
D3Z7F0 LDHB lactate dehydrogenase B -1.10 -1.85 1.39 2.84 
Q9Z2I0 LETM1 leucine zipper and EF-hand containing transmembrane protein 1 -2.32 -1.32 1.49 3.96 
P16045 LGALS1 galectin 1 2.78 1.18 -3.62 -1.20 
Q9JIA1 LGI1 leucine rich glioma inactivated 1 1.15 1.61 1.64 2.14 
Q9D1T0 LINGO1 leucine rich repeat and Ig domain containing 1 -1.70 -1.27 1.76 1.13 
Q9WU79 LOC102724788/PRODH proline dehydrogenase 1 1.07 -1.25 -2.49 -1.11 
Q3V2D0 LONP1 lon peptidase 1, mitochondrial -1.48 1.14 -1.65 1.05 
Q91ZX7 LRP1 LDL receptor related protein 1 1.16 1.35 -1.62 1.23 
Q6PB66 LRPPRC leucine rich pentatricopeptide repeat containing -1.89 -1.17 -1.33 -1.18 
B9EHV0 LRRC7 leucine rich repeat containing 7 -2.64 -1.86 -1.31 -1.58 




Q3ZB60 MAG myelin associated glycoprotein 1.36 1.33 1.31 1.52 
A2ARP8 MAP1A microtubule associated protein 1A 1.53 -1.12 1.36 -1.01 
B2RQQ5 MAP1B microtubule associated protein 1B 1.10 1.02 1.64 -1.20 
P20357 MAP2 microtubule associated protein 2 1.23 -1.29 1.29 -1.12 
Q3TMJ8 MAP2K1 mitogen-activated protein kinase kinase 1 -1.48 -2.27 -1.21 1.68 
E9QPW8 Map4 Microtubule-associated protein -1.35 -1.80 -1.83 1.32 
Q7TSJ2 MAP6 microtubule associated protein 6 1.36 2.18 -1.14 -1.24 
Q3U4H0 MAPRE1 microtubule associated protein RP/EB family member 1 -1.04 1.32 -1.06 -3.04 
Q2UZW7 MAPRE3 microtubule associated protein RP/EB family member 3 1.14 1.97 -1.14 -2.07 
P10637-3 MAPT microtubule associated protein tau -1.17 -1.16 1.93 -1.26 
E0CZH6 MARC2 mitochondrial amidoxime reducing component 2 -1.17 -1.39 -1.61 1.63 
P26645 Marcks myristoylated alanine rich protein kinase C substrate -1.09 -1.68 3.37 -1.24 
P28667 MARCKSL1 MARCKS like 1 -2.95 -1.19 1.79 -10.60 
F6RT34 MBP myelin basic protein 1.76 1.44 1.11 2.75 
P14152 MDH1 malate dehydrogenase 1 -1.35 -2.14 1.59 3.33 
P08249 MDH2 malate dehydrogenase 2 -1.37 1.46 -1.68 1.19 
Q3TQP6 ME1 malic enzyme 1 -1.63 -3.97 -1.16 1.28 
Q8BMF3 ME3 malic enzyme 3 -1.87 -1.35 -1.18 1.68 
D3YYS6 MGLL monoglyceride lipase -1.78 -2.36 -1.65 2.29 
Q8VHK5 MLC1 
megalencephalic 
leukoencephalopathy with subcortical 
cysts 1 
1.62 1.46 -1.86 -1.72 
Q3UY21 MOG myelin oligodendrocyte glycoprotein 2.18 1.11 1.07 4.21 
Q9CQX8 MRPS36 mitochondrial ribosomal protein S36 -1.86 1.75 -1.83 -1.15 
P26041 MSN moesin 1.51 1.17 -2.71 -1.08 
Q3USP9 Mt3 metallothionein 3 1.89 1.51 -1.84 -1.23 
A2AFW6 MTCH2 mitochondrial carrier 2 -1.85 -1.02 1.02 -1.09 
Q3UH59 MYH10 myosin heavy chain 10 -1.43 -1.74 2.75 1.08 
Q8VDD5 MYH9 myosin heavy chain 9 -1.93 -3.90 1.12 3.12 
E9Q405 MYO18A myosin XVIIIA -2.01 1.29 -1.08 -1.16 
D3YZ62 MYO5A myosin VA -1.33 -1.07 1.41 2.11 
E9Q174 MYO6 myosin VI 1.74 1.75 -2.40 -1.13 
Q9DB05 NAPA NSF attachment protein alpha -1.53 -1.57 -1.55 1.03 
P28663 NAPB NSF attachment protein beta -1.25 -2.55 1.29 2.86 
D3YVA2 NCALD neurocalcin delta 1.02 -4.28 1.88 1.57 
P13595 NCAM1 neural cell adhesion molecule 1 -1.62 -1.06 1.56 -1.89 
O35136 NCAM2 neural cell adhesion molecule 2 1.13 -1.33 1.60 -1.54 
Q9Z0E0 NCDN neurochondrin -1.06 -1.48 1.57 1.19 
Q8BLF1 NCEH1 neutral cholesterol ester hydrolase 1 -1.89 -1.10 -1.61 1.08 
A1L0U6 NCKAP1 NCK associated protein 1 -1.21 -2.30 -1.10 1.84 
Q3TGR3 NCL nucleolin 1.40 -1.47 -1.19 1.23 
B2L0N7 ND1 NADH dehydrogenase subunit 1 -1.09 -5.60 2.14 6.75 
Q3TD08 NDRG1 N-myc downstream regulated 1 2.11 1.64 -1.55 1.61 
Q9QYG0-2 NDRG2 NDRG family member 2 -1.57 -4.12 1.13 2.68 
Q9QYF9 NDRG3 NDRG family member 3 -1.60 -1.48 1.27 1.71 
Q99LC3 NDUFA10 NADH:ubiquinone oxidoreductase subunit A10 -1.92 -2.19 1.36 2.95 
Q5M9K5 NDUFA12 NADH:ubiquinone oxidoreductase subunit A12 -1.41 -1.06 -1.65 1.50 
Q9CQZ5 NDUFA6 NADH:ubiquinone oxidoreductase subunit A6 -1.05 -1.32 -1.64 1.94 
Q9DCJ5 NDUFA8 NADH:ubiquinone oxidoreductase subunit A8 -1.62 -1.56 1.32 2.87 





Q9DCS9 NDUFB10 NADH:ubiquinone oxidoreductase subunit B10 -1.50 1.32 -1.34 1.18 
Q3UIQ2 NDUFS1 NADH:ubiquinone oxidoreductase core subunit S1 -1.77 -1.84 -1.75 1.40 
Q9DCT2 NDUFS3 NADH:ubiquinone oxidoreductase core subunit S3 -1.76 -1.61 -1.07 2.67 
P52503 NDUFS6 NADH:ubiquinone oxidoreductase subunit S6 1.34 2.44 -1.96 -2.98 
D3YUM1 NDUFV1 NADH:ubiquinone oxidoreductase core subunit V1 -1.63 -1.18 -1.49 1.51 
Q9D6J6 NDUFV2 NADH:ubiquinone oxidoreductase core subunit V2 -1.20 1.09 -1.36 1.24 
P08551 NEFL neurofilament light -1.78 -1.06 1.34 -1.97 
Q810U3 NFASC neurofascin 1.68 1.97 -1.33 1.49 
Q3UJC3 NMT1 N-myristoyltransferase 1 1.34 -2.10 1.23 1.89 





NODAL modulator 1 -1.30 1.56 -1.44 -2.26 
F6QYF8 NPEPPS aminopeptidase puromycin sensitive -1.48 -1.15 1.00 2.32 
Q3U536 NPM1 nucleophosmin -1.11 -2.05 1.06 -1.15 
H3BIX4 Nptn neuroplastin -1.89 -1.55 -1.47 -1.33 
Q3UH37 NPTXR neuronal pentraxin receptor 1.14 1.15 -1.10 -2.73 
Q810U4-2 NRCAM neuronal cell adhesion molecule 1.33 1.40 -1.42 -1.78 
P46460 NSF N-ethylmaleimide sensitive factor, vesicle fusing ATPase -1.11 -1.03 1.23 1.78 
Q3UHE3 NTRK2 neurotrophic receptor tyrosine kinase 2 -1.06 1.41 -1.30 -1.48 
Q3TG75 OAT ornithine aminotransferase 1.42 1.38 -2.26 -1.19 
Q9D8W7 OCIAD2 OCIA domain containing 2 -1.53 2.32 -1.78 -1.68 
Q60597 OGDH oxoglutarate dehydrogenase -1.69 -1.11 -1.33 1.60 
B2RXT3 OGDHL oxoglutarate dehydrogenase-like -1.23 1.20 -1.68 1.81 
H7BX01 OPA1 OPA1, mitochondrial dynamin like GTPase -1.95 -1.47 -1.40 1.44 
D3Z7I9 OSBPL1A oxysterol binding protein like 1A -1.33 -1.86 1.72 3.15 
D3YWF6 Otub1 OTU domain, ubiquitin aldehyde binding 1 -1.67 -2.53 2.73 1.26 
Q3U9P7 OXCT1 3-oxoacid CoA-transferase 1 -2.63 1.08 -1.50 -2.07 
Q4KMM3 OXR1 oxidation resistance 1 -1.57 -1.86 -1.02 1.39 
Q8BZV8 P2RY12 purinergic receptor P2Y12 -3.22 -1.30 1.43 -1.22 
Q3TF72 P4HB prolyl 4-hydroxylase subunit beta -1.47 -2.33 -2.09 -1.15 
Q3TYF2 PACSIN1 protein kinase C and casein kinase substrate in neurons 1 -1.77 -1.49 -1.34 2.06 
Q08642 PADI2 peptidyl arginine deiminase 2 3.55 1.18 -2.02 1.82 
Q3TRX4 PALM paralemmin -1.16 1.01 1.75 -1.53 
Q3T9S7 PC pyruvate carboxylase -1.25 -1.05 -1.48 1.96 
A0PJE6 PCCB propionyl-CoA carboxylase beta subunit -1.63 -1.03 -1.64 -1.12 
Q9QYX7 PCLO piccolo presynaptic cytomatrix protein -1.73 -2.28 1.05 1.53 
Q9QXV0 PCSK1N proprotein convertase subtilisin/kexin type 1 inhibitor 1.39 2.21 1.66 -1.74 
Q3UFJ3 PDHA1 pyruvate dehydrogenase (lipoamide) alpha 1 -2.01 -1.10 -1.32 2.12 
Q9D051 PDHB pyruvate dehydrogenase (lipoamide) beta -1.43 -1.30 -1.23 2.25 
Q8BKZ9 PDHX pyruvate dehydrogenase complex component X -1.74 2.02 -1.54 -2.34 





Q3THH1 PDIA6 protein disulfide isomerase family A member 6 -1.26 -3.73 1.84 1.37 
Q8BFP9 PDK1 pyruvate dehydrogenase kinase 1 -1.18 1.55 -1.95 -1.05 
D3YYH0 PEX5L peroxisomal biogenesis factor 5 like 1.35 -1.18 -1.58 1.11 
P12382 PFKL phosphofructokinase, liver type -1.14 -4.01 1.67 4.30 
Q99K08 PFKM phosphofructokinase, muscle -1.04 -1.90 1.50 1.96 
Q8C605 PFKP phosphofructokinase, platelet -1.22 -1.92 1.03 1.96 
Q3U7Z6 PGAM1 phosphoglycerate mutase 1 -1.04 1.11 1.03 1.31 
A1A4A7 PGAM5 
PGAM family member 5, 
mitochondrial serine/threonine 
protein phosphatase 
-2.21 1.19 1.01 -2.80 
A2CEK3 PGM1 phosphoglucomutase 1 1.15 -1.23 -1.05 2.01 
Q8CAA7 PGM2L1 phosphoglucomutase 2 like 1 -1.96 -1.70 1.26 1.77 
Q5SQG5 PHB prohibitin -1.01 1.53 -1.31 -1.09 
Q3V235 PHB2 prohibitin 2 -1.64 -1.15 -1.19 1.71 
Q61753 PHGDH phosphoglycerate dehydrogenase 1.69 1.31 -1.27 -1.10 
Q6DIC7 PI4KA phosphatidylinositol 4-kinase alpha -1.71 -3.11 1.82 4.52 
J3QPW1 PITPNA phosphatidylinositol transfer protein alpha -1.03 -2.77 1.99 1.41 
Q2M4J2 PLCB1 phospholipase C beta 1 -1.73 -1.61 1.31 2.38 
O35405 PLD3 phospholipase D family member 3 -1.71 -2.03 -1.07 1.75 
Q9DBG5 PLIN3 perilipin 3 -1.53 -3.52 -2.70 1.53 
Q3UYM8 PLP1 proteolipid protein 1 2.00 1.40 1.23 3.68 
Q7TME0 PLPPR4 phospholipid phosphatase related 4 -1.56 1.37 -1.06 -5.81 
Q3TYF5 PPP1CA protein phosphatase 1 catalytic subunit alpha -2.38 -4.02 1.95 5.57 
Q60829 PPP1R1B protein phosphatase 1 regulatory inhibitor subunit 1B 1.20 -1.40 -1.03 -1.29 
Q3TDD9 PPP1R21 protein phosphatase 1 regulatory subunit 21 -1.04 1.44 -1.62 -1.94 
Q6R891 PPP1R9B protein phosphatase 1 regulatory subunit 9B -1.43 -1.40 1.40 -1.34 
Q8BN07 PPP2CB protein phosphatase 2 catalytic subunit beta -2.22 -3.41 1.07 4.05 
Q7TMX2 PPP2R1A protein phosphatase 2 scaffold subunit Aalpha -1.52 -4.97 1.31 3.00 
Q3UZJ4 PPP2R5E protein phosphatase 2 regulatory subunit B'epsilon -1.21 1.09 -1.13 -1.42 
B2RRX2 PPP3CA protein phosphatase 3 catalytic subunit alpha -1.86 -3.38 2.17 5.15 
Q63810 PPP3R1 protein phosphatase 3 regulatory subunit B, alpha 1.10 -2.66 2.08 2.17 
B1AXW5 PRDX1 peroxiredoxin 1 1.71 1.45 -1.75 -1.08 
P20108 PRDX3 peroxiredoxin 3 -1.40 -1.77 -1.09 2.64 
H3BJQ7 PRDX5 peroxiredoxin 5 -1.43 -1.53 -1.31 2.21 
Q6GT24 PRDX6 peroxiredoxin 6 3.02 1.25 -2.59 1.26 
Q8K1M3 PRKAR2A protein kinase cAMP-dependent type II regulatory subunit alpha -1.72 -2.42 1.21 2.26 
P31324 PRKAR2B protein kinase cAMP-dependent type II regulatory subunit beta -1.58 -1.10 1.62 -1.47 
P16054 PRKCE protein kinase C epsilon 1.25 1.84 1.10 -1.97 
Q2NKI4 PRKCG protein kinase C gamma 1.49 1.28 1.15 -1.98 
B2RUD7 PSAP prosaposin 1.14 1.27 -2.54 1.17 
Q3ULZ3 PSAT1 phosphoserine aminotransferase 1 1.54 1.37 -1.53 1.23 
Q3UWT6 PSMA2 proteasome subunit alpha 2 -2.25 -2.85 1.08 2.49 
Q8BWM0 PTGES2 prostaglandin E synthase 2 -1.69 -1.33 -1.76 1.93 
Q9D0J8 Ptms parathymosin 1.47 1.11 -1.18 -1.65 




O35295 PURB purine rich element binding protein B -1.07 -1.27 1.54 -1.08 
Q3TFQ8 PYGB glycogen phosphorylase B 1.79 1.22 -1.18 1.53 
Q9WUB3 PYGM glycogen phosphorylase, muscle associated -1.35 -1.39 1.68 2.92 
D3YWR7 QDPR quinoid dihydropteridine reductase 2.09 1.64 -1.78 1.89 
A2AL34 RAB14 RAB14, member RAS oncogene family -1.16 -1.66 1.28 2.33 
Q3TU36 RAP1GDS1 Rap1 GTPase-GDP dissociation stimulator 1 -1.90 -2.69 1.53 2.53 
Q9Z268 RASAL1 RAS protein activator like 1 -1.43 -1.38 1.59 1.39 
Q8CHX7 RFTN2 raftlin family member 2 1.37 1.96 -1.46 -1.23 
Q4VAE6 RHOA ras homolog family member A -1.68 -2.14 1.53 2.60 
Q3UDZ1 RHOG ras homolog family member G 1.51 1.66 -1.82 1.35 
P52760 RIDA reactive intermediate imine deaminase A homolog 3.93 1.62 -2.75 1.35 
Q3UM23 RNH1 ribonuclease/angiogenin inhibitor 1 1.60 1.50 -1.74 -1.37 
P47708 RPH3A rabphilin 3A -1.69 -1.80 1.26 1.79 
Q3TIQ2 RPL12 ribosomal protein L12 1.35 1.32 -1.42 -1.82 
D3YX54 Rpl13-ps3 60S ribosomal protein L13 1.56 1.63 -1.38 -1.99 
Q3T9U9 RPL3 ribosomal protein L3 1.26 -1.02 -1.10 -1.28 
Q3TK73 RPL7 ribosomal protein L7 1.68 1.47 -1.28 -1.58 
Q3U900 RPN1 ribophorin I -1.09 -1.10 -1.06 -1.98 
A2ACG7 RPN2 ribophorin II -2.17 -1.93 1.02 2.38 
Q3U9P0 RPS10 ribosomal protein S10 1.69 -1.36 1.05 1.20 
Q3UJS5 RPS14 ribosomal protein S14 1.53 1.42 -1.01 -1.61 
Q5M9M4 RPS15A ribosomal protein S15a 1.85 1.18 -1.42 -1.49 
Q3TW65 RPS18 ribosomal protein S18 1.81 1.23 -1.32 -1.57 
Q5M9P3 RPS19 ribosomal protein S19 2.30 1.61 -1.04 -1.29 
D3YVC1 RPS2 ribosomal protein S2 1.67 1.46 -1.54 -1.82 
Q8C1L7 RPS21 ribosomal protein S21 2.00 1.28 -1.33 -1.62 
D3YV43 RPS3 ribosomal protein S3 1.52 1.29 -1.06 -1.63 
Q3UXQ6 RPS4Y1 ribosomal protein S4, Y-linked 1 1.61 1.13 -1.26 -1.66 
Q91V55 RPS5 ribosomal protein S5 1.60 1.57 -1.49 -2.00 
Q3TL53 RPS6 ribosomal protein S6 1.74 1.25 -1.59 -1.90 
Q6ZWN5 RPS9 ribosomal protein S9 1.80 2.02 -1.37 -1.99 
Q9CTF6 RRAS2 related RAS viral (r-ras) oncogene homolog 2 -2.96 -2.35 1.94 -2.43 
A3QM89 RTN1 reticulon 1 1.24 -3.15 2.36 1.79 
Q9ES97 RTN3 reticulon 3 1.14 1.14 1.61 -1.17 
Q99P72 RTN4 reticulon 4 -1.49 -2.47 1.33 1.69 
Q9D394 RUFY3 RUN and FYVE domain containing 3 -1.15 1.55 -1.07 -1.68 
Q9D3M4 S100A1 S100 calcium binding protein A1 1.91 -1.46 -1.70 1.91 
Q9EP69 SACM1L SAC1 suppressor of actin mutations 1 like (yeast) -1.08 1.48 -1.32 -2.07 
Q8R127 SCCPDH saccharopine dehydrogenase (putative) -1.46 1.92 1.43 5.44 
Q9CZC8 SCRN1 secernin 1 -1.31 -2.04 1.98 -1.40 
Q8K2B3 SDHA succinate dehydrogenase complex flavoprotein subunit A -2.12 1.23 -1.77 1.17 
Q0QEZ4 SDHB succinate dehydrogenase complex iron sulfur subunit B -1.53 -1.33 -1.08 1.63 
Q3UZ06 SEC22B SEC22 homolog B, vesicle trafficking protein (gene/pseudogene) -1.59 -1.34 -1.06 1.77 
Q8C1E4 SEC23A Sec23 homolog A, coat complex II component -2.12 -2.40 1.71 5.25 
G3X972 SEC24C SEC24 homolog C, COPII coat complex component -1.32 1.30 1.17 -1.32 
Q8C1B7 SEPT11 septin 11 -1.05 1.54 -1.74 -1.25 




B7ZNM7 SEPT5 septin 5 -1.22 1.14 1.27 2.31 
Q5DTS3 SEPT7 septin 7 -1.15 -1.14 1.08 2.27 
B1AQY9 SEPT8 septin 8 1.52 1.90 -1.14 1.19 
Q3UEI6 SERBP1 SERPINE1 mRNA binding protein 1 2.05 1.70 -1.16 -1.55 
Q91V61 SFXN3 sideroflexin 3 -1.58 -1.63 1.04 1.73 
Q8BRQ9 SFXN5 sideroflexin 5 1.02 1.05 -2.17 -1.32 
Q8VD37 SGIP1 SH3 domain GRB2 like endophilin interacting protein 1 -1.74 -1.71 1.11 1.70 
Q3TJB4 SH3GL1 SH3 domain containing GRB2 like 1, endophilin A2 -8.80 -6.60 1.72 3.30 
A2ALV1 SH3GL2 SH3 domain containing GRB2 like 2, endophilin A1 1.15 1.10 1.19 1.56 
A2AWI7 SH3GLB2 SH3 domain containing GRB2 like, endophilin B2 -2.26 -3.05 1.29 2.45 
Q3UJK6 SIRT2 sirtuin 2 -1.08 1.00 -1.34 1.49 
E9QM38 SLC12A2 solute carrier family 12 member 2 1.02 1.44 -1.17 1.50 
Q91V14 SLC12A5 solute carrier family 12 member 5 -1.27 -1.43 1.45 3.09 
Q3TXX4 SLC17A7 solute carrier family 17 member 7 -1.36 -3.51 3.05 5.68 
Q8C3T7 SLC1A3 solute carrier family 1 member 3 -1.07 -4.37 -2.27 1.82 
Q3US35 SLC1A4 solute carrier family 1 member 4 2.04 -1.27 -1.58 1.14 
Q8BH59 SLC25A12 solute carrier family 25 member 12 -1.47 1.02 -1.62 1.46 
Q9DB41 SLC25A18 solute carrier family 25 member 18 1.75 1.23 -3.23 -1.31 
Q9D6M3 SLC25A22 solute carrier family 25 member 22 -1.66 1.42 -1.50 -2.42 
Q3THU8 SLC25A3 solute carrier family 25 member 3 -1.02 1.06 -1.09 2.17 
Q8BVI9 SLC25A4 solute carrier family 25 member 4 -1.65 -1.22 -1.63 1.32 
P51881 SLC25A5 solute carrier family 25 member 5 -1.21 -1.69 1.06 2.75 
Q3TPL8 SLC2A3 solute carrier family 2 member 3 -1.27 1.24 1.16 1.68 
Q49S98 SLC32A1 solute carrier family 32 member 1 -1.15 1.27 1.70 -1.11 
G3UWA6 SLC3A2 solute carrier family 3 member 2 -1.44 -1.63 1.17 1.71 
A2AMH3 SLC44A1 solute carrier family 44 member 1 1.96 1.96 -1.76 1.63 
B1AWV9 SLC4A10 solute carrier family 4 member 10 1.18 -1.78 2.23 2.89 
E9Q8N8 SLC4A4 solute carrier family 4 member 4 -1.03 -1.92 1.19 1.04 
P60879 SNAP25 synaptosome associated protein 25 -1.63 1.42 -1.15 -2.08 
Q8R570 SNAP47 synaptosome associated protein 47 -1.14 1.23 -1.00 -1.71 
Q3UI39 SNAP91 synaptosome associated protein 91 -1.20 -2.42 1.69 2.44 
O55042 SNCA synuclein alpha -1.12 1.42 1.02 -1.72 
Q3TRW3 SND1 staphylococcal nuclease and tudor domain containing 1 -1.15 1.31 -1.46 -2.47 
P08228 SOD1 superoxide dismutase 1 2.63 1.69 1.16 -1.42 
A3KGU5 SPTAN1 spectrin alpha, non-erythrocytic 1 -1.19 -2.18 1.69 1.38 
Q62261 SPTBN1 spectrin beta, non-erythrocytic 1 -1.28 -1.14 1.29 -1.10 
Q3UGZ4 SPTBN2 spectrin beta, non-erythrocytic 2 -2.60 -1.94 -1.20 -1.38 
B1AQX9 SRCIN1 SRC kinase signaling inhibitor 1 -1.37 1.58 1.11 -2.08 
Q8C2H3 STMN1 stathmin 1 1.79 1.35 1.21 -1.13 
Q99JB2 STOML2 stomatin like 2 -1.73 1.60 -1.76 -2.27 
Q5D0A4 STX1A syntaxin 1A -1.14 -1.64 1.32 2.32 
P61264 STX1B syntaxin 1B 3.49 -7.25 1.35 1.84 
O08599 STXBP1 syntaxin binding protein 1 -1.29 -1.69 1.65 3.48 
Q3U6C7 SUCLA2 succinate-CoA ligase ADP-forming beta subunit 1.13 1.50 -1.31 1.79 
Q9WUM5 SUCLG1 succinate-CoA ligase alpha subunit -2.00 1.20 -1.74 1.28 
Q9CX34 SUGT1 SGT1 homolog, MIS12 kinetochore complex assembly cochaperone 1.05 1.06 -1.45 -1.39 
Q8BG39 SV2B synaptic vesicle glycoprotein 2B -1.14 -2.62 1.86 3.04 
O88935 SYN1 synapsin I -1.11 1.18 1.36 1.50 
Q64332 SYN2 synapsin II 1.32 1.57 1.14 -1.49 
J3QQ18 SYNGAP1 synaptic Ras GTPase activating protein 1 -1.85 -1.61 1.21 1.96 




D3Z7R4 SYT1 synaptotagmin 1 -1.14 -26.10 18.49 4.34 
Q3TPT3 SYT1 synaptotagmin 1 -1.39 -1.88 1.54 2.92 
Q5DTI3 SYT2 synaptotagmin 2 -1.13 1.04 1.13 2.21 
Q0D2K7 SYT7 synaptotagmin 7 -2.00 -1.73 1.19 1.20 
Q9WVA4 TAGLN2 transgelin 2 1.35 -1.22 -4.21 -1.31 
Q9R1Q8 TAGLN3 transgelin 3 1.06 1.14 -1.72 1.14 
Q8CCT4 TCEAL5 transcription elongation factor A like 5 1.24 1.32 1.14 -2.01 
P11983 TCP1 t-complex 1 -1.40 1.18 1.25 -2.11 
Q8C872 TFRC transferrin receptor -2.04 -1.67 1.98 -1.88 
Q9D880 TIMM50 translocase of inner mitochondrial membrane 50 -1.67 -1.84 -1.08 2.09 
P40142 TKT transketolase 1.01 1.00 -1.25 1.82 
Q68FD6 TLN2 talin 2 -1.17 1.29 -1.04 -1.62 





thymosin, beta 4, X chromosome 1.23 1.24 1.21 -2.63 
Q8BYI9 TNR tenascin R 1.43 -1.14 -1.21 1.59 
Q3TSX8 TOMM70 translocase of outer mitochondrial membrane 70 -1.59 -1.30 -1.85 1.02 
H7BXC3 TPI1 triosephosphate isomerase 1 -1.28 -2.01 2.12 3.86 
Q545Y3 Tpm1 tropomyosin 1, alpha 1.63 -1.02 -1.89 1.22 
Q3TW28 TPP2 tripeptidyl peptidase 2 -1.29 -1.02 1.54 -1.52 
Q3URG1 TPPP tubulin polymerization promoting protein -1.19 -1.81 1.55 4.51 
Q0KL02 TRIO trio Rho guanine nucleotide exchange factor -1.92 -2.10 1.46 1.07 
P52196 TST thiosulfate sulfurtransferase 1.68 -1.15 -3.25 1.03 
P68368 TUBA4A tubulin alpha 4a 1.51 1.03 1.28 3.48 
P99024 TUBB tubulin beta class I -1.54 -3.97 1.44 3.74 
B2RSN3 TUBB2B tubulin beta 2B class IIb -2.41 -1.60 1.74 -3.84 
Q9ERD7 TUBB3 tubulin beta 3 class III -1.77 -1.81 -1.50 1.45 
Q9D6F9 TUBB4A tubulin beta 4A class IVa 1.57 -1.06 -1.05 1.92 
Q8BFR5 TUFM Tu translation elongation factor, mitochondrial -1.64 -1.35 -1.10 2.11 
B9EHN0 UBA1 ubiquitin like modifier activating enzyme 1 -2.05 -1.69 1.08 1.96 
Q8BJ53 Ubap2l ubiquitin-associated protein 2-like 1.66 1.20 -1.47 -2.03 
Q3TCH2 UCHL1 ubiquitin C-terminal hydrolase L1 -1.24 -1.73 1.12 1.65 
Q3U548 UGP2 UDP-glucose pyrophosphorylase 2 1.08 -1.11 -1.30 1.58 
Q9D855 UQCRB ubiquinol-cytochrome c reductase binding protein -1.30 -1.22 -1.05 2.12 
Q3THM1 UQCRC1 ubiquinol-cytochrome c reductase core protein I -1.55 -1.24 -1.56 2.21 
Q9DB77 UQCRC2 ubiquinol-cytochrome c reductase core protein II -2.02 1.09 -1.34 1.07 
Q9CR68 UQCRFS1 ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 -1.20 1.17 -1.87 1.21 
Q3U4W8 USP5 ubiquitin specific peptidase 5 -1.46 -3.06 1.68 4.40 
Q4FE56 USP9X ubiquitin specific peptidase 9, X-linked -1.40 -1.55 1.40 -1.06 
B0QZN5 VAMP2 vesicle associated membrane protein 2 -1.00 -1.15 1.55 -1.49 
G3UY93 VARS valyl-tRNA synthetase 1.10 1.51 -1.57 -2.37 
Q3TXD3 VAT1 vesicle amine transport 1 1.70 1.43 -1.90 -1.30 
Q80TB8 VAT1L vesicle amine transport 1 like -1.07 1.17 1.23 -2.57 
G3XA35 VCAN versican 2.36 1.58 -2.69 1.75 




F2Z471 VDAC1 voltage dependent anion channel 1 -1.40 -1.06 -1.28 1.46 
J3QMG3 VDAC3 voltage dependent anion channel 3 -1.40 1.41 -1.03 -1.43 
Q0VGU4 VGF VGF nerve growth factor inducible 1.44 1.52 -1.49 -2.26 
Q3TJ43 VPS35 VPS35, retromer complex component 1.01 1.22 -1.13 -1.50 
Q4W4C9 VSNL1 visinin like 1 1.16 -3.02 2.62 3.22 
Q8CGF6 WDR47 WD repeat domain 47 -1.20 1.17 1.38 -1.54 




monooxygenase activation protein 
beta 




monooxygenase activation protein 
epsilon 




monooxygenase activation protein eta 




monooxygenase activation protein 
theta 





Table A9 Proteins identified by ≥ 2 peptides and with a change >20% in Cln3-/- muscle (Chapter 6) 







hypothetical protein LOC66273 isoform 2 AAMDC 40254393 36.69 2.15 0.58 2 
transthyretin TTR 7305599 88.12 1.94 0.33 6 
hemopexin HPX 1881768 89.40 1.62 0.35 27 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12 NDUFA12 47117166 35.57 1.58 0.49 2 
alpha-1-antitrypsin 1-3 SERPINA1C 6678083 115.46 1.56 0.35 12 
dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate 
dehydrogenase complex DLST 21313536 55.77 1.55 0.65 3 
citrate lyase beta subunit CLYBL 19073015 76.41 1.54 0.81 3 
fatty acid-binding protein, heart FABP3 6753810 103.10 1.54 0.29 7 
Long-chain specific acyl-CoA dehydrogenase, mitochondrial ACADL 32130423 77.55 1.53 0.48 3 
Hydroxyacyl glutathione hydrolase HAGH 13435786 67.98 1.51 0.44 3 
myoglobin MB 21359820 157.45 1.48 0.50 3 
collagen alpha-1(VI) chain precursor COL6A1 6753484 78.49 1.47 0.21 6 
Me1 protein ME1 13096987 56.07 1.46 0.37 4 
phosphatidylethanolamine binding protein PEBP1 1517864 69.12 1.46 0.11 44 
cofilin-2 CFL2 6671746 72.97 1.46 0.34 10 
brain protein 44 BRP44 21312594 80.01 1.46 0.19 3 
ubiquitin-like modifier-activating enzyme 1 isoform 1 UBA1 6678483 49.73 1.45 0.13 9 
unnamed protein product SYNM 26343513 82.33 1.44 0.03 2 
Serpina1d protein SERPINA1D 18256880 74.93 1.44 0.35 4 
alpha-1-antitrypsin 1-4 precursor SERPINA1D 6678085 74.93 1.43 0.28 10 
alpha-1 antitrypsin precursor SERPINA1B 309079 115.46 1.42 0.24 44 




histidine triad nucleotide-binding protein 1 HINT1 33468857 87.78 1.41 0.71 3 
unnamed protein product HSPA5 12835845 56.83 1.39 0.22 5 
apolipoprotein A-I precursor - mouse APOE 109571 72.11 1.38 0.17 114 
Heat shock protein 2 HSPB2 39850111 76.34 1.37 0.53 2 
type VI collagen alpha 3 subunit COL6A3 3236370 75.36 1.37 0.04 13 
protein disulfide-isomerase precursor P4HB 42415475 76.05 1.37 0.54 2 
cytochrome b-c1 complex subunit 1, mitochondrial precursor UQCRC1 46593021 132.46 1.36 0.49 2 
unnamed protein product TUBB6 12853521 105.62 1.35 0.53 4 
tubulin beta-2B chain TUBB2B 21746161 105.62 1.35 0.41 3 
cytochrome b-c1 complex subunit 6, mitochondrial UQCRH 21539599 112.29 1.34 0.43 3 
cytochrome b-c1 complex subunit 7 UQCRB 13385726 64.76 1.32 0.36 4 
pyruvate dehydrogenase E1 component subunit beta, mitochondrial precursor PDHB 18152793 94.57 1.31 0.15 4 
creatine kinase S-type, mitochondrial precursor CKMT2 38259206 125.99 1.30 0.25 2 
isocitrate dehydrogenase 3 (NAD+), gamma IDH3G 51773592 144.48 1.30 0.20 2 
histone H2B type 1-C/E/F/G/I HIST1H2BC 4504257 63.18 1.29 0.59 16 
stretch-responsive fibronectin protein type 3 CMYA5 45774102 86.22 1.29 0.40 2 
cytochrome c, somatic CYCS 6681095 112.54 1.29 0.44 8 
unnamed protein product DCI 12836323 77.43 1.29 0.51 4 
Lectin, galactose binding, soluble 1 LGALS1 12805209 125.67 1.28 0.26 5 
skeletal muscle calsequestrin CASQ1 2618621 153.89 1.28 0.52 24 
phosphate carrier protein, mitochondrial precursor SLC25A3 19526818 84.37 1.27 0.37 3 
reticulon-4 isoform C RTN4 13195648 114.10 1.27 0.19 5 
S-adenosylhomocysteine hydrolase AHCY 56541076 40.63 1.27 0.00 2 
isocitrate dehydrogenase IDH2 1236984 140.97 1.27 0.42 33 
Tubulin, beta 2C TUBB2C 13542680 110.42 1.27 0.35 3 




calpastatin type II CAST 11603006 70.39 1.26 0.22 5 
NADH-ubiquinone oxidoreductase 18 kDa IP subunit NDUFS4 4836509 59.78 1.26 0.14 14 
unnamed protein product NDUFA5 12844779 64.30 1.26 0.05 4 
tubulin beta-3 chain TUBB3 12963615 99.07 1.25 0.41 4 
heat shock protein 65 HSPD1 51455 62.32 1.24 0.14 254 
manganese superoxide dismutase SOD2 832851 106.34 1.24 0.38 24 
unnamed protein product RPS2 12835827 40.94 1.24 0.19 5 
unnamed protein product CFL1 12861068 72.97 1.24 0.06 4 
unnamed protein product SUCLG1 12836764 101.38 1.23 0.14 6 
Trim72 protein TRIM72 45500997 77.98 1.23 0.05 2 
Acyl-Coenzyme A dehydrogenase, medium chain ACADM 15488707 61.84 1.23 0.27 3 
citrate synthase, mitochondrial precursor CS 13385942 114.82 1.22 0.21 4 
tubulin beta-5 chain TUBB5 7106439 99.07 1.22 0.29 7 
myelin basic protein isoform 1 MBP 69885032 82.32 1.21 0.03 2 
acyl carrier protein, mitochondrial precursor NDUFAB1 27754007 101.75 1.21 0.09 2 
NADH dehydrogenase (ubiquinone] 1 beta subcomplex subunit 10 NDUFB10 58037109 54.70 1.21 0.11 2 
isocitrate dehydrogenase 3, beta subunit IDH3B 18700024 73.44 1.21 0.07 3 
ES1 protein homolog, mitochondrial precursor D10JHU81E 20070420 88.12 1.20 0.52 3 
unnamed protein product MYOM3 26329053 66.75 1.20 0.27 3 
Acetyl-Coenzyme A acyltransferase 2 (mitochondrial 3-oxoacyl-Coenzyme A 
thiolase) ACAA2 20810027 114.58 1.20 0.34 3 
synemin isoform M SYNM 41687955 82.33 1.20 0.27 2 
mlrq-like protein NDUFA4 1401252 78.69 1.20 0.27 70 
heterogeneous nuclear ribonucleoprotein A3 isoform c HNRNPA3 157277969 136.04 1.20 0.19 2 
synaptophysin-like protein 2 SYPL2 6678874 212.22 1.20 0.15 8 
cytochrome c oxidase subunit 6C COX6C 16716343 66.56 1.20 0.34 3 




eukaryotic initiation factor 4A-II isoform c EIF4A2 176866061 69.57 0.80 0.19 2 
myosin heavy chain MYH4 199980 64.49 0.79 0.24 95 
ubiquitin-40S ribosomal protein S27a precursor RPS27A 13195690 57.89 0.79 0.13 5 
ATP synthase subunit b, mitochondrial precursor ATP5F1 78214312 39.68 0.79 0.20 2 
aldehyde dehydrogenase AHD-M1 ALDH2 560645 62.31 0.79 0.05 31 
Chain E, Crystal Structure Of The Catalytic Subunit Of Camp- Dependent 
Protein Kinase Complexed Wit PRKACA 14719578 84.67 0.78 0.10 3 
dystrophin DMD 6681203 69.54 0.78 0.09 8 
alcohol dehydrogenase-B2 ADH5 191722 85.80 0.78 0.10 55 
Chain A, Adipocyte Lipid Binding Protein Complexed With 1-Anilino-8- 
Naphthalene Sulfonate FABP4 5822455 92.82 0.78 0.11 12 
myosin light chain 6B MYL6B 26986555 58.97 0.77 0.01 2 
polymerase I and transcript release factor PTRF 6679567 50.29 0.77 0.13 8 
unnamed protein product CAV1 26330776 130.09 0.77 0.05 2 
myozenin-2 MYOZ2 10946916 61.94 0.76 0.01 6 
60S ribosomal protein L17 isoform a RPL17 4506617 67.15 0.75 0.12 13 
cAMP-dependent protein kinase type II-alpha regulatory subunit PRKAR2A 22550094 64.03 0.75 0.01 3 
26S proteasome non-ATPase regulatory subunit 2 PSMD2 19882201 57.10 0.74 0.03 3 
Isocitrate dehydrogenase 1 (NADP+), soluble IDH1 57242927 60.86 0.74 0.02 2 
mKIAA1248 protein NDRG2 50510857 54.32 0.73 0.11 2 
cytochrome b5 CYB5 13385268 181.78 0.73 0.07 4 
alpha-crystallin B chain CRYAB 6753530 75.77 0.73 0.16 7 
epidermal keratin 10 KRT10 7638398 44.93 0.71 0.21 5 
calnexin precursor CANX 6671664 44.28 0.70 0.24 11 
unnamed protein product EIF4A1 50815 74.90 0.69 0.04 286 
GTP-binding nuclear protein Ran RAN 5453555 78.64 0.68 0.01 17 




Voltage-dependent L-type calcium channel subunit alpha-1S CACNA1S 60391852 63.39 0.67 0.19 2 
carbonic anhydrase 3 CAR3 31982861 111.53 0.64 0.14 2 
troponin I, slow skeletal muscle TNNI1 10946862 73.19 0.62 0.19 5 
unnamed protein product KRT1 12859782 73.21 0.50 0.11 5 
Troponin T, slow skeletal muscle TNNT1 66773945 101.48 0.49 0.15 2 
parvalbumin alpha PVALB 31980767 113.92 0.29 0.26 2 
immunoglobulin kappa chain V-region (V-J) KV5A8 197166 64.03 0.27 0.04 96 
